FORMULATIONS

Abstract

The invention provides lipid nanoparticle-based compositions with improved properties for delivery of biologically active agents, engineered cells, and methods for delivery of the agents.

Description

Lipid nanoparticle (“LNP”) compositions with improved properties for delivery of biologically active agents, in particular RNAs, mRNAs, and guide RNAs are provided herein. The LNP compositions facilitate delivery of RNA agents across cell membranes, and in particular embodiments, they introduce components and compositions for gene editing into living cells.

Biologically active agents that are particularly difficult to deliver to cells include proteins, nucleic acid-based drugs, and derivatives thereof. Compositions for delivery of promising gene editing technologies into cells, such as for delivery of CRISPR/Cas9 system components, are of particular interest.

A number of components and systems for editing genes in cells in vivo now exist, providing tremendous potential for treating diseases. CRISPR/Cas gene editing systems are active as ribonucleoprotein complexes in a cell. An RNA-directed nuclease binds to and directs cleavage of a DNA sequence in the cell. This site-specific nuclease activity facilitates gene editing through the cell's own natural processes. For example, the cell responds to double-stranded DNA breaks (DSBs) with an error-prone repair process known as non-homologous end joining (“NHEJ”). During NHEJ, nucleotides may be added or removed from the DNA ends by the cell, resulting in a sequence altered from the cleaved sequence. In other circumstances, cells repair DSBs by homology-directed repair (“HDR”) or homologous recombination (“HR”) mechanisms, in which an endogenous or exogenous template can be used to direct repair of the break. Several of these editing technologies take advantage of cellular mechanisms for repairing single-stranded breaks (SSBs) or DSBs.

Compositions for delivery of the protein and nucleic acid components of CRISPR/Cas to a cell, such as a cell in a patient, are needed. In particular, compositions for delivering mRNA encoding the CRISPR protein component, and for delivering CRISPR guide RNAs are of particular interest. Compositions with useful properties for in vitro and in vivo delivery that can stabilize and deliver RNA components, are also of particular interest.

We herein provide lipid nanoparticle-based compositions with useful properties, in particular for delivery of CRISPR/Cas gene editing components.

In certain embodiments, the LNP compositions comprise: an RNA component; and a lipid component, wherein the lipid component comprises: (1) about 50-60 mol-% amine lipid; (2) about 8-10 mol-% neutral lipid; and (3) about 2.5-4 mol-% PEG lipid, wherein the remainder of the lipid component is helper lipid, and wherein the N/P ratio of the LNP composition is about 6, In additional embodiments, the LNP compositions comprise (1) an RNA component; (2) about 50-60 mol-% amine lipid; (3) about 27-39.5 mol-% helper lipid; (4) about 8-10 mol-% neutral lipid; and (5) about 2.5-4 mol-% PEG lipid, wherein the N/P ratio of the LNP composition is about 5-7.

In other embodiments, the LNP compositions comprise an RNA component and a lipid component, wherein the lipid component comprises: (1) about 50-60 mol-% amine lipid; (2) about 5-15 mol-% neutral lipid; and (3) about 2.5-4 mol-% PEG lipid, wherein the remainder of the lipid component is helper lipid, and wherein the N/P ratio of the LNP composition is about 3-10. In additional embodiments, the LNP compositions comprise a lipid component that includes (1) about 40-60 mol-% amine lipid; (2) about 5-15 mol-% neutral lipid; and (3) about 2.5-4 mol-% PEG lipid, wherein the remainder of the lipid component is helper lipid, and wherein the N/P ratio of the LNP composition is about 6. In another embodiment, the LNP compositions comprise a lipid component that includes (1) about 50-60 mol-% amine, lipid; (2) about 5-15 mol-% neutral lipid; and (3) about 1.5-10 mol-% PEG lipid, wherein the remainder of the lipid component is helper lipid, and wherein the N/P ratio of the LNP composition is about 6.

In some embodiments, the LNP compositions comprise an RNA component and a lipid component, wherein the lipid component comprises: (1) about 40-60 mol-% amine lipid; (2) about 0-5 mol-% neutral lipid, e,g., phospholipid; and (3) about 1.5-10 mol-% PEG lipid, wherein the remainder of the lipid component is helper lipid, and wherein the N/P ratio of the LNP composition is about 3-10. In some embodiments, the LNP compositions comprise an RNA component and a lipid component, wherein the lipid component comprises: (1) about 40-60 mol-% amine lipid; (2) less than about 1 mol-% neutral lipid, e.g., phospholipid; and (3) about 1.5-10 mol-% PEG lipid, wherein the remainder of the lipid component is helper lipid, and wherein the N/P ratio of the LNP composition is about 3-10. In certain embodiments, the LNP composition is essentially free of neutral lipid. In some embodiments, the LNP compositions comprise an RNA component and a lipid component, wherein the lipid component comprises: (1) about 40-60 mol-% amine lipid; and (2) about 1.5-10 mol-% PEG lipid, wherein the remainder of the lipid component is helper lipid. wherein the N/P ratio of the LNP composition is about 3-10, and wherein the LNP composition is free of neutral lipid, e.g., phospholipid. In certain embodiments, the LNP composition is essentially free of or free of a neutral phospholipid. In certain embodiments, the LNP composition is essentially free of or free of a neutral lipid, e.g., phospholipid.

In certain embodiments, the RNA component comprises an mRNA, such as an RNA-guided DNA-binding agent (e.g., a Cas nuclease or Class 2 Cas nuclease). In certain embodiments, the RNA component comprises a gRNA.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows the percentage of TTR gene editing achieved in mouse liver after delivery of CRISPR/Cas gene editing components Cas9 mRNA and gRNA in LNP compositions as indicated at a single dose of 1 mpk (FIG. 1A)) or 0.5 mpk (FIG. 1B).

FIG. 2 shows particle distribution data for LNP compositions comprising Cas9 mRNA and gRNA.

FIG. 3 depicts physicochemical properties of LNP compositions, comparing log differential molar mass (FIG. 3A) and average molecular weight measurements (FIG. 3B) for the compositions.

FIG. 4 shows polydispersity calculations in FIG. 4A and Burchard-Stockmeyer analysis in FIG. 4B, analyzing the LNP compositions of FIG. 3.

FIG. 5 provides the results of an experiment evaluating the effect of LNP compositions with increased PEG lipid concentrations on serum TTR knockdown, gene editing in the liver, and cytokine MCP-1 levels after a single dose administration in rats. FIG. 5A graphs serum TTR levels; FIG. 5B graphs percent editing in liver samples; and FIG. 5C provides MCP-1 levels in pg/mL.

FIG. 6 shows that LNP compositions maintain potency for gene editing with various PEG lipids (as measured by serum TTR levels (FIGS. 6A and 6B) and percent editing (FIG. 6C).

FIG. 7 shows that Lipid A analogs effectively deliver gene editing cargos in LNP compositions as measured by % liver editing after a single dose administration in mouse.

FIG. 8 shows a dose response curve of percent editing with various LNP compositions in primary cyno hepatocytes.

FIG. 9A and FIG. 9B show serum TTR and percent editing results when the ratio of gRNA to mRNA varies, and FIG. 9C and FIG. 9D show serum TTR and percent editing results in liver when the amount of Cas9 mRNA is held constant and gRNA varies following a single dose administration in mouse.

FIG. 10A and FIG. 10B show serum TTR and liver editing results after administration of LNP compositions with and without neutral lipid.

DETAILED DESCRIPTION

The present disclosure provides embodiments of lipid nanoparticle (LNP) compositions of RNAs, including CRISPR/Cas component RNAs (the “cargo”) for delivery to a cell and methods for their use. The LNP compositions may exhibit improved properties as compared to prior delivery technologies. The LNP composition may contain an RNA component and a lipid component, as defined herein. In certain embodiments, the RNA component includes a Cas nuclease, such as a Class 2 Cas nuclease. In certain embodiments, the cargo or RNA component includes an mRNA encoding a Class 2 Cas nuclease and a guide RNA or nucleic acids encoding guide RNAs. Methods of gene editing and methods of making engineered cells are also provided.

CRISPR/Cas Cargo

The CRISPR/Cas cargo delivered via LNP formulation may include an mRNA molecule encoding a protein of interest. For example, an mRNA for expressing a protein such as green fluorescent protein (GFP), and RNA-guided DNA-binding agent, or a Cas nuclease is included. LNP compositions that include a Cas nuclease snRNA, for example a Class 2 Cas nuclease mRNA that allows for expression in a cell of a Cas9 protein are provided. Further, the cargo may contain one or more guide RNAs or nucleic acids encoding guide RNAs. A template nucleic acid, e.g., for repair or recombination, may also be included in the composition or a template nucleic acid may be used in the methods described herein.

“mRNA” refers to a polynucleotide that comprises an open reading frame that can be translated into a polypeptide (i.e., can serve as a substrate for translation by a ribosome and amino-acylated tRNAs). mRNA can comprise a phosphate-sugar backbone including ribose residues or analogs thereof, e.g., 2′-methoxy ribose residues. In some embodiments, the sugars of an mRNA phosphate-sugar backbone consist essentially of ribose residues, 2′-methoxy ribose residues, or a combination thereof. In general, mRNAs do not contain a substantial quantity of thymidine residues (e.g., 0 residues or fewer than 30, 20, 10, 5, 4, 3, or 2 thymidine residues; or less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 4%, 3%, 2%, 1%, 0.5%, 0.2%, or 0.1% thymidine content). An mRNA can contain modified uridines at some or all of its uridine positions.

CRISPR/Cas Nuclease Systems

One component of the disclosed formulations is an mRNA encoding RNA-guided DNA-binding agent, such as a Cas nuclease.

As used herein, an “RNA-guided DNA binding agent” means a polypeptide or complex of polypeptides having RNA and DNA binding activity, or a DNA-binding subunit of such a complex, wherein the DNA binding activity is sequence-specific and depends on the sequence of the RNA. Exemplary RNA-guided DNA binding agents include Cas cleavases/nickases and inactivated forms thereof (“dCas DNA binding agents”). “Cas nuclease”, as used herein, encompasses Cas cleavases, Cas nickases, and dCas DNA binding agents. Cas cleavases/nickases and dCas DNA binding agents include a Csm or Cmr complex of a type III CRISPR system, the Cas10, Csm1, or Cmr2 subunit thereof, a Cascade complex of a type 1 CRISPR system, the Cas3 subunit thereof, and Class 2 Cas nucleases. As used herein, a “Class 2 Cas nuclease” is a single-chain polypeptide with RNA-guided DNA binding activity. Class 2 Cas nucleases include Class 2 Cas cleavases/nickases H840A, D10A, or N863A variants), which further have RNA-guided DNA cleavase or nickase activity, and Class 2 dCas DNA binding agents, in which cleavase/nickase activity is inactivated. Class 2 Cas nucleases include, for example, Cas9, Cpf1, C2c1, C2c2, C2c3, HF Cas9 (e.g., N497A, R661A, Q695A, Q926A variants), HypaCas9 (e.g., N692A, M694A, Q695A, H698A variants), eSPCas9(1.0) (e.g. K810A, K1003 A, R1060A variants), and eSPCas9(1.1) (e.g., K848A, K1003A, R1060A variants) proteins and modifications thereof. Cpf1 protein, Zetsche et al., Cell, 163: 1-13 (2015), is homologous to Cas9, and contains a RuvC-like nuclease domain. Cpf1 sequences of Zetsche are incorporated by reference in their entirety. See, e.g., Zetsche, Tables S1 and S3. See, e.g., Makarova et al., Nat Rev Microbiol, 13(11): 722-36 (2015); Shmakov et al., Molecular Cell, 60:385-397 (2015).

In some embodiments, the RNA-guided DNA-binding agent is a Class 2 Cas nuclease. In some embodiments, the RNA-guided DNA-binding agent has cleavase activity, which can also be referred to as double-strand endonuclease activity. In some embodiments, the RNA-guided DNA-binding agent comprises a Cas nuclease, such as a Class 2 Cas nuclease (which may be, e.g., a Cas nuclease of Type II, V, or VI). Class 2 Cas nucleases include, for example, Cas9, Cpf1, C2c1, C2c2, and C2c3 proteins and modifications thereof. Examples of Cas9 nucleases include those of the type 11 CRISPR systems of S. pyogenes, S. aureus, and other prokaryotes (see, e.g., the list in the next paragraph), and modified (e.g., engineered or mutant) versions thereof See, e.g., U.S. 2016/0312198 A1; U.S. 2016/0312199 A1. Other examples of Cas nucleases include a Csm or Cmr complex of a type III CRISPR system or the Cas10, Csm1, or Cmr2 subunit thereof; and a Cascade complex of a type I CRISPR system, or the Cas3 subunit thereof. In some embodiments, the Cas nuclease may be from a Type-IIA, Type-IIB, or Type-IIC system. For discussion of various CRISPR systems and Cas nucleases see, e.g., Makarova et al., Nat. Rev. Microbial. 9:467-477 (2011); Makarova et al., Nat. Rev. Microbial, 13: 722-36 (2015); Shmakov et al., Molecular Cell, 60:385-397 (2015).

Non-limiting exemplary species that the Cas nuclease can be derived from include Streptococcus pyogenes, Streptococcus thermophilus, Streptococcus sp., Staphylococcus aureus, Listeria innocua, Lactobacillus gasseri, Francisella novicida, Wolinella succinogenes, Sutterella wadsworthensis, Gammaproteobacterium, Neisseria meningitidis, Campylobacter jejuni, Pasteurella multocida, Fibrobacter succinogene, Rhodospirillum rubrum, Nocardiopsis dassonvillei, Streptomyces pristinaespiralis, Streptomyces viridochromogenes, Streptomyces viridochromogenes, Streptosporangium roseum, Streptosporangium roseum, Alicyclobacillus acidocaldarius, Bacillus pseudomycoides, Bacillus selenitireducens, Exiguobacterium sibiricum, Lactobacillus delbrueckii, Lactobacillus salivarius, Lactobacillus buchneri, Treponema denticola, Microscilla marina, Burkholderiales bacterium, Polaromonas naphthalenivorans, Polaromonas sp., Crocosphaera watsonii, Cyanothece sp., Microcystis aeruginosa, Synechococcus sp., Acetahalobilum arabaticum, Ammanifex degensii, Caldicelulosiruptor becscii, Candidatus desulforudis, Clostridium botulinum, Clostridium difficile, Finegoldia magna, Natranaerobius thermophilus, Pelotomaculum thermopropionicum, Acidithiobacillus caldus, Acidithiabacillus ferrooxidans, Allochromatium vinosum, Marinobacter sp., Nitrosococcus halophilus, Nitrosococcus watsoni, Pseudoalteromonas haloplanktis, Ktedonobacter racemifer, Methanohalobium evestigatum, Anabaena variabilis, Nodularia spumigena, Nostoc sp., Arthrospira maxima, Arthrospira platensis, Arthrospira sp., Lyngbya sp., Microcoleus chthonoplastes, Oscillatoria sp., Petrotoga mobilis, Thermosipho africanus, Streptococcus pasteurianus, Neisseria cinerea, Campylobacter lari, Parvibaculum lavamentivorans, Corynebacterium diphtheria, Acidaminococcus sp., Lachnospiraceae bacterium ND2006, and Acaryochloris marina.

In some embodiments, the Cas nuclease is the Cas9 nuclease from Streptococcus pyogenes. In some embodiments, the Cas nuclease is the Cas9 nuclease from Streptococcus thermophilus. In some embodiments, the Cas nuclease is the Cas9 nuclease from Neisseria meningitidis. In some embodiments, the Cas nuclease is the Cas9 nuclease is from Staphylococcus aureus. In some embodiments, the Cas nuclease is the Cpf1 nuclease from Francisella novicida. In some embodiments, the Cas nuclease is the Cpf1 nuclease from Acidaminococcus sp. In some embodiments, the Cas nuclease is the Cpf1 nuclease from Lachnospiraceae bacterium ND2006. In further embodiments, the Cas nuclease is the Cpf1 nuclease from Francisella tularensis, Lachnospiraceae bacterium, Butyrivibrio proteoc/asticus, Peregrinibacteria bacterium, Parcubacteria bacterium, Smithella, Acidaminococcus, Ccmdidatus Alethanopiastna termitum, Eubcicterium eligens, Moraxella bovoculi, Leptospira inadai, Porphyromonas crevioricanis, Prevotella disiens, or Porphyromonas macacae. In certain embodiments, the Cas nuclease is a Cpf1 nuclease from an Acidaminococcus or Lachnospiraceae.

Wild type Cas9 has two nuclease domains: RuvC and HNH. The RuvC domain cleaves the non-target DNA strand, and the HNH domain cleaves the target strand of DNA. In some embodiments, the Cas9 nuclease comprises more than one RuvC domain and/or more than one HNH domain. In some embodiments, the Cas9 nuclease is a wild type Cas9. In some embodiments, the Cas9 is capable of inducing a double strand break in target DNA. In certain embodiments, the Cas nuclease may cleave dsDNA, it may cleave one strand of dsDNA, or it may not have DNA cleavase or nickase activity. An exemplary Cas9 amino acid sequence is provided as SEQ ID NO: 3. An exemplary Cas9 mRNA ORF sequence, which includes start and stop codons, is provided as SEQ ID NO: 4. An exemplary Cas9 mRNA coding sequence, suitable for inclusion in a fusion protein, is provided as SEQ ID NO: 10.

In some embodiments, chimeric Cas nucleases are used, where one domain or region of the protein is replaced by a portion of a different protein. In some embodiments, a Cas nuclease domain may be replaced with a domain from a different nuclease such as Fok1. In some embodiments, a Cas nuclease may be a modified nuclease.

In other embodiments, the Cas nuclease may be from a Type-I CRISPR/Cas system. In some embodiments, the Cas nuclease may be a component of the Cascade complex of a Type-1 CRISPR/Cas system. In some embodiments, the Cas nuclease may be a Cas3 protein. In some embodiments, the Cas nuclease may be from a Type-III CRISPR/Cas system. In some embodiments, the Cas nuclease may have an RNA cleavage activity.

In some embodiments, the RNA-guided DNA-binding agent has single-strand nickase activity, i.e., can cut one DNA strand to produce a single-strand break, also known as a “nick.” In some embodiments, the RNA-guided DNA-binding agent comprises a Cas nickase. A nickase is an enzyme that creates a nick in dsDNA, i.e., cuts one strand but not the other of the DNA double helix. In some embodiments, a Cas nickase is a version of a Cas nuclease (e.g., a Cas nuclease discussed above) in which an endonucleolytic active site is inactivated, e.g., by one or more alterations (e.g., point mutations) in a catalytic domain. See, e.g., U.S. Pat. No. 8,889,356 for discussion of Cas nickases and exemplary catalytic domain alterations. In some embodiments, a Cas nickase such as a Cas9 nickase has an inactivated RuvC or HNH domain. An exemplary Cas9 nickase amino acid sequence is provided as SEQ ID NO: 6. An exemplary Cas9 nickase mRNA ORF sequence, which includes start and stop codons, is provided as SEQ ID NO: 7. An exemplary Cas9 nickase mRNA coding sequence, suitable for inclusion in a fusion protein, is provided as SEQ ID NO: 11.

In some embodiments, the RNA-guided DNA-binding agent is modified to contain only one functional nuclease domain. For example, the agent protein may be modified such that one of the nuclease domains is mutated or fully or partially deleted to reduce its nucleic acid cleavage activity. In some embodiments, a nickase is used having a RuvC domain with reduced activity. In some embodiments, a nickase is used having an inactive RuvC domain. In some embodiments, a nickase is used having an HNH domain with reduced activity. In some embodiments, a nickase is used having an inactive HNH domain.

In some embodiments, a conserved amino acid within a Cas protein nuclease domain is substituted to reduce or alter nuclease activity. In some embodiments, a Cas nuclease may comprise an amino acid substitution in the RuvC or RuvC-like nuclease domain. Exemplary amino acid substitutions in the RuvC or RuvC-like nuclease domain include D10A (based on the S. pyogenes Cas9 protein). See, e.g., Zetsche et al. (2015) Cell October 22:163(3): 759-771. In some embodiments, the Cas nuclease may comprise an amino acid substitution in the HNH or HNH-like nuclease domain. Exemplary amino acid substitutions in the HNH or HNH-like nuclease domain include E762A, H840A, N863A, H983A, and D986A (based on the S. pyogenes Cas9 protein). See, e.g., Zetsche et al. (2015). Further exemplary amino acid substitutions include D917A, E1006A, and D1255A (based on the Francisella novicida U112 Cpf1 (FnCpf1) sequence (UniProtKB—A0Q7Q2 (CPF1_FRATN)).

In some embodiments, an mRNA encoding a nickase is provided in combination with a pair of guide RNAs that are complementary to the sense and antisense strands of the target sequence, respectively. In this embodiment, the guide RNAs direct the nickase to a target sequence and introduce a DSB by generating a nick on opposite strands of the target sequence (i.e., double nicking). In some embodiments, use of double nicking may improve specificity and reduce off-target effects. In some embodiments, a nickase is used together with two separate guide RNAs targeting opposite strands of DNA to produce a double nick in the target DNA. In some embodiments, a nickase is used together with two separate guide RNAs that are selected to be in close proximity to produce a double nick in the target DNA.

In some embodiments, the RNA-guided DNA-binding agent lacks cleavase and nickase activity. In some embodiments, the RNA-guided DNA-binding agent comprises a dCas DNA-binding polypeptide. A dCas polypeptide has DNA-binding activity while essentially lacking catalytic (cleavase/nickase) activity. In some embodiments, the dCas polypeptide is a dCas9 polypeptide. In some embodiments, the RNA-guided DNA-binding agent lacking cleavase and nickase activity or the dCas DNA-binding polypeptide is a version of a Cas nuclease (e.g., a Cas nuclease discussed above) in which its endonucleolytic active sites are inactivated, e.g., by one or more alterations (e.g., point mutations) in its catalytic domains. See, e.g., U.S. 2014/0186958 A1; U.S. 2015/0166980 A1, An exemplary dCas9 amino acid sequence is provided as SEQ ID NO: 8. An exemplary Cas9 mRNA ORF sequence, which includes start and stop codons, is provided as SEQ ID NO: 9. An exemplary Cas9 mRNA coding sequence, suitable for inclusion in a fusion protein, is provided as SEQ ID NO: 12.

In some embodiments, the RNA-guided DNA-binding agent comprises one or more heterologous functional domains (e.g., is or comprises a fusion polypeptide).

In some embodiments, the heterologous functional domain may facilitate transport of the RNA-guided DNA-binding agent into the nucleus of a cell. For example, the heterologous functional domain may be a nuclear localization signal (NLS). In some embodiments, the RNA-guided DNA-binding agent may be fused with 1-10 NLS(s). In some embodiments, the RNA-guided DNA-binding agent may be fused with 1-5 NLS(s). In some embodiments, the RNA-guided DNA-binding agent may be fused with one NLS. Where one NLS is used, the NLS may be linked at the N-terminus or the C-terminus of the RNA-guided DNA-binding agent sequence. It may also be inserted within the RNA-guided DNA binding agent sequence. In other embodiments, the RNA-guided DNA-binding agent may be fused with more than one NLS. In some embodiments, the RNA-guided DNA-binding agent may be fused with 2, 3, 4, or 5 NLSs. In some embodiments, the RNA-guided DNA-binding agent may be fused with two NLSs. In certain circumstances, the two NLSs may be the same (e.g., two SV40 NLSs) or different. In some embodiments, the RNA-guided DNA-binding agent is fused to two SV40 NLS sequences linked at the carboxy terminus. In some embodiments, the RNA-guided DNA-binding agent may be fused with two NLSs, one linked at the N-terminus and one at the C-terminus. In some embodiments, the RNA-guided DNA-binding agent may be fused with 3 NLSs. In some embodiments, the RNA-guided DNA-binding agent may be fused with no NLS. In some embodiments, the NLS may be a monoparticle sequence, such as, e.g., the SV40 NLS, PKKKRKV or PKKKRRV. In some embodiments, the NLS may be a bipartite sequence, such as the NLS of nucleoplasmin, KRPAATKKAGQAKKKK. In a specific embodiment, a single PKKKRKV NLS may be linked at the C-terminus of the RNA-guided DNA-binding agent. One or more linkers are optionally included at the fusion site.

In some embodiments, the heterologous functional domain may be capable of modifying the intracellular half-life of the RNA-guided DNA binding agent. In some embodiments, the half-life of the RNA-guided DNA binding agent may be increased. In some embodiments, the half-life of the RNA-guided DNA-binding agent may be reduced. In some embodiments, the heterologous functional domain may be capable of increasing the stability of the RNA-guided DNA-binding agent. In some embodiments, the heterologous functional domain may be capable of reducing the stability of the RNA-guided DNA-binding agent. In some embodiments, the heterologous functional domain may act as a signal peptide for protein degradation. In some embodiments, the protein degradation may be mediated by proteolytic enzymes, such as, for example, proteasomes, lysosomal proteases, or calpain proteases. In some embodiments, the heterologous functional domain may comprise a PEST sequence. In some embodiments, the RNA-guided DNA-binding agent may be modified by addition of ubiquitin or a polyubiquitin chain. In some embodiments, the ubiquitin may be a ubiquitin-like protein (UBL). Non-limiting examples of ubiquitin-like proteins include small ubiquitin-like modifier (SUMO), ubiquitin cross-reactive protein (UCRP, also known as interferon-stimulated gene-15 (ISG15)), ubiquitin-related modifier-1 (URM1), neuronal-precursor-cell-expressed developmentally downregulated protein-8 (NEDD8, also called Rub1 in S. cerevislee), human leukocyte antigen F-associated (FAT10), autophagy-8 (ATG8) and -12 (ATG12), Fau ubiquitin-like protein (FUB1), membrane-anchored UBL (MUB), ubiquitin fold-modifier-1 (UFM1), and ubiquitin-like protein-5 (UBL5).

In some embodiments, the heterologous functional domain may be a marker domain. Non-limiting examples of marker domains include fluorescent proteins, purification tags, epitope tags, and reporter gene sequences. In some embodiments, the marker domain may he a fluorescent protein. Non-limiting examples of suitable fluorescent proteins include green fluorescent proteins (e.g., GFP, GFP-2, tagGFP, turboGFP, sfGFP, EGFP, Emerald, Azami Green, Monomeric Azami Green, CopGFP, AceGFP, ZsGreen1), yellow fluorescent proteins (e.g., YFP, EYFP, Citrine, Venus, YPet, PhiYFP, ZsYellow1), blue fluorescent proteins (e.g., EBFP, EBFP2, Azurite, mKalamal, GFPuv, Sapphire, T-sapphire,), cyan fluorescent proteins (e.g., ECFP, Cerulean, CyPet, AmCyan1, Midoriishi-Cyan), red fluorescent proteins (e.g., mKate, mKate2, mPlum, DsRed monomer, mCherry, mRFP1, DsRed-Express, DsRed2, DsRed-Monomer, HcRed-Tandem, HcRed1, AsRed2, eqFP611, mRasberry, mStrawberry, Jred), and orange fluorescent proteins (mOrange, mKO, Kusabira-Orange, Monomeric Kusabira-Orange, mTangerine, tdTomato) or any other suitable fluorescent protein. In other embodiments, the marker domain may be a purification tag and/or an epitope tag. Non-limiting exemplary tags include glutathione-S-transferase (GST), chitin binding protein (CBP), maltose binding protein (MBP), thioredoxin (TRX), poly(NANP), tandem affinity purification (TAP) tag, myc, AcV5, AU1, AU5, E, ECS, E2, FLAG, HA, nus, Softag 1, Softag 3, Strep, SBP, Glu-Glu, HSV, KT3, S, S1, T7, V5, VSV-G, 6×His, 8×His, biotin carboxyl carrier protein (BCCP), poly-His, and calmodulin. Non-limiting exemplary reporter genes include glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT), beta-galactosidase, beta-glucuronidase, luciferase, or fluorescent proteins.

In additional embodiments, the heterologous functional domain may target the RNA-guided DNA-binding agent to a specific organelle, cell type, tissue, or organ. In some embodiments, the heterologous functional domain may target the RNA-guided DNA-binding agent to mitochondria.

In further embodiments, the heterologous functional domain may be an effector domain. When the RNA-guided DNA-binding agent is directed to its target sequence, e.g., when a Cas nuclease is directed to a target sequence by a gRNA, the effector domain may modify or affect the target sequence. In some embodiments, the effector domain may be chosen from a nucleic acid binding domain, a nuclease domain (e.g., a non-Cas nuclease domain), an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. In some embodiments, the heterologous functional domain is a nuclease, such as a FokI nuclease. See, e.g., U.S. Pat. No. 9,023,649. In some embodiments, the heterologous functional domain is a transcriptional activator or repressor. See, e.g., Qi et al., “Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression,” Cell 152:1173-83 (2013); Perez-Pinera et al., “RNA-guided gene activation by CRISPR-Cas9-based transcription factors,” Nat. Methods 10:973-6 (2013); Mali et al., “CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering,” Nat. Biotechnol. 31:833-8 (2013); Gilbert et al., “CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes,” Cell 154:442-51 (2013). As such, the RNA-guided DNA-binding agent essentially becomes a transcription factor that can be directed to bind a desired target sequence using a guide RNA. In certain embodiments, the DNA modification domain is a methylation domain, such as a demethylation or methyltransferase domain. In certain embodiments, the effector domain is a DNA modification domain, such as a base-editing domain. In particular embodiments, the DNA modification domain is a nucleic acid editing domain that introduces a specific modification into the DNA, such as a deaminase domain, See, e.g., WO 2015/089406; U.S. 2016/0304846. The nucleic acid editing domains, deaminase domains, and Cas9 variants described in WO 2015/089406 and U.S. 2016/0304846 are hereby incorporated by reference.

The nuclease may comprise at least one domain that interacts with a guide RNA (“gRNA”). Additionally, the nuclease may be directed to a target sequence by a gRNA. In Class 2 Cas nuclease systems, the gRNA interacts with the nuclease as well as the target sequence, such that it directs binding to the target sequence. In some embodiments, the gRNA provides the specificity for the targeted cleavage, and the nuclease may be universal and paired with different gRNAs to cleave different target sequences. Class 2 Cas nuclease may pair with a gRNA scaffold structure of the types, orthologs, and exemplary species listed above.

Guide RNA (gRNA)

In some embodiments of the present disclosure, the cargo for the LNP formulation includes at least one gRNA. The gRNA may guide the Cas nuclease or Class 2 Cas nuclease to a target sequence on a target nucleic acid molecule. In some embodiments, a gRNA binds with and provides specificity of cleavage by a Class 2 Cas nuclease. In some embodiments, the gRNA and the Cas nuclease may form a ribonucleoprotein (RNP), e.g., a CRISPR/Cas complex such as a CRISPR/Cas9 complex which may be delivered by the LNP composition. In some embodiments, the CRISPR/Cas complex may be a Type-II CRISPR/Cas9 complex. In some embodiments, the CRISPR/Cas complex may be a Type-V CRISPR/Cas complex, such as a Cpf1/guide RNA complex. Cas nucleases and cognate gRNAs may be paired. The gRNA scaffold structures that pair with each Class 2 Cas nuclease vary with the specific CRISPR/Cas system.

“Guide RNA”, “gRNA”, and simply “guide” are used herein interchangeably to refer to either a crRNA (also known as CRISPR RNA), or the combination of a crRNA and a trRNA (also known as tracrRNA). The crRNA and trRNA may be associated as a single RNA molecule (single guide RNA, sgRNA) or in two separate RNA molecules (dual guide RNA, dgRNA). “Guide RNA” or “gRNA” refers to each type. The trRNA may be a naturally-occurring sequence, or a trRNA sequence with modifications or variations compared to naturally-occurring sequences.

As used herein, a “guide sequence” refers to a sequence within a guide RNA that is complementary to a target sequence and functions to direct a guide RNA to a target sequence for binding or modification (e.g., cleavage) by an RNA-guided DNA binding agent. A “guide sequence” may also be referred to as a “targeting sequence,” or a “spacer sequence.” A guide sequence can be 20 base pairs in length, e.g., in the case of Streptococcus pyogenes (i.e., Spy Cas9) and related Cas9 homologs/orthologs. Shorter or longer sequences can also be used as guides, e.g., 15-, 16-, 17-, 18-, 19-, 21-, 22-, 23-, 24-, or 25-nucleotides in length. In some embodiments, the target sequence is in a gene or on a chromosome, for example, and is complementary to the guide sequence. In some embodiments, the degree of complementarity or identity between a guide sequence and its corresponding target sequence may be about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%. In some embodiments, the guide sequence and the target region may be 100% complementary or identical. In other embodiments, the guide sequence and the target region may contain at least one mismatch. For example, the guide sequence and the target sequence may contain 1, 2, 3, or 4 mismatches, where the total length of the target sequence is at least 17, 18, 19, 20 or more base pairs. In some embodiments, the guide sequence and the target region may contain 1-4 mismatches where the guide sequence comprises at least 17, 18, 19, 20 or more nucleotides. In some embodiments, the guide sequence and the target region may contain 1, 2, 3, or 4 mismatches where the guide sequence comprises 20 nucleotides.

Target sequences for Cas proteins include both the positive and negative strands of genomic DNA (i.e., the sequence given and the sequence's reverse compliment), as a nucleic acid substrate for a Cas protein is a double stranded nucleic acid. Accordingly, where a guide sequence is said to be “complementary to a target sequence”, it is to be understood that the guide sequence may direct a guide RNA to bind to the reverse complement of a target sequence. Thus, in some embodiments, where the guide sequence binds the reverse complement of a target sequence, the guide sequence is identical to certain nucleotides of the tareet sequence (e.g., the target sequence not including the PAM) except for the substitution of U for T in the guide sequence.

The length of the targeting sequence may depend on the CRISPR/Cas system and components used. For example, different Class 2 Cas nucleases from different bacterial species have varying optimal targeting sequence lengths. Accordingly, the targeting sequence may comprise 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or more than 50 nucleotides in length. In some embodiments, the targeting sequence length is 0, 1, 2, 3, 4, or 5 nucleotides longer or shorter than the guide sequence of a naturally-occurring CRISPR/Cas system. In certain embodiments, the Cas nuclease and gRNA scaffold will be derived from the same CRISPR/Cas system. In some embodiments, the targeting sequence may comprise or consist of 18-24 nucleotides. In some embodiments, the targeting sequence may comprise or consist of 19-21 nucleotides. In some embodiments, the targeting sequence may comprise or consist of 20 nucleotides.

In some embodiments, the sgRNA is a “Cas9 sgRNA” capable of mediating RNA-guided DNA cleavage by a Cas9 protein. In some embodiments, the sgRNA is a “Cpf1 sgRNA” capable of mediating RNA-guided DNA cleavage by a Cpf1 protein. In certain embodiments, the gRNA comprises a crRNA and tracr RNA sufficient for forming an active complex with a Cas9 protein and mediating RNA-guided DNA cleavage. In certain embodiments, the gRNA comprises a crRNA sufficient for forming an active complex with a Cpf1 protein and mediating RNA-guided DNA cleavage. See Zetsche 2015.

Certain embodiments of the invention also provide nucleic acids, e.g., expression cassettes, encoding the gRNA described herein. A “guide RNA nucleic acid” is used herein to refer to a guide RNA (e.g. an sgRNA or a dgRNA) and a guide RNA expression cassette, which is a nucleic acid that encodes one or more guide RNAs.

In some embodiments, the nucleic acid may be a DNA molecule. In some embodiments, the nucleic acid may comprise a nucleotide sequence encoding a crRNA. In some embodiments, the nucleotide sequence encoding the crRNA comprises a targeting sequence flanked by all or a portion of a repeat sequence from a naturally-occurring CRISPR/Cas system. In some embodiments, the nucleic acid may comprise a nucleotide sequence encoding a tracr RNA. In some embodiments, the crRNA and the tracr RNA may be encoded by two separate nucleic acids. In other embodiments, the crRNA and the tracr RNA may be encoded by a single nucleic acid. In some embodiments, the crRNA and the tracr RNA may be encoded by opposite strands of a single nucleic acid. In other embodiments, the crRNA and the tracr RNA may be encoded by the same strand of a single nucleic acid. In some embodiments, the gRNA nucleic acid encodes an sgRNA. In some embodiments, the gRNA nucleic acid encodes a Cas9 nuclease sgRNA. In some embodiments, the gRNA nucleic acid encodes a Cpf1 nuclease sgRNA.

The nucleotide sequence encoding the guide RNA may be operably linked to at least one transcriptional or regulatory control sequence, such as a promoter, a 3′ UTR, or a 5′ UTR. In one example, the promoter may be a tRNA promoter, e.g, tRNA^Lys3, or a tRNA chimera, See Mefferd et al., RNA, 2015 21:1683-9; Scherer et al., Nucleic Acids Res. 2007 35: 2620-2628. In certain embodiments, the promoter may be recognized by RNA polymerase III (Pol III). Non-limiting examples of Pol III promoters also include U6 and H1 promoters. In some embodiments, the nucleotide sequence encoding the guide RNA may be operably linked to a mouse or human U6 promoter. In some embodiments, the gRNA nucleic acid is a modified nucleic acid. In certain embodiments, the gRNA nucleic acid includes a modified nucleoside or nucleotide. In some embodiments, the gRNA nucleic acid includes a 5′ end modification, for example a modified nucleoside or nucleotide to stabilize and prevent integration of the nucleic acid. In some embodiments, the gRNA nucleic acid comprises a double-stranded DNA having a 5′ end modification on each strand. In certain embodiments, the gRNA nucleic acid includes an inverted dideoxy-T or an inverted abasic nucleoside or nucleotide as the 5′ end modification. In some embodiments, the gRNA nucleic acid includes a label such as biotin, desthiobioten-TEG, digoxigenin, and fluorescent markers, including, for example, FAM, ROX, TAMRA, and AlexaFluor.

In certain embodiments, more than one gRNA nucleic acid, such as a gRNA, can be used with a CRISPR/Cas nuclease system. Each gRNA nucleic acid may contain a different targeting sequence, such that the CRISPR/Cas system cleaves more than one target sequence. In some embodiments, one or more gRNAs may have the same or differing properties such as activity or stability within a CRISPR/Cas complex. Where more than one gRNA is used, each gRNA can be encoded on the same or on different gRNA nucleic acid. The promoters used to drive expression of the more than one gRNA may be the same or different.

Modified RNAs

In certain embodiments, the LNP compositions comprise modified RNAs.

Modified nucleosides or nucleotides can be present in an RNA, for example a gRNA or mRNA. A gRNA or mRNA comprising one or more modified nucleosides or nucleotides, for example, is called a “modified” RNA to describe the presence of one or more non-naturally and/or naturally occurring components or configurations that are used instead of or in addition to the canonical A, G, C, and U residues. In some embodiments, a modified RNA is synthesized with a non-canonical nucleoside or nucleotide, here called “modified.”

Modified nucleosides and nucleotides can include one or more of: (i) alteration, e.g., replacement, of one or both of the non-linking phosphate oxygens and/or of one or more of the linking phosphate oxygens in the phosphodiester backbone linkage (an exemplary backbone modification); (ii) alteration, e.g., replacement, of a constituent of the ribose sugar, e.g., of the 2′ hydroxyl on the ribose sugar (an exemplary sugar modification); (iii) wholesale replacement of the phosphate moiety with “dephospho” linkers (an exemplary backbone modification); (iv) modification or replacement of a naturally occurring nucleobase, including with a non-canonical nucleobase (an exemplary base modification); (v) replacement or modification of the ribose-phosphate backbone (an exemplary backbone modification); (vi) modification of the 3′ end or 5′ end of the oligonucleotide, e.g., removal, modification or replacement of a terminal phosphate group or conjugation of a moiety, cap or linker (such 3′ or 5′ cap modifications may comprise a sugar and/or backbone modification); and (vii) modification or replacement of the sugar (an exemplary sugar modification). Certain embodiments comprise a 5′ end modification to an mRNA, gRNA, or nucleic acid. Certain embodiments comprise a 3′ end modification to an mRNA, gRNA, or nucleic acid. A modified RNA can contain 5′ end and 3′ end modifications. A modified RNA can contain one or more modified residues at non-terminal locations. In certain embodiments, a gRNA includes at least one modified residue. In certain embodiments, an mRNA includes at least one modified residue.

As used herein, a first sequence is considered to “comprise a sequence with at least X % identity to” a second sequence if an alignment of the first sequence to the second sequence shows that X % or more of the positions of the second sequence in its entirety are matched by the first sequence. For example, the sequence AAGA comprises a sequence with 100% identity to the sequence AAG because an alignment would give 100% identity in that there are matches to all three positions of the second sequence. The differences between RNA and DNA (generally the exchange of uridine for thymidine or vice versa) and the presence of nucleoside analogs such as modified uridines do not contribute to differences in identity or complementarity among polynucleotides as long as the relevant nucleotides (such as thymidine, uridine, or modified uridine) have the same complement (e.g., adenosine for all of thymidine, uridine, or modified uridine, another example is cytosine and 5-methylcytosine, both of which have guanosine or modified guanosine as a complement). Thus, for example, the sequence 5′-AXG where X is any modified uridine, such as pseudouridine, N1-methyl pseudouridine, or 5-methoxyuridine, is considered 100% identical to AUG in that both are perfectly complementary to the same sequence (5′-CAU). Exemplary alignment algorithms are the Smith-Waterman and Needleman-Wunsch algorithms, which are well-known in the art. One skilled in the art will understand what choice of algorithm and parameter settings are appropriate for a given pair of sequences to be aligned; for sequences of generally similar length and expected identity >50% for amino acids or >75% for nucleotides, the Needleman-Wunsch algorithm with default settings of the Needleman-Wunsch algorithm interface provided by the EBI at the www.ebi.ac.uk web server is generally appropriate.

mRNAs

In some embodiments, composition or formulation disclosed herein comprises an mRNA comprising an open reading frame (ORF) encoding an RNA-guided DNA binding agent, such as a Cas nuclease, or Class 2 Cas nuclease as described herein. In some embodiments, an mRNA comprising an ORF encoding an RNA-guided DNA binding agent, such as a Cas nuclease or Class 2 Cas nuclease, is provided, used, or administered. In some embodiments, the ORF encoding an RNA-guided DNA binding agent is a “modified RNA-guided DNA binding agent ORF” or simply a “modified ORF,” which is used as shorthand to indicate that the ORF is modified in one or more of the following ways: (1) the modified ORF has a uridine content ranging from its minimum uridine content to 150% of the minimum uridine content; (2) the modified ORF has a uridine dinucleotide content ranging from its minimum uridine dinucleotide content to 150% of the minimum uridine dinucleotide content; (3) the modified ORF has at least 90% identity to any one of SEQ ID NOs: 1, 4, 7, 9, 10, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 50, 52, 54, 65, or 66; (4) the modified ORF consists of a set of codons of which at least 75% of the codons are minimal uridine codon(s) for a given amino acid, e.g. the codon(s) with the fewest uridines (usually 0 or 1 except for a codon for phenylalanine, where the minimal uridine codon has 2 uridines); or (5) the modified ORF comprises at least one modified uridine. In some embodiments, the modified ORF is modified in at least two, three, or four of the foregoing ways. In some embodiments, the modified ORF comprises at least one modified uridine and is modified in at least one, two, three, or all of (1)-(4) above.

“Modified uridine” is used herein to refer to a nucleoside other than thymidine with the same hydrogen bond acceptors as uridine and one or more structural differences from uridine. In some embodiments, a modified uridine is a substituted uridine, i.e., a uridine in which one or more non-proton substituents (e.g., alkoxy, such as methoxy) takes the place of a proton. In some embodiments, a modified uridine is pseudouridine. In some embodiments, a modified uridine is a substituted pseudouridine, i.e., a pseudouridine in which one or more non-proton substituents (e.g., alkyl, such as methyl) takes the place of a proton. In some embodiments, a modified uridine is any of a substituted uridine, pseudouridine, or a substituted pseudouridine.

“Uridine position” as used herein refers to a position in a polynucleotide occupied by a uridine or a modified uridine. Thus, for example, a polynucleotide in which “100% of the uridine positions are modified uridines” contains a modified uridine at every position that would be a uridine in a conventional RNA (where all bases are standard A, U, C, or G bases) of the same sequence. Unless otherwise indicated, a U in a polynucleotide sequence of a sequence table or sequence listing in, or accompanying, this disclosure can be a uridine or a modified uridine.

TABLE 1
Minimal Uridine Codons
	Amino Acid	Minimal uridine codon
	A	Alanine	GCA or GCC or GCG
	G	Glycine	GGA or GGC or GGG
	V	Valine	GUC or GUA or GUG
	D	Aspartic acid	GAC
	E	Glutamic acid	GAA or GAG
	I	Isoleucine	AUG or AUA or AUG
	T	Threonine	ACA or ACC or ACG
	N	Asparagine	AAC
	K	Lysine	AAG or AAA
	S	Serine	AGC
	R	Arginine	AGA or AGG
	L	Leucine	CUG or CUA or CUC
	P	Proline	CCG or CCA or CCC
	H	Histidine	CAC or CAA or CAG
	Q	Glutamine	CAG or CAA
	F	Phenylalanine	UUC
	Y	Tyrosine	UAC
	C	Cysteine	UGC
	W	Tryptophan	UGG
	M	Methionine	AUG

In any of the foregoing embodiments, the modified ORF may consist of a set of codons of which at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% of the codons are codons listed in the Table of Minimal Uridine Codons. In any of the foregoing embodiments, the modified ORF may comprise a sequence with at least 90%, 95%, 98%, 99%, or 100% identity to any one of SEQ ID NO: 1, 4, 7, 9, 10, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 50, 52, 54, 65, or 66.

In any of the foregoing embodiments, the modified ORF may comprise a sequence with at least 90%, 95%, 98%, 99%, or 100% identity to any one of SEQ ID NO: 1, 4, 7, 9, 10, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 50, 52, 54, 65, or 66.

In any of the foregoing embodiments, the modified ORF may have a uridine content ranging from its minimum uridine content to 150%, 145%, 140%, 135%, 130%, 125%, 120%,115%, 110%, 105%, 104%, 103%, 102%, or 101% of the minimum uridine content.

In any of the foregoing embodiments, the modified ORF may have a uridine dinucleotide content ranging from its minimum uridine dinucleotide content to 150%, 145%, 140%, 135%, 130%, 125%, 120%, 115%, 110%, 105%, 104%, 103%, 102%, or 101% of the minimum uridine dinucleotide content.

In any of the foregoing embodiments, the modified ORF may comprise a modified uridine at least at one, a plurality of, or all uridine positions. In some embodiments, the modified uridine is a uridine modified at the 5 position, e.g., with a halogen, methyl, or ethyl. In some embodiments, the modified uridine is a pseudouridine modified at the I position, e.g., with a halogen, methyl, or ethyl. The modified uridine can be, for example, pseudouridine, N1-methyl-pseudouridine, 5-methoxyuridine, 5-iodouridine, or a combination thereof. In some embodiments, the modified uridine is 5-methoxyuridine. In some embodiments, the modified uridine is 5-iodouridine. In some embodiments, the modified uridine is pseudouridine. In some embodiments, the modified uridine is N1-methyl-pseudouridine. In some embodiments, the modified uridine is a combination of pseudouridine and N1-methyl-pseudouridine. In some embodiments, the modified uridine is a combination of pseudouridine and 5-methoxyuridine. In some embodiments, the modified uridine is a combination of N1-methyl pseudouridine and 5-methoxyuridine. In some embodiments, the modified uridine is a combination of 5-iodouridine and N1-methyl-pseudouridine. In some embodiments, the modified uridine is a combination of pseudouridine and 5-iodouridine. In some embodiments, the modified uridine is a combination of 5-iodouridine and 5-methoxyuridine.

In some embodiments, at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% of the uridine positions in an mRNA according to the disclosure are modified uridines. In some embodiments, 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridine positions in an mRNA according to the disclosure are modified uridines, e.g., 5-methoxyuridine, 5-iodouridine, N1-methyl pseudouridine, pseudouridine, or a combination thereof. In some embodiments, 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridine positions in an mRNA, according to the disclosure are 5-methoxyuridine. In some embodiments, 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridine positions in an mRNA according to the disclosure are pseudouridine. In some embodiments, 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridine positions in an mRNA according to the disclosure are N1-methyl pseudouridine. In some embodiments, 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridine positions in an mRNA according to the disclosure are 5-iodouridine. In some embodiments, 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridine positions in an mRNA according to the disclosure are 5-methoxyuridine, and the remainder are N1-methyl pseudouridine. In some embodiments, 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridine positions in an mRNA according to the disclosure are 5-iodouridine, and the remainder are N1-methyl pseudouridine.

In any of the foregoing embodiments, the modified ORF may comprise a reduced uridine dinucleotide content, such as the lowest possible uridine dinucleotide (UU) content, e.g. an ORF that (a) uses a minimal uridine codon (as discussed above) at every position and (b) encodes the same amino acid sequence as the given ORF. The uridine dinucleotide (UU) content can be expressed in absolute terms as the enumeration of UU dinucleotides in an ORF or on a rate basis as the percentage of positions occupied by the uridines of uridine dinucleotides (for example, AUUAU would have a uridine dinucleotide content of 40% because 2 of 5 positions are occupied by the uridines of a uridine dinucleotide). Modified uridine residues are considered equivalent to uridines for the purpose of evaluating minimum uridine dinucleotide content.

In some embodiments, the mRNA comprises at least one UTR from an expressed mammalian mRNA, such as a constitutively expressed mRNA. An mRNA is considered constitutively expressed in a mammal if it is continually transcribed in at least one tissue of a healthy adult mammal. In some embodiments, the mRNA comprises a 5′ UTR, 3′ UTR, or 5′ and 3′ UTRs from an expressed mammalian RNA, such as a constitutively expressed mammalian mRNA. Actin mRNA is an example of a constitutively expressed mRNA.

In some embodiments, the mRNA comprises at least one UTR from Hydroxysteroid 17-Beta Dehydrogenase 4 (HSD17B4 or HSD), e.g., a 5′ UTR from HSD. In some embodiments, the mRNA comprises at least one UTR from a globin mRNA, for example, human alpha globin (HBA) mRNA, human beta globin (HBB) mRNA, or Xenopus laevis beta globin (XBG) mRNA. In some embodiments, the mRNA comprises a 5′ UTR, 3′ UTR, or 5′ and 3′ UTRs from a globin mRNA, such as HBA, HBB, or XBG. In some embodiments, the mRNA comprises a 5′ UTR from bovine growth hormone, cytomegalovirus (CMV), mouse Hba-a1, HSD, an albumin gene, HBA, HBB, or XBG. In some embodiments, the mRNA comprises a 3′ UTR from bovine growth hormone, cytomegalovirus, mouse Hba-a1, HSD, an albumin gene, HBA, HBB, or XBG. In some embodiments, the mRNA comprises 5′ and 3′ UTRs from bovine growth hormone, cytomegalovirus, mouse Hba-a1, HSD, an albumin gene, HBA, HBB, XBG, heat shock protein 90 (Hsp90), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), beta-actin, alpha-tubulin, tumor protein (p53), or epidermal growth factor receptor (EGFR).

In some embodiments, the mRNA comprises 5′ and 3′ UTRs that are from the same source, e.g., a constitutively expressed mRNA such as actin, albumin, or a globin such as HBA, HBB, or XBG.

In some embodiments, the mRNA does not comprise a 5′ UTR, e.g., there are no additional nucleotides between the 5′ cap and the start codon. In some embodiments, the mRNA comprises a Kozak sequence (described below) between the 5′ cap and the start codon, but does not have any additional 5′ UTR. In some embodiments, the mRNA does not comprise a 3′ UTR, e.g., there are no additional nucleotides between the stop codon and the poly-A tail.

In some embodiments, the mRNA comprises a Kozak sequence. The Kozak sequence can affect translation initiation and the overall yield of a polypeptide translated from an mRNA. A Kozak sequence includes a methionine codon that can function as the start codon. A minimal Kozak sequence is NNNRUGN wherein at least one of the following is true: the first N is A or G and the second N is G. In the context of a nucleotide sequence, R means a purine (A or G). In some embodiments, the Kozak sequence is RNNRUGN, NNNRUGG, RNNRUGG, RNNAUGN, NNNAUGG, or RNNAUGG. In some embodiments, the Kozak sequence is rccRUGg with zero mismatches or with up to one or two mismatches to positions in lowercase. In some embodiments, the Kozak sequence is rccAUGg with zero mismatches or with up to one or two mismatches to positions in lowercase. In some embodiments, the Kozak sequence is gccRccAUGG with zero mismatches or with up to one, two, or three mismatches to positions in lowercase. In some embodiments, the Kozak sequence is gccAccAUG with zero mismatches or with up to one, two, three, or four mismatches to positions in lowercase. In some embodiments, the Kozak sequence is GCCACCAUG. In some embodiments, the Kozak sequence is gccgccRccAUGG with zero mismatches or with up to one, two, three, or four mismatches to positions in lowercase.

In some embodiments, the mRNA comprising an ORF encoding an RNA-guided DNA binding agent comprises a sequence having at least 90% identity to SEQ ID NO: 43, optionally wherein the ORF of SEQ ID NO: 43 (i.e., SEQ ID NO: 4) is substituted with an alternative ORF of any one of SEQ ID NO: 7, 9, 10, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 50, 52, 54, 65, or 66.

In some embodiments, the mRNA comprising an ORF encoding an RNA-guided DNA binding agent comprises a sequence having at least 90% identity to SEQ ID NO: 44, optionally wherein the ORF of SEQ ID NO: 44 (i.e., SEQ ID NO: 4) is substituted with an alternative ORF of any one of SEQ ID NO: 7, 9, 10, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 50, 52, 54, 65, or 66.

In some embodiments, the mRNA comprising an ORF encoding an RNA-guided DNA binding agent comprises a sequence having at least 90% identity to SEQ ID NO: 56, optionally wherein the ORF of SEQ ID NO: 56 (i.e., SEQ ID NO: 4) is substituted with an alternative ORF of any one of SEQ ID NO: 7, 9, 10, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 50, 52, 54, 65, or 66.

In some embodiments, the mRNA comprising an ORF encoding an RNA-guided DNA binding agent comprises a sequence having at least 90% identity to SEQ ID NO: 57, optionally wherein the ORF of SEQ ID NO: 57 (i.e., SEQ ID NO: 4) is substituted with an alternative ORF of any one of SEQ ID NO: 7, 9, 10, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 50, 52, 54, 65, or 66.

In some embodiments, the mRNA comprising an ORF encoding an RNA-guided DNA binding agent comprises a sequence having at least 90% identity to SEQ ID NO: , optionally wherein the ORF of SEQ ID NO: 58 (i.e., SEQ ID NO: 4) is substituted with an alternative ORF of any one of SEQ ID NO: 7, 9, 10, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 50, 52, 54, 65, or 66.

In some embodiments, the mRNA comprising an ORF encoding an RNA-guided DNA binding agent comprises a sequence having at least 90% identity to SEQ ID NO: 59, optionally wherein the ORE of SEQ ID NO: 59 (i.e., SEQ ID NO: 4) is substituted with art alternative ORF of any one of SEQ ID NO: 7, 9, 10, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 50, 52, 54, 65, or 66.

In some embodiments, the mRNA comprising an ORF encoding an RNA-guided DNA binding agent comprises a sequence having at least 90% identity to SEQ ID NO: 60, optionally wherein the ORF of SEQ ID NO: 60 (i.e., SEQ ID NO: 4) is substituted with an alternative ORE of any one of SEQ ID NO: 7, 9, 10, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 50, 52, 54, 65, or 66.

In some embodiments, the mRNA comprising an ORF encoding an RNA-guided DNA binding agent comprises a sequence having at least 90% identity to SEQ ID NO: 61, optionally wherein the ORF of SEQ ID NO: 61 (i.e., SEQ ID NO: 4) is substituted with an alternative ORF of any one of SEQ ID NO: 7, 9, 10, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 50, 52, 54, 65, or 66.

In some embodiments, the mRNA comprises an alternative ORF of any one of SEQ ID NO: 7, 9, 10, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 50, 52, 54, 65, or 66.

In some embodiments, the degree of identity to the optionally substituted sequences of SEQ ID NOs 43, 44, or 56-61 is 95%. In some embodiments, the degree of identity to the optionally substituted sequences of SEQ ID NOs 43, 44, or 56-61 is 98%. In some embodiments, the degree of identity to the optionally substituted sequences of SEQ ID NOs 43, 44, or 56-61 is 99%. In some embodiments, the degree of identity to the optionally substituted sequences of SEQ ID NOs 43, 44, or 56-61 is 100%.

In some embodiments, an mRNA disclosed herein comprises a 5′ cap, such as a Cap0, Cap1, or Cap2. A 5′ cap is generally a 7-methylguanine ribonucleotide (which may be further modified, as discussed below e.g. with respect to ARCA) linked through a 5′-triphosphate to the 5′ position of the first nucleotide of the 5′-to-3′ chain of the mRNA, i.e., the first cap-proximal nucleotide. In Cap0, the riboses of the first and second cap-proximal nucleotides of the mRNA both comprise a 2′-hydroxyl. In Cap1, the riboses of the first and second transcribed nucleotides of the mRNA comprise a 2′-methoxy and a 2′-hydroxyl, respectively. In Cap2, the riboses of the first and second cap-proximal nucleotides of the mRNA both comprise a 2′-methoxy. See, e.g., Katibah et al. (2014) Proc Natl Acad Sci USA 111(33):12025-30; Abbas et al. (2017) Proc Natl Acad Sci USA 114(11):E2106-E2115. Most endogenous higher eukaryotic mRNAs, including mammalian mRNAs such as human mRNAs, comprise Cap1 or Cap2. Cap0 and other cap structures differing from Cap1 and Cap2 may be immunogenic in mammals, such as humans, due to recognition as “non-self” by components of the innate immune system such as IFIT-1 and IFIT-5, which can result in elevated cytokine levels including type I interferon. Components of the innate immune system such as IFIT-1 and IFIT-5 may also compete with eIF4E for binding of an mRNA with a cap other than Cap1 or Cap2, potentially inhibiting translation of the mRNA.

A cap can be included co-transcriptionally. For example, ARCA (anti-reverse cap analog; Thermo Fisher Scientific Cat. No. AM8045) is a cap analog comprising a 7-methylguanine 3′-methoxy-5′-triphosphate linked to the 5′ position of a guanine ribonucleotide which can be incorporated in vitro into a transcript at initiation. ARCA results in a Cap0 cap in which the 2′ position of the first cap-proximal nucleotide is hydroxyl. See, e.g., Stepinski et al., (2001) “Synthesis and properties of mRNAs containing the novel ‘anti-reverse’ cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl(3′deoxy)GpppG,” RNA 7: 1486-1495. The ARCA structure is shown below.

CleanCap™ AG (m7G(5′)ppp(5′)(2′OMeA)pG; TriLink Biotechnologies Cat. No. N-7113) or CleanCap™ GG (m7G(5′)ppp(5′)(2′OMeG)pG; TriLink Biotechnologies Cat. No. N-7133) can be used to provide a Cap1 structure co-transcriptionally, 3′-O-methylated versions of ClearCap™ AG and CleanCap™ GG are also available from TriLink Biotechnologies as Cat. Nos. N-7413 and N-7433, respectively. The CleanCap™ AG structure is shown below.

Alternatively, a cap can be added to an RNA post-transcriptionally. For example, Vaccinia capping enzyme is commercially available (New England Biolabs Cat. No. M2080S) and has RNA triphosphatase and guanylyttransferase activities, provided by its D1 subunit, and guanine methyltransferase, provided by its D12 subunit. As such, it can add a 7-methylguanine to an RNA, so as to give Cap0, in the presence of S-adenosyl methionine and GTP. See, e.g., Guo, P, and Moss, B. (1990) Proc. Natl. Acad. Sci. USA 87, 4023-4027; Mao, X. and Shuman, S. (1994) J. Biol. Chem. 269, 24172-24479.

In some embodiments, the mRNA further comprises a poly-adenylated (poly-A) tail. In some embodiments, the poly-A tail comprises at least 20, 30, 40, 50, 60, 70, 80, 90, or 100 adenines, optionally up to 300 adenines. In some embodiments, the poly-A tail comprises 95, 96, 97, 98, 99, or 100 adenine nucleotides. In some instances, the poly-A tail is “interrupted” with one or more non-adenine nucleotide “anchors” at one or more locations within the poly-A tail. The poly-A tails may comprise at least 8 consecutive adenine nucleotides, but also comprise one or more non-adenine nucleotide. As used herein, “non-adenine nucleotides” refer to any natural or non-natural nucleotides that do not comprise adenine. Guanine, thymine, and cytosine nucleotides are exemplary non-adenine nucleotides. Thus, the poly-A tails on the mRNA described herein may comprise consecutive adenine nucleotides located 3′ to nucleotides encoding an RNA-guided DNA-binding agent or a sequence of interest. In some instances, the poly-A tails on mRNA comprise non-consecutive adenine nucleotides located 3′ to nucleotides encoding an RNA-guided DNA-binding agent or a sequence of interest, wherein non-adenine nucleotides interrupt the adenine nucleotides at regular or irregularly spaced intervals.

In some embodiments, the mRNA further comprises a poly-adenylated (poly-A) tail. In some embodiments, the poly-A tail comprises at least 20, 30, 40, 50, 60, 70, 80, 90, or 100 adenines, optionally up to 300 adenines, In some embodiments, the poly-A tail comprises 95, 96, 97, 98, 99, or 100 adenine nucleotides. In some instances, the poly-A tail is “interrupted” with one or more non-adenine nucleotide “anchors” at one or more locations within the poly-A tail. The poly-A tails may comprise at least 8 consecutive adenine nucleotides, but also comprise one or more non-adenine nucleotide. As used herein, “non-adenine nucleotides” refer to any natural or non-natural nucleotides that do not comprise adenine. Guanine, thymine, and cytosine nucleotides are exemplary non-adenine nucleotides. Thus, the poly-A tails on the mRNA described herein may comprise consecutive adenine nucleotides located 3′ to nucleotides encoding an RNA-guided DNA-binding agent or a sequence of interest. In some instances, the poly-A tails on mRNA comprise non-consecutive adenine nucleotides located 3′ to nucleotides encoding an RNA-guided DNA-binding agent or a sequence of interest, wherein non-adenine nucleotides interrupt the adenine nucleotides at regular or irregularly spaced intervals.

In some embodiments, the one or more non-adenine nucleotides are positioned to interrupt the consecutive adenine nucleotides so that a poly(A) binding protein can bind to a stretch of consecutive adenine nucleotides. In some embodiments, one or more non-adenine nucleotide(s) is located after at least 8, 9, 10, 11, or 12 consecutive adenine nucleotides. In some embodiments, the one or more non-adenine nucleotide is located after at least 8-50 consecutive adenine nucleotides. In some embodiments, the one or more non-adenine nucleotide is located after at least 8-100 consecutive adenine nucleotides. In some embodiments, the non-adenine nucleotide is after one, two, three, four, five, six, or seven adenine nucleotides and is followed by at least 8 consecutive adenine nucleotides.

The poly-A tail may comprise one sequence of consecutive adenine nucleotides followed by one or more non-adenine nucleotides, optionally followed by additional adenine nucleotides.

In some embodiments, the poly-A tail comprises or contains one non-adenine nucleotide or one consecutive stretch of 2-10 non-adenine nucleotides. In some embodiments, the non-adenine nucleotide(s) is located after at least 8, 9, 10, 11, or 12 consecutive adenine nucleotides. In some instances, the one or more non-adenine nucleotides are located after at least 8-50 consecutive adenine nucleotides. In some embodiments, the one or more non-adenine nucleotides are located after at least 8, 9, 10, 11, 12, 13, 14, 15. 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38. 39, 40, 41, 42, 43, 41, 45, 46, 47, 48, 49, or 50 consecutive adenine nucleotides.

In some embodiments, the non-adenine nucleotide is guanine, cytosine, or thymine. In some instances, the non-adenine nucleotide is a guanine nucleotide. In some embodiments, the non-adenine nucleotide is a cytosine nucleotide. In some embodiments, the non-adenine nucleotide is a thymine nucleotide. In some instances, where more than one non-adenine nucleotide is present, the non-adenine nucleotide may be selected from: a) guanine and thymine nucleotides; b) guanine and cytosine nucleotides; c) thymine and cytosine nucleotides; or d) guanine, thymine and cytosine nucleotides. An exemplary poly-A tail comprising non-adenine nucleotides is provided as SEQ ID NO: 62.

In some embodiments, the mRNA is purified. In some embodiments, the mRNA is purified using a precipation method (e.g., LiCl precipitation, alcohol precipitation, or an equivalent method, e.g., as described herein). In some embodiments, the mRNA is purified using a chromatography-based method, such as an HPLC-based method or an equivalent method (e.g., as described herein), In some embodiments, the mRNA is purified using both a precipitation method (e.g., LiCl precipitation) and an HPLC-based method.

In some embodiments, at least one gRNA is provided in combination with an mRNA disclosed herein. In some embodiments, a gRNA is provided as a separate molecule from the mRNA. In some embodiments, a gRNA is provided as a part, such as a part of a UTR, of an mRNA disclosed herein.

Chemically Modified gRNA

In some embodiments, the gRNA is chemically modified. A gRNA comprising one or more modified nucleosides or nucleotides is called a “modified” gRNA or “chemically modified” gRNA, to describe the presence of one or more non-naturally and/or naturally occurring components or configurations that are used instead of or in addition to the canonical A, G, C, and U residues. In some embodiments, a modified gRNA is synthesized with a non-canonical nucleoside or nucleotide, is here called “modified.” Modified nucleosides and nucleotides can include one or more of: (i) alteration, e.g., replacement, of one or both of the non-linking phosphate oxygens and/or of one or more of the linking phosphate oxygens in the phosphodiester backbone linkage (an exemplary backbone modification); (ii) alteration, e.g., replacement, of a constituent of the ribose sugar, e.g., of the 2′ hydroxyl on the ribose sugar (an exemplary sugar modification); (iii) wholesale replacement of the phosphate moiety with “dephospho” linkers (an exemplary backbone modification); (iv) modification or replacement of a naturally occurring nucleobase, including with a non-canonical nucleobase (an exemplary base modification); (v) replacement or modification of the ribose-phosphate backbone (an exemplary backbone modification); (vi) modification of the 3′ end or 5′ end of the oligonucleotide, e.g., removal, modification or replacement of a terminal phosphate group or conjugation of a moiety, cap or linker (such 3′ or 5′ cap modifications may comprise a sugar andlor backbone modification); and (vii) modification or replacement of the sugar (an exemplary sugar modification).

In some embodiments, a gRNA comprises a modified uridine at some or all uridine positions. In some embodiments, the modified uridine is a uridine modified at the 5 position, e.g., with a halogen or C1-C6 alkoxy. In some embodiments, the modified undine is a pseudouridine modified at the I position, e.g., with a C1-C6 alkyl. The modified uridine can be, for example, pseudouridine, N1-methyl-pseudouridine, 5-methoxyuridine, 5-iodouridine, or a combination thereof. In some embodiments the modified uridine is 5-methoxy-oridine. In some embodiments the modified uridine is 5-iodouridine. In some embodiments the modified uridine is pseudouridine. In some embodiments the modified uridine is N1-methyl-pseudouridine. In some embodiments, the modified uridine is a combination of pseudouridine and N1-methyl-pseudouridine. In some embodiments, the modified uridine is a combination of pseudouridine and 5-methoxyuridine. In some embodiments, the modified uridine is a combination of N1-methyl pseudouridine and 5-methoxyuridine. In some embodiments, the modified uridine is a combination of 5-iodouridine and N1-methyl-pseudouridine. In some embodiments, the modified uridine is a combination of pseudouridine and 5-iodouridine. In some embodiments, the modified uridine is a combination of 5-iodouridine and 5-methoxyuridine.

In some embodiments, at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% of the uridine positions in a gRNA according to the disclosure are modified uridines. In some embodiments, 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridine positions in a gRNA according to the disclosure are modified uridines, e.g., 5-methoxyuridine, 5-iodouridine, NI-methyl pseudouridine, pseudouridine, or a combination thereof. In some embodiments, 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridine positions in a gRNA according to the disclosure are 5-methoxyuridine. In some embodiments, 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridine positions in a gRNA according to the disclosure are pseudouridine. In some embodiments, 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridine positions in a gRNA according to the disclosure are N1-methyl pseudouridine. In some embodiments, 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridine positions in a gRNA according to the disclosure are 5-iodouridine. In some embodiments, 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridine positions in a gRNA according to the disclosure are 5-methoxyuridine, and the remainder are N1-methyl pseudouridine. In some embodiments, 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridine positions in a gRNA according to the disclosure are 5-iodouridine, and the remainder are N1-methyl pseudouridine.

Chemical modifications such as those listed above can be combined to provide modified gRNAs comprising nucleosides and nucleotides (collectively “residues”) that can have two, three, four, or more modifications. For example, a modified residue can have a modified sugar and a modified nucleobase. In some embodiments, every base of a gRNA is modified, e.g., all bases have a modified phosphate group, such as a phosphorothioate group. In certain embodiments, all, or substantially all, of the phosphate groups of an gRNA molecule are replaced with phosphorothioate groups. In some embodiments, modified gRNAs comprise at least one modified residue at or near the 5′ end of the RNA. In some embodiments, modified gRNAs comprise at least one modified residue at or near the 3′ end of the RNA.

In some embodiments, the gRNA comprises one, two, three or more modified residues. In some embodiments, at least 5% (e.g., at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%. at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100%) of the positions in a modified gRNA are modified nucleosides or nucleotides.

Unmodified nucleic acids can be prone to degradation by, e.g., intracellular nucleases or those found in serum. For example, nucleases can hydrolyze nucleic acid phosphodiester bonds. Accordingly, in one aspect the gRNAs described herein can contain one or more modified nucleosides or nucleotides, e.g., to introduce stability toward intracellular or serum-based nucleases. In some embodiments, the modified gRNA molecules described herein can exhibit a reduced innate immune response when introduced into a population of cells, both in vivo and ex vivo, The term “innate immune response” includes a cellular response to exogenous nucleic acids, including single stranded nucleic acids, which involves the induction of cytokine expression and release, particularly the interferons, and cell death.

In some embodiments of a backbone modification, the phosphate group of a modified residue can be modified by replacing one or more of the oxygens with a different substituent. Further, the modified residue, e.g., modified residue present in a modified nucleic acid, can include the wholesale replacement of an unmodified phosphate moiety with a modified phosphate group as described herein. In some embodiments, the backbone modification of the phosphate backbone can include alterations that result in either an uncharged linker or a charged linker with unsymmetrical charge distribution.

Examples of modified phosphate groups include, phosphorothioate, phosphoroselenates, borano phosphates, borano phosphate esters, hydrogen phosphonates, phosphoroamidates, alkyl or aryl phosphonates and phosphotriesters. The phosphorous atom in an unmodified phosphate group is achiral. However, replacement of one of the non-bridging oxygens with one of the above atoms or groups of atoms can render the phosphorous atom chiral. The stereogenic phosphorous atom can possess either the configuration (herein Rp) or the “S” configuration (herein Sp). The backbone can also be modified by replacement of a bridging oxygen, (i.e., the oxygen that links the phosphate to the nucleoside), with nitrogen (bridged phosphoroamidates), sulfur (bridged phosphorothioates) and carbon (bridged methylenephosphonates). The replacement can occur at either linking oxygen or at both of the linking oxygens.

The phosphate group can be replaced by non-phosphorus containing connectors in certain backbone modifications. In some embodiments, the charged phosphate group can be replaced by a neutral moiety. Examples of moieties which can replace the phosphate group can include, without limitation, e.g., methyl phosphonate, hydroxylamino, siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioformacetal, formacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino.

Template Nucleic Acid

The compositions and methods disclosed herein may include a template nucleic acid. The template may be used to alter or insert a nucleic acid sequence at or near a target site for a Cas nuclease. In some embodiments, the methods comprise introducing a template to the cell. In some embodiments, a single template may be provided. In other embodiments, two or more templates may be provided such that editing may occur at two or more target sites. For example, different templates may be provided to edit a single gene in a cell, or two different genes in a cell.

In some embodiments, the template may be used in homologous recombination. In some embodiments, the homologous recombination may result in the integration of the template sequence or a portion of the template sequence into the target nucleic acid molecule. In other embodiments, the template may be used in homology-directed repair, which involves DNA strand invasion at the site of the cleavage in the nucleic acid. In some embodiments, the homology-directed repair may result in including the template sequence in the edited target nucleic acid molecule. In yet other embodiments, the template may be used in gene editing mediated by non-homologous end joining. In some embodiments, the template sequence has no similarity to the nucleic acid sequence near the cleavage site. In some embodiments, the template or a portion of the template sequence is incorporated. In some embodiments, the template includes flanking inverted terminal repeat (ITR) sequences.

In some embodiments, the template may comprise a first homology arm and a second homology arm (also called a first and second nucleotide sequence) that are complementary to sequences located upstream and downstream of the cleavage site, respectively. Where a template contains two homology arms, each arm can be the same length or different lengths, and the sequence between the homology arms can be substantially similar or identical to the target sequence between the homology arms, or it can be entirely unrelated. In some embodiments, the degree of complementarity or percent identity between the first nucleotide sequence on the template and the sequence upstream of the cleavage site, and between the second nucleotide sequence on the template and the sequence downstream of the cleavage site, may permit homologous recombination, such as, e.g., high-fidelity homologous recombination, between the template and the target nucleic acid molecule. In some embodiments, the degree of complementarity may be about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100%. In some embodiments, the degree of complementarity may be about 95%, 97%, 98%, 99%, or 100%. In some embodiments, the degree of complementarity may be at least 98%, 99%, or 100%. In some embodiments, the degree of complementarity may be 100%. In some embodiments, the percent identity may be about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100%. In some embodiments, the percent identity may be about 95%, 97%, 98%, 99%, or 100%. In some embodiments, the percent identity may be at least 98%, 99%, or 100%. In some embodiments, the percent identity may be 100%.

In some embodiments, the template sequence may correspond to, comprise, or consist of an endogenous sequence of a target cell. It may also or alternatively correspond to, comprise, or consist of an exogenous sequence of a target cell. As used herein, the term “endogenous sequence” refers to a sequence that is native to the cell. The term “exogenous sequence” refers to a sequence that is not native to a cell, or a sequence whose native location in the genome of the cell is in a different location. In some embodiments, the endogenous sequence may be a genomic sequence of the cell. In some embodiments, the endogenous sequence may be a chromosomal or extrachromosomal sequence. In some embodiments, the endogenous sequence may be a plasmid sequence of the cell. In some embodiments, the template sequence may be substantially identical to a portion of the endogenous sequence in a cell at or near the cleavage site, but comprise at least one nucleotide change. In some embodiments, editing the cleaved target nucleic acid molecule with the template may result in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of the target nucleic acid molecule, In some embodiments, the mutation may result in one or more amino acid changes in a protein expressed from a gene comprising the target sequence. In some embodiments, the mutation may result in one or more nucleotide changes in an RNA expressed from the target gene. In some embodiments, the mutation may alter the expression level of the target gene. In some embodiments, the mutation may result in increased or decreased expression of the target gene. in some embodiments, the mutation may result in gene knock-down. In some embodiments, the mutation may result in gene knock-out. In some embodiments, the mutation may result in restored gene function. In some embodiments, editing of the cleaved target nucleic acid molecule with the template may result in a change in an exon sequence, an intron sequence, a regulatory sequence, a transcriptional control sequence, a translational control sequence, a splicing site, or a non-coding sequence of the target nucleic acid molecule, such as DNA.

In other embodiments, the template sequence may comprise an exogenous sequence. In some embodiments, the exogenous sequence may comprise a protein or RNA coding sequence operably linked to an exogenous promoter sequence such that, upon integration of the exogenous sequence into the target nucleic acid molecule, the cell is capable of expressing the protein or RNA encoded by the integrated sequence. In other embodiments, upon integration of the exogenous sequence into the target nucleic acid molecule, the expression of the integrated sequence may be regulated by an endogenous promoter sequence. In some embodiments, the exogenous sequence may provide a cDNA sequence encoding a protein or a portion of the protein. In yet other embodiments, the exogenous sequence may comprise or consist of an exon sequence, an intron sequence, a reaulatory sequence, a transcriptional control sequence, a translational control sequence, a splicing site, or a non-coding sequence. In some embodiments, the integration of the exogenous sequence may result in restored gene function. In some embodiments, the integration of the exogenous sequence may result in a gene knock-in. In some embodiments, the integration of the exogenous sequence may result in a gene knock-out.

The template may be of any suitable length. In some embodiments, the template may comprise 10, 15, 20, 25, 50, 75, 100, 150, 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, or more nucleotides in length. The template may be a single-stranded nucleic acid. The template can be double-stranded or partially double-stranded nucleic acid. In certain embodiments, the single stranded template is 20, 30, 40, 50, 75, 100, 125, 150, 175, or 200 nucleotides in length. In some embodiments, the template may comprise a nucleotide sequence that is complementary to a portion of the target nucleic acid molecule comprising the target sequence (i.e., a “homology arm”). In some embodiments, the template may comprise a homology arm that is complementary to the sequence located upstream or downstream of the cleavage site on the target nucleic acid molecule.

In some embodiments, the template contains ssDNA or dsDNA containing flanking invert-terminal repeat (ITR) sequences. In some embodiments, the template is provided as a vector, plasmid, minicircle, nanocircle, or PCR product.

Purification of Nucleic Acids

In some embodiments, the nucleic acid is purified. In some embodiments, the nucleic acid is purified using a precipation method (e.g., LiCl precipitation, alcohol precipitation, or an equivalent method, e.g., as described herein). In some embodiments, the nucleic acid is purified using a chromatography-based method, such as an HPLC-based method or an equivalent method (e.g., as described herein). In some embodiments, the nucleic is purified using both a precipitation method (e.g., LiCl precipitation) and an HPLC-based method.

Target Sequences

In some embodiments, a CRISPR/Cas system of the present disclosure may be directed to and cleave a target sequence on a target nucleic acid molecule. For example, the target sequence may be recognized and cleaved by the Cas nuclease. In certain embodiments, a target sequence for a Cas nuclease is located near the nuclease's cognate PAM sequence. In some embodiments, a Class 2 Cas nuclease may be directed by a gRNA to a target sequence of a target nucleic acid molecule, where the gRNA hybridizes with and the Class 2 Cas protein cleaves the target sequence. In some embodiments, the guide RNA hybridizes with and a Class 2 Cas nuclease cleaves the target sequence adjacent to or comprising its cognate PAM. In some embodiments, the target sequence may be complementary to the targeting sequence of the guide RNA. In some embodiments, the degree of complementarity between a targeting sequence of a guide RNA and the portion of the corresponding target sequence that hybridizes to the guide RNA may be about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100%. In some embodiments, the percent identity between a targeting sequence of a guide RNA and the portion of the corresponding target sequence that hybridizes to the guide RNA may be about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100%. In some embodiments, the homology region of the target is adjacent to a cognate PAM sequence. In some embodiments, the target sequence may comprise a sequence 100% complementary with the targeting sequence of the guide RNA. In other embodiments, the target sequence may comprise at least one mismatch, deletion, or insertion, as compared to the targeting sequence of the guide RNA.

The length of the target sequence may depend on the nuclease system used. For example, the targeting sequence of a guide RNA for a CRISPRICas system may comprise 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or more than 50 nucleotides in length and the target sequence is a corresponding length, optionally adjacent to a PAM sequence. In some embodiments, the target sequence may comprise 15-24 nucleotides in length. In some embodiments, the target sequence may comprise 17-21 nucleotides in length. In some embodiments, the target sequence may comprise 20 nucleotides in length. When nickases are used, the target sequence may comprise a pair of target sequences recognized by a pair of nickases that cleave opposite strands of the DNA molecule. In some embodiments, the target sequence may comprise a pair of target sequences recognized by a pair of nickases that cleave the same strands of the DNA molecule. In some embodiments, the target sequence may comprise a part of target sequences recognized by one or more Cas nucleases.

The target nucleic acid molecule may be any DNA or RNA molecule that is endogenous or exogenous to a cell. In some embodiments, the target nucleic acid molecule may be an episomal DNA, a plasmid, a genomic DNA, viral genome, mitochondrial DNA, or chromosomal DNA from a cell or in the cell. In some embodiments, the target sequence of the target nucleic acid molecule may be a genomic sequence from a cell or in a cell, including a human cell.

In further embodiments, the target sequence may be a viral sequence. In further embodiments, the target sequence may be a pathogen sequence. In yet other embodiments, the target sequence may be a synthesized sequence. In further embodiments, the target sequence may be a chromosomal sequence. In certain embodiments, the target sequence may comprise a translocation junction, e.g., a translocation associated with a cancer. In some embodiments, the target sequence may be on a eukaryotic chromosome, such as a human chromosome. In certain embodiments, the target sequence is a liver-specific sequence, in that it is expressed in liver cells.

In some embodiments, the target sequence may be located in a coding sequence of a gene, an intron sequence of a gene, a regulatory sequence, a transcriptional control sequence of a gene, a translational control sequence of a gene, a splicing site or a non-coding sequence between genes. In some embodiments, the gene may be a protein coding gene. In other embodiments, the gene may be a non-coding RNA gene. In some embodiments, the target sequence may comprise all or a portion of a disease-associated gene. In some embodiments, the target sequence may be located in a non-genic functional site in the genome, for example a site that controls aspects of chromatin organization, such as a scaffold site or locus control region.

In embodiments involving a Cas nuclease, such as a Class 2 Cas nuclease, the target sequence may be adjacent to a protospacer adjacent motif (“PAM”). In some embodiments, the PAM may be adjacent to or within 1, 2, 3, or 4, nucleotides of the 3′ end of the target sequence. The length and the sequence of the PAM may depend on the Cas protein used. For example, the PAM may be selected from a consensus or a particular PAM sequence for a specific Cas9 protein or Cas9 ortholog, including those disclosed in FIG. 1 of Ran et al., Nature, 520: 186-191 (2015), and FIG. S5 of Zetsche 2015, the relevant disclosure of each of which is incorporated herein by reference. In some embodiments, the PAM may be 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. Non-limiting exemplary PAM sequences include NGG, NGGNG, NG, NAAAAN, NNAAAAW, NNNNACA, GNNNCNNA, TTN, and NNNNGATT (wherein N is defined as any nucleotide, and W is defined as either A or T). In some embodiments, the PAM sequence may be NGG. In some embodiments, the PAM sequence may be NGGNG. In some embodiments, the PAM sequence may be TTN. In some embodiments, the PAM sequence may be NNAAAAW.

Lipid Formulation

Disclosed herein are various embodiments of LNP formulations for RNAs, including CRISPR/Cas camos. Such LNP formulations include an “amine lipid”, along with a helper lipid, a neutral lipid, and a PEG lipid. In some embodiments, such LNP formulations include an “amine lipid”, along with a helper lipid and a PEG lipid. In some embodiments, the LNP formulations include less than 1 percent neutral phospholipid. In some embodiments, the LNP formulations include less than 0.5 percent neutral phospholipid. By “lipid nanoparticle” is meant a particle that comprises a plurality of (i.e. more than one) lipid molecules physically associated with each other by intermolecular forces.

Amine Lipids

The LNP compositions for the delivery of biologically active agents comprise an “amine lipid”, which is defined as Lipid A or its equivalents, including acetal analogs of Lipid A.

In some embodiments, the amine lipid is Lipid A, which is (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl) propyl octadeca-9,12-dienoate, also called 3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadeca-9,12-dienoate. Lipid A can be depicted as:

Lipid A may be synthesized according to WO2015/095340 (e.g., pp. 84-86). In certain embodiments, the amine lipid is an equivalent to Lipid A.

In certain embodiments, an amine lipid is an analog of Lipid A. In certain embodiments, a Lipid A analog is an acetal analog of Lipid A. In particular LNP compositions, the acetal analog is a C4-C12 acetal analog. In some embodiments, the acetal analog is a C5-C12 acetal analog. In additional embodiments, the acetal analog is a C5-C10 acetal analog. In further embodiments, the acetal analog is chosen from a C4, C5, C6, C7, C9, C10, C11, and C 12 acetal analog.

Amine lipids suitable for use in the LNPs described herein are biodegradable in vivo and suitable for delivering a biologically active avent, such as an RNA to a cell. The amine lipids have low toxicity (e.g., are tolerated in an animal model without adverse effect in amounts of greater than or equal to 10 mg/kg of RNA cargo). In certain embodiments, LNPs comprising an amine lipid include those where at least 75% of the amine lipid is cleared from the plasma within 8, 10, 12, 24, or 48 hours, or 3, 4, 5, 6, 7, or 10 days. In certain embodiments, LNPs comprising an amine lipid include those where at least 50% of the mRNA or gRNA is cleared from the plasma within 8, 10, 12, 24, or 48 hours, or 3, 4, 5, 6, 7, or 10 days. In certain embodiments, LNPs comprising an amine lipid include those where at least 50% of the LNP is cleared from the plasma within 8, 10, 12, 24, or 48 hours, or 3, 4, 5, 6, 7, or 10 days, for example by measuring a lipid (e.g., an amine lipid), RNA (e.g., mRNA), or another component. In certain embodiments, lipid-encapsulated versus free lipid, RNA, or nucleic acid component of the LNP is measured.

Lipid clearance may be measured as described in literature. See Maier, M. A., et al. Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics. Mol. Tiler, 2013, 21(8), 1570-78 (“Maier”). For example, in Maier, LNP-siRNA systems containing luciferases-targeting siRNA were administered to six- to eight-week old male C57Bl/6 mice at 0.3 mg/kg by intravenous bolus injection via the lateral tail vein. Blood, liver, and spleen samples were collected at 0.083, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, and 168 hours post-dose. Mice were perfused with saline before tissue collection and blood samples were processed to obtain plasma. All samples were processed and analyzed by LC-MS. Further, Maier describes a procedure for assessing toxicity after administration of LNP-siRNA formulations. For example, a luciferase-targeting siRNA was administered at 0, 1, 3, 5, and 10 mg/kg (5 animals/group) via single intravenous bolus injection at a dose volume of 5 mL/kg to male Sprague-Dawley rats. After 24 hours, about 1 mL of blood was obtained from the jugular vein of conscious animals and the serum was isolated. At 72 hours post-dose, all animals were euthanized for necropsy. Assessments of clinical signs, body weight, serum chemistry, organ weights and histopathology were performed. Although Maier describes methods for assessing siRNA-LNP formulations, these methods may be applied to assess clearance, pharmacokinetics, and toxicity of administration of LNP compositions of the present disclosure.

The amine lipids may lead to an increased clearance rate. In some embodiments, the clearance rate is a lipid clearance rate, for example the rate at which a lipid is cleared from the blood, serum, or plasma. In some embodiments, the clearance rate is an RNA clearance rate, for example the rate at which an mRNA or a gRNA is cleared from the blood, serum, or plasma. In some embodiments, the clearance rate is the rate at which LNP is cleared from the blood, serum, or plasma. In some embodiments, the clearance rate is the rate at which LNP is cleared from a tissue, such as liver tissue or spleen tissue. In certain embodiments, a high clearance rate leads to a safety profile with no substantial adverse effects. The amine lipids may reduce LNP accumulation in circulation and in tissues. In some embodiments, a reduction in LNP accumulation in circulation and in tissues leads to a safety profile with no substantial adverse effects.

The amine lipids of the present disclosure are ionizable (e.g., may form a salt) depending upon the pH of the medium they are in. For example, in a slightly acidic medium, the amine lipids may be protonated and thus bear a positive charge. Conversely, in a slightly basic medium, such as, for example, blood, where pH is approximately 7.35, the amine lipids may not be protonated and thus bear no charge. In some embodiments, the amine lipids of the present disclosure may be protonated at a pH of at least about 9. In some embodiments, the amine lipids of the present disclosure may be protonated at a pH of at least about 9. In some embodiments, the amine lipids of the present disclosure may be protonated at a pH of at least about 10.

The pH at which an amine lipid is predominantly protonated is related to its intrinsic pKa. In some embodiments, the amine lipids of the present disclosure may each, independently, have a pKa in the range of from about 5.1 to about 7.4. In some embodiments, the amine lipids of the present disclosure may each, independently, have a pKa in the range of from about 5.5 to about 6.6. In some embodiments, the amine lipids of the present disclosure may each, independently, have a pKa in the range of from about 5.6 to about 6.4. In some embodiments, the amine lipids of the present disclosure may each, independently, have a pKa in the range of from about 5.8 to about 6.2. For example, the amine lipids of the present disclosure may each, independently, have a pKa in the range of from about 5.8 to about 6.5. The pKa of an amine lipid can be an important consideration in formulating LNPs as it has been found that cationic lipids with a pKa ranging from about 5.1 to about 7.4 are effective for delivery of cargo in vivo, e.g., to the liver. Furthermore, it has been found that cationic lipids with a pKa ranging from about 5.3 to about 6.4 are effective for delivery in vivo, e.g., to tumors. See, e.g., WO 2014/136086,

Additional Lipids

“Neutral lipids” suitable for use in a lipid composition of the disclosure include, for example, a variety of neutral, uncharged or zwitterionic lipids. Examples of neutral phospholipids suitable for use in the present disclosure include, but are not limited to, 5-heptadecylbenzene-1,3-diol (resorcinol), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), pohsphocholine (DOPC), dimyristoylphosphatidylcholine (DMPC), phosphatidylcholine (PLPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DAPC), phosphatidylethanolamine (PE), egg phosphatidylcholine (EPC), dilauryloylphosphatidylcholine (DLPC), dimyristoylphosphatidylcholine (DMPC), 1-myristoyl-2-palmitoyl phosphatidylcholine (MPPC), 1-palmitoyl-2-myristoyl phosphatidylcholine (PMPC), 1-palmitoyl-2-stearoyl phosphatidylcholine (PSPC), 1,2-diarachidoyl-sn-glycero-3-phosphocholine (DBPC), 1-stearoyl-2-palmitoyl phosphatidylcholine (SPPC), 1,2-dieicosenoyl-sn-glycero-3-phosphocholine (DEPC), palmitoyloleoyl phosphatidylcholine (POPC), lysophosphatidyl choline, dioleoyl phosphatidylethanolamine (DOPE), dilinoleoyiphosphatidylcholine distearoylphosphatidylethanolamine (DSPE), dimyristoyl phosphatidylethanolamine (DMPE), dipalmitoyl phosphatidylethanolamine (DPPE), palmitoyloleoyl phosphatidylethanolamine (POPE), lysophosphatidylethanolamine and combinations thereof. In one embodiment, the neutral phospholipid may be selected from the group consisting of distearoylphosphatidylcholine (DSPC) and dimyristoyl phosphatidyl ethanolamine (DMPE). In another embodiment, the neutral phospholipid may be distearoylphosphatidylcholine (DSPC). In another embodiment, the neutral phospholipid may be dipahnitoylphosphatidylcholine (DPPC).

“Helper lipids” include steroids, sterols, and alkyl resorcinois. Helper lipids suitable for use in the present disclosure include, but are not limited to, cholesterol, 5-heptadecylresorcinol, and cholesterol hemisuccinate, In one embodiment, the helper lipid may be cholesterol. In one embodiment, the helper lipid may be cholesterol hemisuccinate.

PEG lipids are stealth lipids that alter the length of time the nanoparticles can exist in vivo (e.g., in the blood). PEG lipids may assist in the formulation process by, for example, reducing particle aggregation and controlling particle size. PEG lipids used herein may modulate phannacokinetic properties of the LNPs. Typically, the PEG lipid comprises a lipid moiety and a polymer moiety based on PEG.

In some embodiments, the lipid moiety may be derived from diacylglycerol or diacylglycamide, including those comprising a dialkylglycerol or dialkylglycamide group having alkyl chain length independently comprising from about C4 to about C40 saturated or unsaturated carbon atoms, wherein the chain may comprise one or more functional groups such as, for example, an amide or ester. In some embodiments, the alkyl chain length comprises about C10 to C20. The dialkylglycerol or dialkylalyeamide group can further comprise one or more substituted alkyl groups. The chain lengths may be symmetrical or assymetric.

Unless otherwise indicated, the term “PEG” as used herein means any polyethylene glycol or other polyalkylene ether polymer. In one embodiment, PEG moiety is an optionally substituted linear or branched polymer of ethylene glycol or ethylene oxide. In certain embodiments, PEG moiety is Alternatively, the PEG moiety may be substituted, e.g., by one or more alkyl, alkoxy, acyl, hydroxy, or aryl groups. In one embodiment, the PEG moiety includes PEG copolymer such as PEG-polyurethane or PEG-polypropylene (see, e.g., J. Milton Harris, Poly(ethylene glycol) chemistry: biotechnical and biomedical applications (1992)); alternatively, the PEG moiety does not include PEG copolymers, e.g., it may be a PEG monopolymer. In one embodiment, the PEG has a molecular weight of from about 130 to about 50,000, in a sub-embodiment, about 150 to about 30,000, in a sub-embodiment, about 150 to about 20,000, in a sub-embodiment about 150 to about 15,000, in a sub-embodiment, about 150 to about 10,000, in a sub-embodiment, about 150 to about 6,000, in a sub-embodiment, about 150 to about 5,000, in a sub-embodiment, about 150 to about 4,000, in a sub-embodiment, about 150 to about 3,000, in a sub-embodiment, about 300 to about 3,000, in a sub-embodiment, about 1,000 to about 3,000, and in a sub-embodiment, about 1,500 to about 2,500.

In certain embodiments, the PEG (e.g., conjugated to a lipid moiety or lipid, such as a stealth lipid), is a “PEG-2K,” also termed “PEG 2000,” which has an average molecular weight of about 2,000 daltons. PEG-2K is represented herein by the following formula (I), wherein n is 45, meaning that the number averaged degree of polymerization comprises about 45 subunits

However, other PEG embodiments known in the art may be used, including, e.g., those where the number-averaged degree of polymerization comprises about 23 subunits (n=23), and/or 68 subunits (n=68). In some embodiments, n may range from about 30 to about 60. In some embodiments, n may range from about 35 to about 55. In some embodiments, n may range from about 40 to about 50. In some embodiments, n may range from about 42 to about 48. In some embodiments, n may be 45. In some embodiments, R may be selected from H, substituted alkyl, and unsubstituted alkyl. In some embodiments, R may be unsubstituted alkyl. In some embodiments, R may be methyl.

In any of the embodiments described herein, the PEG lipid may be selected from PEG-dilauroylidycerol, PEG-dimyristoylglycerol (PEG-DMG) (catalog #GM-020 from NOF, Tokyo, Japan), PEG-dipalmitoylglycerol, PEG-distearoylglycerol (PEG-DSPE) (catalog #DSPE-020CN, NOF, Tokyo, Japan), PEG-dilaurylglycamide, PEG-dimyristylglycamide, PEG-dipalmitoylglyeamide, and PEG-distearoylglycamide, PEG-cholesterol (1-[8′-(Cholest-5-en-3[beta]-oxy)carboxamido-3′,6′-dioxaoctanyl]carbamoyl-[omega]-methyl-poly(ethylene glycol), PEG-DMB (3,4-ditetradecoxylbenzyl-[omega]-methyl-poly(ethylene glycol)ether), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG2k-DMG) (cat. #880150P from Avanti Polar Lipids, Alabaster, Ala., USA), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG2k-DSPE) (cat. #880120C from Avanti Polar Lipids, Alabaster, Ala., USA), 1,2-distearoyl-sn-glycerol, methoxypolyethylene glycol (PEG2k-DSG; GS-020, NOF Tokyo, Japan), poly(ethylene glycol)-2000-dimethacrylate (PEG2k-DMA), and 1,2-distearyloxypropyl-3-amine-N-[methoxy(polyethylene glycol)-2000] (PEG2k-DSA). In one embodiment, the PEG lipid may be PEG2k-DMG. In some embodiments, the PEG lipid may be PEG2k-DSG. In one embodiment, the PEG lipid may be PEG2k-DSPE. In one embodiment, the PEG lipid may be PEG2k-DMA. In one embodiment, the PEG lipid may be PEG2k-C-DMA. In one embodiment, the PEG lipid may be compound S027, disclosed in WO2016/010840 at paragraphs [00240] to [00244]. In one embodiment, the PEG lipid may be PEG2k-DSA. En one embodiment, the PEG lipid may be PEG2k-C11. In some embodiments, the PEG lipid may be PEG2k-C14. In some embodiments, the PEG lipid may be PEG2k-C16. In some embodiments, the PEG lipid may be PEG2k-C18.

LNP Formulations

Embodiments of the present disclosure provide lipid compositions described according to the respective molar ratios of the component lipids in the formulation. In one embodiment, the mol-% of the amine lipid may be from about 30 mol-% to about 60 mol-%. In one embodiment, the mol-% of the amine lipid may be from about 40 mol-% to about 60 mol-%. In one embodiment, the mol-% of the amine lipid may be from about 45 mol-% to about 60 mol-%. In one embodiment, the mol-% of the amine lipid may be from about 50 mol-% to about 60 mol-%. In one embodiment, the mol-% of the amine lipid may be from about 55 mol-% to about 60 mol-%. In one embodiment, the mol-% of the amine lipid may be from about 50 mol-% to about 55 mol-%. In one embodiment, the mol-% of the amine lipid may be about 50 mol-%. In one embodiment, the mol-% of the amine lipid may be about 55 mol-%. In some embodiments, the amine lipid mol-% of the LNP batch will be ±30%, ±25%, ±20%, ±15%, ±10%, ±5%, or ±2.5% of the target mol-%. In some embodiments, the amine lipid mol-% of the LNP batch will be ±4 mol-%, ±3 mol-%, ±2 mol-%, ±1.5 mol-%, ±1 mol-%, ±0.5 mol-%, or ±0.25 mol-% of the target mol-%. All mol-% numbers are given as a fraction of the lipid component of the LNP compositions. In certain embodiments, LNP inter-lot variability of the amine lipid mol-% will be less than 15%, less than 10% or less than 5%.

In one embodiment, the mol-% of the neutral lipid, e.g., neutral phospholipid, may be from about 5 mol-% to about 15 mol-%. In one embodiment, the mol-% of the neutral lipid, e.g., neutral phospholipid, may be from about 7 mol-% to about 12 mol-%. In one embodiment, the mol-% of the neutral lipid, e.g., neutral phospholipid, may be from about 0 mol-% to about 5 mol-%. In one embodiment, the mol-% of the neutral lipid, e.g., neutral phospholipid, may be from about 0 mol-% to about 10 mol-%. In one embodiment, the mol-% of the neutral lipid, e.g., neutral phospholipid, may be from about 5 mol-% to about 10 mol-%. In one embodiment, the mol-% of the neutral lipid, e.g., neutral phospholipid, may be from about 8 mol-% to about 10 mol-%.

In one embodiment, the mol-% of the neutral lipid, e.g., neutral phospholipid, may be about 5 mol-%, about 6 mol-%, about 7 mol-%, about 8 mol-%, about 9 mol-%, about 10 mol-%, about 11 mol-%, about 12 mol-%, about 13 mol-%, about 14 mol-%, or about 15 mol-%. In one embodiment, the mol-% of the neutral lipid, e.g., neutral phospholipid, may be about 9 mol-%.

In one embodiment, the mol-% of the neutral lipid, e.g., neutral phospholipid, may be from about 1 mol-% to about 5 mol-%. In one embodiment, the mol-% of the neutral lipid may be from about 0.1 mol-% to about 1 mol-%. In one embodiment, the mol-% of the neutral lipid such as neutral phospholipid may be about 0.1 mol-%, about 0.2 mol-%, about 0,5 mol-%, 1 mol-%, about 1.5 mol-%, about 2 mol-%, about 2.5 moi-%, about 3 mol-%, about 3.5 mol-%, about 4 mol-%, about 4.5 mol-%, or about 5 mol-%.

In one embodiment, the mol-% of the neutral lipid, e.g., neutral phospholipid, may be less than about 1 mol-%. In one embodiment, the mol-% of the neutral lipid, neutral phospholipid, may be less than about 0.5 mol-%, In one embodiment, the mol-% of the neutral lipid, e.g., neutral phospholipid, may be about 0 mol-%, about 0.1 mol-%, about 0.2 mol-%, about 0.3 mol-%, about 0.4 mol-%, about 0.5 mol-%, about 0.6 mol-%, about 0.7 mol-%, about 0.8 mol-%, about 0.9 mol-%, or about 1 mol-%. In some embodiments, the formulations disclosed herein are free of neutral lipid (i.e., 0 mol-% neutral lipid). In some embodiments, the formulations disclosed herein are essentially free of neutral lipid (i.e., about 0 mol-% neutral lipid). In some embodiments, the formulations disclosed herein are free of neutral phospholipid (i.e., 0 mol-% neutral phospholipid). In some embodiments, the formulations disclosed herein are essentially free of neutral phospholipid (i.e., about 0 mol-% neutral phospholipid).

In some embodiments, the neutral lipid mol-% of the LNP batch will be ±30%, ±25%, ±20%, ±10%, ±5%., or ±12.5% of the target neutral lipid mol-%. In certain embodiments, LNP inter-lot variability will be less than 15%, less than 10% or less than 5%.

In one embodiment, the mol-% of the helper lipid may be from about 20 mol-% to about 60 mol-%. In one embodiment, the mol-% of the helper lipid may be from about 25 mol-% to about 55 mol-%. In one embodiment, the mol-% of the helper lipid may be from about 25 mol-% to about 50 mol-%. In one embodiment, the mol-% of the helper lipid may be from about 25 mol-% to about 40 mol-%. In one embodiment, the mol-% of the helper lipid may he from about 30 mol-% to about 50 mol-%. In one embodiment, the mol-% of the helper lipid may be from about 30 mol-% to about 40 mol-%. In one embodiment, the mol-% of the helper lipid is adjusted based on amine lipid, neutral lipid, and PEG lipid concentrations to bring the lipid component to 100 mol-%. In one embodiment, the mol-% of the helper lipid is adjusted based on amine lipid and PEG lipid concentrations to bring the lipid component to 100 mol-%. In one embodiment, the mol-% of the helper lipid is adjusted based on amine lipid and PEG lipid concentrations to bring the lipid component to at least 99 mol-%. In some embodiments, the helper mol-% of the LNP batch will be ±30%, ±25%, ±20%,±15%,±10%, ±5%, or ±12.5% of the target mol-%. In certain embodiments, LNP inter-lot variability will be less than 15%, less than 10% or less than 5%.

In one embodiment, the mol-% of the PEG lipid may be from about 1 mol-% to about 10 mol-%. In one embodiment, the mol-% of the PEG lipid may be from about 2 mol-% to about 10 mol-%. In one embodiment, the mol-% of the PEG lipid may be from about 2 mol-% to about 8 mol-%. In one embodiment, the mol-% of the PEG lipid may be from about 2 mol-% to about 4 mol-%. In one embodiment, the mol-% of the PEG lipid may be from about 2.5 mol-% to about 4 mol-%. In one embodiment, the mol-% of the PEG lipid may be about 3 mol-%. In one embodiment, the mol.-% of the PEG lipid may be about 2.5 mol-%. In some embodiments, the PEG lipid mol-% of the LNP batch will be ±30%, ±25%, ±20%, ±15%, ±10%, ±5%, or ±12.5% of the target PEG lipid mol-%. In certain embodiments, LNP inter-lot variability will be less than 15%, less than 10% or less than 5%.

In certain embodiments, the cargo includes an mRNA encoding an RNA-guided DNA-binding agent (e.g. a Cas nuclease, a Class 2 Cas nuclease, or Cas9), and a gRNA or a nucleic acid encoding a gRNA, or a combination of mRNA and gRNA. In one embodiment, an LNP composition may comprise a Lipid A or its equivalents. In some aspects, the amine lipid is Lipid A. In some aspects, the amine lipid is a Lipid A equivalent, e.g. an analog of Lipid A. In certain aspects, the amine lipid is an acetal analog of Lipid A. In various embodiments, an LNP composition comprises an amine lipid, a neutral lipid, a helper lipid, and a PEG lipid. In certain embodiments, the helper lipid is cholesterol. In certain embodiments, the neutral lipid is DSPC. In specific embodiments, PEG lipid is PEG2k-DMG. In some embodiments, an LNP composition may comprise a Lipid A, a helper lipid, a neutral lipid, and a PEG lipid. In some embodiments, an LNP composition comprises an amine lipid, DSPC, cholesterol, and a PEG lipid. In some embodiments, the LNP composition comprises a PEG lipid comprising DMG. In certain embodiments, the amine lipid is selected from Lipid A, and an equivalent of Lipid A, including an acetal analog of Lipid A. In additional embodiments, an LNP composition comprises Lipid A, cholesterol, DSPC, and PEG2k-DMG.

In various embodiments, an LNP composition comprises an amine lipid, a helper lipid, a neutral lipid, and a PEG lipid. In various embodiments, an LNP composition comprises an amine lipid, a helper lipid, a neutral phospholipid, and a PEG lipid. In various embodiments, an LNP composition comprises a lipid component that consists of an amine lipid, a helper lipid, a neutral lipid, and a PEG lipid. In various embodiments, an LNP composition comprises an amine lipid, a helper lipid, and a PEG lipid. In certain embodiments, an LNP composition does not comprise a neutral lipid, such as a neutral phospholipid. In various embodiments, an LNP composition comprises a lipid component that consists of an amine lipid, a helper lipid, and a PEG lipid. In certain embodiments, the neutral lipid is chosen from one or more of DSPC, DPPC, DAPC, DMPC, DOPC, DOPE, and DSPE. In certain embodiments, the neutral lipid is DSPC. In certain embodiments, the neutral lipid is DPPC. In certain embodiments, the neutral lipid is DAPC. In certain embodiments, the neutral lipid is DMPC. In certain embodiments, the neutral lipid is DOPC. In certain embodiments, the neutral lipid is DOPE. In certain embodiments, the neutral lipid is DSPE. In certain embodiments, the helper lipid is cholesterol. In specific embodiments, the PEG lipid is PEG2k-DMG. In some embodiments, an LNP composition may comprise a Lipid A, a helper lipid, and a PEG lipid. In some embodiments, an LNP composition may comprise a lipid component that consists of Lipid A, a helper lipid, and a PEG lipid. In some embodiments, an LNP composition comprises an amine lipid, cholesterol, and a PEG lipid. In some embodiments, an LNP composition comprises a lipid component that consists of an amine lipid, cholesterol, and a PEG lipid. In some embodiments, the LNP composition comprises a PEG lipid comprising DMG. In certain embodiments, the amine lipid is selected from Lipid A and an equivalent of Lipid A, including an acetal analog of Lipid A. In certain embodiments, the amine lipid is a C5-C12 or a C4-C12 acetal analog of Lipid A. In additional embodiments, an LNP composition comprises Lipid A, cholesterol, and PEG2k-DMG.

Embodiments of the present disclosure also provide lipid compositions described according to the molar ratio between the positively charged amine groups of the amine lipid (N) and the negatively charged phosphate groups (P) of the nucleic acid to be encapsulated. This may be mathematically represented by the equation N/P. In some embodiments, an LNP composition may comprise a lipid component that comprises an amine lipid, a helper lipid, a neutral lipid, and a PEG lipid; and a nucleic acid component, wherein the N/P ratio is about 3 to 10. In some embodiments, an LNP composition may comprise a lipid component that comprises an amine lipid, a helper lipid, and a PEG lipid; and a nucleic acid component, wherein the N/P ratio is about 3 to 10. In some embodiments, an LNP composition may comprise a lipid component that comprises an amine lipid, a helper lipid, a neutral lipid, and a helper lipid; and an RNA component, wherein the N/P ratio is about 3 to 10. In some embodiments, an LNP composition may comprise a lipid component that comprises an amine lipid, a helper lipid, and a PEG lipid; and an RNA component, wherein the N/P ratio is about 3 to 10. In one embodiment, the N/P ratio may be about 5 to 7. In one embodiment, the N/P ration may be about 3 to 7. In one embodiment, the N/P ratio may be about 4.5 to 8. In one embodiment, the N/P ratio may be about 6. In one embodiment, the N/P ratio may he 6±1. In one embodiment, the N/P ratio may be 6±0.5. In some embodiments, the N/P ratio will be ±30%, ±25%, ±20%, ±15%, ±10%, ±5%, or ±2.5% of the target N/P ratio. In certain embodiments, LNP inter-lot variability will be less than 15%. less than 10% or less than 5%.

In some embodiments, the nucleic acid component, e.g., an RNA component, may comprise an mRNA, such as an snRNA encoding a Cas nuclease. An RNA component includes RNA, optionally with additional nucleic acid and/or protein, e.g., RNP cargo. In one embodiment, RNA comprises a Cas9 mRNA. In some compositions comprising an mRNA encoding a Cas nuclease, the LNP further comprises a gRNA nucleic acid, such as a gRNA. In some embodiments, the RNA component comprises a Cas nuclease mRNA and a gRNA. In some embodiments, the RNA component comprises a Class 2 Cas nuclease mRNA and a sRNA.

In certain embodiments, an LNP composition may comprise an mRNA encoding a Cas nuclease such as a Class 2 Cas nuclease, an amine lipid, a helper lipid, a neutral lipid, and a PEG lipid. In certain embodiments, an LNP composition may comprise an mRNA encoding a Cas nuclease such as a Class 2 Cas nuclease, an amine lipid, a helper lipid, and a PEG lipid. In certain LNP compositions comprising an mRNA encoding a Cas nuclease such as a Class 2 Cas nuclease, the helper lipid is cholesterol, In other compositions comprising an mRNA encoding a Cas nuclease such as a Class 2 Cas nuclease, the neutral lipid is DSPC. In additional embodiments comprising an mRNA encoding a Cas nuclease such as a Class 2 Cas nuclease, the PEG lipid is PEG2k-DMG or PEG2k-C11. In specific compositions comprising an mRNA encoding a Cas nuclease such as a Class 2 Cas nuclease, the amine lipid is selected from Lipid A and its equivalents, such as an acetal analog of Lipid A.

In some embodiments, an LNP composition may comprise a gRNA. In certain embodiments, an LNP composition may comprise an amine lipid, a gRNA, a helper lipid, a neutral lipid, and a PEG lipid. In certain embodiments, an LNP composition may comprise an amine lipid, a gRNA, a helper lipid, and a PEG lipid. In certain LNP compositions comprising a gRNA, the helper lipid is cholesterol. In some compositions comprising a gRNA, the neutral lipid is DSPC. In additional embodiments comprising a gRNA, the PEG lipid is PEG2k-DMG or PEG2k-C11. In certain embodiments, the amine lipid is selected from Lipid A and its equivalents, such as an acetal analog of Lipid A.

In one embodiment, an LNP composition may comprise an sgRNA. In one embodiment, an LNP composition may comprise a Cas9 sgRNA. In one embodiment, an LNP composition may comprise a Cpf1 sgRNA. In some compositions comprising an sgRNA, the LNP includes an amine lipid, a helper lipid, a neutral lipid, and a PEG lipid. In some compositions comprising an sgRNA, the LNP includes an amine lipid, a helper lipid, and a PEG lipid. In certain compositions comprising an sgRNA, the helper lipid is cholesterol. In other compositions comprising an sgRNA, the neutral lipid is DSPC. In additional embodiments comprising an sgRNA, the PEG lipid is PEG2k-DMG or PEG2k-C11. In certain embodiments, the amine lipid is selected from Lipid A and its equivalents, such as acetal analogs of Lipid A.

In certain embodiments, an LNP composition comprises an mRNA encoding a Cas nuclease and a gRNA, which may be an sgRNA. In one embodiment, an LNP composition may comprise an amine lipid, an mRNA encoding a Cas nuclease, a gRNA, a helper lipid, a neutral lipid, and a PEG lipid. In one embodiment, an LNP composition may comprise a lipid component consisting of an amine lipid, a helper lipid, a neutral lipid, and a PEG lipid; and a nucleic acid component consisting of an mRNA encoding a Cas nuclease, and a gRNA. In one embodiment, an LNP composition may comprise a lipid component consisting of an amine lipid, a helper lipid, and a PEG lipid; and a nucleic acid component consisting of an mRNA encoding a Cas nuclease, and a gRNA. In certain compositions comprising an mRNA encoding a Cas nuclease and a gRNA, the helper lipid is cholesterol. In some compositions comprising an mRNA encoding a Cas nuclease and a gRNA, the neutral lipid is DSPC. Certain compositions comprising an mRNA encoding a Cas nuclease and a gRNA comprise less than about 1 mol-% neutral lipid, e.g. neutral phospholipid. Certain compositions comprising an mRNA encoding a Cas nuclease and a gRNA comprise less than about 0.5 mol-% neutral lipid, e.g. neutral phospholipid. In certain compositions, the LNP does not comprise a neutral lipid, e.g., neutral phospholipid. In additional embodiments comprising an mRNA encoding a Cas nuclease and a gRNA, the PEG lipid is PEG2k-DMG or PEG2k-C11. In certain embodiments, the amine lipid is selected from Lipid A and its equivalents, such as acetal analogs of Lipid A.

In certain embodiments, the LNP compositions include a Cas nuclease mRNA, such as a Class 2 Cas mRNA and at least one gRNA. In certain embodiments, the LNP composition includes a ratio of gRNA to Gas nuclease mRNA, such as Class 2 Gas nuclease mRNA from about 25:1 to about 1:25, In certain embodiments, the LNP formulation includes a ratio of gRNA to Cas nuclease mRNA, such as Class 2 Cas nuclease mRNA from about 10:1 to about 1:10. In certain embodiments, the LNP formulation includes a ratio of gRNA to Cas nuclease mRNA, such as Class 2 Cas nuclease mRNA from about 8:1 to about 1:8. As measured herein, the ratios are by weight. In some embodiments, the LNP formulation includes a ratio of gRNA to Cas nuclease mRNA, such as Class 2 Cas mRNA from about 5:1 to about 1:5. In some embodiments, ratio range is about 3:1 to 1:3, about 2:1 to 1:2, about 5:1 to 1:2, about 5:1 to 1:1, about 3:1 to 1:2, about 3:1 to 1:1, about 3:1, about 2:1 to 1:1. In some embodiments, the gRNA to mRNA ratio is about 3:1 or about 2:1 In some embodiments the ratio of gRNA to Cas nuclease mRNA, such as Class 2 Cas nuclease is about 1:1. The ratio may be about 25:1, 10:1, 5:1, 3:1, 1:1, 1:3, 1:5, 1:0, or 1:25.

The LNP compositions disclosed herein may include a template nucleic acid. The template nucleic acid may be co-formulated with an mRNA encoding a Cas nuclease, such as a Class 2 Cas nuclease mRNA. In some embodiments, the template nucleic acid may be co-formulated with a guide RNA. In some embodiments, the template nucleic acid may be co-formulated with both an mRNA encoding a Cas nuclease and a guide RNA. In some embodiments, the template nucleic acid may be formulated separately from an mRNA encoding a Cas nuclease or a guide RNA. The template nucleic acid may be delivered with, or separately from the LNP compositions. In some embodiments, the template nucleic acid may be single- or double-stranded, depending on the desired repair mechanism. The template may have regions of homology to the target DNA, or to sequences adjacent to the target DNA.

In some embodiments, LNPs are formed by mixing an aqueous RNA solution with an organic solvent-based lipid solution, e.g., 100% ethanol. Suitable solutions or solvents include or may contain: water, PBS, Iris buffer, NaCl, citrate buffer, ethanol, chloroform, diethylether, cyclohexane, tetrahydrofuran, methanol, isopropanol. A pharmaceutically acceptable buffer, e.g., for in vivo administration of LNPs, may be used. In certain embodiments, a buffer is used to maintain the pH of the composition comprising LNPs at or above pH 6.5. In certain embodiments, a buffer is used to maintain the pH of the composition comprising LNPs at or above pH 7.0. In certain embodiments, the composition has a pH ranging from about 7.2 to about 7.7. In additional embodiments, the composition has a pH ranging from about 7.3 to about 7.7 or ranging from about 7.4 to about 7.6. In further embodiments, the composition has a pH of about 7.2, 7.3, 7.4, 7.5, 7.6, or 7.7. The pH of a composition may be measured with a micro pH probe. In certain embodiments, a cryoprotectant is included in the composition. Non-limiting examples of cryoprotectants include sucrose, trehalose, glycerol, DMSO, and ethylene glycol. Exemplary compositions may include up to 10% cryoprotectant, such as, for example, sucrose. In certain embodiments, the LNP composition may include about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% cryoprotectant. In certain embodiments, the LNP composition may include about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% sucrose. In some embodiments, the LNP composition may include a buffer. In some embodiments, the buffer may comprise a phosphate buffer (PBS), a Tris buffer, a citrate buffer, or mixtures thereof. In certain exemplary embodiments, the buffer comprises NaCl. In certain emboidments, NaCl is omitted. Exemplary amounts of NaCl may range from about 20 mM to about 45 mM. Exemplary amounts of NaCl may range from about 40 mM to about 50 mM. In some embodiments, the amount of NaCl is about 45 mM. In some embodiments, the buffer is a Tris buffer. Exemplary amounts of Tris may range from about 20 mM to about 60 mM. Exemplary amounts of Tris may range from about 40 mM to about 60 mM. In some embodiments, the amount of Tris is about 50 mM. In some embodiments, the buffer comprises NaCl and Tris. Certain exemplary embodiments of the LNP compositions contain 5% sucrose and 45 mM NaCl in Tris buffer. In other exemplary embodiments, compositions contain sucrose in an amount of about 5% w/v, about 45 mM NaCl, and about 50 mM Tris at pH 7.5. The salt, buffer, and cryoprotectant amounts may be varied such that the osmolality of the overall formulation is maintained. For example, the final osmolality may he maintained at less than 450 mOsm/L. In further embodiments, the osmolality is between 350 and 250 mOsm/L. Certain embodiments have a final osmolality of 300+/−20 mOsm/L.

In some embodiments, inicrofluidic mixing, T-mixing, or cross-mixing is used. In certain aspects, flow rates, junction size, junction geometry, junction shape, tube diameter, solutions, and/or RNA and lipid concentrations may be varied. LNPs or LNP compositions may be concentrated or purified, e.g., via dialysis, tangential flow filtration, or chromatography. The LNPs may be stored as a suspension, an emulsion, or a lyophilized powder, for example. In some embodiments, an LNP composition is stored at 2-8° C., in certain aspects, the LNP compositions are stored at room temperature. In additional embodiments, an LNP composition is stored frozen, for example at −20′ C or −80° C. In other embodiments, an LNP composition is stored at a temperature ranging from about 0° C. to about −80° C. Frozen LNP compositions may be thawed before use, for example on ice, at room temperature, or at 25° C.

The LNPs may be, e.g., microspheres (including unilamellar and multilamellar vesicles, e.g., “liposomes”—lamellar phase lipid bilayers that, in some embodiments, are substantially spherical—and, in more particular embodiments, can comprise an aqueous core, e.g., comprising a substantial portion of RNA molecules), a dispersed phase in an emulsion, micelles, or an internal phase in a suspension.

Moreover, the LNP compositions are biodegradable, in that they do not accumulate to cytotoxic levels in vivo at a therapeutically effective dose. In some embodiments, the LNP compositions do not cause an innate immune response that leads to substantial adverse effects at a therapeutic dose level. In some embodiments, the LNP compositions provided herein do not cause toxicity at a therapeutic dose level.

In some embodiments, the pdi may range from about 0.005 to about 0.75. In some embodiments, the pdi may range from about 0.01 to about 0.5. In some embodiments, the pdi may range from about zero to about 0.4. In some embodiments, the pdi may range from about zero to about 0.35. In some embodiments, the pdi may range from about zero to about 0.35. In some embodiments, the pdi may range from about zero to about 0.3. In some embodiments, the pdi may range from about zero to about 0.25. In some embodiments, the pdi may range from about zero to about 0.2. In some embodiments, the pdi may be less than about 0.08, 0.1, 0.15, 0.2, or 0.4.

The LNPs disclosed herein have a size (e.g., Z-average diameter) of about 1 to about 250 nm. In some embodiments, the LNPs have a size of about 10 to about 200 nm. In further embodiments, the LNPs have a size of about 20 to about 150 nm. In some embodiments, the LNPs have a size of about 50 to about 150 nm. In some embodiments, the LNPs have a size of about 50 to about 100 nm. In some embodiments, the LNPs have a size of about 50 to about 120 nm. In some embodiments, the LNPs have a size of about 60 to about 100 nm. In some embodiments, the LNPs have a size of about 75 to about 150 nm. In some embodiments, the LNPs have a size of about 75 to about 120 nm. In some embodiments, the LNPs have a size of about 75 to about 100 nm. Unless indicated otherwise, all sizes referred to herein are the average sizes (diameters) of the fully formed nanoparticles, as measured by dynamic light scattering on a Malvern Zetasizer. The nanoparticle sample is diluted in phosphate buffered saline (PBS) so that the count rate is approximately 200-400 kcps. The data is presented as a weighted-average of the intensity measure (Z-average diameter).

In some embodiments, the LNPs are formed with an average encapsulation efficiency ranging from about 50% to about 100%. In some embodiments, the LNPs are formed with an average encapsulation efficiency ranging from about 50% to about 70%. In some embodiments, the LNPs are formed with an average encapsulation efficiency ranging from about 70% to about 90%. In some embodiments, the LNPs are formed with an average encapsulation efficiency ranging from about 90% to about 100%. In some embodiments, the LNPs are formed with an average encapsulation efficiency ranging from about 75% to about 95%.

In some embodiments, the LNPs are formed with an average molecular weight ranging from about 1.00E+05 g/mol to about 1.00E+10 g/mol. In some embodiments, the LNPs are formed with an average molecular weight ranging from about 5.00E+05 g/mol to about 7.00E+07 g/mol. In some embodiments, the LNPs are formed with an average molecular weight ranging from about 1.00E+06 g/mol to about 1.00E+10 g/mol. In some embodiments, the LNPs are formed with an average molecular weight ranging from about 1.00E+07 g/mol to about 1.00E+09 g/mol. In some embodiments, the LNPs are formed with an average molecular weight ranging from about 5.00E+06 g/mol to about 5.00E+09 g/mol.

In some embodiments, the polydispersity (Mw/Mn; the ratio of the weight averaged molar mass (Mw) to the number averaged molar mass (Mn)) may range from about 1.000 to about 2.000. In some embodiments, the Mw/Mn may range from about 1.00 to about 1.500. In some embodiments, the Mw/Mn may range from about 1.020 to about 1.400. In some embodiments, the Mw/Mn may range from about 1.010 to about 1.100. In some embodiments, the Mw/Mn may range from about 1.100 to about 1.350.

Methods of Engineering Cells; Engineered Cells

The LNP compositions disclosed herein may be used in methods for engineering cells through gene editing, both in vivo and in vitro. In some embodiments, the methods involve contacting a cell with an LNP composition described herein.

In some embodiments, methods involve contacting a cell in a subject, such as a mammal, such as a human. In some embodiments, the cell is in an organ, such as a liver, such as a mammalian liver, such as a human liver. In some embodiments, the cell is a liver cell, such as a mammalian liver cell, such as a human liver cell. In some embodiments, the cell is a hepatocyte, such as a mammalian hepatocyte, such as a human hepatocyte. In some embodiments, the liver cell is a stem cell. In some embodiments, the human liver cell may be a liver sinusoidal endothelial cell (LSEC). In some embodiments, the human liver cell may be a Kupffer cell. In some embodiments, the human liver cell may be a hepatic stellate cell. In some embodiments, the human liver cell may be a tumor cell. In some embodiments, the human liver cell may be a liver stem cell. In additional embodiments, the cell comprises ApoE-binding receptors. In some embodiments, the liver cell such as a hepatocyte is in situ. In some embodiments, the Jiver cell such as a hepatocyte is isolated, e.g., in a culture, such as in a primary culture. Also provided are methods corresponding to the uses disclosed herein, which comprise administering the LNP compositions disclosed herein to a subject or contacting a cell such as those described above with the LNP compositions disclosed herein

In some embodiments, engineered cells are provided, for example an engineered cell derived from any one of the cell types in the preceding paragraph. Such engineered cells are produced according to the methods described herein. In some embodiments, the engineered cell resides within a tissue or organ, e.g., a liver within a subject.

In some of the methods and cells described herein, a cell comprises a modification, for example an insertion or deletion (“indel”) or substitution of nucleotides in a target sequence. In some embodiments, the modification comprises an insertion of 1, 2, 3, 4 or 5 or more nucleotides in a target sequence. In some embodiments, the modification comprises an insertion of either 1 or 2 nucleotides in a target sequence. In other embodiments, the modification comprises a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or 25 or more nucleotides in a target sequence. In some embodiments, the modification comprises a deletion of either 1 or 2 nucleotides in a target sequence. In some embodiments, the modification comprises an indel which results in a frameshift mutation in a target sequence. In some embodiments, the modification comprises a substitution of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or 25 or more nucleotides in a target sequence. In some embodiments, the modification comprises a substitution of either 1 or 2 nucleotides in a target sequence. In some embodiments, the modification comprises one or more of an insertion, deletion, or substitution of nucleotides resulting from the incorporation of a template nucleic acid, for example any of the template nucleic acids described herein.

In some embodiments, a population of cells comprising engineered cells is provided, for example a population of cells comprising cells engineered according to the methods described herein. In some embodiments, the population comprises engineered cells cultured in vitro. In some embodiments, the population resides within a tissue or organ, e.g., a liver within a subject. In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95% or more of the cells within the population is engineered. In certain embodiments, a method disclosed herein results in at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95% editing efficiency (or “percent editing”), defined by detetion of indels. In other embodiments, a method disclosed herein, results in at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95% DNA modification efficiency, defined by detecting a change in sequence, whether by insertion, deletion, substitution or otherwise. In certain embodiments, a method disclosed herein results in an editing efficiency level or a DNA modification efficiency level of between about 5% to about 100%, about 10% to about 50%, about 20 to about 100%, about 20 to about 80%, about 40 to about 100%, or about 40 to about 80% in a cell population.

In some of the methods and cells described herein, cells within the population comprise a modification, e.g., an indel or substitution at a target sequence. In some embodiments, the modification comprises an insertion of 1, 2, 3, 4 or 5 or more nucleotides in a target sequence, In some embodiments, the modification comprises an insertion of either 1 or 2 nucleotides in a target sequence. In other embodiments, the modification comprises a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or 25 or more nucleotides in a target sequence. In some embodiments, the modification comprises a deletion of either 1 or 2 nucleotides in a target sequence. In some embodiments, the modification results in a frameshift mutation in a target sequence. In some embodiments, the modification comprises an indel which results in a frameshift mutation in a target sequence. In some embodiments, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or more of the engineered cells in the population comprise a frameshift mutation. In some embodiments, the modification comprises a substitution of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or 25 or more nucleotides in a target sequence. In some embodiments, the modification comprises a substitution of either 1 or 2 nucleotides in a target sequence. In some embodiments, the modification comprises one or more of an insertion, deletion, or substitution of nucleotides resulting from the incorporation of a template nucleic acid, for example any of the template nucleic acids described herein.

Methods of Gene Editing

The LNP compositions disclosed herein may be used for gene editing in vivo and in vitro. In one embodiment, one or more LNP compositions described herein may be administered to a subject in need thereof. In one embodiment, one or more LNP compositions described herein may contact a cell. In one embodiment, a therapeutically effective amount of a composition described herein may contact a cell of a subject in need thereof. In one embodiment, a genetically engineered cell may be produced by contacting a cell with an LNP composition described herein. In various embodiments, the methods comprise introducing a template nucleic acid to a cell or subject, as set forth above.

In some embodiments, the methods involve administering the LNP composition to a cell associated with a liver disorder. In some embodiments, the methods involve treating a liver disorder. In certain embodiments, the methods involve contacting a hepatic cell with the LNP composition. In certain embodiments, the methods involve contacting a hepatocyte with the LNP composition. In some embodiments, the methods involve contacting an ApoE binding cell with the LNP composition.

In one embodiment, an LNP composition comprising an mRNA encoding a Class 2 Cas nuclease and a gRNA may be administered to a cell, such as an ApoE binding cell. In additional embodiments, a template nucleic acid is also introduced to the cell. In certain instances, an LNP composition comprising, a Class 2 Cas nuclease and an sgRNA may be administered to a cell, such as an ApoE binding cell. In one embodiment, an LNP composition comprising an mRNA encoding a Class 2 Cas nuclease, a gRNA, and a template may be administered to a cell. In certain instances, an LNP composition comprising a Cas nuclease and an sgRNA may be administered to a liver cell. In some cases, the liver cell is in a subject.

In certain embodiments, a subject may receive a single dose of an LNP composition. In other examples, a subject may receive multiple doses of an LNP composition. In some embodiments, the LNP composition is administered 2-5 times. Where more than one dose is administered, the doses may be administered about 1, 2, 3, 4, 5, 6, 7, 14, 21, or 28 days apart; about 2, 3, 4, 5, or 6 months apart; or about 1, 2, 3, 4, or 5 years apart. In certain embodiments, editing improves upon readministration of an LNP composition.

In one embodiment, an LNP composition comprising an mRNA encoding a Cas nuclease such as a Class 2 Cas nuclease, may be administered to a cell, separately from the administration of a composition comprising a gRNA. In one embodiment, an LNP composition comprising an mRNA encoding a Cas nuclease such as a Class 2 Cas nuclease and a gRNA may be administered to a cell, separately from the administration of a template nucleic acid to the cell. In one embodiment, an LNP composition comprising an mRNA encoding a Cas nuclease such as a Class 2 Cas nuclease may be administered to a cell, followed by the sequential administration of an LNP composition comprising a gRNA and then a template to the cell. In embodiments where an LNP composition comprising an mRNA encoding a Cas nuclease is administered before an LNP composition comprising a gRNA, the administrations may be separated by about 4, 6, 8, 12, or 24 hours; or 2, 3, 4, 5, 6, or 7 days.

In one embodiment, the LNP compositions may be used to edit a gene resulting in a gene knockout. In an embodiment, the LNP compositions may be used to edit a gene resulting in gene knockdown in a population of cells. In another embodiment, the LNP compositions may be used to edit a gene resulting in a gene correction. In a further embodiment, the LNP compositions may be used to edit a cell resulting in gene insertion.

In one embodiment, administration of the LNP compositions may result in gene editing which results in persistent response. For example, administration may result in a duration of response of a day, a month, a year, or longer. As used herein, “duration of response” means that, after cells have been edited using an LNP composition disclosed herein, the resulting modification is still present for a certain period of time after administration of the LNP composition. The modification may be detected by measuring target protein levels. The modification may be detected by detecting the target DNA. In some embodiments, the duration of response may be at least 1 week. In other embodiments, the duration of response may be at least 2 weeks. In one embodiment, the duration of response may be at least 1 month. In some embodiments, the duration of response may be at least 2 months. In one embodiment, the duration of response may be at least 4 months. In one embodiment, the duration of response may be at least 6 months. In certain embodiments, the duration of response may be about 26 weeks. In some embodiments, the duration of response may be at least 1 year. In some embodiments, the duration of response may be at least 5 years. In some embodiments, the duration of response may be at least 10 years. In some embodiments, a persistent response is detectable after at least 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, or 24 months, either by measuring target protein levels or by detection of the target DNA. In some embodiments, a persistent response is detectable after at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or 20 years, either by measuring target protein levels or by detection of the target DNA.

The LNP compositions can be administered parenterally. The LNP compositions may be administered directly into the blood stream, into tissue, into muscle, or into an internal organ. Administration may be systemic, e.g., to injection or infusion. Administration may be local. Suitable means for administration include intravenous, intraarterial, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, subretinal, intravitreal, intra-anterior chamber, intramuscular, intrasynovial, intradermal, and subcutaneous. Suitable devices for administration include needle (including microneedle) injectors, needle-free injectors, osmotic pumps, and infusion techniques.

The LNP compositions will generally, but not necessarily, be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term “excipient” includes any ingredient other than the compound(s) of the disclosure, the other lipid component(s) and the biologically active agent. An excipient may impart either a functional (e.g. drug release rate controlling) and/or a non-functional (e.g. processing aid or diluent) characteristic to the formulations. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.

Parenteral formulations are typically aqueous or oily solutions or suspensions. Where the formulation is aqueous, excipients such as sugars (including but not restricted to glucose, mannitol, sorbitol, etc.) salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated with a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water (WFI).

While the invention is described in conjunction with the illustrated embodiments, it is understood that they are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, including equivalents of specific features, which may be included within the invention as defined by the appended claims.

Both the foregoing general description and detailed description, as well as the following examples, are exemplary and explanatory only and are not restrictive of the teachings. The section headings used herein are for organizational purposes only and are not to be construed as limiting the desired subject matter in any way. In the event that any literature incorporated by reference contradicts any term defined in this specification, this specification controls. All ranges given in the application encompass the endpoints unless stated otherwise.

It should be noted that, as used in this application, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, reference to “a composition” includes a plurality of compositions and reference to “a cell” includes a plurality of cells and the like. The use of “or” is inclusive and means “and/or” unless stated otherwise.

Numeric ranges are inclusive of the numbers defining the range. Measured and measureable values are understood to be approximate, taking into account significant digits and the error associated with the measurement. The term “about” or “approximately” means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. The use of a modifier such as “about” before a range or before a list of values, modifies each endpoint of the range or each value in the list. “About” also includes the value or enpoint. For example, “about 50-55” encompasses “about 50 to about 55”. Also, the use of “comprise”, “comprises”, “comprising”, “contain”, “contains”, “containing”, “include”, “includes”, and “including” is not limiting.

Unless specifically noted in the above specification, embodiments in the specification that recite “comprising” various components are also contemplated as “consisting of” or “consisting essentially of” the recited components; embodiments in the specification that recite “consisting of” various components are also contemplated as “comprising” or “consisting essentially of” the recited components; embodiments in the specification that recite “about” various components are also contemplated as “at” the recited components; and embodiments in the specification that recite “consisting essentially of” various components are also contemplated as “consisting of” or “comprising” the recited components (this interchangeability does not apply to the use of these terms in the claims).

EXAMPLES

Example 1

LNP Compositions for In Vivo Editing in Mice

Small scale preparations of various LNP compositions were prepared to investigate their properties. In assays for percent liver editing in mice, Cas9 mRNA and chemically modified sgRNA targeting a mouse TTR sequence were formulated in LNPs with varying PEG mol-%, Lipid A mol-%, and N:P ratios as described in Table 2, below.

TABLE 2
LNP compositions.
LNP #	Lipid A mol-%	PEG-DMG mol-%	N:P ratio
(various)	45	2, 2.5, 3, 4, 5	4.5
(various)	45	2, 2.5, 3, 4, 5	6
(various)	50	2, 2.5, 3, 4, 5	4.5
(various)	50	2, 2.5, 3, 4, 5	6
(various)	55	2, 2.5, 3, 4, 5	4.5
(various)	55	2, 2.5, 3, 4, 5	6

In FIG. 1, LNP formulations are identified on the X-axis based on their Lipid A mol-% and N:P ratios, labeled “% CL; N:P”. As indicated in the legend to FIG. 1, PEG-2k-DMG concentrations of 2, 2.5, 3, 4, or 5 mol-% were formulated with (1) 45 mol-%, Lipid A; 4.5 N:P (“45; 4.5”); (2) 45 mol-% Lipid A; 6 N:P (“45; 6”); (3) 50 mol-% Lipid A; 4.5 N:P (“50; 4.5”); (4) 50 mol-% Lipid A; 6 N:P (“50; 6”); (5) 55 mol-% Lipid A; 4.5 N:P (“55; 4.5”); and (6) 55 mol-% Lipid A; 6 N:P (“55; 6”). The DSPC mol-% was kept constant at 9 mol-% and the cholesterol mol-% was added to bring the balance of each formulation lipid component to 100 mol-%. Each of the 30 formulations was formulated as described below, and administered as single dose at 1 mg per kg or 0.5 mg per kg doses of total RNA, (FIG. 1A and FIG. 1B, respectively).

LNP Formulation—NanoAssemblr

The lipid nanoparticle components were dissolved in 100% ethanol with the lipid component molar ratios set forth above. The RNA cargos were dissolved in 25 mM citrate, 100 mM NaCl, pH 5.0, resulting in a concentration of RNA cargo of approximately 0.45 mg/mL. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 4.5 or about 6, with the ratio of mRNA to gRNA at 1:1 by weight.

The LNPs were formed by microfluidic mixing of the lipid and RNA solutions using a Precision Nanosystems NanoAssemblr™ Benchtop Instrument, according to the manufacturer's protocol. A 2:1 ratio of aqueous to organic solvent was maintained during mixing using differential flow rates. After mixing, the LNPs were collected, diluted in water (approximately 1:1 v/v), held for 1 hour at room temperature, and further diluted with water (approximately 1:1 v/v) before final buffer exchange. The final buffer exchange into 50 mM Tris, 45 mM NaCl, 5% (w/v) sucrose, pH 7.5 (TSS) was completed with PD-10 desalting columns (GE). If required, formulations were concentrated by centrifugation with Amicon 100 kDa centrifugal filters (Millipore). The resulting mixture was then filtered using a 0.2 μm sterile filter. The final LNP was stored at −80° C. until further use.

Formulation Analytics

Dynamic Light Scattering (“DLS”) is used to characterize the polydispersity index (“pdi”) and size of the LNPs of the present disclosure. DLS measures the scattering of light that results from subjecting a sample to a light source. PDI, as determined from DLS measurements, represents the distribution of particle size (around the mean particle size) in a population, with a perfectly uniform population having a PDI of zero.

Electropheretic light scattering is used to characterize the surface charge of the LNP at a specified pH. The surface charge, or the zeta potential, is a measure of the magnitude of electrostatic repulsion/attraction between particles in the LNP suspension.

Assymetric-Flow Field Flow Fractionation—Multi-Angle Light Scattering (AF4-MALS) is used to separate particles in the formulation by hydrodynamic radius and then measure the molecular weights, hydrodynamic radii and root mean square radii of the fractionated particles. This allows the ability to assess molecular weight and size distributions as well as secondary characteristics such as the Burchard-Stockmeyer Plot (ratio of root mean square (“rms”) radius to hydrodynamic radius over time suggesting the internal core density of a particle) and the rms conformation plot (log of rms radius versus log of molecular weight where the slope of the resulting linear fit gives a degree of compactness versus elongation).

Nanoparticle tracking analysis (NTA, Malvern Nanosight) can be used to determine formulation particle size distribution as well as particle concentration. LNP samples are diluted appropriately and injected onto a microscope slide. A camera records the scattered light as the particles are slowly infused through field of view. After the movie is captured, the Nanoparticle Tracking Analysis processes the movie by tracking pixels and calculating a diffusion coefficient. This diffusion coefficient can be translated into the hydrodynamic radius of the particle. The instrument also counts the number of individual particles counted in the analysis to give particle concentration.

Cryo-electron microscopy (“cryo-EM”) can be used to determine the particle size, morphology, and structural characteristics of an LNP.

Lipid compositional analysis of the LNPs can be determined from liquid chromotography followed by charged aerosol detection (LC-CAD). This analysis can provide a comparison of the actual lipid content versus the theoretical lipid content.

LNP formulations are analyzed for average particle size, polydispersity index (pdi), total RNA content, encapsulation efficiency of RNA, and zeta potential. LNP formualtions may be further characterized by lipid analysis, AF4-MALS, NTA, and/or cryo-EM. Average particle size and polydispersity are measured by dynamic light scattering (DLS) using a Malvern Zetasizer DLS instrument. LNP samples were diluted 30× in PBS prior to being measured by DLS. Z-average diameter which is an intensity-based measurement of average particle size was reported along with number average diameter and pdi. A Malvern Zetasizer instrument is also used to measure the zeta potential of the LNP. Samples are diluted 1:17 (50 μL into 800 μL) in 0.1× PBS, pH 7.4 prior to measurement.

A fluorescence-based assay (Ribogreen®, ThermoFisher Scientific) is used to determine total RNA concentration and free RNA. Encapsulation efficiency is calclulated as (Total RNA−Free RNA)/Total RNA. LNP samples are diluted appropriately with 1× TE buffer containing 0.2% Triton-X 100 to determine total RNA or 1× TE buffer to determine free RNA. Standard curves are prepared by utilizing the starting RNA solution used to make the formulations and diluted in 1× TE buffer+/−0.2% Triton-X 100. Diluted RiboGreen® dye (according to the manufacturer's instructions) is then added to each of the standards and samples and allowed to incubate for approximately 10 minutes at room temperature, in the absence of light. A SpectraMax M5 Microplate Reader (Molecular Devices) is used to read the samples with excitation, auto cutoff and emission wavelengths set to 488 nm, 515 nm, and 525 nm respectively. Total RNA and free RNA are determined from the appropriate standard curves.

Encapsulation efficiency is calclulated as (Total RNA−Free RNA)/Total RNA. The same procedure may be used for determining the encapsulation efficiency of a DNA-based or nucleic acid-containing cargo component. For single-strand DNA Oligreen Dye may be used, and for double-strand DNA, Picogreen Dye.

AF4-MALS is used to look at molecular weight and size distributions as well as secondary statistics from those calculations. LNPs are diluted as appropriate and injected into an AF4 separation channel using an HPLC autosampler where they are focused and then eluted with an exponential gradient in cross flow across the channel. All fluid is driven by an HPLC pump and Wyatt Eclipse Instrument. Particles eluting from the AF4 channel flow through a UV detector, multi-angle light scattering detector, quasi-elastic light scattering detector and differential refractive index detector. Raw data is processed by using a Debeye model to determine molecular weight and rms radius from the detector signals.

Lipid components in LNPs are analyzed quantitatively by HPLC coupled to a charged aerosol detector (CAD). Chromatographic separation of 4 lipid components is achieved by reverse phase HPLC. CAD is a destructive mass-based detector which detects all non-volatile compounds and the signal is consistent regardless of analyte structure.

Cas9 mRNA and gRNA Cargos

The Cas9 mRNA cargo was prepared by in vitro transcription. Capped and polyadenylated Cas9 mRNA comprising 1× NLS (SEQ ID NO:48) was generated by in vitro transcription using a linearized plasmid DNA template and T7 RNA polymerase. Plasmid DNA containing a T7 promoter and a 100 nt poly(A/T) region was linearized by incubating at 37° C. for 2 hrs with XbaI with the following conditions: 200 ng/μL plasmid. 2 U/μL XbaI (NEB), and 1× reaction buffer. The XbaI was inactivated by heating the reaction at 65° C. for 20 min. The linearized plasmid was purified from enzyme and buffer salts using a silica maxi spin column (Epoch Life Sciences) and analyzed by agarose gel to confirm linearization. The IVT reaction to generate Cas9 modified mRNA was incubated at 37° C. for 4 hours in the following conditions: 50 ng/μL linearized plasmid; 2 mM each of GTP, ATP, CTP, and N1-methyl pseudo-UTP (Trilink); 10 mM ARCA (Trilink); 5 U/μL T7 RNA polymerase (NEB); 1 U/μL Murine RNase inhibitor (NEB); 0.004 U/μL Inorganic E. coli pyrophosphatase (NEB); and 1× reaction buffer. After the 4 hr incubation, TURBO DNase (ThermoFisher) was added to a final concentration of 0.01 U/μL, and the reaction was incubated for an additional 30 minutes to remove the DNA template. The Cas9 mRNA was purified from enzyme and nucleotides using a MegaClear Transcription Clean-up kit per the manufacturer's protocol (ThermoFisher). Alternatively, the Cas9 mRNA was purified with a LiCl precipitation method.

The sgRNA in this example was chemically synthesized and sourced from a commercial supplier. The sg282 sequence is provided below, with 2′-O-methyl modifications and phosphorothioate linkages as represented below (m=2′-OMe; *=phosphorothioate):

(SEQ ID NO: 42)
mU*mU*mA*CAGCCACGUCUACAGCAGUUUUAGAmGmCmUmAmGmAmAm
AmUmAmGmCAAGUUAAAAUAAGGCUAGUCCGUUAUCAmAmCmUmUmGmAm
AmAmAmAmGmUmGmGmCmAmCmCmGmAmGmUmCmGmGmUmGmCmU*mU
*mU*mU..

LNPs

The final LNPs were characterized to determine the encapsulation efficiency, polydispersity index, and average particle size according to the analytical methods provided above.

The LNPs were dosed to mice (single dose at 1 mg/kg or 0.5 mg/kg) and genomic DNA was isolated for NGS analysis as described below.

LNP Delivery In Vivo

CD-1 female mice, ranging from 6 to 10 weeks of age were used in each study. Animals were weighed and grouped according to body weight for preparing dosing solutions based on group average weight. LNPs were dosed via the lateral tail vein in a volume of 0.2 mL per animal (approximately 10 mL per kilogram body weight). The animals were observed at approximately 6 hours post dose for adverse effects. Body weight was measured at twenty-four hours post-administration, and animals were euthanized at various time points by exsanguination via cardiac puncture under isoflurane anesthesia. Blood was collected into serum separator tubes or into tubes containing buffered sodium citrate for plasma as described herein. For studies involving in vivo editing, liver tissue was collected from the median lobe or from three independent lobes (e.g., the right median, left median, and left lateral lobes) from each animal for DNA extraction and analysis.

Cohorts of mice were measured for liver editing by Next-Generation Sequencing (NGS) and serum TTR levels (data not shown).

Transthyretin (TTR) ELISA Analysis

Blood was collected and the serum was isolated as indicated. The total mouse TTR serum levels were determined using a Mouse Prealbumin (Transthyretin) ELISA Kit (Aviva Systems Biology, Cat. OKIA00111). Rat TTR serum levels were measured using a rat specific ELISA kit (Aviva Systems Biology catalog number OKIA00159) according to manufacture's protocol. Briefly, sera were serial diluted with kit sample diluent to a final dilution of 10,000-fold. This diluted sample was then added to the ELISA plates and the assay was then carried out according to directions.

NGS Sequencing

In brief, to quantitatively determine the efficiency of editing at the target location in the genome, genomic DNA was isolated and deep sequencing was utilized to identify the presence of insertions and deletions introduced by gene editing.

PCR primers were designed around the target site (e.g., TTR), and the genomic area of interest was amplified. Primer sequences are provided below. Additional PCR was performed according to the manufacturer's protocols (Illumina) to add the necessary chemistry for sequencing. The amplicons were sequenced on an Illumina MiSeq instrument. The reads were aligned to the human reference genome (e.g., hg38) after eliminating those having low quality scores. The resulting files containing the reads were mapped to the reference genome (BAM files), where reads that overlapped the target region of interest were selected and the number of wild type reads versus the number of reads which contain an insertion, substitution, or deletion was calculated.

The editing percentage (e.g., the “editing efficiency” or “percent editing”) is defined as the total number of sequence reads with insertions or deletions over the total number of sequence reads, including wild type.

FIG. 1 shows editing percentages in mouse liver as measured by NGS. As shown in FIG. 1A, when 1 mg per kg RNA is dosed, in vivo editing percentages range from about 20% to over 60% liver editing. At a 0.5 mg per kg dose, FIG. 1B, about 10% to 60% liver editing was observed. In this mouse in vivo testing, all compositions effectively delivered Cas9 mRNA and gRNA to the liver cells, with evidence of active CRISPR/Cas nuclease activity at the target site measured by NGS for each LNP composition. LNPs containing 5% PEG lipid had lower encapsulation (data not shown), and somewhat reduced potency.

Example 2

LNP Composition Analytics

Analytical characterization of LNPs shows improved physicochemical parameters in LNPs formulated with increasing amounts of Lipid A and PEG-lipid. Compositons that comprise either 2 mol-% or 3 mol-% PEG lipid (PEG2k-DMG) are provided in Table 3 below.

	TABLE 3
	LNP898	LNP897	LNP966	LNP969
CL/chol./	45/44/9/2	45/43/9/3	50/38/9/3	55/33/9/3
DSPC/PEG
(theoretical
mol-%)
mRNA	Cas9	Cas9	Cas9 U-dep	Cas9 U-dep
	SEQ ID	SEQ ID	SEQ ID	SEQ ID
	NO: 48	NO: 48	NO: 43	NO: 43
gRNA	G502	G502	G534	G534
	SEQ ID	SEQ ID	SEQ ID	SEQ ID
	NO: 70	NO: 70	NO: 72	NO: 72
N/P	4.5	4.5	6.0	6.0

LNP Formulation—Cross Flow

The LNPs were formed by impinging jet mixing of the lipid in ethanol with two volumes of RNA solutions and one volume of water. The lipid in ethanol is mixed through a mixing cross with the two volumes of RNA solution. A fourth stream of water is mixed with the outlet stream of the cross through an inline tee. (See WO2016010840 at FIG. 2.) The LNPs were maintained at room temperature for 1 hour, and then further diluted with water (approximately 1:1 v/v). Diluted LNPs were concentrated using tangential flow filtration on a flat sheet cartridge (Sartorius, 100 kD MWCO) and then buffer exchanged by diafiltration into 50 mM Tris, 45 mM NaCl, 5% (w/v) sucrose, pH 7.5 (TSS). Alternatively, the final buffer exchange into TSS was completed with PD-10 desalting columns (GE). If required, formulations were concentrated by centrifugation with Amicon 100 kDa centrifugal filters (Millipore). The resulting mixture was then filtered using a 0.2 μm sterile filter. The final LNP was stored at 4° C. or −80° C. until further use.

Cas9 mRNA and sgRNA were prepared as in Example 1, except that capped and poly-adenylated Cas9 U-depleted (Cas9 Udep) mRNA comprises SEQ ID N:43. Sg282 is described in Example 1, and the sequence for sg534 (“G534”) is provided below:

(SEQ ID NO: 72)
mA*mC*mG*CAAAUAUCAGUCCAGCGGUUUUAGAmGmCmUmAmGmAmA
mAmUmAmGmCAAGUUAAAAUAAGGCUAGUCCGUUAUCAmAmCmUmUm
GmAmAmAmAmAmGmUmGmGmCmAmCmCmGmAmGmUmCmGmGmUmGm
CmU*mU*mU*mU

LMP formulations were analyzed for average particle size, polydispersity (pdi), total RNA content and encapsulation efficiency of RNA as described in Example 1.

Analysis of average, particle size, polydispersity (PDI), total RNA content and encapsulation efficiency of RNA are shown in Table 4. In addition to the theoretical lipid concentrations of the LNP compositions, lipid analysis demonstrated the actual mol-% lipid levels, as indicated in Table 5 below.

TABLE 4
		Z-		Number	RNA
LNP		Ave.		Ave.	Conc	Eneaps.
ID #	N/P	(nm)	FBI	(nm)	(mg/mL)	(%)
LNP898	4.5	87.91	0.030	71.33	1.53	98
LNP897	4.5	74.05	0.036	58.55	1.43	98
LNP966	6.0	82.78	0.010	67.86	2.12.	98
LNP969	6.0	92.97	0.042	75.52	2.09	97

TABLE 5
	Lipid Ratio
	(Lipid A/Chol/	Lipid A	Chol	DSPC	PEG
	DSPC/PEG)	mg/mL	mg/mL	mg/mL	mg/mL
LNP	(theoretical	(theoretical	(theoretical	(theoretical	(theoretical
ID #	and actual)	and actual)	and actual)	and actual)	and actual)
LNP898	45/44/9/2	18.0	8.0	3.3	2.3
	46.1/42.6/9.2/2	18.3	7.7	3.4	2.4
LNP897	45/43/9/3	18.0	7.8	3.3	3.5
	44.8/42.9/9.2/3.1	17.8	7.7	3.4	3.6
LNP966	50/38/9/3	33.4	11.5	5.6	5.8
	50.0/38.0/8.8/3.1	35.6	12.3	5.8	6.5
LNP969	55/33/9/3	33.4	9.1	5.1	5.3
	54.8/33.2/8.8/3.2	31.6	8.7	4.7	5.4

To further analyze the physicochemical properties, LNP897, LNP898, LNP966, and LNP969 were subjected to Asymmetric-Flow Field Flow Fractionation—Multi-Angle Light Scattering (AF4-MALS) analysis. The AF4-MALS instrument measures particle size and molecular weight distribtions, and provides information about particle conformation and density.

LNPs are injected into an AF4 separation channel using an HPLC autosampler where they are focused and then eluted with an exponential gradient in cross flow across the channel. All fluid is driven by an HPLC pump and Wyatt Eclipse Instrument. Particles eluting from the AF4 channel flow through a UV detector, Wyatt Heleos II multi-angle light scattering detector, quasi-elastic light scattering detector and Wyatt Optilab T-rEX differential refractive index detector. Raw data is processed in Wyatt Astra 7 Software by using a Debeye model to determine molecular weight and cats radius from the detector signals.

A log differential molar mass plot for the LNPs is provided as FIG. 2A. In brief, the X-axis indicates molar mass (g/mol), and the Y-axis indicates the differential number fraction. The log differential molar mass plot shows the distribution of the different molecular weights measured for a specific formulation. This gives data towards the mode of the molecular weights as well as the overall distribution of molecular weights within the formulation, which gives a better picture of particle heterogeniety than average molecular weight.

The heterogeniety of the different LNP formulations are determined by measuring the different molar mass moments and calculating the ratio of the weight averaged molar mass (Mw) to the number averaged molar mass (Mn) to give a polydispersity of Mw/Mn. The graph of the polydispersity for these different formulations is provided in FIG. 2B.

The data indicate tighter particle distributions with 3 mol-% PEG, and with 50 and 55 mol-% Lipid A at N/P 6.0 as shown in FIG. 2A. This is reflected in a tight polydispersity as shown in FIG. 2B

Example 3

AF4 MALS Data—Additional Formulations

Analytical characterization of LNPs shows improved physicochemical parameters in LNPs formulated with increasing amounts of Lipid A. Compositons that comprise either 45 mol-%, 50 mol-%, or 55 mol-% Lipid A with two different gRNA are provided in Table 6 below.

	TABLE 6
	LNP1021	LNP1022	LNP1023	LNP1024	LNP1025
CL/chol./DSPC/PEG	50/38/9/3	55/33/9/3	45/43/9/3	50/38/9/3	55/33/9/3
(theoretical mol-%)
mRNA	Cas9 Udep	Cas9 Udep	Cas9 Udep	Cas9 Udep	Cas9 Udep
	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID
	NO: 43	NO: 43	NO: 43	NO: 43	NO: 43
gRNA	G502	G502	G502	G509	G509
	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID
	NO: 70	NO: 70	N0: 70	NO: 71	NO: 71
N/P	6.0	6.0	4.5	6.0	6.0

The LNPs were formed as described in Example 2.

Cas9 mRNA and sgRNA were prepared as described above.

The LNPs compositions were characterized to determine the encapsulation efficiency, polydispersity index, and average particle size as described in Example 1.

Analysis of average particle size, polydispersity (PDI), total RNA content and encapsulation efficiency of RNA are shown in Table 7. In addition to the theoretical lipid concentrations of the LNP compositions, lipid analysis demonstrated the actual mol-% lipid levels, as indicated in Table 8, below.

TABLE 7
		Z-		Number	RNA
LNP		Ave.		Ave.	Conc.	Encaps.
ID #	N/P	(nm)	PDI	(nm)	(mg/mL)	(%)
LNP1021	6.0	83.18	0.027	67.15	1.63	98
LNP1022	6.0	94.08	0.005	78.28	1.60	97
LNP1023	4.5	74.01	0.017	61.11	1.61	97
LNP1024	6.0	85.37	0.002	70.42	1.59	97
LNP1025	6.0	94.47	0.018	77.71	1.60	98

TABLE 8
	Lipid Ratio
	(Lipid A/Chol/	Lipid A	Chol.	DSPC	PEG
	DSPC/PEG)	mg/mL	mg/mL	mg/mL	mg/mL
LNP	(theoretical	(theoretical	(theoretical	(theoretical	(theoretical
ID #	and actual)	and actual)	and actual)	and actual)	and actual)
LNP1021	50/38/9/3	23.6	8.1	3.9	4.1
	50.9/37.4/8.6/3.1	21.6	7.2.	3.4	3.8
LNP1022	55/33/9/3	23.6	6.4	3.6	3.7
	55.2/33.0/8.7/3.1	20.4	5.5	3.0	3.4
LNP1023	45/43/9/3	17.7	7.7	3.3	3.4
	45.9/42.4/8.6/3.1	15.3	6.4	2.7	3.0
LNP1024	50/38/9/3	23.6	8.1	3.9	4.1
	50.5/37.9/8.5/3.0	22.4	7.6	3.5	3.9
LNP1024	55/33/9/3	23.6	6.4	3.6	3.7
	55.5/33.1/8.5/3.0	21.3	5.8	3.0	3.4

To further analyze the physicochemical properties, LNP1021, LNP1022, LNP1023, LNP1024 and LNP1025 were subjected to Asymmetric-Flow Field Flow Fractionation—Multi-Angle Light Scattering (AF4-MALS) analysis. The AF4-MALS instrument measures particle size and molecular weight distribtions, and provides information about particle conformation and density.

LNPs were run on AF4-MALS as described in Example 1.

A log differential molar mass plot for the LNPs is provided as FIG. 3A. In brief, the X-axis indicates molar mass (g/mol), and the Y-axis indicates the differential number fraction. The log differential molar mass plot shows the distribution of the different molecular weights calculated for a specific formulation. This gives data towards the mode of the molecular weights as well as the overall distribution of molecular weights within the formulation, which gives a better picture of particle heterogeniety than average molecular weight.

Average molecular weight is plotted in FIG. 3B. The average molecular weight is the average of the entire distribution but gives no information about the shape of that distribution. LNP1022 and LNP1025 have the same average molecular weight but LNP1022 has a slightly broader distribution.

The heterogeniety of the different LNP formulations are calculated by look at the different molar mass moments and calculating the ratio of the weight averaged molar mass (Mw) to the number averaged molar mass (Mn) to give a polydispersity of Mw/Mn. The graph of the polydispersity for these different formulations is provided in FIG. 4A.

Additionally, a Burchard-Stockmeyer plot of the LNP formulations is provided as FIG. 4B. The Burchard-Stockmeyer plot shows the ratio of the rms radius versus the hydrodynamic radius across the elution of the formulation from the AF4 channel. This gives information towards the internal density of a lipid nanoparticle. FIG. 4B shows that LNP1021, LNP1022 and LNP1023 have different profiles in this measurement.

Example 4

Increased PEG Lipid Maintains Potency with Reduced Cytokine Response

In another study, PEG DMG lipid was compared in LNP formulations comprising 2 mol-% or 3 mol-% of the PEG lipid. Compositons that comprise either 2 mol-%, or 3 mol-%, PEG DMG are provided in Table 9 below.

	TABLE 9
	LNP809	LNP810
	CL/chol./DSPC/PEG	45/44/9/2	45/43/9/3
	(theoretical mol-%)
	mRNA	Cas9	Cas9
		SEQ ID NO: 48	SEQ ID NO: 48
	gRNA	G390	G390
		SEQ ID NO: 69	SEQ ID NO: 69
	N/P	4.5	4.5

The LNPs were formed by the process described in Example 2.

Cas9 mRNA and sgRNA were prepared as in Example 1, with the sequence of sg390 (“G390”) provided below:

(SEQ ID NO: 69)
mG*mC*mC*GAGUCUGGAGAGCUGCAGUUUUAGAmGmCmUmAmGmAmAm
AmUmAmGmCAAGUUAAAAUAAGGCUAGUCCGUUAUCAmAmCmUmUmGmAm
AmAmAmAmGmUmGmGmCmAmCmCmGmAmGmUmCmGmGmUmGmCmU*mU
*mU*mU.

LNP formulations were analyzed for average particle size, polydispersity (pdi), total RNA content and encapsulation efficiency of RNA as described in Example 1.

Analysis of average particle size, polydispersity (PDI), total RNA content and encapsulation efficiency of RNA are shown in Table 10. In addition to the theoretical lipid concentrations of the LNP compositions, lipid analysis demonstrated the actual mol-% lipid levels, as indicated in Table 11: below.

TABLE 10
		Z-		Number	RNA
LNP		Ave.		Ave.	Conc.	Encaps.
ID #	N/P	(nm)	PDI	(nm)	(mg/mL)	(%)
LNP809	4.5	89.85	0.060	72.10	2.45	97
LNP810	4.5	75.26	0.025	61.17	2.14	97

TABLE 11
	Lipid Ratio
	(Lipid A/Chol/	Lipid A	Chol.	DSPC	PEG
	DSPC/PEG)	mg/mL	mg/mL	mg/mL	mg/mL
LNP	(theoretical	(theoretical	(theoretical	(theoretical	(theoretical
ID #	and actual)	and actual)	and actual)	and actual)	and actual)
LNP809	45/44/9/2	28.6	12.7	5.3	3.7
	45.7/43.3/9.0/2.1	30.5	13.1	5.6	4.0
LNP810	45/43/9/3	25.2	10.9	4.7	4.9
	45.0/42.3/9.7/3.0	24.7	10.5	4.9	4.7

Rat serum cytokines were evaluated using a Luminex magnetic bead multiplex assay (Milliplex MAP magnetic bead assay from Millipore Sigma, catalog number RECYTMAG-65K) analyzing MCP-1, IL-6, TNF-alpha and IFN-gamma. The assay beads were read on the BioRad BioPlex-200 and cytokine concentrations calculated off a standard curve using 4 parameter logistic fit with BioPlex Manager Software version 6.1. Data is graphed in FIG. 5. See FIG. 5A (serum TTR), FIG. 5B (liver editing), and FIG. 5C (cytokine p MCP1).

Rat TTR serum levels were measured using a rat specific ELISA kit (Aviva Systems Biology catalog number OKIA00159) according to manufacture's protocol. Briefly, serums were serially diluted with kit sample diluent to a final dilution of 10,000-fold. This diluted sample was then added to the ELISA plates and the assay was then carried out according to directions.

Genomic DNA was isolated from approximately 10 mg of liver tissue and analyzed using NGS as described above. PCR primer sequences for amplification are described below.

FIG. 5A and FIG. 5B show that serum TTR knockdown and liver editing were sufficient in the 2 mol-% and 3 mol-% PEG formulations. FIG. 5C shows that MCP-1 response is reduced using 3 mol-% PEG formulations.

Example 5

LNP Delivery to Non-Human Primates

Three studies were conducted with LNP formulations prepared as described in Example 1. The particular molar amounts and cargos are provided in Tables 12-26. Each formulation containing Cas9 mRNA and guide RNA (gRNA) had a mRNA:gRNA ratio of 1:1 by weight. Doses of LNP (in mg/kg, total RNA content), route of administration and whether animals received pre-treatment of dexamethasone are indicated in the Tables. For animals receiving dexamethasone (Dex) pre-treatment, Dex was administered at 2 mg/kg by IV bolus injection, 1 hour prior to LNP or vehicle administration.

For blood chemistry analysis, blood was drawn from animals at times as indicated in the tables below for each factor that was measured. Cytokine induction was measured in pre- and post-treated NHPs. A minimum of 0.5 mL of whole blood was collected from a peripheral vein of restrained, conscious animals into a 4 mL serum separator tube. Blood was allowed to clot for a minimum of 30 minutes at room temperature followed by centrifugation at 2000×g for 15 minutes. Serum was aliquoted into 2 polypropylene microtubes of 120 μL each and stored at −60 to −86° C. until analysis. A non-human primate U-Plex Cytokine custom kit from Meso Scale Discovery (MSD) was used for analysis. The following parameters were included in the analysis INF-g, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p40, MCP-I and INF-a, with focus on IL-6 and MCP-1. Kit reagents and standards were prepared as directed in the manufacturer's protocol. NHP serum was used neat. The plates were run on an MSD Sector Imager 6000 with analysis performed with MSD Discovery work bench software Version 4012.

Complement levels were measured in pre- and post-treated animals by enzyme Immunoassay. Whole blood (0.5 mL) was collected from a peripheral vein of restrained, conscious animals into a tube containing 0.5 mL k₂EDTA. Blood was centrifuged at 2000×g for 15 minutes. Plasma was aliquoted into 2 polypropylene microtubes of 120 μL each and stored at −60 to −86° C. until analysis. A Quidel MicroVue Complement Plus EIA kit (C3a-Cat #A031) or (Bb-Cat #A027) was used for analysis. Kit reagents and standards were prepared as directed in the manufacturer's protocol. The plates were run on an MSD Sector Imager 6000 at optical density at 450 nm. The results were analyzed using a 4-parameter curve fit.

The data for cytokine induction and complement activation are provided in the Tables below. “BLQ” means below the limit of quantification.

TABLE 12
Study 1.
	Molar Ratios (Lipid
	A, Cholesterol,					Dose level,
Treatment	DSPC, and PEG2k-			sample		total RNA
group	DMG, respectively	N:P	Cargo	size (n)	Route	content (mg/kg)	Dex
(I) TSS	n/a	n/a	n/a	3	IV -	n/a	no
(vehicle)					infusion
(2) LNP699	45/44/9/2	4.5	Cas9 mRNA	3	IV -	3	no
G502			(SEQ ID NO:		infusion
			2); G000502
(3) LNP688	45/44/9/2	4.5	Cas9 mRNA	3	IV -	3	no
G506			(SEQ ID NO:		infusion
			2); G000506
(4) LNP689	45/44/9/2	4.5	Cas9 mRNA	3	IV -	3	no
G509			(SEQ ID NO:		infusion
			2); G000509
(5) LNP690	45/44/9/2	4.5	Cas9 mRNA	3	IV -	3	no
G510			(SEQ ID NO:		infusion
			2); G000510

TABLE 13
Study 2.
	Mohr Ratios (Lipid
	A, Cholesterol,					Dose level,
Treatment	DSPC, and PEG2k-			sample		total RNA
group	DMG, respectively	N:P	Cargo	size (n)	Route	content (mg/kg)	Dex
(1) TSS	n/a	n/a		1	IV-	n/a	yes
(vehicle)					bolus
(2) TSS	n/a	n/a		1	IV-	n/a	no
(vehicle)					bolus
(3) LNP898	45/44/9/2	4.5	Cas9 mRNA	1	IV -	3	yes
G502			(SEQ ID NO:		infusion
			2); G000502
(4) LNP898	45/44/9/2	4.5	Cas9 mRNA	1	IV -	3	no
G502			(SEQ ID NO:		infusion
			2); G000502
(5) LNP897	45/43/9/3	4.5	Cas9 mRNA	1	IV-	3	yes
G502			(SEQ ID NO:		bolus
			2); G000502
(6) LNP897	45/43/9/3	4.5	Cas9 mRNA	1	IV-	3	no
G502			(SEQ ID NO:		bolos
			2); G000502
(7) LNP897	45/43/9/3	4.5	Cas9 mRNA	1	IV -	3	yes
G502			(SEQ ID NO:		infusion
			2); G000502
(8) LNP897	45/43/9/3	4.5	Cas9 mRNA	1	IV -	3	no
G502			(SEQ ID NO:		infusion
			2); G000502
(9) LNP916	45/43/9/3	4.5	eGFP mRNA	1	IV -	6	yes
GFP			(SEQ ID NO: )		infusion
(10) LNP916	45/43/9/3	4.5	eGFP mRNA	1	IV -	6	no
GFP			(SEQ ID NO: )		infusion

TABLE 14
Study 3.
	Molar Ratios (Lipid
	A, Cholesterol,					Dose level,
Treatment	DSPC, and PEG2k-			sample		total RNA
group	DMG, respectively	N:P	Cargo	size (n)	Route	content (mg/kg)	Dex
(1) TSS	n/a	n/a	n/a	3	IV-	n/a	no
					bolus
(2) LNP1021	50/38/9/3	6	Cas9 mRNA	3	IV-	1	no
G502			(SEQ ID NO:		bolus
			1); G000502
(3) LNP1021	50/38/9/4	6	Cas9 mRNA	I	IV-	1	yes
G502			(SEQ ID NO:		bolus
			1); G000502
(4) LNP1022	55/33/9/3	6	Cas9 mRNA	3	IV-	1	no
G502			(SEQ ID NO:		bolus
			1); G000502
(5) LNP1023	45/43/9/3	4.5	Cas9 mRNA	3	IV-	3	no
G502			(SEQ ID NO:		bolus
			1); G000502
(6) LNP1024	50/38/9/3	6	Cas9 mRNA	3	IV-	1	no
G509			(SEQ ID NO:		bolus
			1); G000509
(7) LNP1024	50/38/9/4	6	Cas9 mRNA	1	IV-	1	yes
G509			(SEQ ID NO:		bolus
			1); G000509
(8) LNP1025	55/33/9/3	6	CasmRNA	3	IV-	1	no
G509			(SEQ ID NO:		bolus
			1); G000509
(9) LNP1021	50/38/9/3	6	Cas9 mRNA	1	IV-	3	no
G502			(SEQ ID NO:		bolus
			1); G000502
(10) LNP1022	50/38/9/3	6	Cas9 mRNA	1	IV-	3	no
G502			(SEQ ID NO:		bolus
			1); G000502

TABLE 15
IL-6 measurements from Study 1.
	Treatment Group	Pre-Bleed	6 hour	24 hour
	(1) TSS (vehicle)	5.71 ± 2.70	29.1 ± 20.37	7.05 ± 3.49
	(2) LNP699 G502	9.73 ± 8.34	1296.41 ± 664.71	5.43 ± 7.68
	(3) LNP688 G506	16.83 ± 4.08	1749.47 ± 1727.22	38.57 ± 39.39
	(4) LNP689 G509	18.11 ± 11.51	1353.49 ± 766.66	32.42 ± 18.40
	(5) LNP690 G510	13.95 ± 1.85	11838 ± 17161.74	90.07 ± 96.02

TABLE 16
MCP-1 measurements from Study 1.
Treatment Group	Pre-Bleed	6 hour	24 hour
(1) TSS (vehicle)	810.49 ± 178.27	1351.16 ± 397.31	745.25 ± 56.49
(2) LNP699 G502	842.31 ± 350.65	19298.49 ± 11981.14	2092.89 ± 171.21
(3) LNP688 G506	1190.79 ± 383.64	13500.17 ± 12691.60	1414.71 ± 422.43
(4) LNP689 G509	838.63 ± 284.42	14427.7 ± 8715.48	1590 ± 813.23
(5) LNP690 G510	785.32 ± 108.97	52557.24 ± 48034.68	6319.77 ± 983.37

TABLE 17
Complement C3a measurements from Study 1.
Treatment Group	Pre-Bleed	6 hour	day 7
(1) TSS (vehicle)	23.9 ± 11.95	25.51 ± 14.79	30.67 ± 18.36
(2) LNP699 G502	32.36 ± 11.29	94.33 ± 58.45	38.50 ± 12.69
(3) LNP688 G506	22.30 ± 1.73	127.00 ± 22.34	37.80 ± 6.86
(4) LNP689 G509	35.83 ± 21.94	174.00 ± 44.51	50.83 ± 21.92
(5) LNP690 G510	36.30 ± 8.21	163.00 ± 40.60	42.50 ± 12.44

TABLE 18
Complement bb measurements from Study 1.
Treatment Group	04-bb	Pre-Bleed	6 hour	day 7
(1) TSS (vehicle)	Control	1.53 ± 0.19	3.37 ± 2.13	1.43 ± 0.71
(2) LNP699 G502	G502	1.45 ± 0.39	9.01 ± 5.28	1.57 ± 0.54
(3) LNP688 G506	G506	1.45 ± 0.78	11.78 ± 2.33	1.78 ± 0.84
(4) LNP689 G509	G509	1.95 ± 0.99	15.73 ± 2.23	2.83 ± 0.88
(5) LNP690 G510	G510	2.12 ± 0.44	13.57 ± 1.23	2.21 ± 0.72

TABLE 19
IL-6 measurements from Study 2.
Treatment group	Pre-Bleed	90 min	6 hour	24 hour	Day 7
(1) TSS (vehicle)	1.77	11.46	4.2	2.76	3.01
(2) TSS (vehicle)	5.23	18.11	20.36	13.2	6.36
(3) LNP898 G502	2.02	1305.75	1138.22	383.32	16.02
(4) LNP898 G502	2.34	37.19	91.59	14.11	3.07
(5) LNP897 G502	2.1	55.79	6.89	2.26	2.01
(6) LNP897 G502	6.8	10.1	44.72	5.4	2.01
(7) LNP897 G502	1.97	44.87	32.61	2.97	1.11
(8) LNP897 G502	3.14	37.68	73.41	8.58	2.22
(9) LNP916 GFP	1.6	BLQ	95.32	27.58	BLQ
(10) LNP916 GFP	2.43	BLQ	883.01	66.71	BLQ

TABLE 20
MCP-1 measurements from Study 2.
Treatment group	Pre-Bleed	90 min	6 hour	24 hour	Day 7
(1) TSS (vehicle)	312.12	197.24	145.36	177.02	403.82
(2) TSS (vehicle)	232.44	175.08	187.72	136.64	325.69
(3) LNP898 G502	249.1	2183.5	1814.64	1887.41	372.38
(4) LNP898 G502	349.51	430.49	5635.55	953.05	236.6
(5) LNP897 G502	492.3	989.98	409.08	302.97	506.82
(6) LNP897 G502	283.79	225.1	1141.08	484.59	259.46
(7) LNP897 G502	223.16	349.79	398.57	172.67	287.09
(8) LNP897 G502	584.42	853.51	3880.81	1588.46	692.99
(9) LNP916 GFP	325.84	BLQ	1189.97	2279.82	BLQ
(10) LNP916 GFP	175.47	BLQ	3284.16	2023.53	BLQ

TABLE 21
Complement C3a measurements from Study 2.
Treatment group	Pre-Bleed	90 min	6 hour	24 hour	Day 7
(1) TSS (vehicle)	0.087	0.096	0.048	0.033	0.038
(2) TSS (vehicle)	0.369	0.311	0.146	0.1	0.106
(3) LNP898 G502	0.087	0.953	0.647	0.277	0.065
(4) LNP898 G502	0.099	0.262	0.123	0.049	0.044
(5) LNP897 G502	0.067	0.479	0.209	0.036	0.036
(6) LNP897 G502	0.141	0.433	0.34	0.11	0.074
(7) LNP897 G502	0.1	0.345	0.396	0.096	0.127
(8) LNP897 G502	0.261	0.458	0.409	0.244	0.313
(9) LNP916 GFP	0.149	BLQ	0.714	0.382	BLQ
(10) LNP916 GFP	0.117	BLQ	0.752	0.723	BLQ

TABLE 22
Complement bb measurements from Study 2.
Treatment group	Pre-Bleed	90 min	6 hour	24 hour	Day 7
(1) TSS (vehicle)	0.087	0.096	0.048	0.033	0.038
(2) TSS (vehicle)	0.369	0.311	0.146	0.1	0.106
(3) LNP898 G502	0.087	0.953	0.647	0.277	0.065
(4) LNP898 G502	0.099	0.262	0.123	0.049	0.044
(5) LNP897 G502	0.067	0.479	0.209	0.036	0.036
(6) LNP897 G502	0.141	0.433	0.34	0.11	0.074
(7) LNP897 G502	0.1	0.345	0.396	0.096	0.127
(8) LNP897 G502	0.261	0.458	0.409	0.244	0.313
(9) LNP916 GFP	0.149	BLQ	0.714	0.382	BLQ
(10) LNP916 GFP	0.117	BLQ	0.752	0.723	BLQ

TABLE 23
IL-6 measurements from Study 3.
Treatment
group	Pre-bleed	90 min	6 hour	24 hour	Day 7
(1) TSS	1.89 ± 0.97	2.56 ± 1.41	0.90 ± 0.71	BLQ	0.08
(2) LNP1021	210 ± 0.35	7.44 ± 5.16	6.94 ± 8.45	1.07 ± 1.11	1.76 ± 0.98
G502
(3) LNP1021	0.79	2.96	4.25	0.67	0.27
G502
(4) LNP1022	1.54 ± 1.32	20.42 ± 31.60	13.94 ± 10.10	0.98 ± 0.41	2.04 ± 0.65
G502
(5) LNP1023	2.92 ± 1.68	6.28 ± 7.18	6.06 ± 2.31	3.62 ± 4.68	2.00 ± 1.21
G502
(6) LNP1024	1.43 ± 0.62	2.64 ± 1.92	7.72 ± 11.96	0.45 ± 0.19	0.88 ± 0.79
G509
(7) LNP1024	1.35 ± 0.74	2.64 ± 2.35	1.71 ± 0.41	0.36 ± 0.58	0.51 ± 0.32
G509
(8) LNP1025	1.64	2.68	25.65	0.58	2.00
G509
(9) LNP1021	0.56	6.15	28.80	0.85	0.61
G502
(10) LNP1022	1.76	8.66	2907.86	11.26	1.72
G502

TABLE 24
MCP-1 measurements from Study 2.
Treatment group	Pre-bleed	90 min	6 hour	24 hour	Day 7
(1) TSS	204.01 ± 46.39	197.62 ± 19.54	310.84 ± 45.87	179.07 ± 20.77	234.61 ± 71.79
(2) LNP1021	303.67 ± 36.37	337.63 ± 195.18	755.20 ± 581.45	339.75 ± 206.20	214.82 ± 40.81
G502
(3) LNP1021	229.30	358.10	3182.00	413.56	178.30
G502
(4) LNP1022	393.63 ± 187.81	467.72 ± 221.61	1852.94 ± 2199.66	497.12 ± 412.30	382.19 ± 67.27
G502
(5) LNP1023	213.72 ± 8.85	196.18 ± 62.81	1722.18 ± 1413.90	197.83 ± 74.01	156.16 ± 18.87
G502
(6) LNP1024	237.76 ± 96.36	210.37 ± 95.17	468.53 ± 250.42	22.32 ± 69.06	141.20 ± 71.90
G509
(7) LNP1024	207.36	183.07	1885.66	235.70	163.11
G509
(8) LNP1025	259.57 ± 112.98	299.21 ± 304.89	1193.10 ± 974.04	258.82 ± 88.53	219.86 ± 219.86
G509
(9) LNP1021	199.29	286.04	2001.23	197.57	196.44
G502
(10) LNP1022	305.81	970.65	7039.06	8379.05	203.47
G502

TABLE 25
Complement C3a measurements from Study 3.
Treatment group	Pre-bleed	90 min	6 hour	24 hour	Day 7
(1) TSS	42.47 ± 10.30	55.40 ± 13.58	29.30 ± 14.46	41.70 ± 23.65	27.43 ± 12.43
(2) LNP1021 G502	34.37 ± 0.50	86.50 ± 3.66	90.07 ± 4.85	56.60 ± 2.25	32.53 ± 0.93
(3) LNP1021 G502	34.30	128.00	93.30	33.40	28.20
(4) LNP1022 G502	41.55 ± 13.51	151.37 ± 109.98	82.00 ± 31.82	45.57 ± 18.58	32.77 ± 6.45
(5) LNP1023 G502	31.67 ± 3.19	74.40 ± 22.08	74.13 ± 48.61	33.83 ± 9.75	27.70 ± 8.05
(6) LNP1024 G509	56.60 ± 25.61	100.37 ± 77.95	74.73 ± 70.15	55.20 ± 48.34	49.97 ± 39.94
(7) LNP1024 G509	33.80	33.90	33.70	26.10	20.90
(8) LNP1025 G509	39.90 ± 13.01	75.73 ± 1.38	46.13 ± 30.56	25.00 ± 3.80	23.90 ± 7.18
(9) LNP1021 G502	34	85.70	133.00	62.00	25.50
(10) LNP1022 G502	29.8	68.10	113.00	71.70	23.30

TABLE 26
Complement bb measurements from Study 3.
Treatment group	Pre-bleed	90 min	6 hour	24 hour	Day 7
(1) TSS	1.46 ± 0.70	2.18 ± 0.78	1.96 ± 0.64	0.945 ± 0.15	1.34 ± 0.50
(2) LNP1021 G502	1.77 ± 0.60	6.51 ± 3.66	11.00 ± 4.85	3.59 ± 2.25	2.07 ± 0.93
(3) LNP1021 G502	1.24	2.90	11.50	2.97	1.24
(4) LNP1022 G502	1.52 ± 0.34	5.67 ± 2.28	10.2 ± 3.36	3.66 ± 1.68	1.84 ± 0.24
(5) LNP1023 G502	1.65 ± 0.94	4.4 ± 1	7.68 ± 4.67	2.64 ± 1.18	2.08 ± 1.32
(6) LNP1024 G509	1.61 ± 0.13	4.52 ± 1.81	4.50 ± 3.22	1.63 ± 0.84	1.63 ± 0.32
(7) LNP1024 G509	0.96	2.99	2.64	1.13	1.07
(8) LNP1025 G509	1.37 ± 0.17	4.9 ± 4.51	3.79 ± 3.84	1.66 ± 1.43	1.35 ± 0.44
(9) LNP1021 G502	1.41	5.67	11.50	4.64	1.38
(10) LNP1022 G502	1.28	5.22	14.10	5.64	1.87

Example 6

PEG Lipid Screen

In another study, alternative PEG lipids were compared in LNP formulations comprising 2 mol-% or 3 mol-% of the PEG lipid.

Three PEG lipids were used in the study: Lipid 1 (DMG-PEG2k; Nof), is depicted as:

Lipid 2, synthesized as described in Heyes, et al., J. Controlled Release, 107 (2005), pp, 278-279 (See “Synthesis of PEG2000-C-DMA”), can be depicted as:

and Lipid 3, disclosed in WO2016/010840 (see compound S027, paragraphs [00240] to [00244]) and WO2011/076807, can be depicted as:

Lipid A was formulated with each PEG lipid at 2 mol-% and 3 mol-%. The lipid nanoparticle components were dissolved in 100% ethanol with the lipid component molar ratios set forth above. In brief, the RNA cargos were prepared in 25 mM citrate, 100 mM NaCl, pH 5.0, resulting in a concentration of RNA cargo of approximately 0.45 mg/mL. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 4.5 with the ratio of mRNA to gRNA at 1:1 by weight.

TABLE 27
	LNP	LNP	LNP	LNP	LNP	LNP
LNP #	784	785	786	787	788	789
CL/chol./DSPC/PEG	45/44/9/2	45/43/9/3	45/44/9/2	45/43/9/3	45/44/9/2	45/43/9/3
(theoretical mol-%)
mRNA	Cas9	Cas9	Cas9	Cas9	Cas9	Cas9
	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID
	NO: 48	NO: 48	NO: 48	NO: 48	NO: 48	NO: 48
gRNA	G282	G282	G282	G282,	G282,	G282
	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID
	NO: 42	NO: 42	NO: 42	NO: 42	NO: 42	NO: 42
PEG Type	Lipid 1	Lipid 1	Lipid 2	Lipid 2	Lipid 3	Lipid 3
N/P	4.5	4.5	4.5	4.5	4.5	4.5

Cas9 mRNA, sg282, and LNPs were prepared as described in Example 1.

LNP compositions with Lipid 1, Lipid 2, or Lipid 3 were were administered to female CD-1 mice and assessed as described in Example 1 at 1 mg/kg and 0.5 mg/kg of the body weight. Cohorts of mice were measured for liver editing by Next-Generation Sequencing (NGS) and serum TTR levels according to the methods of Example 1.

FIG. 6A and FIG. 6B compare serum TTR levels between PEG lipid formulations. FIG. 6A shows serum TTR in μg/mL, and FIG. 6B shows the data as a percent knockdown (% TSS). FIG. 6C shows percent editing achieved in the liver. The data indicate that LNP compositions with each of the tested PEG lipids tested potency at 2 mol-% and 3 mol-%, with Lipid 1 consistently performing slightly better than Lipid 2 and Lipid 3.

Example 7

Lipid A Analogs

A number of structural analogs of Lipid A were synthesized and tested in the LNP compositions described herein.

Synthesis: Lipid A is made by reacting 4,4-bis(octyloxy)butanoic acid (“Intermediate 13b” in Example 13 of WO2015/095340) with (9Z,12Z)-3-hydroxy-2-(hydroxymethyl)propyl octadeca-9,12-dienoate (“Intermediate 13c”), prior to addition of the head group by reacting the product of Intermediate 13b and Intermediate 13c with 3-diethylamino-1-propanol. (See pp. 84-86 of WO2015/095340.)

Intermediate 13b from WO2015/095340 (4,4 bis(octyloxy)butanoic acid) was synthesized via 4,4-bis(octyloxy)butanenitrile as follows:

Intermediate 13a: 4,4-bis(octyloxy)butanenitrile

To a mixture of 4,4-diethoxybutanenitrile (9,4 g, 60 mmol) and octan-1-ol (23.1 g, 178 mmol) was added pyridinium p-toluenesulfonate (748 mg, 3.0 mmol) at rt. The mixture was warmed to 1.05° C. and stirred for 18 hours with the reaction vessel open to air and not fitted with a refluxing condenser. The reaction mixture was then cooled to room temperature and purified on silica gel (0-5% gradient of ethyl acetate in hexanes) to provide 10.1 g (31.0 mmol) of Intermediate 13a as a clear oil. ¹H MAR (400 MHz, CDCl₃) δ 4.55 (t, J=5.3 Hz, 1H), 3.60 (dt, J=9.2, 6.6 Hz, 2H), 3.43 (dt, J=9.2, 6.6 Hz, 2H), 2.42 (t, J=7.4 Hz, 2H), 1.94 (td, J=7.4, 5.3 Hz, 2H), 1.63-1.50 (m, 4H), 1.38-1.19 (m, 20H), 0.93-0.82 (m, 6H) ppm.

Next, to a solution of Intermediate 13a (8.42 g, 31 mmol) in ethanol (30 mL) was added 31 mL of aqueous potassium hydroxide (2.5 M, 30.9 mL, 77.3 mmol) at room temperature. Upon fitting the vessel with a reflux condenser, the mixture was heated to 110° C. and stirred for 24 hours. The mixture was then cooled to room temperature, acidified with aqueous hydrochloride acid (1N) to pH 5, and extracted into hexanes three times. The combined organic extracts were washed with water (twice) and brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo to afford 8.15 g (23.6 mmol) of Intermediate 13b as a clear oil, which was used without further purification. ¹H NMR (400 MHz, CDCl₃) δ 4.50 (t, J=5.5 Hz, 1H), 3.57 (dt, J=9.4, 6.7 Hz, 2H), 3.41 (dt, J=9.3, 6.7 Hz, 2H), 2.40 (t, J=7.4 Hz, 2H), 1.92 (td, J=7.4, 5.3 Hz, 2H), 1.56 (m, 4H), 1.37-1.21 (m, 20H), 0.92-0.83 (m, 6H) ppm (structure below).

Intermediate 13b

Using the methods described above, the C(5, 6, 7, 9, and 10)-acetal acid intermediates, called Intermediates B3-F3 and depicted below, were prepared using the appropriate alkan-1-ol reagents.

Intermediate B3 4,4-bis(pentyloxy)butanoic Acid

¹H NMR (400 MHz, CDCl₃) δ 4.52 (t, J=5.5 Hz, 1H), 3.58 (dt, J=9.3, 6.6 Hz, 2H), 3.41 (dt, J=9.3, 6.7 Hz, 2H), 2.45 (t, J=7.4 Hz, 2H), 1.94 (m, 2H), 1.57 (m, 4H), 1.32 (m, J=3.7 Hz, 8H), 0.95-0.83 (m, 6H) ppm.

Intermediate C3: 4,4-bis(hexyloxy)butanoic Acid

¹H NMR (400 MHz, CDCl₃) δ 4.44 (t, J=5,6 Hz, 1H), 3.49 (dt, J=9.3, 6.9 Hz, 2H), 3.39 (dt, J=9.3, 6.8 Hz, 2H), 2.12 (t, J=7.6 Hz, 2H), 1.79 (q, J=7.0 Hz, 2H), 1.54 (m, 4H), 1.29 (m, 12H), 0.94-0.82 (m, 6H) ppm.

Intermediate D3: 4,4-bis(heptyloxy)butanoic Acid

¹H NMR (400 MHz, CDCl₃) δ 8.85 (br s, 1H), 4.46 (t, J=5.6 Hz, 1H), 3.52 (dt, J=9.4, 6.8 Hz, 2H), 3.39 (dt, J=9.3, 6.8 Hz, 2H), 2.26 (t, J=7.6 Hz, 2H), 1.85 (q, J=7.0 Hz, 2H), 1.53 (m, 4H), 1.29 (m, 16H), 0.94-0.80 (m, 6H) ppm.

Intermediate E3: 4,4-bis(nonyloxy)butanoic Acid

¹H NMR (400 MHz, CDCl₃) δ 5.32 (br s, 1H), 4.44 (t, J=5.6 Hz, 1H), 3.49 (dt, J=9.3, 6.9 Hz, 2H), 3.38 (dt, J=9.4, 6.9 Hz, 2H), 2.10 (t, J=7.6 Hz, 2H), 1.78 (q, J=7.0 Hz, 2H), 1.53 (m, 4H), 1.27 (m, 24H), 0.88 (t, J=6.6 Hz, 6H) ppm.

Intermediate F3: 4,4-bis(decyloxy)butanoic Acid

¹H NMR, (400 MHz, CDCl₃) δ 4.48 (t, J=5.5 Hz, 1H), 3.55 (m, 2H), 3.42 (m, 2H), 2.29 (dd, J=10.8, 7.5 Hz, 2H), 1.90-1.82 (m, 2H), 1.55 (m, 4H), 1.27 (m, 28H), 0.88 (t, J=6.7 Hz, 6H) ppm.

Acetal analogs of Lipid A (C(8)) were synthesized by reacting the C(5, 6, 7, 9, or 10)-acetal acid intermediates (B3-F3) with Intermediate 13c, prior to reacting the product of that step with 3-diethylamino-1-propanol. (See pp 84-86 of WO2015/095340.) Each analog was synthesized and characterized by ¹H NMR (data not shown).

The C7, C9, and C10 analogs were formulated at 45 mol-% Lipid A Analog, 2 mol-% DMG-PEG2k, 9 mol-% DSPC, and 44 mol-% cholesterol, with an N:P ratio of 4.5. Each analog was also formulated at 55 mol-% Lipid A Analog, 2.5 mol-% DMG-PEG2k, 9 mol-% DSPC, and 38.5 mol-% cholesterol, with an NT ratio of 6. The lipid nanoparticle components were dissolved in 100% ethanol with the lipid component molar ratios set forth above. The RNA cargos were prepared in 25 mM citrate, 100 mM NaCl, pH 5.0, resulting in a concentration of RNA cargo of approximately 0.45 mg/mL.

The RNA cargo included Cas9 mRNA comprising SEQ ID NO:43 and sg282, prepared as described above. The LNPs were formed as described in Example 1.

An expanded panel of acetal analogs, including LNP compositions comprising the C(5) and C(6) Lipid A analogs were tested alongside the prior panel. The two new analogs were formulated at 55 mol-% Lipid A Analog, 2.5 mol-% DMG-PEG2k, 9 mol-% DPSC, and 33,5 mol-% cholesterol, with an N/P ratio of 6, as described above. Analysis indicated that sizes for all LNPs is below 120 nm, PDT is below 0.2 and %-encapsulated RNA is higher than 80%. Analytical results for the formulations are in Table 28, below.

TABLE 28
LNP	Lipid A	Analog			RNA Conc		Z-avg.		Number mean
ID	Analogs	mol-%	PEG %	N/P	(mg/mL)	% EE	(nm)	PDI	(nm)
LNP	C5 analog	55	2.5	6	0.063	88	118.8	0.103	88.17
1122	(LP000030-001)
LNP	C6 analog	55	2.5	6	0.067	95	107.6	0.038	88.1
1123	(LP000031-001)
LNP	C7 analog	55	2.5	6	0.068	98	100	0.012	81.55
1004	(LP000020-001)
LNP	LP000001-011	55	2.5	6	0.067	98	95.06	0.01	78.95
1002
LNP	C9 analog	55	2.5	6	0.067	97	95.43	0.022	80.35
1006	(LP000021-001)
LNP	C10 analog	55	2.5	6	0.069	95	103.9	0.008	86.79
1008	(LP000022-001)

The analogs were assessed for pKa using 6-(p-toluidino)-6-napthalene sulfonic acid (“TNS”) dissolved in water. In this assay 0.1 M phosphate buffer was prepared at different pH values ranging from 4.5 to 10.5. Each analog was individually prepared in 100% ethanol, The lipid and TNS were then added in individual pH buffer and transferred to a plate to analyze at 321-488 nm wavelength on the SpectraMax plate reader. Values were plotted to generate pKa, log IC₅₀ is used as pKa.

Female CD-1 mice were dosed as described in Example 1 with 0.3 mg/kg (FIG. 7A-FIG. 7E), or with 0.1 mg per kg (FIG. 7F-FIG. 7G), In brief, CD-1 female mice from Charles River Laboratories, n=5 per group, were administered the LNP compositions at varying doses. At necropsy (7 days post dose), serum was collected for TTR analysis and liver was collected for editing analysis. Serum TTR and percent editing assays were performed as described in Example 1. The serum TTR levels and liver editing from FIG. 7A-FIG. 7E indicate that all the analogs performed comparably to Lipid A at 0.3 milligrams per kilogram body weight. FIG. 7F-FIG. 7G indicate that while Lipid A had the highest potency, the newly synthesized analogs all have suitable TTR knockdown and liver editing.

Example 8

Dose Response Curve—Primary Cyno Hepatocytes

Primary liver hepatocytes. Primary cynomolgus liver hepatocytes (PCH) (Gibco) were thawed and resuspended in hepatocyte thawing medium with supplements (Gibco, Cat. CM7000) followed by centrifugation at 80 g for 4 minutes. The supernatant was discarded and the pelleted cells resuspended in hepatocyte plating medium plus supplement pack (Invitrogen, Cat. A1217601 and CM3000). Cells were counted and plated on Bio-coat collagen I coated 96-well plates (ThermoFisher, Cat. 877272) at a density of 50,000 cells/well. Plated cells were allowed to settle and adhere for 24 hours in a tissue culture incubator (37° C. and 5% CO₂ atmosphere) prior to LNP administration. After incubation cells were checked for monolayer formation and media was replaced with hepatocyte culture medium with serum-free supplement pack (Invitroven, Cat. A1217601 and CM4000).

LNP formulations for this study (LNP1021, LNP1022, LNP1023, LNP1024, LNP1025, and LNP897) were prepared as described above.

Various doses of lipid nanoparticle formulations containing modified sgRNAs were tested on primary cyno hepatocytes to generate a dose response curve. After plating and 24 hours in culture, LNPs were incubated in hepatocyte maintenance media containing 6% cyno serum at 37° C. for 5 minutes. Post-incubation the LNPs were added onto the primary cyno hepatocytes in an 8 point 2-fold dose response curve starting at 100 ng mRNA. The cells were lysed 72 hours post treatment for NGS analysis as described in Example 1. Percent editing was determined for various LNP compositions and the data are graphed in FIG. 8A. The % editing with Cas9 mRNA (SEQ ID NO 48) and U-depleted Cas9 mRNA (SEQ I NO:43) is presented in FIG. 8B. LNP compositions are described in Table 2 (LNP 897) and Table 5 (LNP 1021, 1022, 1023, 1024, and 1025).

The results show a quantitative assay for comparative potency assessements, demonstrating both mRNA and LNP composition affect potency.

Example 9

RNA Cargo: mRNA and gRNA Coformulations

This study evaluated in vivo efficacy in mice of different ratios of gRNA to mRNA. CleanCap™ capped Cas9 mRNAs with the ORF of SEQ ID NO: 4, HSD 5′ UTR, human albumin 3′ UTR, a Kozak sequence, and a poly-A tail were made by IVT synthesis as indicated in Example 1 with N1-methylpseudouridine triphosphate in place of uridine triphosphate.

LNP formulations prepared from the mRNA described and sg282 (SEQ ID NO: 42; G282) as described in Example 2 with Lipid A, cholesterol, DSPC, and PEG2k-DMG in a 50:38:9:3 molar ratio and with an N:P ratio of 6. The gRNA:Cas9 mRNA weight ratios of the formulations were as shown in Table 29.

TABLE 29
	Guide:Cas9			Z-Ave		Number
LNP	mRNA Ratio	RNA Conc	EE	Size	Partick	Ave
ID	(w/w)	(mg/mL)	(%)	(nm)	PDI	(nm)
1110	8:1	0.92	99	69.52	0.022	56.47
1111	4:1	0.86	97	76.65	0.065	57.36
1112	2:1	0.90	99	76.58	0.036	63.11
1113	1:1	0.97	99	76.60	0.071	58.92
1114	1:2	1.05	99	76.34	0.018	62.82
1115	1:4	0.65	99	82.64	0.018	66.63
1116	1:8	0.75	100	82.01	0.039	65.05

For in vivo characterization, the above LNPs were administered to mice at 0.1 mg total RNA (mg guide RNA+mg mRNA) per kg (n=5 per group). At 7 to 9 days post-dose, animals were sacrificed, blood and the liver were collected, and serum TTR and liver editing were measured as described in Example 1. Serum TTR and liver editing results are shown in FIGS. 9A and 9B. Negative control mice were dosed with TSS vehicle.

In addition, the above LNPs were administered to mice at a constant mRNA dose of 0.05 mg mRNA per kg (n=5 per group), while varying the gRNA dose from 0.06 mg per kg to 0.4 mg per kg. At 7 to 9 days post-dose, animals were sacrificed, blood and the liver were collected, and serum TTR and liver editing were measured. Serum TTR and liver editing results are shown in FIG. 9C and FIG. 9D. Negative control mice were dosed with TSS vehicle.

Example 10

Neutral Lipids

To evaluate the in vivo efficacy of LNPs, LNP formulations were prepared with the mRNA of Example 2 and sg534 (SEQ ID NO: 72; G534), as described in Example 2. The lipid nanoparticle components were dissolved in 100% ethanol with the lipid component molar ratios set forth below. In brief, the RNA cargos were prepared in a buffer of 25 mM citrate and 100 mM NaCl at pH 5.0, resulting in a concentration of RNA cargo of approximately 0.45 mg/mL. The LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of about 6 with the ratio of gRNA to mRNA at 1:2 by weight.

LNP formulations were analyzed for average particle size, polydispersity (pdi), total RNA content and encapsulation efficiency of RNA as described in Example 1. Analysis of average particle size, polydispersity (PDI), total RNA content and encapsulation efficiency of RNA are shown in Table 30. Molar ratios of lipid are provided as amine lipid (Lipid A)/neutral lipid/helper lipid (cholesterol)/PEG lipid (PEG2k-DMG). The neutral lipid was DSP, DPPC, or absent, as specified.

TABLE 30
LNP compositions and data. (Molar ratios of lipid are provided as amine lipid
(Lipid A)/neutral lipid/helper lipid (cholesterol)/PEG lipid (PEG2k-DMG).)
Sample	Neutral	Molar	RNA Conc		Z-avg.		Number mean	% Liver	Serum TTR	% TTR
ID	Lipid	Ratios	(mg/mL)	% EE	(am)	PDI	(nm)	Editing	(μg/mL)	KD
TSS								0.0	1248.9
control
CO241	—	50.0/0.0/	1.46	94	75.64	0.090	54.2.1	1.8	1070.2	14.3
		47.0/3.0
CO242	—	59.0/0.0/	1.51	94	92.25	0.019	75.56	12.0	819.6	34.4
		38.0/3.0
CO243	—	54.5/0.0/	1.62	94	78.90	0.052	61.49	3.3	1260.5	−0.9
		42.5/3.0
CO244	DSPC	50.0/9.0/	1.50	93	101.3	0.044	80.73	27.4	741.0	40.7
		39.0/2.0
CO034	DSPC	50.0/9.0/	1.48	97	84.23	0.040	66.96	34.2	630.1	49.6
		38.0/3.0
CO245	DSPC	52.5/4.0/	1.55	95	81.88	0.054	64.54	5.8	846.6	32.2
		42.5/3.0
CO246	DPPC	50.0/9.0/	1.52	96	87.11	0.040	70.04	35.9	528.6	57.7
		38.0/3.0
CO247	DPPC	52.5/4.0/	1.54	97	83.67	0.050	66.43	18.3	726.6	41.8
		42.5/3.0

For in vivo characterization, the above LNPs were administered intravenously to female Sprague Dawley rats at 0.3 mg total RNA (guide RNA and mRNA) per kg bodyweight. There were five rats per group. At seven days post-dosing, animals were sacrificed, blood and the liver were collected, and serum TTR and liver editing were measured as described in Example 1. Negative control animals were dosed with TSS vehicle. Serum TTR and liver editing results are shown in FIGS. 10A and 10B, and in Table 30 (above).

Brief Description of Disclosed Sequences

SEQ ID NO Description
1         DNA coding sequence of Cas9 using the thymidine analog of the
          minimal uridine codons listed in Table 3, with start and stop codons
2         DNA coding sequence of Cas9 using codons with generally high
          expression in humans
3         Amino acid sequence of Cas9 with one nuclear localization signal
          (1xNLS) as the C-terminal 7 amino acids
4         Cas9 mRNA ORF using minimal uridine codons as listed in Table 3,
          with start and stop codons
5         Cas9 mRNA ORF using codons with generally high expression in
          humans, with start and stop codons
6         Amino acid sequence of Cas9 nickase with 1xNLS as the C-terminal
          7 amino acids
7         Cas9 nickase mRNA ORF encoding SEQ ID NO: 6 using minimal
          uridine codons as listed in Table 3, with start and stop codons
8         Amino acid sequence of dCas9 with 1xNLS as the C-terminal 7
          amino acids
9         dCas9 mRNA ORF encoding SEQ ID NO: 8 using minimal uridine
          codons as listed in Table 3, with start and stop codons
10        Cas9 mRNA coding sequence using minimal uridine codons as
          listed in Table 3 (no start or stop codons; suitable for inclusion in
          fusion protein coding sequence)
11        Cas9 nickase mRNA coding sequence using minimal uridine codons
          as listed in Table 3 (no start or stop codons; suitable for inclusion in
          fusion protein coding sequence)
12        dCas9 mRNA coding sequence using minimal uridine codons as
          listed in Table 3 (no start or stop codons; suitable for inclusion in
          fusion protein coding sequence)
13        Amino acid sequence of Cas9 (without NLS)
14        Cas9 mRNA ORF encoding SEQ ID NO: 13 using minimal uridine
          codons as listed in Table 3, with start and stop codons
15        Cas9 coding sequence encoding SEQ ID NO: 13 using minimal
          uridine codons as listed in Table 3 (no start or stop codons; suitable
          for inclusion in fusion protein coding sequence)
16        Amino acid sequence of Cas9 nickase (without NLS)
17        Cas9 nickase mRNA ORF encoding SEQ ID NO: 16 using minimal
          uridine codons as listed in Table 3, with start and stop codons
18        Cas9 nickase coding sequence encoding SEQ ID NO: 16 using
          minimal uridine codons as listed in Table 3 (no start or stop codons;
          suitable for inclusion in fusion protein coding sequence)
19        Amino acid sequence of dCas9 (without NLS)
20        dCas9 mRNA ORF encoding SEQ ID NO: 13 using minimal uridine
          codons as listed in Table 3, with start and stop codons
21        dCas9 coding sequence encoding SEQ ID NO: 13 using minimal
          uridine codons as listed in Table 3 (no start or stop codons; suitable
          for inclusion in fusion protein coding sequence)
22        Amino acid sequence of Cas9 with two nuclear localization signals
          (2xNLS) as the C-terminal amino acids
23        Cas9 mRNA ORF encoding SEQ ID NO: 13 using minimal uridine
          codons as listed in Table 3, with start and stop codons
24        Cas9 coding sequence encoding SEQ ID NO: 13 using minimal
          uridine codons as listed in Table 3 (no start or stop codons; suitable
          for inclusion in fusion protein coding sequence)
25        Amino acid sequence of Cas9 nickase with two nuclear localization
          signals as the C-terminal amino acids
26        Cas9 nickase mRNA ORF encoding SEQ ID NO: 16 using minimal
          uridine codons as listed in Table 3, with start and stop codons
27        Cas9 nickase coding sequence encoding SEQ ID NO: 16 using
          minimal uridine codons as listed in Table 3 (no start or stop codons;
          suitable for inclusion in fusion protein coding sequence)
28        Amino acid sequence of dCas9 with two nuclear localization signals
          as the C-terminal amino acids
29        dCas9 mRNA ORF encoding SEQ ID NO: 13 using minimal uridine
          codons as listed in Table 3, with start and stop codons
30        dCas9 coding sequence encoding SEQ ID NO: 13 using minimal
          uridine codons as listed in Table 3 (no start or stop codons; suitable
          for inclusion in fusion protein coding sequence)
31        T7 Promoter
32        Human beta-globin 5′ UTR
33        Human beta-globin 3′ UTR
34        Human alpha-globin 5′ UTR
35        Human alpha-globin 3′ UTR
36        Xenopus laevis beta-globin 5′ UTR
37        Xenopus laevis beta-globin 3′ UTR
38        Bovine Growth Hormone 5′ UTR
39        Bovine Growth Hormone 3′ UTR
40        Mus musculus hemoglobin alpha, adult chain 1 (Hba-a1), 3′UTR
41        HSD17B4 5′ UTR
42        G282 single guide RNA targeting the mouse TTR gene
43        Cas9 transcript with 5′ UTR of HSD, ORF corresponding to SEQ
          ID NO: 4, Kozak sequence, and 3′ UTR of ALB
44        Cas9 transcript with 5′ UTR of HSD, ORF corresponding to SEQ
          ID NO: 4, and 3′ UTR of ALB
45        Alternative Cas9 ORF with 19.36% U content
46        Cas9 transcript with 5′ UTR of HSD, ORF corresponding to SEQ
          ID NO: 45, Kozak sequence, and 3′ UTR of ALB
47        Cas9 transcript with 5′ UTR of HSD, ORF corresponding to SEQ
          ID NO: 45, and 3′ UTR of ALB
48        Cas9 transcript comprising Cas9 ORF using codons with generally
          high expression in humans
49        Cas9 transcript comprising Kozak sequence with Cas9 ORF using
          codons with generally high expression in humans
50        Cas9 ORF with splice junctions removed; 12.75% U content
51        Cas9 transcript with 5′ UTR of HSD, ORF corresponding to SEQ
          ID NO: 50, Kozak sequence, and 3′ UTR of ALB
52        Cas9 ORF with minimal uridine codons frequently used in humans
          in general; 12.75% U content
53        Cas9 transcript with 5′ UTR of HSD, ORF corresponding to SEQ
          ID NO: 52, Kozak sequence, and 3′ UTR of ALB
54        Cas9 ORF with minimal uridine codons infrequently used in
          humans in general; 12.75% U content
55        Cas9 transcript with 5′ UTR of HSD, ORF corresponding to SEQ
          ID NO: 54, Kozak sequence, and 3′ UTR of ALB
56        Cas9 transcript with AGG as first three nucleotides for use with
          CleanCap ™, 5′ UTR of HSD, ORF corresponding to SEQ ID NO:
          4, Kozak sequence, and 3′ UTR of ALB
57        Cas9 transcript with 5′ UTR from CMV, ORF corresponding to
          SEQ ID NO: 4, Kozak sequence, and 3′ UTR of ALB
58        Cas9 transcript with 5′ UTR from HBB, ORF corresponding to SEQ
          ID NO: 4, Kozak sequence, and 3′ UTR of HBB
59        Cas9 transcript with 5′ UTR from XBG, ORF corresponding to SEQ
          ID NO: 4, Kozak sequence, and 3′ UTR of XBG
60        Cas9 transcript with AGG as first three nucleotides for use with
          CleanCap ™, 5′ UTR from XBG, ORF corresponding to SEQ ID
          NO: 4, Kozak sequence, and 3′ UTR of XBG
61        Cas9 transcript with AGG as first three nucleotides for use with
          CleanCap ™, 5′ UTR from HSD, ORF corresponding to SEQ ID
          NO: 4, Kozak sequence, and 3′ UTR of ALB
62        30/30/39 poly-A sequence
63        poly-A 100 sequence
64        G209 single guide RNA targeting the mouse TTR gene
65        ORF encoding Neisseria meningitidis Cas9 using minimal uridine
          codons as listed in Table 3, with start and stop codons
66        ORF encoding Neisseria meningitidis Cas9 using minimal uridine
          codons as listed in Table 3 (no start or stop codons; suitable for
          inclusion in fusion protein coding sequence)
67        Transcript comprising SEQ ID NO: 65 (encoding Neisseria
          meningitidis Cas9)
68        Amino acid sequence of Neisseria meningitidis Cas9
69        G390 single guide RNA targeting the rat TTR gene
70        G502 single guide RNA targeting the cynomolgus monkey TTR
          gene
71        G509 single guide RNA targeting the cynomolgus monkey TTR
          gene
72        G534 single guide RNA targeting the rat TTR gene

See the Sequence Table below for the sequences themselves. Transcript sequences generally include GGG as the first three nucleotides for use with ARCA or AGG as the first three nucleotides for use with CleanCap™. Accordingly, the first three nucleotides can be modified for use with other capping approaches, such as Vaccinia capping enzyme. Promoters and poly-A sequences are not included in the transcript sequences. A promoter such as a T7 promoter (SEQ ID NO: 31) and a poly-A sequence such as SEQ ID NO: 62 or 63 can be appended to the disclosed transcript sequences at the 5′ and 3′ ends, respectively. Most nucleotide sequences are provided as DNA but can be readily converted to RNA by changing Ts to Us.

The following sequence table provides a listing of sequences disclosed herein. It is understood that if a DNA sequence (comprising Ts) is referenced with respect to an RNA, then Ts should be replaced with Us (which may be modified or unmodified depending on the context), and vice versa.

Sequence Table
		SEQ
Description	Sequence	ID No.
Cas9 DNA	ATGGACAAGAAGTACAGCATCGGACTGGACATCGGAACAAAC	1
coding	AGCGTCGGATGGGCAGTCATCACAGACGAATACAAGGTCCCG
sequence 2	AGCAAGAAGTTCAAGGTCCTGGGAAACACAGACAGACACAGC
	ATCAAGAAGAACCTGATCGGAGCACTGCTGTTCGACAGCGGA
	GAAACAGCAGAAGCAACAAGACTGAAGAGAACAGCAAGAAG
	AAGATACACAAGAAGAAAGAACAGAATCTGCTACCTGCAGGA
	AATCTTCAGCAACGAAATGGCAAAGGTCGACGACAGCTTCTTC
	CACAGACTGGAAGAAAGCTTCCTGGTCGAAGAAGACAAGAAG
	CACGAAAGACACCCGATCTTCGGAAACATCGTCGACGAAGTC
	GCATACCACGAAAAGTACCCGACAATCTACCACCTGAGAAAG
	AAGCTGGTCGACAGCACAGACAAGGCAGACCTGAGACTGATC
	TACCTGGCACTGGCACACATGATCAAGTTCAGAGGACACTTCC
	TGATCGAAGGAGACCTGAACCCGGACAACAGCGACGTCGACA
	AGCTGTTCATCCAGCTGGTCCAGACATACAACCAGCTGTTCGA
	AGAAAACCCGATCAACGCAAGCGGAGTCGACGCAAAGGCAAT
	CCTGAGCGCAAGACTGAGCAAGAGCAGAAGACTGGAAAACCT
	GATCGCACAGCTGCCGGGAGAAAAGAAGAACGGACTGTTCGG
	AAACCTGATCGCACTGAGCCTGGGACTGACACCGAACTTCAA
	GAGCAACTTCGACCTGGCAGAAGACGCAAAGCTGCAGCTGAG
	CAAGGACACATACGACGACGACCTGGACAACCTGCTGGCACA
	GATCGGAGACCAGTACGCAGACCTGTTCCTGGCAGCAAAGAA
	CCTGAGCGACGCAATCCTGCTGAGCGACATCCTGAGAGTCAAC
	ACAGAAATCACAAAGGCACCCCTGAGCGCAAGCATGATCAAG
	AGATACGACGAACACCACCAGGACCTGACACTGCTGAAGGCA
	CTGGTCAGACAGCAGCTGCCGGAAAAGTACAAGGAAATCTTC
	TTCGACCAGAGCAAGAACGGATACGCAGGATACATCGACGGA
	GGAGCAAGCCAGGAAGAATTCTACAAGTTCATCAAGCCGATC
	CTGGAAAAGATGGACGGAACAGAAGAACTGCTGGTCAAGCTG
	AACAGAGAAGACCTGCTGAGAAAGCAGAGAACATTCGACAAC
	GGAAGCATCCCGCACCAGATCCACCTGGGAGAACTGCACGCA
	ATCCTGAGAAGACAGGAAGACTTCTACCCGTTCCTGAAGGAC
	AACAGAGAAAAGATCGAAAAGATCCTGACATTCAGAATCCCG
	TACTACGTCGGACCGCTGGCAAGAGGAAACAGCAGATTCGCA
	TGGATGACAAGAAAGAGCGAAGAAACAATCACACCGTGGAAC
	TTCGAAGAAGTCGTCGACAAGGGAGCAAGCGCACAGAGCTTC
	ATCGAAAGAATGACAAACTTCGACAAGAACCTGCCGAACGAA
	AAGGTCCTGCCGAAGCACAGCCTGCTGTACGAATACTTCACAG
	TCTACAACGAACTGACAAAGGTCAAGTACGTCACAGAAGGAA
	TGAGAAAGCCGGCATTCCTGAGCGGAGAACAGAAGAAGGCAA
	TCGTCGACCTGCTGTTCAAGACAAACAGAAAGGTCACAGTCA
	AGCAGCTGAAGGAAGACTACTTCAAGAAGATCGAATGCTTCG
	ACAGCGTCGAAATCAGCGGAGTCGAAGACAGATTCAACGCAA
	GCCTGGGAACATACCACGACCTGCTGAAGATCATCAAGGACA
	AGGACTTCCTGGACAACGAAGAAAACGAAGACATCCTGGAAG
	ACATCGTCCTGACACTGACACTGTTCGAAGACAGAGAAATGAT
	CGAAGAAAGACTGAAGACATACGCACACCTGTTCGACGACAA
	GGTCATGAAGCAGCTGAAGAGAAGAAGATACACAGGATGGGG
	AAGACTGAGCAGAAAGCTGATCAACGGAATCAGAGACAAGCA
	GAGCGGAAAGACAATCCTGGACTTCCTGAAGAGCGACGGATT
	CGCAAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCT
	GACATTCAAGGAAGACATCCAGAAGGCACAGGTCAGCGGACA
	GGGAGACAGCCTGCACGAACACATCGCAAACCTGGCAGGAAG
	CCCGGCAATCAAGAAGGGAATCCTGCAGACAGTCAAGGTCGT
	CGACGAACTGGTCAAGGTCATGGGAAGACACAAGCCGGAAAA
	CATCGTCATCGAAATGGCAAGAGAAAACCAGACAACACAGAA
	GGGACAGAAGAACAGCAGAGAAAGAATGAAGAGAATCGAAG
	AAGGAATCAAGGAACTGGGAAGCCAGATCCTGAAGGAACACC
	CGGTCGAAAACACACAGCTGCAGAACGAAAAGCTGTACCTGT
	ACTACCTGCAGAACGGAAGAGACATGTACGTCGACCAGGAAC
	TGGACATCAACAGACTGAGCGACTACGACGTCGACCACATCG
	TCCCGCAGAGCTTCCTGAAGGACGACAGCATCGACAACAAGG
	TCCTGACAAGAAGCGACAAGAACAGAGGAAAGAGCGACAAC
	GTCCCGAGCGAAGAAGTCGTCAAGAAGATGAAGAACTACTGG
	AGACAGCTGCTGAACGCAAAGCTGATCACACAGAGAAAGTTC
	GACAACCTGACAAAGGCAGAGAGAGGAGGACTGAGCGAACT
	GGACAAGGCAGGATTCATCAAGAGACAGCTGGTCGAAACAAG
	ACAGATCACAAAGCACGTCGCACAGATCCTGGACAGCAGAAT
	GAACACAAAGTACGACGAAAACGACAAGCTGATCAGAGAAGT
	CAAGGTCATCACACTGAAGAGCAAGCTGGTCAGCGACTTCAG
	AAAGGACTTCCAGTTCTACAAGGTCAGAGAAATCAACAACTA
	CCACCACGCACACGACGCATACCTGAACGCAGTCGTCGGAAC
	AGCACTGATCAAGAAGTACCCGAAGCTGGAAAGCGAATTCGT
	CTACGGAGACTACAAGGTCTACGACGTCAGAAAGATGATCGC
	AAAGAGCGAACAGGAAATCGGAAAGGCAACAGCAAAGTACTT
	CTTCTACAGCAACATCATGAACTTCTTCAAGACAGAAATCACA
	CTGGCAAACGGAGAAATCAGAAAGAGACCGCTGATCGAAACA
	AACGGAGAAACAGGAGAAATCGTCTGGGACAAGGGAAGAGA
	CTTCGCAACAGTCAGAAAGGTCCTGAGCATGCCGCAGGTCAA
	CATCGTCAAGAAGACAGAAGTCCAGACAGGAGGATTCAGCAA
	GGAAAGCATCCTGCCGAAGAGAAACAGCGACAAGCTGATCGC
	AAGAAAGAAGGACTGGGACCCGAAGAAGTACGGAGGATTCG
	ACAGCCCGACAGTCGCATACAGCGTCCTGGTCGTCGCAAAGGT
	CGAAAAGGGAAAGAGCAAGAAGCTGAAGAGCGTCAAGGAAC
	TGCTGGGAATCACAATCATGGAAAGAAGCAGCTTCGAAAAGA
	ACCCGATCGACTTCCTGGAAGCAAAGGGATACAAGGAAGTCA
	AGAAGGACCTGATCATCAAGCTGCCGAAGTACAGCCTGTTCG
	AACTGGAAAACGGAAGAAAGAGAATGCTGGCAAGCGCAGGA
	GAACTGCAGAAGGGAAACGAACTGGCACTGCCGAGCAAGTAC
	GTCAACTTCCTGTACCTGGCAAGCCACTACGAAAAGCTGAAGG
	GAAGCCCGGAAGACAACGAACAGAAGCAGCTGTTCGTCGAAC
	AGCACAAGCACTACCTGGACGAAATCATCGAACAGATCAGCG
	AATTCAGCAAGAGAGTCATCCTGGCAGACGCAAACCTGGACA
	AGGTCCTGAGCGCATACAACAAGCACAGAGACAAGCCGATCA
	GAGAACAGGCAGAAAACATCATCCACCTGTTCACACTGACAA
	ACCTGGGAGCACCGGCAGCATTCAAGTACTTCGACACAACAA
	TCGACAGAAAGAGATACACAAGCACAAAGGAAGTCCTGGACG
	CAACACTGATCCACCAGAGCATCACAGGACTGTACGAAACAA
	GAATCGACCTGAGCCAGCTGGGAGGAGACGGAGGAGGAAGCC
	CGAAGAAGAAGAGAAAGGTCTAG
Cas9 DNA	ATGGATAAGAAGTACTCAATCGGGCTGGATATCGGAACTAATT	2
coding	CCGTGGGTTGGGCAGTGATCACGGATGAATACAAAGTGCCGT
sequence 1	CCAAGAAGTTCAAGGTCCTGGGGAACACCGATAGACACAGCA
	TCAAGAAAAATCTCATCGGAGCCCTGCTGTTTGACTCCGGCGA
	AACCGCAGAAGCGACCCGGCTCAAACGTACCGCGAGGCGACG
	CTACACCCGGCGGAAGAATCGCATCTGCTATCTGCAAGAGATC
	TTTTCGAACGAAATGGCAAAGGTCGACGACAGCTTCTTCCACC
	GCCTGGAAGAATCTTTCCTGGTGGAGGAGGACAAGAAGCATG
	AACGGCATCCTATCTTTGGAAACATCGTCGACGAAGTGGCGTA
	CCACGAAAAGTACCCGACCATCTACCATCTGCGGAAGAAGTT
	GGTTGACTCAACTGACAAGGCCGACCTCAGATTGATCTACTTG
	GCCCTCGCCCATATGATCAAATTCCGCGGACACTTCCTGATCG
	AAGGCGATCTGAACCCTGATAACTCCGACGTGGATAAGCTTTT
	CATTCAACTGGTGCAGACCTACAACCAACTGTTCGAAGAAAAC
	CCAATCAATGCTAGCGGCGTCGATGCCAAGGCCATCCTGTCCG
	CCCGGCTGTCGAAGTCGCGGCGCCTCGAAAACCTGATCGCACA
	GCTGCCGGGAGAGAAAAAGAACGGACTTTTCGGCAACTTGAT
	CGCTCTCTCACTGGGACTCACTCCCAATTTCAAGTCCAATTTTG
	ACCTGGCCGAGGACGCGAAGCTGCAACTCTCAAAGGACACCT
	ACGACGACGACTTGGACAATTTGCTGGCACAAATTGGCGATCA
	GTACGCGGATCTGTTCCTTGCCGCTAAGAACCTTTCGGACGCA
	ATCTTGCTGTCCGATATCCTGCGCGTGAACACCGAAATAACCA
	AAGCGCCGCTTAGCGCCTCGATGATTAAGCGGTACGACGAGC
	ATCACCAGGATCTCACGCTGCTCAAAGCGCTCGTGAGACAGCA
	ACTGCCTGAAAAGTACAAGGAGATCTTCTTCGACCAGTCCAAG
	AATGGGTACGCAGGGTACATCGATGGAGGCGCTAGCCAGGAA
	GAGTTCTATAAGTTCATCAAGCCAATCCTGGAAAAGATGGACG
	GAACCGAAGAACTGCTGGTCAAGCTGAACAGGGAGGATCTGC
	TCCGGAAACAGAGAACCTTTGACAACGGATCCATTCCCCACCA
	GATCCATCTGGGTGAGCTGCACGCCATCTTGCGGCGCCAGGAG
	GACTTTTACCCATTCCTCAAGGACAACCGGGAAAAGATCGAG
	AAAATTCTGACGTTCCGCATCCCGTATTACGTGGGCCCACTGG
	CGCGCGGCAATTCGCGCTTCGCGTGGATGACTAGAAAATCAG
	AGGAAACCATCACTCCTTGGAATTTCGAGGAAGTTGTGGATAA
	GGGAGCTTCGGCACAAAGCTTCATCGAACGAATGACCAACTTC
	GACAAGAATCTCCCAAACGAGAAGGTGCTTCCTAAGCACAGC
	CTCCTTTACGAATACTTCACTGTCTACAACGAACTGACTAAAG
	TGAAATACGTTACTGAAGGAATGAGGAAGCCGGCCTTTCTGTC
	CGGAGAACAGAAGAAAGCAATTGTCGATCTGCTGTTCAAGAC
	CAACCGCAAGGTGACCGTCAAGCAGCTTAAAGAGGACTACn-
	CAAGAAGATCGAGTGTTTCGACTCAGTGGAAATCAGCGGGGT
	GGAGGACAGATTCAACGCTTCGCTGGGAACCTATCATGATCTC
	CTGAAGATCATCAAGGACAAGGACTTCCTTGACAACGAGGAG
	AACGAGGACATCCTGGAAGATATCGTCCTGACCTTGACCCTTT
	TCGAGGATCGCGAGATGATCGAGGAGAGGCTTAAGACCTACG
	CTCATCTCTTCGACGATAAGGTCATGAAACAACTCAAGGGCCG
	CCGGTACACTGGTTGGGGCCGCCTCTCCCGCAAGCTGATCAAC
	GGTATTCGCGATAAACAGAGCGGTAAAACTATCCTGGATTTCC
	TCAAATCGGATGGCTTCGCTAATCGTAACTTCATGCAATTGAT
	CCACGACGACAGCCTGACCTTTAAGGAGGACATCCAAAAAGC
	ACAAGTGTCCGGACAGGGAGACTCACTCCATGAACACATCGC
	GAATCTGGCCGGTTCGCCGGCGATTAAGAAGGGAATTCTGCA
	AACTGTGAAGGTGGTCGACGAGCTGGTGAAGGTCATGGGACG
	GCACAAACCGGAGAATATCGTGATTGAAATGGCCCGAGAAAA
	CCAGACTACCCAGAAGGGCCAGAAAAACTCCCGCGAAAGGAT
	GAAGCGGATCGAAGAAGGAATCAAGGAGCTGGGCAGCCAGAT
	CCTGAAAGAGCACCCGGTGGAAAACACGCAGCTGCAGAACGA
	GAAGCTCTACCTGTACTATTTGCAAAATGGACGGGACATGTAC
	GTGGACCAAGAGCTGGACATCAATCGGTTGTCTGATTACGACG
	TGGACCACATCGTTCCACAGTCCTTTCTGAAGGATGACTCGAT
	CGATAACAAGGTGTTGACTCGCAGCGACAAGAACAGAGGGAA
	GTCAGATAATGTGCCATCGGAGGAGGTCGTGAAGAAGATGAA
	GAATTACTGGCGGCAGCTCCTGAATGCGAAGCTGATTACCCAG
	AGAAAGTTTGACAATCTCACTAAAGCCGAGCGCGGCGGACTC
	TCAGAGCTGGATAAGGCTGGATTCATCAAACGGCAGCTGGTC
	GAGACTCGGCAGATTACCAAGCACGTGGCGCAGATCTTGGAC
	TCCCGCATGAACACTAAATACGACGAGAACGATAAGCTCATC
	CGGGAAGTGAAGGTGATTACCCTGAAAAGCAAACTTGTGTCG
	GACTTTCGGAAGGACTTTCAGTTTTACAAAGTGAGAGAAATCA
	ACAACTACCATCACGCGCATGACGCATACCTCAACGCTGTGGT
	CGGTACCGCCCTGATCAAAAAGTACCCTAAACTTGAATCGGAG
	TTTGTGTACGGAGACTACAAGGTCTACGACGTGAGGAAGATG
	ATAGCCAAGTCCGAACAGGAAATCGGGAAAGCAACTGCGAAA
	TACTTCTTTTACTCAAACATCATGAACTTTTTCAAGACTGAAAT
	TACGCTGGCCAATGGAGAAATCAGGAAGAGGCCACTGATCGA
	AACTAACGGAGAAACGGGCGAAATCGTGTGGGACAAGGGCAG
	GGACTTCGCAACTGTTCGCAAAGTGCTCTCTATGCCGCAAGTC
	AATATTGTGAAGAAAACCGAAGTGCAAACCGGCGGATTTTCA
	AAGGAATCGATCCTCCCAAAGAGAAATAGCGACAAGCTCATT
	GCACGCAAGAAAGACTGGGACCCGAAGAAGTACGGAGGATTC
	GATTCGCCGACTGTCGCATACTCCGTCCTCGTGGTGGCCAAGG
	TGGAGAAGGGAAAGAGCAAAAAGCTCAAATCCGTCAAAGAGC
	TGCTGGGGATTACCATCATGGAACGATCCTCGTTCGAGAAGAA
	CCCGATTGATTTCCTCGAGGCGAAGGGTTACAAGGAGGTGAA
	GAAGGATCTGATCATCAAACTCCCCAAGTACTCACTGTTCGAA
	CTGGAAAATGGTCGGAAGCGCATGCTGGCTTCGGCCGGAGAA
	CTCCAAAAAGGAAATGAGCTGGCCTTGCCTAGCAAGTACGTC
	AACTTCCTCTATCTTGCTTCGCACTACGAAAAACTCAAAGGGT
	CACCGGAAGATAACGAACAGAAGCAGCTTTTCGTGGAGCAGC
	ACAAGCATTATCTGGATGAAATCATCGAACAAATCTCCGAGTT
	TTCAAAGCGCGTGATCCTCGCCGACGCCAACCTCGACAAAGTC
	CTGTCGGCCTACAATAAGCATAGAGATAAGCCGATCAGAGAA
	CAGGCCGAGAACATTATCCACTTGTTCACCCTGACTAACCTGG
	GAGCCCCAGCCGCCTTCAAGTACTTCGATACTACTATCGATCG
	CAAAAGATACACGTCCACCAAGGAAGTTCTGGACGCGACCCT
	GATCCACCAAAGCATCACTGGACTCTACGAAACTAGGATCGAT
	CTGTCGCAGCTGGGTGGCGATGGCGGTGGATCTCCGAAAAAG
	AAGAGAAAGGTGTAATGA
Cas9 amino	MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIK	3
acid	KNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNE
sequence	MAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT
	IYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNS
	DVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENL
	IAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDT
	YDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKA
	PLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA
	GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTF
	DNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYV
	GPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMT
	NFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFL
	SGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED
	RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMI
	EERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSG
	KTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLH
	EHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARE
	NQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKL
	YLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNK
	VLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD
	NLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKY
	DENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDA
	YLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK
	ATAKYFFYSNIMNFFKTEITLANGEIRKRPLITNGETGEIVWDKG
	RDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIAR
	KKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
	ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKR
	MLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ
	LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPI
	REQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLI
	HQSITGLYETRIDLSQLGGDGGGSPKKKRKV
Cas9 mRNA	AUGGACAAGAAGUACAGCAUCGGACUGGACAUCGGAACAAA	4
open reading	CAGCGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCC
frame (ORF)	CGAGCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACAC
2	AGCAUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAG
	CGGAGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAA
	GAAGAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUG
	CAGGAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAG
	CUUCUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAG
	ACAAGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUC
	GACGAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCA
	CCUGAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACC
	UGAGACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUC
	AGAGGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAA
	CAGCGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAU
	ACAACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGA
	GUCGACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAG
	CAGAAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAA
	AGAAGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUG
	GGACUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGA
	AGACGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACG
	ACCUGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCA
	GACCUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCU
	GCUGAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGG
	CACCGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACAC
	CACCAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCA
	GCUGCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCA
	AGAACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAG
	GAAGAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAU
	GGACGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAG
	ACCUGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUC
	CCGCACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGA
	AGACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGA
	AAAGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACG
	UCGGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUG
	ACAAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGA
	AGAAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCG
	AAAGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAG
	GUCCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGU
	CUACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAA
	UGAGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCA
	AUCGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGU
	CAAGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCU
	UCGACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAAC
	GCAAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAA
	GGACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCC
	UGGAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGA
	GAAAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUU
	CGACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACA
	CAGGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUC
	AGAGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAA
	GAGCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCC
	ACGACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCA
	CAGGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGC
	AAACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGC
	AGACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGA
	AGACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGA
	AAACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAA
	GAAUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGC
	CAGAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCA
	GAACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAG
	ACAUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGC
	GACUACGACGUCGACCACAUCGUCCCGCAGAGCUUCCUGAAG
	GACGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAA
	GAACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCG
	UCAAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCA
	AAGCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGC
	AGAGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCA
	UCAAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCAC
	GUCGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGA
	CGAAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACAC
	UGAAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAG
	UUCUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACA
	CGACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCA
	AGAAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGAC
	UACAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGA
	ACAGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACA
	GCAACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCA
	AACGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGG
	AGAAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCG
	CAACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUC
	GUCAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGGAAGGA
	AAGCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGGAA
	GAAAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGAC
	AGCCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGU
	CGAAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAAC
	UGCUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAG
	AACCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGU
	CAAGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGU
	UCGAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCA
	GGAGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAA
	GUACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGC
	UGAAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUUC
	GUCGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACA
	GAUCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAA
	ACCUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGAC
	AAGCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUU
	CACACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACU
	UCGACACAACAAUCGACAGAAAGAGAUACACAAGCACAAAG
	GAAGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAGG
	ACUGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAG
	ACGGAGGAGGAAGCCCGAAGAAGAAGAGAAAGGUCUAG
Cas9 mRNA	AUGGAUAAGAAGUACUCAAUCGGGCUGGAUAUCGGAACUAA	5
ORF 1	UUCCGUGGGUUGGGCAGUGAUCACGGAUGAAUACAAAGUGC
	CGUCCAAGAAGUUCAAGGUCCUGGGGAACACCGAUAGACAC
	AGCAUCAAGAAAAAUCUCAUCGGAGCCCUGCUGUUUGACUC
	CGGCGAAACCGCAGAAGCGACCCGGCUCAAACGUACCGCGAG
	GCGACGCUACACCCGGCGGAAGAAUCGCAUCUGCUAUCUGC
	AAGAGAUCUUUUCGAACGAAAUGGCAAAGGUCGACGACAGC
	UUCUUCCACCGCCUGGAAGAAUCUUUCCUGGUGGAGGAGGA
	CAAGAAGCAUGAACGGCAUCCUAUCUUUGGAAACAUCGUCG
	ACGAAGUGGCGUACCACGAAAAGUACCCGACCAUCUACCAU
	CUGCGGAAGAAGUUGGUUGACUCAACUGACAAGGCCGACCU
	CAGAUUGAUCUACUUGGCCCUCGCCCAUAUGAUCAAAUUCC
	GCGGACACUUCCUGAUCGAAGGCGAUCUGAACCCUGAUAAC
	UCCGACGUGGAUAAGCUUUUCAUUCAACUGGUGCAGACCUA
	CAACCAACUGUUCGAAGAAAACCCAAUCAAUGCUAGCGGCG
	UCGAUGCCAAGGCCAUCCUGUCCGCCCGGCUGUCGAAGUCGC
	GGCGCCUCGAAAACCUGAUCGCACAGCUGCCGGGAGAGAAA
	AAGAACGGACUUUUCGGCAACUUGAUCGCUCUCUCACUGGG
	ACUCACUCCCAAUUUCAAGUCCAAUUUUGACCUGGCCGAGG
	ACGCGAAGCUGCAACUCUCAAAGGACACCUACGACGACGAC
	UUGGACAAUUUGCUGGCACAAAUUGGCGAUCAGUACGCGGA
	UCUGUUCCUUGCCGCUAAGAACCUUUCGGACGCAAUCUUGC
	UGUCCGAUAUCCUGCGCGUGAACACCGAAAUAACCAAAGCG
	CCGCUUAGCGCCUCGAUGAUUAAGCGGUACGACGAGCAUCA
	CCAGGAUCUCACGCUGCUCAAAGCGCUCGUGAGACAGCAAC
	UGCCUGAAAAGUACAAGGAGAUCUUCUUCGACCAGUCCAAG
	AAUGGGUACGCAGGGUACAUCGAUGGAGGCGCUAGCCAGGA
	AGAGUUCUAUAAGUUCAUCAAGCCAAUCCUGGAAAAGAUGG
	ACGGAACCGAAGAACUGCUGGUCAAGCUGAACAGGGAGGAU
	CUGCUCCGGAAACAGAGAACCUUUGACAACGGAUCCAUUCC
	CCACCAGAUCCAUCUGGGUGAGCUGCACGCCAUCUUGCGGCG
	CCAGGAGGACUUUUACCCAUUCCUCAAGGACAACCGGGAAA
	AGAUCGAGAAAAUUCUGACGUUCCGCAUCCCGUAUUACGUG
	GGCCCACUGGCGCGCGGCAAUUCGCGCUUCGCGUGGAUGAC
	UAGAAAAUCAGAGGAAACCAUCACUCCUUGGAAUUUCGAGG
	AAGUUGUGGAUAAGGGAGCUUCGGCACAAAGCUUCAUCGAA
	CGAAUGACCAACUUCGACAAGAAUCUCCCAAACGAGAAGGU
	GCUUCCUAAGCACAGCCUCCUUUACGAAUACUUCACUGUCU
	ACAACGAACUGACUAAAGUGAAAUACGUUACUGAAGGAAUG
	AGGAAGCCGGCCUUUCUGUCCGGAGAACAGAAGAAAGCAAU
	UGUCGAUCUGCUGUUCAAGACCAACCGCAAGGUGACCGUCA
	AGCAGCUUAAAGAGGACUACUUCAAGAAGAUCGAGUGUUUC
	GACUCAGUGGAAAUCAGCGGGGUGGAGGACAGAUUCAACGC
	UUCGCUGGGAACCUAUCAUGAUCUCCUGAAGAUCAUCAAGG
	ACAAGGACUUCCUUGACAACGAGGAGAACGAGGACAUCCUG
	GAAGAUAUCGUCCUGACCUUGACCCUUUUCGAGGAUCGCGA
	GAUGAUCGAGGAGAGGCUUAAGACCUACGCUCAUCUCUUCG
	ACGAUAAGGUCAUGAAACAACUCAAGCGCCGCCGGUACACU
	GGUUGGGGCCGCCUCUCCCGCAAGCUGAUCAACGGUAUUCG
	CGAUAAACAGAGCGGUAAAACUAUCCUGGAUUUCCUCAAAU
	CGGAUGGCUUCGCUAAUCGUAACUUCAUGCAAUUGAUCCAC
	GACGACAGCCUGACCUUUAAGGAGGACAUCCAAAAAGCACA
	AGUGUCCGGACAGGGAGACUCACUCCAUGAACACAUCGCGA
	AUCUGGCCGGUUCGCCGGCGAUUAAGAAGGGAAUUCUGCAA
	ACUGUGAAGGUGGUCGACGAGCUGGUGAAGGUCAUGGGACG
	OCACAAACCGGAGAAUAUCGUGAUUGAAAUGGCCCGAGAAA
	ACCAGACUACCCAGAAGGGCCAGAAAAACUCCCGCGAAAGG
	AUGAAGCGGAUCGAAGAAGGAAUCAAGGAGCUGGGCAGCCA
	GAUCCUGAAAGAGCACCCGGUGGAAAACACGCAGCUGCAGA
	ACGAGAAGCUCUACCUGUACUAUUUGCAAAAUGGACGGGAC
	AUGUACGUGGACCAAGAGCUGGACAUCAAUCGGUUGUCUGA
	UUACGACGUGGACCACAUCGUUCCACAGUCCUUUCUGAAGG
	AUGACUCGAUCGAUAACAAGGUGUUGACUCGCAGCGACAAG
	AACAGAGGGAAGUCAGAUAAUGUGCCAUCGGAGGAGGUCGU
	GAAGAAGAUGAAGAAUUACUGGCGGCAGCUCCUGAAUGCGA
	AGCUGAUUACCCAGAGAAAGUUUGACAAUCUCACUAAAGCC
	GAGCGCGGCGGACUCUCAGAGCUGGAUAAGGCUGGAUUCAU
	CAAACGGCAGCUGGUCGAGACUCGGCAGAUUACCAAGCACG
	UGGCGCAGAUCUUGGACUCCCGCAUGAACACUAAAUACGAC
	GAGAACGAUAAGCUCAUCCGGGAAGUGAAGGUGAUUACCCU
	GAAAAGCAAACUUGUGUCGGACUUUCGGAAGGACUUUCAGU
	UUUACAAAGUGAGAGAAAUCAACAACUACCAUCACGCGCAU
	GACGCAUACCUCAACGCUGUGGUCGGUACCGCCCUGAUCAA
	AAAGUACCCUAAACUUGAAUCGGAGUUUGUGUACGGAGACU
	ACAAGGUCUACGACGUGAGGAAGAUGAUAGCCAAGUCCGAA
	CAGGAAAUCGGGAAAGCAACUGCGAAAUACUUCUUUUACUC
	AAACAUCAUGAACUUUUUCAAGACUGAAAUUACGCUGGCCA
	AUGGAGAAAUCAGGAAGAGGCCACUGAUCGAAACUAACGGA
	GAAACGGGCGAAAUCGUGUGGGACAAGGGCAGGGACUUCGC
	AACUGUUCGCAAAGUGCUCUCUAUGCCGCAAGUCAAUAUUG
	UGAAGAAAACCGAAGUGCAAACCGGCGGAUUUUCAAAGGAA
	UCGAUCCUCCCAAAGAGAAAUAGCGACAAGCUCAUUGCACG
	CAAGAAAGACUGGGACCCGAAGAAGUACGGAGGAUUCGAUU
	CGCCGACUGUCGCAUACUCCGUCCUCGUGGUGGCCAAGGUG
	GAGAAGGGAAAGAGCAAAAAGCUCAAAUCCGUCAAAGAGCU
	GCUGGGGAUUACCAUCAUGGAACGAUCCUCGUUCGAGAAGA
	ACCCGAUUGAUUUCCUCGAGGCGAAGGGUUACAAGGAGGUG
	AAGAAGGAUCUGAUCAUCAAACUCCCCAAGUACUCACUGUU
	CGAACUGGAAAAUGGUCGGAAGCGCAUGCUGGCUUCGGCCG
	GAGAACUCCAAAAAGGAAAUGAGCUGGCCUUGCCUAGCAAG
	UACGUCAACUUCCUCUAUCUUGCUUCGCACUACGAAAAACU
	CAAAGGGUCACCGGAAGAUAACGAACAGAAGCAGCUUUUCG
	UGGAGCAGCACAAGCAUUAUCUGGAUGAAAUCAUCGAACAA
	AUCUCCGAGUUUUCAAAGCGCGUGAUCCUCGCCGACGCCAAC
	CUCGACAAAGUCCUGUCGGCCUACAAUAAGCAUAGAGAUAA
	GCCGAUCAGAGAACAGGCCGAGAACAUUAUCCACUUGUUCA
	CCCUGACUAACCUGGGAGCCCCAGCCGCCUUCAAGUACUUCG
	AUACUACUAUCGAUCGCAAAAGAUACACGUCCACCAAGGAA
	GUUCUGGACGCGACCCUGAUCCACCAAAGCAUCACUGGACUC
	UACGAAACUAGGAUCGAUCUGUCGCAGCUGGGUGGCGAUGG
	CGGUGGAUCUCCGAAAAAGAAGAGAAAGGUGUAAUGA
Cas9 nickase	MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIK	6
(D10A)	KNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNE
amino acid	MAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT
sequence	IYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNS
	DVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENL
	IAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDT
	YDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKA
	PLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFTDQSKNGYA
	GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTF
	DNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYV
	GPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMT
	NFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFL
	SGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED
	RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMI
	EERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSG
	KTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLH
	EHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARE
	NQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKL
	YLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNK
	VLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD
	NLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKY
	DENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDA
	YLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK
	ATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKG
	RDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIAR
	KKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
	ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKR
	MLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ
	LFVEQHKHYLDEIEQISEFSKRVILADANLDKVLSAYNKHRDKPI
	REQAENIIHLFTLTNLGAPAAFKYPDTTIDRKRYTSTKEVLDATLI
	HQSITGLYETRIDLSQLGGDGGGSPKKKRKV
Cas9 nickase	AUGGACAAGAAGUACAGCAUCGGACUGGCAAUCGGAACAAA	7
(D10A)	CAGCGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCC
mRNA ORF	CGAGCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACAC
	AGCAUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAG
	CGGAGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAA
	GAAGAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUG
	CAGGAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAG
	CUUCUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAG
	ACAAGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUC
	GACGAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCA
	CCUGAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACC
	UGAGACLGAUCUACCUGGCACUGGCACACAUGAUCAAGUUC
	AGAGGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAA
	CAGCGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAU
	ACAACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGA
	GUCGACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAG
	CAGAAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAA
	AGAAGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUG
	GGACUGACACCGAACUUCAAGAGCAACUVCGACCUGGCAGA
	AGACGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACG
	ACCUGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCA
	GACCUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCU
	GCUGAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGG
	CACCGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACAC
	CACCAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCA
	GCUGCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCA
	AGAACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAG
	GAAGAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAU
	GGACGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAG
	ACCUGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUC
	CCGCACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGA
	AGACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGA
	AAAGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACG
	UCGGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUG
	ACAAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGA
	AGAAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCG
	AAAGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAG
	GUCCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGU
	CUACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAA
	UGAGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCA
	AUCGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGU
	CAAGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCU
	UCGACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAAC
	GCAAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAA
	GGACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCC
	UGGAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGA
	GAAAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUU
	CGACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACA
	CAGGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUC
	AGAGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAA
	GAGCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCC
	ACGACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCA
	CAGGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGC
	AAACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGC
	AGACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGA
	AGACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGA
	AAACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAA
	GAAUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGC
	CAGAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCA
	GAACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAG
	ACAUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGC
	GACUACGACGUCGACCACAUCGUCCCGCAGAGCUUCCUGAAG
	GACGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAA
	GAACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCG
	UCAAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCA
	AAGCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGC
	AGAGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCA
	UCAAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGGAC
	GUCGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGA
	CGAAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACAC
	UGAAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAG
	UUCUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACA
	CGACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCA
	AGAAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGAC
	UACAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGA
	ACAGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACA
	GCAACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCA
	AACGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGG
	AGAAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCG
	CAACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUC
	GUCAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGGA
	AAGCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCAA
	GAAAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGAC
	AGCCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGU
	CGAAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAAC
	UGCUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAG
	AACCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGU
	CAAGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGU
	UCGAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCA
	GGAGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAA
	GUACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGC
	UGAAGGGAAGCCCGGAAGACAACGAACAGAAGCAGGUGUUC
	GUCGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACA
	GAUCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAA
	ACCUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGAC
	AAGCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUU
	CACACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACU
	UCGACACAACAAUCGACAGAAAGAGAUACACAAGGACAAAG
	GAAGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAGG
	ACUGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAG
	ACGGAGGAGGAAGCCCGAAGAAGAAGAGAAAGGUCUAG
dCas9	MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIK	8
(D10A	KNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNE
H840A)	MAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT
amine acid	IYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNS
sequence	DVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENL
	IAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDT
	YDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKA
	PLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA
	GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTF
	DNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYV
	GPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMT
	NFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFL
	SGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED
	RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMI
	EERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSG
	KTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLH
	EHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENTVIEMARE
	NQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKL
	YLYYLQNGRDMYVDQELDINRLSDYDVDATVPQSFLKDDSIDNK
	VLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD
	NLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKY
	DENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDA
	YLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK
	ATAKYFFYSNIMNFFKTEITLANGEIRKRPLDETNGETGEIVWDKG
	RDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIAR
	KKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
	ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKR
	MLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ
	LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPI
	REQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLI
	HQSITGLYETRIDLSQLGGDGGGSPKKKRKV
dCas9	AUGGACAAGAAGUACAGCAUCGGACUGGCAAUCGGAACAAA	9
(D10A	CAGCGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCC
H840A)	CGAGCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACAC
mRNA ORF	AGCAUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAG
	CGGAGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAA
	GAAGAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUG
	CAGGAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAG
	CUUCUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAG
	ACAAGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUC
	GACGAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCA
	CCUGAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACC
	UGAGACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUC
	AGAGGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAA
	CAGCGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAU
	ACAACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGA
	GUCGACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAG
	CAGAAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAA
	AGAAGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUG
	GGACUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGA
	AGACGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACG
	ACCUGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCA
	GACCUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCU
	GCUGAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGG
	CACCGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACAC
	CACCAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCA
	GCUGCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCA
	AGAACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAG
	GAAGAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAU
	GGACGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAG
	ACCUGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUC
	CCGCACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGA
	AGACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGA
	AAAGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACG
	UCGGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUG
	ACAAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGA
	AGAAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCG
	AAAGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAG
	GUCCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGU
	CUACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAA
	UGAGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCA
	AUCGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGU
	CAAGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCU
	UCGACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAAC
	GCAAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAA
	GGACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCC
	UGGAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGA
	GAAAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUU
	CGACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACA
	CAGGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUC
	AGAGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAA
	GAGCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCC
	ACGACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCA
	CAGGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGC
	AAACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGC
	AGACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGA
	AGACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGA
	AAACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAA
	GAAUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGC
	CAGAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCA
	GAACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAG
	ACAUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGC
	GACUACGACGUCGACGCAAUCGUCCCGCAGAGCUUCCUGAA
	GGACGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACA
	AGAACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUC
	GUCAAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGC
	AAAGCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGG
	CAGAGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUC
	AUCAAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCA
	CGUCGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACG
	ACGAAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACA
	CUGAAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCA
	GUUCUACAAGGUCAGAGAAAUCAACAACUACCACCACGCAC
	ACGACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUC
	AAGAAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGA
	CUACAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCG
	AACAGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUAC
	AGCAACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGC
	AAACGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACG
	GAGAAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUC
	GCAACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAU
	CGUCAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGG
	AAAGCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCA
	AGAAAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGA
	CAGCCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGG
	UCGAAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAA
	CUGCUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAA
	GAACCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAG
	UCAAGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUG
	UUCGAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGC
	AGGAGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCA
	AGUACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAG
	CUGAAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUU
	CGUCGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAAC
	AGAUCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCA
	AACCUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGA
	CAAGCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGU
	UCACACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUAC
	UUCGACACAACAAUCGACAGAAAGAGAUACACAAGCACAAA
	GGAAGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAG
	GACUGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGA
	GACGGAGGAGGAAGCCCGAAGAAGAAGAGAAAGGUCUAG
Cas9 bare	GACAAGAAGUACAGCAUCGGACUGGACAUCGGAACAAACAG	10
coding	CGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCCCGA
sequence	GCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACACAGC
	AUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAGCGG
	AGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAAGAA
	GAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUGCAG
	GAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAGCUU
	CUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAGACA
	AGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUCGAC
	GAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCACCU
	GAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACCUGA
	GACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUCAGA
	GGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAACAG
	CGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAUACA
	ACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGAGUC
	GACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAGCAG
	AAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAAAGA
	AGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUGGGA
	CUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGAAGA
	CGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACGACC
	UGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCAGAC
	CUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCUGCU
	GAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGGCAC
	CGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACACCAC
	CAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCAGCU
	GCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCAAGA
	ACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAGGAA
	GAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAUGGA
	CGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAGACC
	UGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUCCCG
	CACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGAAG
	ACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGAAA
	AGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACGUC
	GGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUGAC
	AAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGAAG
	AAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCGAA
	AGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAGGU
	CCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGUCU
	ACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAAUG
	AGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCAAU
	CGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGUCA
	AGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCUUC
	GACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAACGC
	AAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAAGG
	ACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCCUG
	GAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGAGA
	AAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUUCG
	ACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACACA
	GGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUCAG
	AGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAAGA
	GCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCCAC
	GACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCACA
	GGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGCAA
	ACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGCAG
	ACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGAAG
	ACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGAAA
	ACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAAGA
	AUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGCCA
	GAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCAGA
	ACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAGAC
	AUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGCGA
	CUACGACGUCGACCACAUCGUCCCGCAGAGCUUCCUGAAGGA
	CGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAAGA
	ACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCGUC
	AAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCAAA
	GCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGCAG
	AGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCAUC
	AAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCACGU
	CGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGACG
	AAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACACUG
	AAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAGUU
	CUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACACG
	ACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCAAG
	AAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGACUA
	CAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGAAC
	AGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACAGC
	AACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCAAA
	CGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGGAG
	AAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCGCA
	ACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUCGU
	CAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGGAAA
	GCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCAAGA
	AAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGACAG
	CCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGUCG
	AAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAACUG
	CUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAGAA
	CCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGUCA
	AGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGUUC
	GAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCAGG
	AGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAAGU
	ACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGCUG
	AAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUUCGU
	CGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACAGA
	UCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAAAC
	CUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGACAA
	GCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUUCA
	CACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACUUC
	GACACAACAAUCGACAGAAAGAGAUACACAAGCACAAAGGA
	AGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAGGAC
	UGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAGAC
	GGAGGAGGAAGCCCGAAGAAGAAGAGAAAGGUC
Cas9 nickase	GACAAGAAGUACAGCAUCGGACUGGCAAUCGGAACAAACAG	11
bare coding	CGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCCCGA
sequence	GCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACACAGC
	AUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAGCGG
	AGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAAGAA
	GAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUGCAG
	GAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAGCUU
	CUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAGACA
	AGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUCGAC
	GAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCACCU
	GAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACCUGA
	GACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUCAGA
	GGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAACAG
	CGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAUACA
	ACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGAGUC
	GACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAGCAG
	AAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAAAGA
	AGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUGGGA
	CUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGAAGA
	CGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACGACC
	UGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCAGAC
	CUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCUGCU
	GAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGGCAC
	CGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACACCAC
	CAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCAGCU
	GCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCAAGA
	ACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAGGAA
	GAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAUGGA
	CGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAGACC
	UGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUCCCG
	CACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGAAG
	ACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGAAA
	AGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACGUC
	GGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUGAC
	AAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGAAG
	AAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCGAA
	AGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAGGU
	CCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGUCU
	ACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAAUG
	AGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCAAU
	CGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGUCA
	AGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCUUC
	GACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAACGC
	AAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAAGG
	ACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCCUG
	GAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGAGA
	AAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUUCG
	ACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACACA
	GGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUCAG
	AGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAAGA
	GCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCCAC
	GACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCACA
	GGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGCAA
	ACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGCAG
	ACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGAAG
	ACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGAAA
	ACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAAGA
	AUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGCCA
	GAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCAGA
	ACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAGAC
	AUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGCGA
	CUACGACGUCGACCACAUCGUCCCGCAGAGCUUCCUGAAGGA
	CGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAAGA
	ACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCGUC
	AAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCAAA
	GCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGCAG
	AGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCAUC
	AAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCACGU
	CGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGACG
	AAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACACUG
	AAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAGUU
	CUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACACG
	ACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCAAG
	AAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGACUA
	CAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGAAC
	AGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACAGC
	AACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCAAA
	CGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGGAG
	AAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCGCA
	ACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUCGU
	CAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGGAAA
	GCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCAAGA
	AAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGACAG
	CCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGUCG
	AAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAACUG
	CUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAGAA
	CCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGUCA
	AGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGUUC
	GAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCAGG
	AGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAAGU
	ACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGCUG
	AAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUUCGU
	CGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACAGA
	UCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAAAC
	CUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGACAA
	GCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUUCA
	CACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACUUC
	GACACAACAAUCGACAGAAAGAGAUACACAAGCACAAAGGA
	AGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAGGAC
	UGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAGAC
	GGAGGAGGAAGCCCGAAGAAGAAGAGAAAGGUC
dCas9 bare	GACAAGAAGUACAGCAUCGGACUGGCAAUCGGAACAAACAG	12
coding	CGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCCCGA
sequence	GCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACACAGC
	AUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAGCGG
	AGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAAGAA
	GAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUGCAG
	GAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAGCUU
	CUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAGACA
	AGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUCGAC
	GAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCACCU
	GAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACCUGA
	GACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUCAGA
	GGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAACAG
	CGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAUACA
	ACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGAGUC
	GACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAGCAG
	AAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAAAGA
	AGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUGGGA
	CUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGAAGA
	CGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACGACC
	UGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCAGAC
	CUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCUGCU
	GAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGGCAC
	CGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACACCAC
	CAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCAGCU
	GCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCAAGA
	ACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAGGAA
	GAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAUGGA
	CGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAGACC
	UGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUCCCG
	CACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGAAG
	ACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGAAA
	AGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACGUC
	GGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUGAC
	AAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGAAG
	AAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCGAA
	AGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAGGU
	CCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGUCU
	ACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAAUG
	AGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCAAU
	CGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGUCA
	AGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCUUC
	GACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAACGC
	AAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAAGG
	ACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCCUG
	GAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGAGA
	AAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUUCG
	ACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACACA
	GGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUCAG
	AGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAAGA
	GCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCCAC
	GACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCACA
	GGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGCAA
	ACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGCAG
	ACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGAAG
	ACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGAAA
	ACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAAGA
	AUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGCCA
	GAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCAGA
	ACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAGAC
	AUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGCGA
	CUACGACGUCGACGCAAUCGUCCCGCAGAGCUUCCUGAAGG
	ACGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAAG
	AACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCGU
	CAAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCAA
	AGCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGCA
	GAGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCAU
	CAAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCACG
	UCGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGAC
	GAAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACACU
	GAAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAGU
	UCUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACAC
	GACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCAA
	GAAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGACU
	ACAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGAA
	CAGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACAG
	CAACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCAA
	ACGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGGA
	GAAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCGC
	AACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUCG
	UCAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGGAA
	AGCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCAAG
	AAAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGACA
	GCCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGUC
	GAAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAACU
	GCUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAGA
	ACCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGUC
	AAGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGUU
	CGAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCAG
	GAGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAAG
	UACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGCU
	GAAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUUCG
	UCGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACAG
	AUCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAAA
	CCUGGACAAGCUCCUGAGCGCAUACAACAAGCACAGAGACA
	AGCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUUC
	ACACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACUU
	CGACACAACAAUCGACAGAAAGAGAUACACAAGCACAAAGG
	AAGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAGGA
	CUGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAGA
	CGGAGGAGGAAGCCCGAAGAAGAAGAGAAAGGUC
Amino acid	MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIK	13
sequence of	KNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNE
Cas9	MAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT
(without	IYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNS
NLS)	DVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENL
	IAQLPGEKKNGLFGNLIALSLGLTPNTKSNFDLAEDAKLQLSKDT
	YDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKA
	PLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA
	GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTF
	DNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYV
	GPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMT
	NFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFL
	SGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED
	RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMI
	EERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSG
	KTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLH
	EHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENTVIEMARE
	NQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKL
	YLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNK
	VLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD
	NLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKY
	DENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDA
	YLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK
	ATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKG
	RDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIAR
	KKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
	ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKR
	MLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ
	LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPI
	REQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLI
	HQSITGLYETRIDLSQLGGD
Cas9 mRNA	AUGGACAAGAAGUACAGCAUCGGACUGGACAUCGGAACAAA	14
ORF	CAGCGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCC
encoding	CGAGCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACAC
SEQ ID NO:	AGCAUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAG
13 using	CGGAGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAA
minimal	GAAGAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUG
uridine	CAGGAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAG
codons as	CUUCUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAG
listed in	ACAAGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUC
Table 3, with	GACGAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCA
start and	CCUGAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACC
stop codons	UGAGACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUC
	AGAGGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAA
	CAGCGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAU
	ACAACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGA
	GUCGACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAG
	CAGAAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAA
	AGAAGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUG
	GGACUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGA
	AGACGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACG
	ACCUGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCA
	GACCUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCU
	GCUGAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGG
	CACCGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACAC
	CACCAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCA
	GCUGCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCA
	AGAACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAG
	GAAGAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAU
	GGACGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAG
	ACCUGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUC
	CCGCACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGA
	AGACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGA
	AAAGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACG
	UCGGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUG
	ACAAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGA
	AGAAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCG
	AAAGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAG
	GUCCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGU
	CUACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAA
	UGAGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCA
	AUCGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGU
	CAAGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCU
	UCGACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAAC
	GCAAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAA
	GGACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCC
	UGGAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGA
	GAAAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUU
	CGACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACA
	CAGGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUC
	AGAGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAA
	GAGCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCC
	ACGACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCA
	CAGGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGC
	AAACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGC
	AGACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGA
	AGACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGA
	AAACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAA
	GAAUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGC
	CAGAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCA
	GAACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAG
	ACAUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGC
	GACUACGACGUCGACCACAUCGUCCCGCAGAGCUUCCUGAAG
	GACGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAA
	GAACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCG
	UCAAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCA
	AAGCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGC
	AGAGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCA
	UCAAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCAC
	GUCGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGA
	CGAAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACAC
	UGAAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAG
	UUCUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACA
	CGACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCA
	AGAAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGAC
	UACAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGA
	ACAGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACA
	GCAACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCA
	AACGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGG
	AGAAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCG
	CAACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUC
	GUCAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGGA
	AAGCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCAA
	GAAAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGAC
	AGCCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGU
	CGAAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAAC
	UGCUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAG
	AACCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGU
	CAAGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGU
	UCGAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCA
	GGAGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAA
	GUACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGC
	UGAAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUUC
	GUCGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACA
	GAUCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAA
	ACCUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGAC
	AAGCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUU
	CACACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACU
	UCGACACAACAAUCGACAGAAAGAGAUACACAAGCACAAAG
	GAAGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAGG
	ACUGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAG
	ACUAG
Cas9 coding	GACAAGAAGUACAGCAUCGGACUGGACAUCGGAACAAACAG	15
sequence	CGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCCCGA
encoding	GCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACACAGC
SEQ ID NO:	AUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAGCGG
13 using	AGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAAGAA
minimal	GAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUGCAG
uridine	GAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAGCUU
codons as	CUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAGACA
listed in	AGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUCGAC
Table 3 (no	GAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCACCU
start or stop	GAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACCUGA
codons;	GACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUCAGA
suitable for	GGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAACAG
inclusion in	CGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAUACA
fusion	ACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGAGUC
protein	GACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAGCAG
coding	AAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAAAGA
sequence)	AGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUGGGA
	CUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGAAGA
	CGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACGACC
	UGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCAGAC
	CUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCUGCU
	GAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGGCAC
	CGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACACCAC
	CAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCAGCU
	GCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCAAGA
	ACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAGGAA
	GAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAUGGA
	CGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAGACC
	UGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUCCCG
	CACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGAAG
	ACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGAAA
	AGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACGUC
	GGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUGAC
	AAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGAAG
	AAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCGAA
	AGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAGGU
	CCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGUCU
	ACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAAUG
	AGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCAAU
	CGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGUCA
	AGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCUUC
	GACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAACGC
	AAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAAGG
	ACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCCUG
	GAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGAGA
	AAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUUCG
	ACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACACA
	GGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUCAG
	AGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAAGA
	GCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCCAC
	GACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCACA
	GGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGCAA
	ACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGCAG
	ACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGAAG
	ACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGAAA
	ACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAAGA
	AUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGCCA
	GAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCAGA
	ACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAGAC
	AUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGCGA
	CUACGACGUCGACCACAUCGUCCCGCAGAGCUUCCUGAAGGA
	CGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAAGA
	ACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCGUC
	AAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCAAA
	GCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGCAG
	AGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCAUC
	AAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCACGU
	CGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGACG
	AAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACACUG
	AAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAGUU
	CUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACACG
	ACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCAAG
	AAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGACUA
	CAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGAAC
	AGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACAGC
	AACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCAAA
	CGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGGAG
	AAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCGCA
	ACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUCGU
	CAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGGAAA
	GCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCAAGA
	AAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGACAG
	CCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGUCG
	AAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAACUG
	CUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAGAA
	CCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGUCA
	AGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGUUC
	GAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCAGG
	AGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAAGU
	ACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGCUG
	AAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUUCGU
	CGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACAGA
	UCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAAAC
	CUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGACAA
	GCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUUCA
	CACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACUUC
	GACACAACAAUCGACAGAAAGAGAUACACAAGCACAAAGGA
	AGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAGGAC
	UGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAGAC
Amino acid	MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIK	16
sequence of	KNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNE
Cas9 nickase	MAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT
(without	IYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNS
NLS)	DVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENL
	IAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDT
	YDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKA
	PLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA
	GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTF
	DNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYV
	GPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMT
	NFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFL
	SGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED
	RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMI
	EERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSG
	KTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLH
	EHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARE
	NQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKL
	YLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNK
	VLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD
	NLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKY
	DENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDA
	YLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK
	ATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKG
	RDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIAR
	KKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
	ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKR
	MLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ
	LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPI
	REQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLI
	HQSITGLYETRIDLSQLGGD
Cas9 nickase	AUGGACAAGAAGUACAGCAUCGGACUGGCAAUCGGAACAAA	17
mRNA ORF	CAGCGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCC
encoding	CGAGCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACAC
SEQ ID NO:	AGCAUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAG
16 using	CGGAGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAA
minimal	GAAGAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUG
uridine	CAGGAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAG
codons as	CUUCUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAG
listed in	ACAAGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUC
Table 3, with	GACGAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCA
start and	CCUGAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACC
stop codons	UGAGACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUC
	AGAGGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAA
	CAGCGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAU
	ACAACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGA
	GUCGACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAG
	CAGAAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAA
	AGAAGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUG
	GGACUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGA
	AGACGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACG
	ACCUGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCA
	GACCUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCU
	GCUGAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGG
	CACCGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACAC
	CACCAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCA
	GCUGCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCA
	AGAACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAG
	GAAGAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAU
	GGACGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAG
	ACCUGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUC
	CCGCACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGA
	AGACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGA
	AAAGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACG
	UCGGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUG
	ACAAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGA
	AGAAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCG
	AAAGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAG
	GUCCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGU
	CUACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAA
	UGAGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCA
	AUCGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGU
	CAAGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCU
	UCGACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAAC
	GCAAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAA
	GGACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCC
	UGGAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGA
	GAAAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUU
	CGACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACA
	CAGGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUC
	AGAGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAA
	GAGCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCC
	ACGACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCA
	CAGGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGC
	AAACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGC
	AGACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGA
	AGACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGA
	AAACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAA
	GAAUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGC
	CAGAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCA
	GAACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAG
	ACAUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGC
	GACUACGACGUCGACCACAUCGUCCCGCAGAGCUUCCUGAAG
	GACGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAA
	GAACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCG
	UCAAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCA
	AAGCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGC
	AGAGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCA
	UCAAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCAC
	GUCGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGA
	CGAAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACAC
	UGAAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAG
	UUCUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACA
	CGACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCA
	AGAAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGAC
	UACAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGA
	ACAGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACA
	GCAACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCA
	AACGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGG
	AGAAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCG
	CAACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUC
	GUCAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGGA
	AAGCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCAA
	GAAAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGAC
	AGCCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGU
	CGAAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAAC
	UGCUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAG
	AACCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGU
	CAAGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGU
	UCGAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCA
	GGAGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAA
	GUACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGC
	UGAAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUUC
	GUCGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACA
	GAUCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAA
	ACCUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGAC
	AAGCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUU
	CACACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACU
	UCGACACAACAAUCGACAGAAAGAGAUACACAAGCACAAAG
	GAAGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAGG
	ACUGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAG
	ACUAG
Cas9 nickase	GACAAGAAGUACAGCAUCGGACUGGCAAUCGGAACAAACAG	18
coding	CGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCCCGA
sequence	GCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACACAGC
encoding	AUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAGCGG
SEQ ID NO:	AGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAAGAA
16 using	GAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUGCAG
minimal	GAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAGCUU
uridine	CUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAGACA
codons as	AGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUCGAC
listed in	GAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCACCU
Table 3 (no	GAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACCUGA
start or stop	GACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUCAGA
codons;	GGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAACAG
suitable for	CGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAUACA
inclusion in	ACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGAGUC
fusion	GACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAGCAG
protein	AAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAAAGA
coding	AGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUGGGA
sequence)	CUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGAAGA
	CGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACGACC
	UGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCAGAC
	CUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCUGCU
	GAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGGCAC
	CGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACACCAC
	CAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCAGCU
	GCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCAAGA
	ACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAGGAA
	GAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAUGGA
	CGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAGACC
	UGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUCCCG
	CACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGAAG
	ACAGGAAGACUUCUACCCGUBCCUGAAGGACAACAGAGAAA
	AGAUCGAAAAGAUCCUGACAUBCAGAAUCCCGUACUACGUC
	GGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUGAC
	AAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGAAG
	AAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCGAA
	AGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAGGU
	CCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGUCU
	ACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAAUG
	AGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCAAU
	CGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGUCA
	AGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCUUC
	GACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAACGC
	AAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAAGG
	ACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCCUG
	GAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGAGA
	AAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUUCG
	ACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACACA
	GGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUCAG
	AGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAAGA
	GCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCCAC
	GACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCACA
	GGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGCAA
	ACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGCAG
	ACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGAAG
	ACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGAAA
	ACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAAGA
	AUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGCCA
	GAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCAGA
	ACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAGAC
	AUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGCGA
	CUACGACGUCGACCACAUCGUCCCGCAGAGCUUCCUGAAGGA
	CGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAAGA
	ACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCGUC
	AAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCAAA
	GCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGCAG
	AGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCAUC
	AAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCACGU
	CGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGACG
	AAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACACUG
	AAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAGUU
	CUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACACG
	ACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCAAG
	AAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGACUA
	CAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGAAC
	AGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACAGC
	AACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCAAA
	CGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGGAG
	AAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCGCA
	ACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUCGU
	CAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGGAAA
	GCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCAAGA
	AAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGACAG
	CCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGUCG
	AAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAACUG
	CUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAGAA
	CCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGUCA
	AGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGUUC
	GAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCAGG
	AGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAAGU
	ACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGCUG
	AAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUUCGU
	CGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACAGA
	UCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAAAC
	CUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGACAA
	GCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUUCA
	CACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACUUC
	GACACAACAAUCGACAGAAAGAGAUACACAAGCACAAAGGA
	AGUCCUGGACOCAACACUGAUCCACCAGAGCAUCACAGGAC
	UGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAGAC
Amino acid	MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIK	19
sequence of	KNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNE
dCas9	MAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT
(without	IYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNS
NLS)	DVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENL
	IAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDT
	YDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKA
	PLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA
	GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTF
	DNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYV
	GPLARGNSRFAWMTRKSEETTTPWNFEEVVDKGASAQSFIERMT
	NFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFL
	SGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED
	RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMI
	EERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSG
	KTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLH
	EHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARE
	NQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKL
	YLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNK
	VLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD
	NLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKY
	DENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDA
	YLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK
	ATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKG
	RDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIAR
	KKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
	ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKR
	MLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ
	LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPI
	REQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLI
	HQSITGLYETRIDLSQLGGD
dCas9	AUGGACAAGAAGUACAGCAUCGGACUGGCAAUCGGAACAAA	20
mRNA ORF	CAGCGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCC
encoding	CGAGCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACAC
SEQ ID NO:	AGCAUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAG
19 using	CGGAGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAA
minimal	GAAGAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUG
uridine	CAGGAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAG
codons as	CUUCUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAG
listed in	ACAAGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUC
Table 3, with	GACGAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCA
start and	CCUGAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACC
stop codons	UGAGACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUC
	AGAGGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAA
	CAGCGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAU
	ACAACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGA
	GUCGACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAG
	CAGAAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAA
	AGAAGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUG
	GGACUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGA
	AGACGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACG
	ACCUGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCA
	GACCUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCU
	GCUGAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGG
	CACCGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACAC
	CACCAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCA
	GCUGCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCA
	AGAACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAG
	GAAGAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAU
	GGACGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAG
	ACCUGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUC
	CCGCACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGA
	AGACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGA
	AAAGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACG
	UCGGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUG
	ACAAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGA
	AGAAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCG
	AAAGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAG
	GUCCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGU
	CUACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAA
	UGAGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCA
	AUCGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGU
	CAAGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCU
	UCGACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAAC
	GCAAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAA
	GGACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCC
	UGGAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGA
	GAAAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUU
	CGACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACA
	CAGGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUC
	AGAGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAA
	GAGCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCC
	ACGACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCA
	CAGGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGC
	AAACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGC
	AGACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGA
	AGACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGA
	AAACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAA
	GAAUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGC
	CAGAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCA
	GAACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAG
	ACAUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGC
	GACUACGACGUCGACGCAAUCGUCCCGCAGAGCUUCCUGAA
	GGACGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACA
	AGAACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUC
	GUCAAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGC
	AAAGCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGG
	CAGAGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUC
	AUCAAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCA
	CGUCGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACG
	ACGAAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACA
	CUGAAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCA
	GUUCUACAAGGUCAGAGAAAUCAACAACUACCACCACGCAC
	ACGACGCAUACCUGAACGCAGUCGUCGGAACAGGACUGAUC
	AAGAAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGA
	CUACAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCG
	AACAGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUAC
	AGCAACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGC
	AAACGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACG
	GAGAAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUC
	GCAACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAU
	CGUCAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGG
	AAAGCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCA
	AGAAAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGA
	CAGCCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGG
	UCGAAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAA
	CUGCUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAA
	GAACCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAG
	UCAAGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUG
	UUCGAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGC
	AGGAGAACUGCAGAAGGGAAACGAACUGGCACUGGCGAGCA
	AGUACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAG
	CUGAAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUU
	CGUCGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAAC
	AGAUCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCA
	AACCUGGACAAGGUCCUGAGCGCAUACAACAAGGACAGAGA
	CAAGCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGU
	UCACACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUAC
	UUCGACACAACAAUCGACAGAAAGAGAUACACAAGCACAAA
	GGAAGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAG
	GACUGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGA
	GACUAG
dCas9	GACAAGAAGUACAGCAUCGGACUGGCAAUCGGAACAAACAG	21
coding	CGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCCCGA
sequence	GCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACACAGC
encoding	AUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAGCGG
SEQ ID NO:	AGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAAGAA
19 using	GAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUGCAG
minimal	GAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAGCUU
uridine	CUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAGACA
codons as	AGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUCGAC
listed in	GAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCACCU
Table 3 (no	GAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACCUGA
start or stop	GACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUCAGA
codons;	GGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAACAG
suitable for	CGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAUACA
inclusion in	ACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGAGUC
fusion	GACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAGCAG
protein	AAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAAAGA
coding	AGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUGGGA
sequence)	CUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGAAGA
	CGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACGACC
	UGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCAGAC
	CUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCUGCU
	GAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGGCAC
	CGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACACCAC
	CAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCAGCU
	GCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCAAGA
	ACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAGGAA
	GAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAUGGA
	CGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAGACC
	UGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUCCCG
	CACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGAAG
	ACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGAAA
	AGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACGUC
	GGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUGAC
	AAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGAAG
	AAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCGAA
	AGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAGGU
	CCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGUCU
	ACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAAUG
	AGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCAAU
	CGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGUCA
	AGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCUUC
	GACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAACGC
	AAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAAGG
	ACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCCUG
	GAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGAGA
	AAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUUCG
	ACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACACA
	GGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUCAG
	AGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAAGA
	GCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCCAC
	GACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCACA
	GGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGCAA
	ACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGCAG
	ACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGAAG
	ACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGAAA
	ACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAAGA
	AUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGCCA
	GAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCAGA
	ACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAGAC
	AUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGCGA
	CUACGACGUCGACGCAAUCGUCCCGCAGAGCUUCCUGAAGG
	ACGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAAG
	AACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCGU
	CAAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCAA
	AGCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGCA
	GAGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCAU
	CAAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCACG
	UCGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGAC
	GAAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACACU
	GAAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAGU
	UCUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACAC
	GACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCAA
	GAAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGACU
	ACAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGAA
	CAGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACAG
	CAACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCAA
	ACGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGGA
	GAAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCGC
	AACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUCG
	UCAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGGAA
	AGCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCAAG
	AAAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGACA
	GCCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGUC
	GAAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAACU
	GCUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAGA
	ACCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGUC
	AAGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGUU
	CGAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCAG
	GAGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAAG
	UACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGCU
	GAAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUUCG
	UCGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACAG
	AUCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAAA
	CCUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGACA
	AGCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUUC
	ACACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACUU
	CGACACAACAAUCGACAGAAAGAGAUACACAAGCACAAAGG
	AAGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAGGA
	CUGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAGA
	CGGAGGAGGAAGC
Amino acid	MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIK	22
sequence of	KNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNE
Cas9 with	MAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT
two nuclear	IYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNS
localization	DVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENL
signals as the	IAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDT
C-terminal	YDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKA
amino acids	PLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA
	GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTF
	DNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYV
	GPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMT
	NFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFL
	SGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED
	RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMI
	EERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSG
	KTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLH
	EHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARE
	NQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKL
	YLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNK
	VLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD
	NLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKY
	DENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDA
	YLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK
	ATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKG
	RDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIAR
	KKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
	ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKR
	MLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ
	LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPI
	REQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLI
	HQSITGLYETRIDLSQLGGD GSGSPKKKRKVDGSPKKKRKVDSG
Cas9 mRNA	AUGGACAAGAAGUACAGCAUCGGACUGGACAUCGGAACAAA	23
ORF	CAGCGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCC
encoding	CGAGCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACAC
SEQ ID NO:	AGCAUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAG
22 using	CGGAGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAA
minimal	GAAGAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUG
uridine	CAGGAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAG
codons as	CUUCUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAG
listed in	ACAAGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUC
Table 3, with	GACGAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCA
start and	CCUGAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACC
stop codons	UGAGACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUC
	AGAGGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAA
	CAGCGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAU
	ACAACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGA
	GUCGACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAG
	CAGAAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAA
	AGAAGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUG
	GGACUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGA
	AGACGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACG
	ACCUGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCA
	GACCUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCU
	GCUGAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGG
	CACCGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACAC
	CACCAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCA
	GCUGCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCA
	AGAACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAG
	GAAGAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAU
	GGACGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAG
	ACCUGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUC
	CCGCACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGA
	AGACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGA
	AAAGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACG
	UCGGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUG
	ACAAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGA
	AGAAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCG
	AAAGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAG
	GUCCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGU
	CUACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAA
	UGAGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCA
	AUCGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGU
	CAAGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCU
	UCGACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAAC
	GCAAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAA
	GGACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCC
	UGGAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGA
	GAAAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUU
	CGACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACA
	CAGGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUC
	AGAGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAA
	GAGCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCC
	ACGACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCA
	CAGGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGC
	AAACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGC
	AGACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGA
	AGACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGA
	AAACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAA
	GAAUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGC
	CAGAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCA
	GAACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAG
	ACAUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGC
	GACUACGACGUCGACCACAUCGUCCCOCAGAGCUUCCUGAAG
	GACGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAA
	GAACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCG
	UCAAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCA
	AAGCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGC
	AGAGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCA
	UCAAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCAC
	GUCGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGA
	CGAAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACAC
	UGAAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAG
	UUCUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACA
	CGACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCA
	AGAAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGAC
	UACAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGA
	ACAGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACA
	GCAACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCA
	AACGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGG
	AGAAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCG
	CAACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUC
	GUCAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGGA
	AAGCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCAA
	GAAAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGAC
	AGCCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGU
	CGAAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAAC
	UGCUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAG
	AACCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGU
	CAAGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGU
	UCGAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCA
	GGAGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAA
	GUACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGC
	UGAAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUUC
	GUCGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACA
	GAUCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAA
	ACCUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGAC
	AAGCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUU
	CACACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACU
	UCGACACAACAAUCGACAGAAAGAGAUACACAAGCACAAAG
	GAAGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAGG
	ACUGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAG
	ACGGAAGCGGAAGCCCGAAGAAGAAGAGAAAGGUCGACGGA
	AGCCCGAAGAAGAAGAGAAAGGUCGACAGCGGAUAG
Cas9 coding	GACAAGAAGUACAGCAUCGGACUGGACAUCGGAACAAACAG	24
sequence	CGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCCCGA
encoding	GCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACACAGC
SEQ ID NO:	AUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAGCGG
23 using	AGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAAGAA
minimal	GAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUGCAG
uridine	GAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAGCUU
codons as	CUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAGACA
listed in	AGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUCGAC
Table 3 (no	GAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCACCU
start or stop	GAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACCUGA
codons;	GACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUCAGA
suitable for	GGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAACAG
inclusion in	CGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAUACA
fusion	ACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGAGUC
protein	GACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAGCAG
coding	AAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAAAGA
sequence)	AGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUGGGA
	CUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGAAGA
	CGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACGACC
	UGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCAGAC
	CUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCUGCU
	GAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGGCAC
	CGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACACCAC
	CAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCAGCU
	GCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCAAGA
	ACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAGGAA
	GAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAUGGA
	CGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAGACC
	UGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUCCCG
	CACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGAAG
	ACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGAAA
	AGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACGUC
	GGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUGAC
	AAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGAAG
	AAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCGAA
	AGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAGGU
	CCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGUCU
	ACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAAUG
	AGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCAAU
	CGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGUCA
	AGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCUUC
	GACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAACGC
	AAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAAGG
	ACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCCUG
	GAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGAGA
	AAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUUCG
	ACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACACA
	GGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUCAG
	AGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAAGA
	GCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCCAC
	GACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCACA
	GGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGCAA
	ACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGCAG
	ACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGAAG
	ACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGAAA
	ACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAAGA
	AUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGCCA
	GAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCAGA
	ACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAGAC
	AUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGCGA
	CUACGACGUCGACCACAUCGUCCCGCAGAGCUUCCUGAAGGA
	CGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAAGA
	ACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCGUC
	AAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCAAA
	GCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGCAG
	AGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCAUC
	AAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCACGU
	CGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGACG
	AAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACACUG
	AAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAGUU
	CUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACACG
	ACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCAAG
	AAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGACUA
	CAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGAAC
	AGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACAGC
	AACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCAAA
	CGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGGAG
	AAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCGCA
	ACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUCGU
	CAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGGAAA
	GCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCAAGA
	AAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGACAG
	CCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGUCG
	AAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAACUG
	CUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAGAA
	CCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGUCA
	AGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGUUC
	GAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCAGG
	AGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAAGU
	ACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGCUG
	AAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUUCGU
	CGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACAGA
	UCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAAAC
	CUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGACAA
	GCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUUCA
	CACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACUUC
	GACACAACAAUCGACAGAAAGAGAUACACAAGCACAAAGGA
	AGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAGGAC
	UGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAGAC
	GGAAGCGGAAGCCCGAAGAAGAAGAGAAAGGUCGACGGAAG
	CCCGAAGAAGAAGAGAAAGGUCGACAGCGGA
Amino acid	MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIK	25
sequence of	KNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNE
Cas9 nickase	MAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT
with two	IYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNS
nuclear	DVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENL
localization	IAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDT
signals as the	YDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKA
C- ter min al	PLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA
amino acids	GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTF
	DNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYV
	GPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMT
	NFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFL
	SGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED
	RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMI
	EERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSG
	KTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLH
	EHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARE
	NQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKL
	YLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNK
	VLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD
	NLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKY
	DENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDA
	YLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK
	ATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKG
	RDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIAR
	KKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
	ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKR
	MLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ
	LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPI
	REQAENIIHLFTLTNLGAPAAFKYPDTTIDRKRYTSTKEVLDATLI
	HQSITGLYETRIDLSQLGGDGSGSPKKKRKVDGSPKKKRKVDSG
Cas9 nickase	AUGGACAAGAAGUACAGCAUCGGACUGGCAAUCGGAACAAA	26
mRNA ORF	CAGCGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCC
encoding	CGAGCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACAC
SEQ ID NO:	AGCAUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAG
25 using	CGGAGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAA
minimal	GAAGAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUG
uridine	CAGGAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAG
codons as	CUUCUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAG
listed in	ACAAGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUC
Table 3, with	GACGAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCA
start and	CCUGAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACC
stop codons	UGAGACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUC
	AGAGGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAA
	CAGCGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAU
	ACAACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGA
	GUCGACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAG
	CAGAAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAA
	AGAAGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUG
	GGACUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGA
	AGACGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACG
	ACCUGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCA
	GACCUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCU
	GCUGAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGG
	CACCGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACAC
	CACCAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCA
	GCUGCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCA
	AGAACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAG
	GAAGAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAU
	GGACGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAG
	ACCUGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUC
	CCGCACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGA
	AGACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGA
	AAAGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACG
	UCGGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUG
	ACAAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGA
	AGAAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCG
	AAAGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAG
	GUCCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGU
	CUACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAA
	UGAGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCA
	AUCGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGU
	CAAGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCU
	UCGACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAAC
	GCAAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAA
	GGACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCC
	UGGAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGA
	GAAAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUU
	CGACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACA
	CAGGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUC
	AGAGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAA
	GAGCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCC
	ACGACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCA
	CAGGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGC
	AAACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGC
	AGACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGA
	AGACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGA
	AAACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAA
	GAAUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGC
	CAGAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCA
	GAACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAG
	ACAUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGC
	GACUACGACGUCGACCACAUCGUCCCGCAGAGCUUCCUGAAG
	GACGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAA
	GAACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCG
	UCAAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCA
	AAGCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGC
	AGAGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCA
	UCAAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCAC
	GUCGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGA
	CGAAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACAC
	UGAAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAG
	UUCUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACA
	CGACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCA
	AGAAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGAC
	UACAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGA
	ACAGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACA
	GCAACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCA
	AACGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGG
	AGAAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCG
	CAACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUC
	GUCAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGGA
	AAGCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCAA
	GAAAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGAC
	AGCCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGU
	CGAAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAAC
	UGCUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAG
	AACCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGU
	CAAGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGU
	UCGAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCA
	GGAGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAA
	GUACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGC
	UGAAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUUC
	GUCGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACA
	GAUCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAA
	ACCUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGAC
	AAGCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUU
	CACACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACU
	UCGACACAACAAUCGACAGAAAGAGAUACACAAGCACAAAG
	GAAGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAGG
	ACUGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAG
	ACGGAAGCGGAAGCCCGAAGAAGAAGAGAAAGGUCGACGGA
	AGCCCGAAGAAGAAGAGAAAGGUCGACAGCGGAUAG
Cas9 nickase	GACAAGAAGUACAGCAUCGGACUGGCAAUCGGAACAAACAG	27
coding	CGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCCCGA
sequence	GCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACACAGC
encoding	AUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAGCGG
SEQ ID NO:	AGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAAGAA
25 using	GAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUGCAG
minimal	GAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAGCUU
uridine	CUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAGACA
codons as	AGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUCGAC
listed in	GAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCACCU
Table 3 (no	GAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACCUGA
start or stop	GACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUCAGA
codons;	GGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAACAG
suitable for	CGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAUACA
inclusion in	ACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGAGUC
fusion	GACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAGCAG
protein	AAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAAAGA
coding	AGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUGGGA
sequence)	CUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGAAGA
	CGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACGACC
	UGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCAGAC
	CUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCUGCU
	GAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGGCAC
	CGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACACCAC
	CAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCAGCU
	GCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCAAGA
	ACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAGGAA
	GAAUUCUACAAGUVCAUCAAGCCGAUCCUGGAAAAGAUGGA
	CGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAGACC
	UGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUCCCG
	CACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGAAG
	ACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGAAA
	AGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACGUC
	GGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUGAC
	AAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGAAG
	AAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCGAA
	AGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAGGU
	CCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGUCU
	ACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAAUG
	AGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCAAU
	CGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGUCA
	AGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCUUC
	GACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAACGC
	AAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAAGG
	ACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCCUG
	GAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGAGA
	AAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUUCG
	ACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACACA
	GGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUCAG
	AGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAAGA
	GCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCCAC
	GACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCACA
	GGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGCAA
	ACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGCAG
	ACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGAAG
	ACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGAAA
	ACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAAGA
	AUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGCCA
	GAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCAGA
	ACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAGAC
	AUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGCGA
	CUACGACGUCGACCACAUCGUCCCGCAGAGCUUCCUGAAGGA
	CGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAAGA
	ACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCGUC
	AAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCAAA
	GCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGCAG
	AGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCAUC
	AAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCACGU
	CGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGACG
	AAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACACUG
	AAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAGUU
	CUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACACG
	ACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCAAG
	AAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGACUA
	CAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGAAC
	AGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACAGC
	AACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCAAA
	CGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGGAG
	AAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCGCA
	ACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUCGU
	CAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGGAAA
	GCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCAAGA
	AAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGACAG
	CCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGUCG
	AAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAACUG
	CUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAGAA
	CCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGUCA
	AGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGUUC
	GAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCAGG
	AGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAAGU
	ACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGCUG
	AAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUUCGU
	CGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACAGA
	UCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAAAC
	CUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGACAA
	GCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUUCA
	CACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACUUC
	GACACAACAAUCGACAGAAAGAGAUACACAAGCACAAAGGA
	AGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAGGAC
	UGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAGAC
	GGAAGCGGAAGCCCGAAGAAGAAGAGAAAGGUCGACGGAAG
	CCCGAAGAAGAAGAGAAAGGUCGACAGCGGA
Amino acid	MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIK	28
sequence of	KNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNE
dCas9 with	MAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT
two nuclear	IYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNS
localization	DVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENL
signals as the	IAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDT
C-terminal	YDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKA
amino acids	PLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA
	GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTF
	DNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYV
	GPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMT
	NFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFL
	SGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED
	RFNASLGTYHDLLKDKDKDFLDNEENEDILEDIVLTLTLFEDREM
	EERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSG
	KTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLH
	EHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARE
	NQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKL
	YLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNK
	VLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD
	NLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKY
	DENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDA
	YLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK
	ATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKG
	RDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIAR
	KKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
	ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKR
	MLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ
	LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPI
	REQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLI
	HQSITGLYETRIDLSQLGGDGSGSPKKKRKVDGSPKKKRKVDSG
dCas9	AUGGACAAGAAGUACAGCAUCGGACUGGCAAUCGGAACAAA	29
mRNA ORF	CAGCGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCC
encoding	CGAGCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACAC
SEQ ID NO:	AGCAUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAG
28 using	CGGAGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAA
minimal	GAAGAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUG
uridine	CAGGAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAG
codons as	CUUCUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAG
listed in	ACAAGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUC
Table 3, with	GACGAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCA
start and	CCUGAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACC
stop codons	UGAGACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUC
	AGAGGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAA
	CAGCGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAU
	ACAACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGA
	GUCGACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAG
	CAGAAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAA
	AGAAGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUG
	GGACUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGA
	AGACGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACG
	ACCUGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCA
	GACCUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCU
	OCUGAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGG
	CACCGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACAC
	CACCAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCA
	GCUGCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCA
	AGAACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAG
	GAAGAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAU
	GGACGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAG
	ACCUGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUC
	CCGCACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGA
	AGACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGA
	AAAGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACG
	UCGGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUG
	ACAAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGA
	AGAAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCG
	AAAGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAG
	GUCCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGU
	CUACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAA
	UGAGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCA
	AUCGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGU
	CAAGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCU
	UCGACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAAC
	GCAAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAA
	GGACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCC
	UGGAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGA
	GAAAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUU
	CGACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACA
	CAGGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUC
	AGAGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAA
	GAGCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCC
	ACGACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCA
	CAGGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGC
	AAACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGC
	AGACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGA
	AGACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGA
	AAACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAA
	GAAUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGC
	CAGAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCA
	GAACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAG
	ACAUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGC
	GACUACGACGUCGACGCAAUCGUCCCGCAGAGCUUCCUGAA
	GGACGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACA
	AGAACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUC
	GUCAAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGC
	AAAGCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGG
	CAGAGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUC
	AUCAAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCA
	CGUCGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACG
	ACGAAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACA
	CUGAAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCA
	GUUCUACAAGGUCAGAGAAAUCAACAACUACCACCACGCAC
	ACGACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUC
	AAGAAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGA
	CUACAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCG
	AACAGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUAC
	AGCAACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGC
	AAACGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACG
	GAGAAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUC
	GCAACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAU
	CGUCAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGG
	AAAGCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCA
	AGAAAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGA
	CAGCCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGG
	UCGAAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAA
	CUGCUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAA
	GAACCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAG
	UCAAGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUG
	UUCGAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGC
	AGGAGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCA
	AGUACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAG
	CUGAAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUU
	CGUCGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAAC
	AGAUCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCA
	AACCUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGA
	CAAGCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGU
	UCACACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUAC
	UUCGACACAACAAUCGACAGAAAGAGAUACACAAGCACAAA
	GGAAGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAG
	GACUGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGA
	GAC
	GGAAGCGGAAGCCCGAAGAAGAAGAGAAAGGUCGACGGAAG
	CCCGAAGAAGAAGAGAAAGGUCGACAGCGGAUAG
dCas9	GACAAGAAGUACAGCAUCGGACUGGCAAUCGGAACAAACAG	30
coding	CGUCGGAUGGGCAGUCAUCACAGACGAAUACAAGGUCCCGA
sequence	GCAAGAAGUUCAAGGUCCUGGGAAACACAGACAGACACAGC
encoding	AUCAAGAAGAACCUGAUCGGAGCACUGCUGUUCGACAGCGG
SEQ ID NO:	AGAAACAGCAGAAGCAACAAGACUGAAGAGAACAGCAAGAA
28 using	GAAGAUACACAAGAAGAAAGAACAGAAUCUGCUACCUGCAG
minimal	GAAAUCUUCAGCAACGAAAUGGCAAAGGUCGACGACAGCUU
uridine	CUUCCACAGACUGGAAGAAAGCUUCCUGGUCGAAGAAGACA
codons as	AGAAGCACGAAAGACACCCGAUCUUCGGAAACAUCGUCGAC
listed in	GAAGUCGCAUACCACGAAAAGUACCCGACAAUCUACCACCU
Table 3 (no	GAGAAAGAAGCUGGUCGACAGCACAGACAAGGCAGACCUGA
start or stop	GACUGAUCUACCUGGCACUGGCACACAUGAUCAAGUUCAGA
codons;	GGACACUUCCUGAUCGAAGGAGACCUGAACCCGGACAACAG
suitable for	CGACGUCGACAAGCUGUUCAUCCAGCUGGUCCAGACAUACA
inclusion in	ACCAGCUGUUCGAAGAAAACCCGAUCAACGCAAGCGGAGUC
fusion	GACGCAAAGGCAAUCCUGAGCGCAAGACUGAGCAAGAGCAG
protein	AAGACUGGAAAACCUGAUCGCACAGCUGCCGGGAGAAAAGA
coding	AGAACGGACUGUUCGGAAACCUGAUCGCACUGAGCCUGGGA
sequence)	CUGACACCGAACUUCAAGAGCAACUUCGACCUGGCAGAAGA
	CGCAAAGCUGCAGCUGAGCAAGGACACAUACGACGACGACC
	UGGACAACCUGCUGGCACAGAUCGGAGACCAGUACGCAGAC
	CUGUUCCUGGCAGCAAAGAACCUGAGCGACGCAAUCCUGCU
	GAGCGACAUCCUGAGAGUCAACACAGAAAUCACAAAGGCAC
	CGCUGAGCGCAAGCAUGAUCAAGAGAUACGACGAACACCAC
	CAGGACCUGACACUGCUGAAGGCACUGGUCAGACAGCAGCU
	GCCGGAAAAGUACAAGGAAAUCUUCUUCGACCAGAGCAAGA
	ACGGAUACGCAGGAUACAUCGACGGAGGAGCAAGCCAGGAA
	GAAUUCUACAAGUUCAUCAAGCCGAUCCUGGAAAAGAUGGA
	CGGAACAGAAGAACUGCUGGUCAAGCUGAACAGAGAAGACC
	UGCUGAGAAAGCAGAGAACAUUCGACAACGGAAGCAUCCCG
	CACCAGAUCCACCUGGGAGAACUGCACGCAAUCCUGAGAAG
	ACAGGAAGACUUCUACCCGUUCCUGAAGGACAACAGAGAAA
	AGAUCGAAAAGAUCCUGACAUUCAGAAUCCCGUACUACGUC
	GGACCGCUGGCAAGAGGAAACAGCAGAUUCGCAUGGAUGAC
	AAGAAAGAGCGAAGAAACAAUCACACCGUGGAACUUCGAAG
	AAGUCGUCGACAAGGGAGCAAGCGCACAGAGCUUCAUCGAA
	AGAAUGACAAACUUCGACAAGAACCUGCCGAACGAAAAGGU
	CCUGCCGAAGCACAGCCUGCUGUACGAAUACUUCACAGUCU
	ACAACGAACUGACAAAGGUCAAGUACGUCACAGAAGGAAUG
	AGAAAGCCGGCAUUCCUGAGCGGAGAACAGAAGAAGGCAAU
	CGUCGACCUGCUGUUCAAGACAAACAGAAAGGUCACAGUCA
	AGCAGCUGAAGGAAGACUACUUCAAGAAGAUCGAAUGCUUC
	GACAGCGUCGAAAUCAGCGGAGUCGAAGACAGAUUCAACGC
	AAGCCUGGGAACAUACCACGACCUGCUGAAGAUCAUCAAGG
	ACAAGGACUUCCUGGACAACGAAGAAAACGAAGACAUCCUG
	GAAGACAUCGUCCUGACACUGACACUGUUCGAAGACAGAGA
	AAUGAUCGAAGAAAGACUGAAGACAUACGCACACCUGUUCG
	ACGACAAGGUCAUGAAGCAGCUGAAGAGAAGAAGAUACACA
	GGAUGGGGAAGACUGAGCAGAAAGCUGAUCAACGGAAUCAG
	AGACAAGCAGAGCGGAAAGACAAUCCUGGACUUCCUGAAGA
	GCGACGGAUUCGCAAACAGAAACUUCAUGCAGCUGAUCCAC
	GACGACAGCCUGACAUUCAAGGAAGACAUCCAGAAGGCACA
	GGUCAGCGGACAGGGAGACAGCCUGCACGAACACAUCGCAA
	ACCUGGCAGGAAGCCCGGCAAUCAAGAAGGGAAUCCUGCAG
	ACAGUCAAGGUCGUCGACGAACUGGUCAAGGUCAUGGGAAG
	ACACAAGCCGGAAAACAUCGUCAUCGAAAUGGCAAGAGAAA
	ACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAAAGA
	AUGAAGAGAAUCGAAGAAGGAAUCAAGGAACUGGGAAGCCA
	GAUCCUGAAGGAACACCCGGUCGAAAACACACAGCUGCAGA
	ACGAAAAGCUGUACCUGUACUACCUGCAGAACGGAAGAGAC
	AUGUACGUCGACCAGGAACUGGACAUCAACAGACUGAGCGA
	CUACGACGUCGACGCAAUCGUCCCGCAGAGCUUCCUGAAGG
	ACGACAGCAUCGACAACAAGGUCCUGACAAGAAGCGACAAG
	AACAGAGGAAAGAGCGACAACGUCCCGAGCGAAGAAGUCGU
	CAAGAAGAUGAAGAACUACUGGAGACAGCUGCUGAACGCAA
	AGCUGAUCACACAGAGAAAGUUCGACAACCUGACAAAGGCA
	GAGAGAGGAGGACUGAGCGAACUGGACAAGGCAGGAUUCAU
	CAAGAGACAGCUGGUCGAAACAAGACAGAUCACAAAGCACG
	UCGCACAGAUCCUGGACAGCAGAAUGAACACAAAGUACGAC
	GAAAACGACAAGCUGAUCAGAGAAGUCAAGGUCAUCACACU
	GAAGAGCAAGCUGGUCAGCGACUUCAGAAAGGACUUCCAGU
	UCUACAAGGUCAGAGAAAUCAACAACUACCACCACGCACAC
	GACGCAUACCUGAACGCAGUCGUCGGAACAGCACUGAUCAA
	GAAGUACCCGAAGCUGGAAAGCGAAUUCGUCUACGGAGACU
	ACAAGGUCUACGACGUCAGAAAGAUGAUCGCAAAGAGCGAA
	CAGGAAAUCGGAAAGGCAACAGCAAAGUACUUCUUCUACAG
	CAACAUCAUGAACUUCUUCAAGACAGAAAUCACACUGGCAA
	ACGGAGAAAUCAGAAAGAGACCGCUGAUCGAAACAAACGGA
	GAAACAGGAGAAAUCGUCUGGGACAAGGGAAGAGACUUCGC
	AACAGUCAGAAAGGUCCUGAGCAUGCCGCAGGUCAACAUCG
	UCAAGAAGACAGAAGUCCAGACAGGAGGAUUCAGCAAGGAA
	AGCAUCCUGCCGAAGAGAAACAGCGACAAGCUGAUCGCAAG
	AAAGAAGGACUGGGACCCGAAGAAGUACGGAGGAUUCGACA
	GCCCGACAGUCGCAUACAGCGUCCUGGUCGUCGCAAAGGUC
	GAAAAGGGAAAGAGCAAGAAGCUGAAGAGCGUCAAGGAACU
	GCUGGGAAUCACAAUCAUGGAAAGAAGCAGCUUCGAAAAGA
	ACCCGAUCGACUUCCUGGAAGCAAAGGGAUACAAGGAAGUC
	AAGAAGGACCUGAUCAUCAAGCUGCCGAAGUACAGCCUGUU
	CGAACUGGAAAACGGAAGAAAGAGAAUGCUGGCAAGCGCAG
	GAGAACUGCAGAAGGGAAACGAACUGGCACUGCCGAGCAAG
	UACGUCAACUUCCUGUACCUGGCAAGCCACUACGAAAAGCU
	GAAGGGAAGCCCGGAAGACAACGAACAGAAGCAGCUGUUCG
	UCGAACAGCACAAGCACUACCUGGACGAAAUCAUCGAACAG
	AUCAGCGAAUUCAGCAAGAGAGUCAUCCUGGCAGACGCAAA
	CCUGGACAAGGUCCUGAGCGCAUACAACAAGCACAGAGACA
	AGCCGAUCAGAGAACAGGCAGAAAACAUCAUCCACCUGUUC
	ACACUGACAAACCUGGGAGCACCGGCAGCAUUCAAGUACUU
	CGACACAACAAUCGACAGAAAGAGAUACACAAGCACAAAGG
	AAGUCCUGGACGCAACACUGAUCCACCAGAGCAUCACAGGA
	CUGUACGAAACAAGAAUCGACCUGAGCCAGCUGGGAGGAGA
	C
	GGAAGCGGAAGCCCGAAGAAGAAGAGAAAGGUCGACGGAAG
	CCCGAAGAAGAAGAGAAAGGUCGACAGCGGA
T7 promoter	TAATACGACTCACTATA	31
Human beta-	ACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAAC	32
globin 5′	AGACACC
UTR
Human beta-	GCTCGCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTT	33
globin 3′	CCCTAAGTCCAACTACTAAACTGGGGGATATTATGAAGGGCCT
UTR	TGAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTG
	C
Human	CATAAACCCTGGCGCGCTCGCGGCCCGGCACTCTTCTGGTCCC	34
alpha-globin	CACAGACTCAGAGAGAACCCACC
5′ UTR
Human	GCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCC	35
alpha-globin	CCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTT
3′ UTR	TGAATAAAGTCTGAGTGGGCGGC
Xenopus	AAGCTCAGAATAAACGCTCAACTTTGGCC	36
laevis beta-
giobin 5′
UTR
Xenopus	ACCAGCCTCAAGAACACCCGAATGGAGTCTCTAAGCTACATA	37
laevis beta-	ATACCAACTTACACTTTACAAAATGTTGTCCCCCAAAATGTAG
giobin 3′	CCATTCGTATCTGCTCCTAATAAAAAGAAAGTTTCTTCACATTC
UTR	T
Bovine	CAGGGTCCTGTGGACAGCTCACCAGCT	38
Growth
Hormone 5′
UTR
Bovine	TTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGA	39
Growth	CCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGA
Hormone 3′	GGAAATTGCATCGCA
UTR
Mus	GCTGCCTTCTGCGGGGCTTGCCTTCTGGCCATGCCCTTCTTCTC	40
musculus	TCCCTTGCACCTGTACCTCTTGGTCTTTGAATAAAGCCTGAGTA
hemoglobin	GGAAG
alpha, adult
chain 1
(Hba-a1),
3′UTR
HSD17B4 5′	TCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGTGTGT	41
UTR	CGTTGCAGGCCTTATTC
G2S2 guide	mU*mU*mA*CAGCCACGUCUACAGCAGUUUUAGAmGm	42
RNA	CmUmAmGmAmAmAmUmAmGmCAAGUUAAAAUAAGG
targeting	CUAGUCCGUUAUCAmAmCmUmUmGmAmAmAmAmAm
TTR	GmUmGmGmCmAmCmCmGmAmGmUmCmGmGmUmGmC
	mU*mU*mU*mU
Cas9	GGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT	43
transcript	GTGTCGTTGCAGGCCTTATTCGGATCCGCCACCATGGACAAGA
with 5′ UTR	AGTACAGCATCGGACTGGACATCGGAACAAACAGCGTCGGAT
ofHSD,	GGGCAGTCATCACAGACGAATACAAGGTCCCGAGCAAGAAGT
ORF	TCAAGGTCCTGGGAAACACAGACAGACACAGCATCAAGAAGA
corresponding	ACCTGATCGGAGCACTGCTGTTCGACAGCGGAGAAACAGCAG
to SEQ	AAGCAACAAGACTGAAGAGAACAGCAAGAAGAAGATACACA
ID NO: 4,	AGAAGAAAGAACAGAATCTGCTACCTGCAGGAAATCTTCAGC
Kozak	AACGAAATOGCAAAGGTCGACGACAGCTTCTTCCACAGACTG
sequence,	GAAGAAAGCTTCCTGGTCGAAGAAGACAAGAAGCACGAAAGA
and 3′ UTR	CACCCGATCTTCGGAAACATCGTCGACGAAGTCGCATACCACG
of ALB	AAAAGTACCCGACAATCTACCACCTGAGAAAGAAGCTGGTCG
	ACAGCACAGACAAGGCAGACCTGAGACTGATCTACCTGGCAC
	TGGCACACATGATCAAGTTCAGAGGACACTTCCTGATCGAAGG
	AGACCTGAACCCGGACAACAGCGACGTCGACAAGCTGTTCAT
	CCAGCTGGTCCAGACATACAACCAGCTGTTCGAAGAAAACCC
	GATCAACGCAAGCGGAGTCGACGCAAAGGCAATCCTGAGCGC
	AAGACTGAGCAAGAGCAGAAGACTGGAAAACCTGATCGCACA
	GCTGCCGGGAGAAAAGAAGAACGGACTGTTCGGAAACCTGAT
	CGCACTGAGCCTGGGACTGACACCGAACTTCAAGAGCAACTTC
	GACCTGGCAGAAGACGCAAAGCTGCAGCTGAGCAAGGACACA
	TACGACGACGACCTGGACAACCTGCTGGCACAGATCGGAGAC
	CAGTACGCAGACCTGTTCCTGGCAGCAAAGAACCTGAGCGAC
	GCAATCCTGCTGAGCGACATCCTGAGAGTCAACACAGAAATC
	ACAAAGGCACCGCTGAGCGCAAGCATGATCAAGAGATACGAC
	GAACACCACCAGGACCTGACACTGCTGAAGGCACTGGTCAGA
	CAGCAGCTGCCGGAAAAGTACAAGGAAATCTTCTTCGACCAG
	AGCAAGAACGGATACGCAGGATACATCGACGGAGGAGCAAGC
	CAGGAAGAATTCTACAAGTTCATCAAGCCGATCCTGGAAAAG
	ATGGACGGAACAGAAGAACTGCTGGTCAAGCTGAACAGAGAA
	GACCTGCTGAGAAAGCAGAGAACATTCGACAACGGAAGCATC
	CCGCACCAGATCCACCTGGGAGAACTGCACGCAATCCTGAGA
	AGACAGGAAGACTTCTACCCGTTCCTGAAGGACAACAGAGAA
	AAGATCGAAAAGATCCTGACATTCAGAATCCCGTACTACGTCG
	GACCGCTGGCAAGAGGAAACAGCAGATTCGCATGGATGACAA
	GAAAGAGCGAAGAAACAATCACACCGTGGAACTTCGAAGAAG
	TCGTCGACAAGGGAGCAAGCGCACAGAGCTTCATCGAAAGAA
	TGACAAACTTCGACAAGAACCTGCCGAACGAAAAGGTCCTGC
	CGAAGCACAGCCTGCTGTACGAATACTTCACAGTCTACAACGA
	ACTGACAAAGGTCAAGTACGTCACAGAAGGAATGAGAAAGCC
	GGCATTCCTGAGCGGAGAACAGAAGAAGGCAATCGTCGACCT
	GCTGTTCAAGACAAACAGAAAGGTCACAGTCAAGCAGCTGAA
	GGAAGACTACTTCAAGAAGATCGAATGCTTCGACAGCGTCGA
	AATCAGCGGAGTCGAAGACAGATTCAACGCAAGCCTGGGAAC
	ATACCACGACCTGCTGAAGATCATCAAGGACAAGGACTTCCTG
	GACAACGAAGAAAACGAAGACATCCTGGAAGACATCGTCCTG
	ACACTGACACTGTTCGAAGACAGAGAAATGATCGAAGAAAGA
	CTGAAGACATACGCACACCTGTTCGACGACAAGGTCATGAAG
	CAGCTGAAGAGAAGAAGATACACAGGATGGGGAAGACTGAG
	CAGAAAGCTGATCAACGGAATCAGAGACAAGCAGAGCGGAA
	AGACAATCCTGGACTTCCTGAAGAGCGACGGATTCGCAAACA
	GAAACTTCATGCAGCTGATCCACGACGACAGCCTGACATTCAA
	GGAAGACATCCAGAAGGCACAGGTCAGCGGACAGGGAGACA
	GCCTGCACGAACACATCGCAAACCTGGCAGGAAGCCCGGCAA
	TCAAGAAGGGAATCCTGCAGACAGTCAAGGTCGTCGACGAAC
	TGGTCAAGGTCATGGGAAGACACAAGCCGGAAAACATCGTCA
	TCGAAATGGCAAGAGAAAACCAGACAACACAGAAGGGACAG
	AAGAACAGCAGAGAAAGAATGAAGAGAATCGAAGAAGGAAT
	CAAGGAACTGGGAAGCCAGATCCTGAAGGAACACCCGGTCGA
	AAACACACAGCTGCAGAACGAAAAGCTGTACCTGTACTACCT
	GCAGAACGGAAGAGACATGTACGTCGACCAGGAACTGGACAT
	CAACAGACTGAGCGACTACGACGTCGACCACATCGTCCCGCA
	GAGCTTCCTGAAGGACGACAGCATCGACAACAAGGTCCTGAC
	AAGAAGCGACAAGAACAGAGGAAAGAGCGACAACGTCCCGA
	GCGAAGAAGTCGTCAAGAAGATGAAGAACTACTGGAGACAGC
	TGCTGAACGCAAAGCTGATCACACAGAGAAAGTTCGACAACC
	TGACAAAGGCAGAGAGAGGAGGACTGAGCGAACTGGACAAG
	GCAGGATTCATCAAGAGACAGCTGGTCGAAACAAGACAGATC
	ACAAAGCACGTCGCACAGATCCTGGACAGCAGAATGAACACA
	AAGTACGACGAAAACGACAAGCTGATCAGAGAAGTCAAGGTC
	ATCACACTGAAGAGCAAGCTGGTCAGCGACTTCAGAAAGGAC
	TTCCAGTTCTACAAGGTCAGAGAAATCAACAACTACCACCACG
	CACACGACGCATACCTGAACGCAGTCGTCGGAACAGCACTGA
	TCAAGAAGTACCCGAAGCTGGAAAGCGAATTCGTCTACGGAG
	ACTACAAGGTCTACGACGTCAGAAAGATGATCGCAAAGAGCG
	AACAGGAAATCGGAAAGGCAACAGCAAAGTACTTCTTCTACA
	GCAACATCATGAACTTCTTCAAGACAGAAATCACACTGGCAA
	ACGGAGAAATCAGAAAGAGACCGCTGATCGAAACAAACGGA
	GAAACAGGAGAAATCGTCTGGGACAAGGGAAGAGACTTCGCA
	ACAGTCAGAAAGGTCCTGAGCATGCCGCAGGTCAACATCGTC
	AAGAAGACAGAAGTCCAGACAGGAGGATTCAGCAAGGAAAG
	CATCCTGCCGAAGAGAAACAGCGACAAGCTGATCGCAAGAAA
	GAAGGACTGGGACCCGAAGAAGTACGGAGGATTCGACAGCCC
	GACAGTCGCATACAGCGTCCTGGTCGTCGCAAAGGTCGAAAA
	GGGAAAGAGCAAGAAGCTGAAGAGCGTCAAGGAACTGCTGG
	GAATCACAATCATGGAAAGAAGCAGCTTCGAAAAGAACCCGA
	TCGACTTCCTGGAAGCAAAGGGATACAAGGAAGTCAAGAAGG
	ACCTGATCATCAAGCTGCCGAAGTACAGCCTGTTCGAACTGGA
	AAACGGAAGAAAGAGAATGCTGGCAAGCGCAGGAGAACTGC
	AGAAGGGAAACGAACTGGCACTGCCGAGCAAGTACGTCAACT
	TCCTGTACCTGGCAAGCCACTACGAAAAGCTGAAGGGAAGCC
	CGGAAGACAACGAACAGAAGCAGCTGTTCGTCGAACAGCACA
	AGCACTACCTGGACGAAATCATCGAACAGATCAGCGAATTCA
	GCAAGAGAGTCATCCTGGCAGACGCAAACCTGGACAAGGTCC
	TGAGCGCATACAACAAGCACAGAGACAAGCCGATCAGAGAAC
	AGGCAGAAAACATCATCCACCTGTTCACACTGACAAACCTGG
	GAGCACCGGCAGCATTCAAGTACTTCGACACAACAATCGACA
	GAAAGAGATACACAAGCACAAAGGAAGTCCTGGACGCAACAC
	TGATCCACCAGAGCATCACAGGACTGTACGAAACAAGAATCG
	ACCTGAGCCAGCTGGGAGGAGACGGAGGAGGAAGCCCGAAG
	AAGAAGAGAAAGGTCTAGCTAGCCATCACATTTAAAAGCATC
	TCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAT
	AGCTTATTCATCTCTTTTTCTTTTTCGTTGGTGTAAAGCCAACA
	CCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCTCTTT
	TCTCTGTGCTTCAATTAATAAAAAATGGAAAGAACCTCGAG
Cas9	GGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGT	44
transcript	GTGTGTCGTTGCAGGCCTTATTCGGATCCATGGACAAGAAGTA
with 5′ UTR	CAGCATCGGACTGGACATCGGAACAAACAGCGTCGGATGGGC
of HSD,	AGTCATCACAGACGAATACAAGGTCCCGAGCAAGAAGTTCAA
ORF	GGTCCTGGGAAACACAGACAGACACAGCATCAAGAAGAACCT
corresponding	GATCGGAGCACTGCTGTTCGACAGCGGAGAAACAGCAGAAGC
to SEQ	AACAAGACTGAAGAGAACAGCAAGAAGAAGATACACAAGAA
ID NO: 4,	GAAAGAACAGAATCTGCTACCTGCAGGAAATCTTCAGCAACG
and 3′ UTR	AAATGGCAAAGGTCGACGACAGCTTCTTCCACAGACTGGAAG
of ALB	AAAGCTTCCTGGTCGAAGAAGACAAGAAGCACGAAAGACACC
	CGATCTTCGGAAACATCGTCGACGAAGTCGCATACCACGAAA
	AGTACCCGACAATCTACCACCTGAGAAAGAAGCTGGTCGACA
	GCACAGACAAGGCAGACCTGAGACTGATCTACCTGGCACTGG
	CACACATGATCAAGTTCAGAGGACACTTCCTGATCGAAGGAG
	ACCTGAACCCGGACAACAGCGACGTCGACAAGCTGTTCATCC
	AGCTGGTCCAGACATACAACCAGCTGTTCGAAGAAAACCCGA
	TCAACGCAAGCGGAGTCGACGCAAAGGCAATCCTGAGCGCAA
	GACTGAGCAAGAGCAGAAGACTGGAAAACCTGATCGCACAGC
	TGCCGGGAGAAAAGAAGAACGGACTGTTCGGAAACCTGATCG
	CACTGAGCCTGGGACTGACACCGAACTTCAAGAGCAACTTCG
	ACCTGGCAGAAGACGCAAAGCTGCAGCTGAGCAAGGACACAT
	ACGACGACGACCTGGACAACCTGCTGGCACAGATCGGAGACC
	AGTACGCAGACCTGTTCCTGGCAGCAAAGAACCTGAGCGACG
	CAATCCTGCTGAGCGACATCCTGAGAGTCAACACAGAAATCA
	CAAAGGCACCGCTGAGCGCAAGCATGATCAAGAGATACGACG
	AACACCACCAGGACCTGACACTGCTGAAGGCACTGGTCAGAC
	AGCAGCTGCCGGAAAAGTACAAGGAAATCTTCTTCGACCAGA
	GCAAGAACGGATACGCAGGATACATCGACGGAGGAGCAAGCC
	AGGAAGAATTCTACAAGTTCATCAAGCCGATCCTGGAAAAGA
	TGGACGGAACAGAAGAACTGCTGGTCAAGCTGAACAGAGAAG
	ACCTGCTGAGAAAGCAGAGAACATTCGACAACGGAAGCATCC
	CGCACCAGATCCACCTGGGAGAACTGCACGCAATCCTGAGAA
	GACAGGAAGACTTCTACCCGTTCCTGAAGGACAACAGAGAAA
	AGATCGAAAAGATCCTGACATTCAGAATCCCGTACTACGTCGG
	ACCGCTGGCAAGAGGAAACAGCAGATTCGCATGGATGACAAG
	AAAGAGCGAAGAAACAATCACACCGTGGAACTTCGAAGAAGT
	CGTCGACAAGGGAGCAAGCGCACAGAGCTTCATCGAAAGAAT
	GACAAACTTCGACAAGAACCTGCCGAACGAAAAGGTCCTGCC
	GAAGCACAGCCTGCTGTACGAATACTTCACAGTCTACAACGAA
	CTGACAAAGGTCAAGTACGTCACAGAAGGAATGAGAAAGCCG
	GCATTCCTGAGCGGAGAACAGAAGAAGGCAATCGTCGACCTG
	CTGTTCAAGACAAACAGAAAGGTCACAGTCAAGCAGCTGAAG
	GAAGACTACTTCAAGAAGATCGAATGCTTCGACAGCGTCGAA
	ATCAGCGGAGTCGAAGACAGATTCAACGCAAGCCTGGGAACA
	TACCACGACCTGCTGAAGATCATCAAGGACAAGGACTTCCTGG
	ACAACGAAGAAAACGAAGACATCCTGGAAGACATCGTCCTGA
	CACTGACACTGTTCGAAGACAGAGAAATGATCGAAGAAAGAC
	TGAAGACATACGCACACCTGTTCGACGACAAGGTCATGAAGC
	AGCTGAAGAGAAGAAGATACACAGGATGGGGAAGACTGAGC
	AGAAAGCTGATCAACGGAATCAGAGACAAGCAGAGCGGAAA
	GACAATCCTGGACTTCCTGAAGAGCGACGGATTCGCAAACAG
	AAACTTCATGCAGCTGATCCACGACGACAGCCTGACATTCAAG
	GAAGACATCCAGAAGGCACAGGTCAGCGGACAGGGAGACAG
	CCTGCACGAACACATCGCAAACCTGGCAGGAAGCCCGGCAAT
	CAAGAAGGGAATCCTGCAGACAGTCAAGGTCGTCGACGAACT
	GGTCAAGGTCATGGGAAGACACAAGCCGGAAAACATCGTCAT
	CGAAATGGCAAGAGAAAACCAGACAACACAGAAGGGACAGA
	AGAACAGCAGAGAAAGAATGAAGAGAATCGAAGAAGGAATC
	AAGGAACTGGGAAGCCAGATCCTGAAGGAACACCCGGTCGAA
	AACACACAGCTGCAGAACGAAAAGCTGTACCTGTACTACCTG
	CAGAACGGAAGAGACATGTACGTCGACCAGGAACTGGACATC
	AACAGACTGAGCGACTACGACGTCGACCACATCGTCCCGCAG
	AGCTTCCTGAAGGACGACAGCATCGACAACAAGGTCCTGACA
	AGAAGCGACAAGAACAGAGGAAAGAGCGACAACGTCCCGAG
	CGAAGAAGTCGTCAAGAAGATGAAGAACTACTGGAGACAGCT
	GCTGAACGCAAAGCTGATCACACAGAGAAAGTTCGACAACCT
	GACAAAGGCAGAGAGAGGAGGACTGAGCGAACTGGACAAGG
	CAGGATTCATCAAGAGACAGCTGGTCGAAACAAGACAGATCA
	CAAAGCACGTCGCACAGATCCTGGACAGCAGAATGAACACAA
	AGTACGACGAAAACGACAAGCTGATCAGAGAAGTCAAGGTCA
	TCACACTGAAGAGCAAGCTGGTCAGCGACTTCAGAAAGGACT
	TCCAGTTCTACAAGGTCAGAGAAATCAACAACTACCACCACGC
	ACACGACGCATACCTGAACGCAGTCGTCGGAACAGCACTGAT
	CAAGAAGTACCCGAAGCTGGAAAGCGAATTCGTCTACGGAGA
	CTACAAGGTCTACGACGTCAGAAAGATGATCGCAAAGAGCGA
	ACAGGAAATCGGAAAGGCAACAGCAAAGTACTTCTTCTACAG
	CAACATCATGAACTTCTTCAAGACAGAAATCACACTGGCAAAC
	GGAGAAATCAGAAAGAGACCGCTGATCGAAACAAACGGAGA
	AACAGGAGAAATCGTCTGGGACAAGGGAAGAGACTTCGCAAC
	AGTCAGAAAGGTCCTGAGCATGCCGCAGGTCAACATCGTCAA
	GAAGACAGAAGTCCAGACAGGAGGATTCAGCAAGGAAAGCAT
	CCTGCCGAAGAGAAACAGCGACAAGCTGATCGCAAGAAAGAA
	GGACTGGGACCCGAAGAAGTACGGAGGATTCGACAGCCCGAC
	AGTCGCATACAGCGTCCTGGTCGTCGCAAAGGTCGAAAAGGG
	AAAGAGCAAGAAGCTGAAGAGCGTCAAGGAACTGCTGGGAAT
	CACAATCATGGAAAGAAGCAGCTTCGAAAAGAACCCGATCGA
	CTTCCTGGAAGCAAAGGGATACAAGGAAGTCAAGAAGGACCT
	GATCATCAAGCTGCCGAAGTACAGCCTGTTCGAACTGGAAAA
	CGGAAGAAAGAGAATGCTGGCAAGCGCAGGAGAACTGCAGA
	AGGGAAACGAACTGGCACTGCCGAGCAAGTACGTCAACTTCC
	TGTACCTGGCAAGCCACTACGAAAAGCTGAAGGGAAGCCCGG
	AAGACAACGAACAGAAGCAGCTGTTCGTCGAACAGCACAAGC
	ACTACCTGGACGAAATCATCGAACAGATCAGCGAATTCAGCA
	AGAGAGTCATCCTGGCAGACGCAAACCTGGACAAGGTCCTGA
	GCGCATACAACAAGCACAGAGACAAGCCGATCAGAGAACAGG
	CAGAAAACATCATCCACCTGTTCACACTGACAAACCTGGGAGC
	ACCGGCAGCATTCAAGTACTTCGACACAACAATCGACAGAAA
	GAGATACACAAGCACAAAGGAAGTCCTGGACGCAACACTGAT
	CCACCAGAGCATCACAGGACTGTACGAAACAAGAATCGACCT
	GAGCCAGCTGGGAGGAGACGGAGGAGGAAGCCCGAAGAAGA
	AGAGAAAGGTCTAGCTAGCCATCACATTTAAAAGCATCTCAGC
	CTACCATGAGAATAAGAGAAAGAAAATGAAGATCAATAGCTT
	ATTCATCTCTTTTTCTTTTTCGTTGGTGTAAAGCCAACACCCTG
	TCTAAAAAACATAAATTTCTTTAATCATTTTGCCTCTTTTCTCT
	GTGCTTCAATTAATAAAAAATGGAAAGAACCTCGAG
Alternative	ATGGATAAGAAGTACTCGATCGGGCTGGATATCGGAACTAATT	45
Cas9 ORF	CCGTGGGTTGGGCAGTGATCACGGATGAATACAAAGTGCCGT
with 19.36%	CCAAGAAGTTCAAGGTCCTGGGGAACACCGATAGACACAGCA
Ucontent	TCAAGAAGAATCTCATCGGAGCCCTGCTGTTTGACTCCGGCGA
	AACCGCAGAAGCGACCCGGCTCAAACGTACCGCGAGGCGACG
	CTACACCCGGCGGAAGAATCGCATCTGCTATCTGCAAGAAATC
	TTTTCGAACGAAATGGCAAAGGTGGACGACAGCTTCTTCCACC
	GCCTGGAAGAATCTTTCCTGGTGGAGGAGGACAAGAAGCATG
	AACGGCATCCTATCTTTGGAAACATCGTGGACGAAGTGGCGTA
	CCACGAAAAGTACCCGACCATCTACCATCTGCGGAAGAAGTT
	GGTTGACTCAACTGACAAGGCCGACCTCAGATTGATCTACTTG
	GCCCTCGCCCATATGATCAAATTCCGCGGACACTTCCTGATCG
	AAGGCGATCTGAACCCTGATAACTCCGACGTGGATAAGCTGTT
	CATTCAACTGGTGCAGACCTACAACCAACTGTTCGAAGAAAAC
	CCAATCAATGCCAGCGGCGTCGATGCCAAGGCCATCCTGTCCG
	CCCGGCTGTCGAAGTCGCGGCGCCTCGAAAACCTGATCGCACA
	GCTGCCGGGAGAGAAGAAGAACGGACTTTTCGGCAACTTGAT
	CGCTCTCTCACTGGGACTCACTCCCAATTTCAAGTCCAATTTTG
	ACCTGGCCGAGGACGCGAAGCTGCAACTCTCAAAGGACACCT
	ACGACGACGACTTGGACAATTTGCTGGCACAAATTGGCGATCA
	GTACGCGGATCTGTTCCTTGCCGCTAAGAACCTTTCGGACGCA
	ATCTTGCTGTCCGATATCCTGCGCGTGAACACCGAAATAACCA
	AAGCGCCGCTTAGCGCCTCGATGATTAAGCGGTACGACGAGC
	ATCACCAGGATCTCACGCTGCTCAAAGCGCTCGTGAGACAGCA
	ACTGCCTGAAAAGTACAAGGAGATTTTCTTCGACCAGTCCAAG
	AATGGGTACGCAGGGTACATCGATGGAGGCGCCAGCCAGGAA
	GAGrrCTATAAGITCATCAAGCCAATCCTGGAAAAGATGGACG
	GAACCGAAGAACTGCTGGTCAAGCTGAACAGGGAGGATCTGC
	TCCGCAAACAGAGAACCTTTGACAACGGAAGCATTCCACACC
	AGATCCATCTGGGTGAGCTGCACGCCATCTTGCGGCGCCAGGA
	GGACTTTTACCCATTCCTCAAGGACAACCGGGAAAAGATCGA
	GAAAATTCTGACGTTCCGCATCCCGTATTACGTGGGCCCACTG
	GCGCGCGGCAATTCGCGCTTCGCGTGGATGACTAGAAAATCA
	GAGGAAACCATCACTCCTTGGAATTTCGAGGAAGTTGTGGATA
	AGGGAGCTTCGGCACAATCCTTCATCGAACGAATGACCAACTT
	CGACAAGAATCTCCCAAACGAGAAGGTGCTTCCTAAGCACAG
	CCTCCTTTACGAATACTTCACTGTCTACAACGAACTGACTAAA
	GTGAAATACGTTACTGAAGGAATGAGGAAGCCGGCCTTTCTG
	AGCGGAGAACAGAAGAAAGCGATTGTCGATCTGCTGTTCAAG
	ACCAACCGCAAGGTGACCGTCAAGCAGCTTAAAGAGGACTAC
	TTCAAGAAGATCGAGTGTTTCGACTCAGTGGAAATCAGCGGA
	GTGGAGGACAGATTCAACGCTTCGCTGGGAACCTATCATGATC
	TCCTGAAGATCATCAAGGACAAGGACTTCCTTGACAACGAGG
	AGAACGAGGACATCCTGGAAGATATCGTCCTGACCTTGACCCT
	TTTCGAGGATCGCGAGATGATCGAGGAGAGGCTTAAGACCTA
	CGCTCATCTCTTCGACGATAAGGTCATGAAACAACTCAAGCGC
	CGCCGGTACACTGGTTGGGGCCGCCTCTCCCGCAAGCTGATCA
	ACGGTATTCGCGATAAACAGAGCGGTAAAACTATCCTGGATTT
	CCTCAAATCGGATGGCTTCGCTAATCGTAACTTCATGCAGTTG
	ATCCACGACGACAGCCTGACCTTTAAGGAGGACATCCAGAAA
	GCACAAGTGAGCGGACAGGGAGACTCACTCCATGAACACATC
	GCGAATCTGGCCGGTTCGCCGGCGATTAAGAAGGGAATCCTG
	CAAACTGTGAAGGTGGTGGACGAGCTGGTGAAGGTCATGGGA
	CGGCACAAACCGGAGAATATCGTGATTGAAATGGCCCGAGAA
	AACCAGACTACCCAGAAGGGCCAGAAGAACTCCCGCGAAAGG
	ATGAAGCGGATCGAAGAAGGAATCAAGGAGCTGGGCAGCCAG
	ATCCTGAAAGAGCACCCGGTGGAAAACACGCAGCTGCAGAAC
	GAGAAGCTCTACCTGTACTATTTGCAAAATGGACGGGACATGT
	ACGTGGACCAAGAGCTGGACATCAATCGGTTGTCTGATTACGA
	CGTGGACCACATCGTTCCACAGTCCTTTCTGAAGGATGACTCC
	ATCGATAACAAGGTGTTGACTCGCAGCGACAAGAACAGAGGG
	AAGTCAGATAATGTGCCATCGGAGGAGGTCGTGAAGAAGATG
	AAGAATTACTGGCGGCAGCTCCTGAATGCGAAGCTGATTACCC
	AGAGAAAGTTTGACAATCTCACTAAAGCCGAGCGCGGCGGAC
	TCTCAGAGCTGGATAAGGCTGGATTCATCAAACGGGAGCTGGT
	CGAGACTCGGCAGATTACCAAGCACGTGGCGCAGATCCTGGA
	CTCCCGCATGAACACTAAATACGACGAGAACGATAAGCTCAT
	CCGGGAAGTGAAGGTGATTACCCTGAAAAGCAAACTTGTGTC
	GGACTTTCGGAAGGACTTTCAGTTTTACAAAGTGAGAGAAATC
	AACAACTACCATCACGCGCATGACGCATACCTCAACGCTGTGG
	TCGGCACCGCCCTGATCAAGAAGTACCCTAAACTTGAATCGGA
	GTTTGTGTACGGAGACTACAAGGTCTACGACGTGAGGAAGAT
	GATAGCCAAGTCCGAACAGGAAATCGGGAAAGCAACTGCGAA
	ATACTTCTTTTACTCAAACATCATGAACTTCTTCAAGACTGAA
	ATTACGCTGGCCAATGGAGAAATCAGGAAGAGGCCACTGATC
	GAAACTAACGGAGAAACGGGCGAAATCGTGTGGGACAAGGGC
	AGGGACTTCGCAACTGTTCGCAAAGTGCTCTCTATGCCGCAAG
	TCAATATTGTGAAGAAAACCGAAGTGCAAACCGGCGGATTTTC
	AAAGGAATCGATCCTCCCAAAGAGAAATAGCGACAAGCTCAT
	TGCACGCAAGAAAGACTGGGACCCGAAGAAGTACGGAGGATT
	CGATTCGCCGACTGTCGCATACTCCGTCCTCGTGGTGGCCAAG
	GTGGAGAAGGGAAAGAGCAAGAAGCTCAAATCCGTCAAAGA
	GCTGCTGGGGATTACCATCATGGAACGATCCTCGTTCGAGAAG
	AACCCGATTGATTTCCTGGAGGCGAAGGGTTACAAGGAGGTG
	AAGAAGGATCTGATCATCAAACTGCCCAAGTACTCACTGTTCG
	AACTGGAAAATGGTCGGAAGCGCATGCTGGCTTCGGCCGGAG
	AACTCCAGAAAGGAAATGAGCTGGCCTTGCCTAGCAAGTACG
	TCAACTTCCTCTATCTTGCTTCGCACTACGAGAAACTCAAAGG
	GTCACCGGAAGATAACGAACAGAAGCAGCTTTTCGTGGAGCA
	GCACAAGCATTATCTGGATGAAATCATCGAACAAATCTCCGAG
	TTTTCAAAGCGCGTGATCCTCGCCGACGCCAACCTCGACAAAG
	TCCTGTCGGCCTACAATAAGCATAGAGATAAGCCGATCAGAG
	AACAGGCCGAGAACATTATCCACTTGTTCACCCTGACTAACCT
	GGGAGCTCCAGCCGCCTTCAAGTACTTCGATACTACTATCGAC
	CGCAAAAGATACACGTCCACCAAGGAAGTTCTGGACGCGACC
	CTGATCCACCAAAGCATCACTGGACTCTACGAAACTAGGATCG
	ATCTGTCGCAGCTGGGTGGCGATGGTGGCGGTGGATCCTACCC
	ATACGACGTGCCTGACTACGCCTCCGGAGGTGGTGGCCCCAAG
	AAGAAACGGAAGGTGTGATAG
Cas9	GGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT	46
transcript	GTGTCGTTGCAGGCCTTATTCGGATCTGCCACCATGGATAAGA
with 5′ UTR	AGTACTCGATCGGGCTGGATATCGGAACTAATTCCGTGGGTTG
of HSD,	GGCAGTGATCACGGATGAATACAAAGTGCCGTCCAAGAAGTT
ORF	CAAGGTCCTGGGGAACACCGATAGACACAGCATCAAGAAGAA
corresponding	TCTCATCGGAGCCCTGCTGTTTGACTCCGGCGAAACCGCAGAA
to SEQ	GCGACCCGGCTCAAACGTACCGCGAGGCGACGCTACACCCGG
ID NO: 45,	CGGAAGAATCGCATCTGCTATCTGCAAGAAATCTTTTCGAACG
Kozak	AAATGGCAAAGGTGGACGACAGCTTCTTCCACCGCCTGGAAG
sequence,	AATCTTTCCTGGTGGAGGAGGACAAGAAGCATGAACGGCATC
and 3′ UTR	CTATCTTTGGAAACATCGTGGACGAAGTGGCGTACCACGAAA
of ALB	AGTACCCGACCATCTACCATCTGCGGAAGAAGTTGGTTGACTC
	AACTGACAAGGCCGACCTCAGATTGATCTACTTGGCCCTCGCC
	CATATGATCAAATTCCGCGGACACTTCCTGATCGAAGGCGATC
	TGAACCCTGATAACTCCGACGTGGATAAGCTGTTCATTCAACT
	GGTGCAGACCTACAACCAACTGTTCGAAGAAAACCCAATCAA
	TGCCAGCGGCGTCGATGCCAAGGCCATCCTGTCCGGCCGGCTG
	TCGAAGTCGCGGCGCCTCGAAAACCTGATCGCACAGCTGCCG
	GGAGAGAAGAAGAACGGACTTTTCGGCAACTTGATCGCTCTCT
	CACTGGGACTCACTCCCAATTTCAAGTCCAATTTTGACCTGGC
	CGAGGACGCGAAGCTGCAACTCTCAAAGGACACCTACGACGA
	CGACTTGGACAATTTGCTGGCACAAATTGGCGATCAGTACGCG
	GATCTGTTCCTTGCCGCTAAGAACCTTTCGGACGCAATCTTGCT
	GTCCGATATCCTGCGCGTGAACACCGAAATAACCAAAGCGCC
	GCTTAGCGCCTCGATGATTAAGCGGTACGACGAGCATCACCAG
	GATCTCACGCTGCTCAAAGCGCTCGTGAGACAGCAACTGCCTG
	AAAAGTACAAGGAGATTTTCTTCGACCAGTCCAAGAATGGGT
	ACGCAGGGTACATCGATGGAGGCGCCAGCCAGGAAGAGTTCT
	ATAAGTTCATCAAGCCAATCCTGGAAAAGATGGACGGAACCG
	AAGAACTGCTGGTCAAGCTGAACAGGGAGGATCTGCTCCGCA
	AACAGAGAACCTTTGACAACGGAAGCATTCCACACCAGATCC
	ATCTGGGTGAGCTGCACGCCATCTTGCGGCGCCAGGAGGACTT
	TTACCCATTCCTCAAGGACAACCGGGAAAAGATCGAGAAAAT
	TCTGACGTTCCGCATCCCGTATTACGTGGGCCCACTGGCGCGC
	GGCAATTCGCGCTTCGCGTGGATGACTAGAAAATCAGAGGAA
	ACCATCACTCCTTGGAATTTCGAGGAAGTTGTGGATAAGGGAG
	CTTCGGCACAATCCTTCATCGAACGAATGACCAACTTCGACAA
	GAATCTCCCAAACGAGAAGGTGCTTCCTAAGCACAGCCTCCTT
	TACGAATACTTCACTGTCTACAACGAACTGACTAAAGTGAAAT
	ACGTTACTGAAGGAATGAGGAAGCCGGCCTTTCTGAGCGGAG
	AACAGAAGAAAGCGATTGTCGATCTGCTGTTCAAGACCAACC
	GCAAGGTGACCGTCAAGCAGCTTAAAGAGGACTACTTCAAGA
	AGATCGAGTGTTTCGACTCAGTGGAAATCAGCGGAGTGGAGG
	ACAGATTCAACGCTTCGCTGGGAACCTATCATGATCTCCTGAA
	GATCATCAAGGACAAGGACTTCCTTGACAACGAGGAGAACGA
	GGACATCCTGGAAGATATCGTCCTGACCTTGACCCTTTTCGAG
	GATCGCGAGATGATCGAGGAGAGGCTTAAGACCTACGCTCAT
	CTCTTCGACGATAAGGTCATGAAACAACTCAAGCGCCGCCGGT
	ACACTGGTTGGGGCCGCCTCTCCCGCAAGCTGATCAACGGTAT
	TCGCGATAAACAGAGCGGTAAAACTATCCTGGATTTCCTCAAA
	TCGGATGGCTTCGCTAATCGTAACTTCATGCAGTTGATCCACG
	ACGACAGCCTGACCTTTAAGGAGGACATCCAGAAAGCACAAG
	TGAGCGGACAGGGAGACTCACTCCATGAACACATCGCGAATC
	TGGCCGGTTCGCCGGCGATTAAGAAGGGAATCCTGCAAACTGT
	GAAGGTGGTGGACGAGCTGGTGAAGGTCATGGGACGGCACAA
	ACCGGAGAATATCGTGATTGAAATGGCCCGAGAAAACCAGAC
	TACCCAGAAGGGCCAGAAGAACTCCCGCGAAAGGATGAAGCG
	GATCGAAGAAGGAATCAAGGAGCTGGGCAGCCAGATCCTGAA
	AGAGCACCCGGTGGAAAACACGCAGCTGCAGAACGAGAAGCT
	CTACCTGTACTATTTGCAAAATGGACGGGACATGTACGTGGAC
	CAAGAGCTGGACATCAATCGGTTGTCTGATTACGACGTGGACC
	ACATCGTTCCACAGTCCTTTCTGAAGGATGACTCCATCGATAA
	CAAGGTGTTGACTCGCAGCGACAAGAACAGAGGGAAGTCAGA
	TAATGTGCCATCGGAGGAGGTCGTGAAGAAGATGAAGAATTA
	CTGGCGGCAGCTCCTGAATGCGAAGCTGATTACCCAGAGAAA
	GTTTGACAATCTCACTAAAGCCGAGCGCGGCGGACTCTCAGAG
	CTGGATAAGGCTGGATTCATCAAACGGCAGCTGGTCGAGACTC
	GGCAGATTACCAAGCACGTGGCGCAGATCCTGGACTCCCGCAT
	GAACACTAAATACGACGAGAACGATAAGCTCATCCGGGAAGT
	GAAGGTGATTACCCTGAAAAGCAAACTTGTGTCGGACTTTCGG
	AAGGACTTTCAGTTTTACAAAGTGAGAGAAATCAACAACTACC
	ATCACGCGCATGACGCATACCTCAACGCTGTGGTCGGCACCGC
	CCTGATCAAGAAGTACCCTAAACTTGAATCGGAGTTTGTGTAC
	GGAGACTACAAGGTCTACGACGTGAGGAAGATGATAGCCAAG
	TCCGAACAGGAAATCGGGAAAGCAACTGCGAAATACTTCTTTT
	ACTCAAACATCATGAACTTCTTCAAGACTGAAATTACGCTGGC
	CAATGGAGAAATCAGGAAGAGGCCACTGATCGAAACTAACGG
	AGAAACGGGCGAAATCGTGTGGGACAAGGGCAGGGACTTCGC
	AACTGTTCGCAAAGTGCTCTCTATGCCGCAAGTCAATATTGTG
	AAGAAAACCGAAGTGCAAACCGGCGGATTTTCAAAGGAATCG
	ATCCTCCCAAAGAGAAATAGCGACAAGCTCATTGCACGCAAG
	AAAGACTGGGACCCGAAGAAGTACGGAGGATTCGATTCGCCG
	ACTGTCGCATACTCCGTCCTCGTGGTGGCCAAGGTGGAGAAGG
	GAAAGAGCAAGAAGCTCAAATCCGTCAAAGAGCTGCTGGGGA
	TTACCATCATGGAACGATCCTCGTTCGAGAAGAACCCGATTGA
	TTTCCTGGAGGCGAAGGGTTACAAGGAGGTGAAGAAGGATCT
	GATCATCAAACTGCCCAAGTACTCACTGTTCGAACTGGAAAAT
	GGTCGGAAGCGCATGCTGGCTTCGGCCGGAGAACTCCAGAAA
	GGAAATGAGCTGGCCTTGCCTAGCAAGTACGTCAACTTCCTCT
	ATCTTGCTTCGCACTACGAGAAACTCAAAGGGTCACCGGAAG
	ATAACGAACAGAAGCAGCTTTTCGTGGAGCAGCACAAGCATT
	ATCTGGATGAAATCATCGAACAAATCTCCGAGTTTTCAAAGCG
	CGTGATCCTCGCCGACGCCAACCTCGACAAAGTCCTGTCGGCC
	TACAATAAGCATAGAGATAAGCCGATCAGAGAACAGGCCGAG
	AACATTATCCACTTGTTCACCCTGACTAACCTGGGAGCTCCAG
	CCGCCTTCAAGTACTTCGATACTACTATCGACCGCAAAAGATA
	CACGTCCACCAAGGAAGTTCTGGACGCGACCCTGATCCACCAA
	AGCATCACTGGACTCTACGAAACTAGGATCGATCTGTCGCAGC
	TGGGTGGCGATGGTGGCGGTGGATCCTACCCATACGACGTGCC
	TGACTACGCCTCCGGAGGTGGTGGCCCCAAGAAGAAACGGAA
	GGTGTGATAGCTAGCCATCACATTTAAAAGCATCTCAGCCTAC
	CATGAGAATAAGAGAAAGAAAATGAAGATCAATAGCTTATTC
	ATCTCTTTTTCTTTTTCGTTGGTGTAAAGCCAACACCCTGTCTA
	AAAAACATAAATTTCTTTAATCATTTTGCCTCTTTTCTCTGTGC
	TTCAATTAATAAAAAATGGAAAGAACCTCGAG
Cas9	GGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT	47
transcript	GTGTCGTTGCAGGCCTTATTCGGATCTATGGATAAGAAGTACT
with 5′ UTR	CGATCGGGCTGGATATCGGAACTAATTCCGTGGGTTGGGCAGT
of HSD,	GATCACGGATGAATACAAAGTGCCGTCCAAGAAGTTCAAGGT
ORF	CCTGGGGAACACCGATAGACACAGCATCAAGAAGAATCTCAT
corresponding	CGGAGCCCTGCTGTTTGACTCCGGCGAAACCGCAGAAGCGAC
to SEQ	CCGGCTCAAACGTACCGCGAGGCGACGCTACACCCGGCGGAA
ID NO: 45,	GAATCGCATCTGCTATCTGCAAGAAATCTTTTCGAACGAAATG
and 3′ UTR	GCAAAGGTGGACGACAGCTTCTTCCACCGCCTGGAAGAATCTT
of ALB	TCCTGGTGGAGGAGGACAAGAAGCATGAACGGCATCCTATCT
	TTGGAAACATCGTGGACGAAGTGGCGTACCACGAAAAGTACC
	CGACCATCTACCATCTGCGGAAGAAGTTGGTTGACTCAACTGA
	CAAGGCCGACCTCAGATTGATCTACTTGGCCCTCGCCCATATG
	ATCAAATTCCGCGGACACTTCCTGATCGAAGGCGATCTGAACC
	CTGATAACTCCGACGTGGATAAGCTGTTCATTCAACTGGTGCA
	GACCTACAACCAACTGTTCGAAGAAAACCCAATCAATGCCAG
	CGGCGTCGATGCCAAGGCCATCCTGTCCGCCCGGCTGTCGAAG
	TCGCGGCGCCTCGAAAACCTGATCGCACAGCTGCCGGGAGAG
	AAGAAGAACGGACTTTTCGGCAACTTGATCGCTCTCTCACTGG
	GACTCACTCCCAATTTCAAGTCCAATTTTGACCTGGCCGAGGA
	CGCGAAGCTGCAACTCTCAAAGGACACCTACGACGACGACTT
	GGACAATTTGCTGGCACAAATTGGCGATCAGTACGCGGATCTG
	TTCCTTGCCGCTAAGAACCTTTCGGACGCAATCTTGCTGTCCG
	ATATCCTGCGCGTGAACACCGAAATAACCAAAGCGCCGCTTA
	GCGCCTCGATGATTAAGCGGTACGACGAGCATCACCAGGATCT
	CACGCTGCTCAAAGCGCTCGTGAGACAGCAACTGCCTGAAAA
	GTACAAGGAGATTTTCTTCGACCAGTCCAAGAATGGGTACGCA
	GGGTACATCGATGGAGGCGCCAGCCAGGAAGAGTTCTATAAG
	TTCATCAAGCCAATCCTGGAAAAGATGGACGGAACCGAAGAA
	CTGCTGGTCAAGCTGAACAGGGAGGATCTGCTCCGCAAACAG
	AGAACCTTTGACAACGGAAGCATTCCACACCAGATCCATCTGG
	GTGAGCTGCACGCCATCTTGCGGCGCCAGGAGGACTTTTACCC
	ATTCCTCAAGGACAACCGGGAAAAGATCGAGAAAATTCTGAC
	GTTCCGCATCCCGTATTACGTGGGCCCACTGGCGCGCGGCAAT
	TCGCGCTTCGCGTGGATGACTAGAAAATCAGAGGAAACCATC
	ACTCCTTGGAATTTCGAGGAAGTTGTGGATAAGGGAGCTTCGG
	CACAATCCTTCATCGAACGAATGACCAACTTCGACAAGAATCT
	CCCAAACGAGAAGGTGCTTCCTAAGCACAGCCTCCTTTACGAA
	TACTTCACTGTCTACAACGAACTGACTAAAGTGAAATACGTTA
	CTGAAGGAATGAGGAAGCCGGCCTTTCTGAGCGGAGAACAGA
	AGAAAGCGATTGTCGATCTGCTGTTCAAGACCAACCGCAAGGT
	GACCGTCAAGCAGCTTAAAGAGGACTACTTCAAGAAGATCGA
	GTGTTTCGACTCAGTGGAAATCAGCGGAGTGGAGGACAGATT
	CAACGCTTCGCTGGGAACCTATCATGATCTCCTGAAGATCATC
	AAGGACAAGGACTTCCTTGACAACGAGGAGAACGAGGACATC
	CTGGAAGATATCGTCCTGACCTTGACCCTTTTCGAGGATCGCG
	AGATGATCGAGGAGAGGCTTAAGACCTACGCTCATCTCTTCGA
	CGATAAGGTCATGAAACAACTCAAGCGCCGCCGGTACACTGG
	TTGGGGCCGCCTCTCCCGCAAGCTGATCAACGGTATTCGCGAT
	AAACAGAGCGGTAAAACTATCCTGGATTTCCTCAAATCGGATG
	GCTTCGCTAATCGTAACTTCATGCAGTTGATCCACGACGACAG
	CCTGACCTTTAAGGAGGACATCCAGAAAGCACAAGTGAGCGG
	ACAGGGAGACTCACTCCATGAACACATCGCGAATCTGGCCGG
	TTCGCCGGCGATTAAGAAGGGAATCCTGCAAACTGTGAAGGT
	GGTGGACGAGCTGGTGAAGGTCATGGGACGGCACAAACCGGA
	GAATATCGTGATTGAAATGGCCCGAGAAAACCAGACTACCCA
	GAAGGGCCAGAAGAACTCCCGCGAAAGGATGAAGCGGATCGA
	AGAAGGAATCAAGGAGCTGGGCAGCCAGATCCTGAAAGAGCA
	CCCGGTGGAAAACACGCAGCTGCAGAACGAGAAGCTCTACCT
	GTACTATTTGCAAAATGGACGGGACATGTACGTGGACCAAGA
	GCTGGACATCAATCGGTTGTCTGATTACGACGTGGACCACATC
	GTTCCACAGTCCTTTCTGAAGGATGACTCCATCGATAACAAGG
	TGTTGACTCGCAGCGACAAGAACAGAGGGAAGTCAGATAATG
	TGCCATCGGAGGAGGTCGTGAAGAAGATGAAGAATTACTGGC
	GGCAGCTCCTGAATGCGAAGCTGATTACCCAGAGAAAGTTTG
	ACAATCTCACTAAAGCCGAGCGCGGCGGACTCTCAGAGCTGG
	ATAAGGCTGGATTCATCAAACGGCAGCTGGTCGAGACTCGGC
	AGATTACCAAGCACGTGGCGCAGATCCTGGACTCCCGCATGA
	ACACTAAATACGACGAGAACGATAAGCTCATCCGGGAAGTGA
	AGGTGATTACCCTGAAAAGCAAACTTGTGTCGGACTTTCGGAA
	GGACTTTCAGTTTTACAAAGTGAGAGAAATCAACAACTACCAT
	CACGCGCATGACGCATACCTCAACGCTGTGGTCGGCACCGCCC
	TGATCAAGAAGTACCCTAAACTTGAATCGGAGTTTGTGTACGG
	AGACTACAAGGTCTACGACGTGAGGAAGATGATAGCCAAGTC
	CGAACAGGAAATCGGGAAAGCAACTGCGAAATACTTCTTTTA
	CTCAAACATCATGAACTTCTTCAAGACTGAAATTACGCTGGCC
	AATGGAGAAATCAGGAAGAGGCCACTGATCGAAACTAACGGA
	GAAACGGGCGAAATCGTGTGGGACAAGGGCAGGGACTTCGCA
	ACTGTTCGCAAAGTGCTCTCTATGCCGCAAGTCAATATTGTGA
	AGAAAACCGAAGTGCAAACCGGCGGATTTTCAAAGGAATCGA
	TCCTCCCAAAGAGAAATAGCGACAAGCTCATTGCACGCAAGA
	AAGACTGGGACCCGAAGAAGTACGGAGGATTCGATTCGCCGA
	CTGTCGCATACTCCGTCCTCGTGGTGGCCAAGGTGGAGAAGGG
	AAAGAGCAAGAAGCTCAAATCCGTCAAAGAGCTGCTGGGGAT
	TACCATCATGGAACGATCCTCGTTCGAGAAGAACCCGATTGAT
	TTCCTGGAGGCGAAGGGTTACAAGGAGGTGAAGAAGGATCTG
	ATCATCAAACTGCCCAAGTACTCACTGTTCGAACTGGAAAATG
	GTCGGAAGCGCATGCTGGCTTCGGCCGGAGAACTCCAGAAAG
	GAAATGAGCTGGCCTTGCCTAGCAAGTACGTCAACTTCCTCTA
	TCTTGCTTCGCACTACGAGAAACTCAAAGGGTCACCGGAAGAT
	AACGAACAGAAGCAGCTTTTCGTGGAGCAGCACAAGGATTAT
	CTGGATGAAATCATCGAACAAATCTCCGAGTTTTCAAAGCGCG
	TGATCCTCGCCGACGCCAACCTCGACAAAGTCCTGTCGGCCTA
	CAATAAGCATAGAGATAAGCCGATCAGAGAACAGGCCGAGAA
	CATTATCCACTTGTTCACCCTGACTAACCTGGGAGCTCCAGCC
	GCCTTCAAGTACTTCGATACTACTATCGACCGCAAAAGATACA
	CGTCCACCAAGGAAGTTCTGGACGCGACCCTGATCCACCAAA
	GCATCACTGGACTCTACGAAACTAGGATCGATCTGTCGCAGCT
	GGGTGGCGATGGTGGCGGTGGATCCTACCCATACGACGTGCCT
	GACTACGCCTCCGGAGGTGGTGGCCCCAAGAAGAAACGGAAG
	GTGTGATAGCTAGCCATCACATTTAAAAGCATCTCAGCCTACC
	ATGAGAATAAGAGAAAGAAAATGAAGATCAATAGCTTATTCA
	TCTCTTTTTCTTTTTCGTTGGTGTAAAGCCAACACCCTGTCTAA
	AAAACATAAATTTCTTTAATCATTTTGCCTCTTTTCTCTGTGCT
	TCAATTAATAAAAAATGGAAAGAACCTCGAG
Cas9	GGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT	48
transcript	GTGTCGTTGCAGGCCTTATTCGGATCCATGCCTAAGAAAAAGC
comprising	GGAAGGTCGACGGGGATAAGAAGTACTCAATCGGGCTGGATA
Cas9 ORF	TCGGAACTAATTCCGTGGGTTGGGCAGTGATCACGGATGAATA
using codons	CAAAGTGCCGTCCAAGAAGTTCAAGGTCCTGGGGAACACCGA
with	TAGACACAGCATCAAGAAAAATCTCATCGGAGCCCTGCTGTTT
generally	GACTCCGGCGAAACCGCAGAAGCGACCCGGCTCAAACGTACC
high	GCGAGGCGACGCTACACCCGGCGGAAGAATCGCATCTGCTAT
expression in	CTGCAAGAGATCTTTTCGAACGAAATGGCAAAGGTCGACGAC
humans	AGCTTCTTCCACCGCCTGGAAGAATCTTTCCTGGTGGAGGAGG
	ACAAGAAGCATGAACGGCATCCTATCTTTGGAAACATCGTCGA
	CGAAGTGGCGTACCACGAAAAGTACCCGACCATCTACCATCTG
	CGGAAGAAGTTGGTTGACTCAACTGACAAGGCCGACCTCAGA
	TTGATCTACTTGGCCCTCGCCCATATGATCAAATTCCGCGGAC
	ACTTCCTGATCGAAGGCGATCTGAACCCTGATAACTCCGACGT
	GGATAAGCTTTTCATTCAACTGGTGCAGACCTACAACCAACTG
	TTCGAAGAAAACCCAATCAATGCTAGCGGCGTCGATGCCAAG
	GCCATCCTGTCCGCCCGGCTGTCGAAGTCGCGGCGCCTCGAAA
	ACCTGATCGCACAGCTGCCGGGAGAGAAAAAGAACGGACTTT
	TCGGCAACTTGATCGCTCTCTCACTGGGACTCACTCCCAATTTC
	AAGTCCAATTTTGACCTGGCCGAGGACGCGAAGCTGCAACTCT
	CAAAGGACACCTACGACGACGACTTGGACAATTTGCTGGCAC
	AAATTGGCGATCAGTACGCGGATCTGTTCCTTGCCGCTAAGAA
	CCTTTCGGACGCAATCTTGCTGTCCGATATCCTGCGCGTGAAC
	ACCGAAATAACCAAAGCGCCGCTTAGCGCCTCGATGATTAAG
	CGGTACGACGAGCATCACCAGGATCTCACGCTGCTCAAAGCG
	CTCGTGAGACAGCAACTGCCTGAAAAGTACAAGGAGATCTTCT
	TCGACCAGTCCAAGAATGGGTACGCAGGGTACATCGATGGAG
	GCGCTAGCCAGGAAGAGTTCTATAAGTTCATCAAGCCAATCCT
	GGAAAAGATGGACGGAACCGAAGAACTGCTGGTCAAGCTGAA
	CAGGGAGGATCTGCTCCGGAAACAGAGAACCTTTGACAACGG
	ATCCATTCCCCACCAGATCCATCTGGGTGAGCTGCACGCCATC
	TTGCGGCGCCAGGAGGACTTTTACCCATTCCTCAAGGACAACC
	GGGAAAAGATCGAGAAAATTCTGACGTTCCGCATCCCGTATTA
	CGTGGGCCCACTGGCGCGCGGCAATTCGCGCTTCGCGTGGATG
	ACTAGAAAATCAGAGGAAACCATCACTCCTTGGAATTTCGAG
	GAAGTTGTGGATAAGGGAGCTTCGGCACAAAGCTTCATCGAA
	CGAATGACCAACTTCGACAAGAATCTCCCAAACGAGAAGGTG
	CTTCCTAAGCACAGCCTCCTTTACGAATACTTCACTGTCTACAA
	CGAACTGACTAAAGTGAAATACGTTACTGAAGGAATGAGGAA
	GCCGGCCTTTCTGTCCGGAGAACAGAAGAAAGCAATTGTCGAT
	CTGCTGTTCAAGACCAACCGCAAGGTGACCGTCAAGCAGCTTA
	AAGAGGACTACTTCAAGAAGATCGAGTGTTTCGACTCAGTGG
	AAATCAGCGGGGTGGAGGACAGATTCAACGCTTCGCTGGGAA
	CCTATCATGATCTCCTGAAGATCATCAAGGACAAGGACTTCCT
	TGACAACGAGGAGAACGAGGACATCCTGGAAGATATCGTCCT
	GACCTTGACCCTTTTCGAGGATCGCGAGATGATCGAGGAGAG
	GCTTAAGACCTACGCTCATCTCTTCGACGATAAGGTCATGAAA
	CAACTCAAGCGCCGCCGGTACACTGGTTGGGGCCGCCTCTCCC
	GCAAGCTGATCAACGGTATTCGCGATAAACAGAGCGGTAAAA
	CTATCCTGGATTTCCTCAAATCGGATGGCTTCGCTAATCGTAA
	CTTCATGCAATTGATCCACGACGACAGCCTGACCTTTAAGGAG
	GACATCCAAAAAGCACAAGTGTCCGGACAGGGAGACTCACTC
	CATGAACACATCGCGAATCTGGCCGGTTCGCCGGCGATTAAGA
	AGGGAATTCTGCAAACTGTGAAGGTGGTCGACGAGCTGGTGA
	AGGTCATGGGACGGCACAAACCGGAGAATATCGTGATTGAAA
	TGGCCCGAGAAAACCAGACTACCCAGAAGGGCCAGAAAAACT
	CCCGCGAAAGGATGAAGCGGATCGAAGAAGGAATCAAGGAG
	CTGGGCAGCCAGATCCTGAAAGAGCACCCGGTGGAAAACACG
	CAGCTGCAGAACGAGAAGCTCTACCTGTACTATTTGCAAAATG
	GACGGGACATGTACGTGGACCAAGAGCTGGACATCAATCGGT
	TGTCTGATTACGACGTGGACCACATCGTTCCACAGTCCTTTCTG
	AAGGATGACTCGATCGATAACAAGGTGTTGACTCGCAGCGAC
	AAGAACAGAGGGAAGTCAGATAATGTGCCATCGGAGGAGGTC
	GTGAAGAAGATGAAGAATTACTGGCGGCAGCTCCTGAATGCG
	AAGCTGATTACCCAGAGAAAGTTTGACAATCTCACTAAAGCCG
	AGCGCGGCGGACTCTCAGAGCTGGATAAGGCTGGATTCATCA
	AACGGCAGCTGGTCGAGACTCGGCAGATTACCAAGCACGTGG
	CGCAGATCTTGGACTCCCGCATGAACACTAAATACGACGAGA
	ACGATAAGCTCATCCGGGAAGTGAAGGTGATTACCCTGAAAA
	GCAAACTTGTGTCGGACTTTCGGAAGGACTTTCAGTTTTACAA
	AGTGAGAGAAATCAACAACTACCATCACGCGCATGACGCATA
	CCTCAACGCTGTGGTCGGTACCGCCCTGATCAAAAAGTACCCT
	AAACTTGAATCGGAGTTTGTGTACGGAGACTACAAGGTCTACG
	ACGTGAGGAAGATGATAGCCAAGTCCGAACAGGAAATCGGGA
	AAGCAACTGCGAAATACTTCTTTTACTCAAACATCATGAACTT
	TTTCAAGACTGAAATTACGCTGGCCAATGGAGAAATCAGGAA
	GAGGCCACTGATCGAAACTAACGGAGAAACGGGCGAAATCGT
	GTGGGACAAGGGCAGGGACTTCGCAACTGTTCGCAAAGTGCT
	CTCTATGCCGCAAGTCAATATTGTGAAGAAAACCGAAGTGCA
	AACCGGCGGATTTTCAAAGGAATCGATCCTCCCAAAGAGAAA
	TAGCGACAAGCTCATTGCACGCAAGAAAGACTGGGACCCGAA
	GAAGTACGGAGGATTCGATTCGCCGACTGTCGCATACTCCGTC
	CTCGTGGTGGCCAAGGTGGAGAAGGGAAAGAGCAAAAAGCTC
	AAATCCGTCAAAGAGCTGCTGGGGATTACCATCATGGAACGA
	TCCTCGTTCGAGAAGAACCCGATTGATTTCCTCGAGGCGAAGG
	GTTACAAGGAGGTGAAGAAGGATCTGATCATCAAACTCCCCA
	AGTACTCACTGTTCGAACTGGAAAATGGTCGGAAGCGCATGCT
	GGCTTCGGCCGGAGAACTCCAAAAAGGAAATGAGCTGGCCTT
	GCCTAGCAAGTACGTCAACTTCCTCTATCTTGCTTCGCACTACG
	AAAAACTCAAAGGGTCACCGGAAGATAACGAACAGAAGCAGC
	TTTTCGTGGAGCAGCACAAGCATTATCTGGATGAAATCATCGA
	ACAAATCTCCGAGTTTTCAAAGCGCGTGATCCTCGCCGACGCC
	AACCTCGACAAAGTCCTGTCGGCCTACAATAAGCATAGAGAT
	AAGCCGATCAGAGAACAGGCCGAGAACATTATCCACTTGTTC
	ACCCTGACTAACCTGGGAGCCCCAGCCGCCTTCAAGTACTTCG
	ATACTACTATCGATCGCAAAAGATACACGTCCACCAAGGAAG
	TTCTGGACGCGACCCTGATCCACCAAAGCATCACTGGACTCTA
	CGAAACTAGGATCGATCTGTCGCAGCTGGGTGGCGATTGATAG
	TCTAGCCATCACATTTAAAAGCATCTCAGCCTACCATGAGAAT
	AAGAGAAAGAAAATGAAGATCAATAGCTTATTCATCTCTTTTT
	CTTTTTCGTTGGTGTAAAGCCAACACCCTGTCTAAAAAACATA
	AATTTCTTTAATCATTTTGCCTCTTTTCTCTGTGCTTCAATTAAT
	AAAAAATGGAAAGAACCTCGAG
Cas9	GGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT	49
transcript	GTGTCGTTGCAGGCCTTATTCGGATCCGCCACCATGCCTAAGA
comprising	AAAAGCGGAAGGTCGACGGGGATAAGAAGTACTCAATCGGGC
Kozak	TGGATATCGGAACTAATTCCGTGGGTTGGGCAGTGATCACGGA
sequence	TGAATACAAAGTGCCGTCCAAGAAGTTCAAGGTCCTGGGGAA
with Cas9	CACCGATAGACACAGCATCAAGAAAAATCTCATCGGAGCCCT
ORF using	GCTGTTTGACTCCGGCGAAACCGCAGAAGCGACCCGGCTCAA
codons with	ACGTACCGCGAGGCGACGCTACACCCGGCGGAAGAATCGCAT
generally	CTGCTATCTGCAAGAGATCTTTTCGAACGAAATGGCAAAGGTC
high	GACGACAGCTTCTTCCACCGCCTGGAAGAATCTTTCCTGGTGG
expression in	AGGAGGACAAGAAGCATGAACGGCATCCTATCTTTGGAAACA
humans	TCGTCGACGAAGTGGCGTACCACGAAAAGTACCCGACCATCT
	ACCATCTGCGGAAGAAGTTGGTTGACTCAACTGACAAGGCCG
	ACCTCAGATTGATCTACTTGGCCCTCGCCCATATGATCAAATT
	CCGCGGACACTTCCTGATCGAAGGCGATCTGAACCCTGATAAC
	TCCGACGTGGATAAGCTTTTCATTCAACTGGTGCAGACCTACA
	ACCAACTGTTCGAAGAAAACCCAATCAATGCTAGCGGCGTCG
	ATGCCAAGGCCATCCTGTCCGCCCGGCTGTCGAAGTCGCGGCG
	CCTCGAAAACCTGATCGCACAGCTGCCGGGAGAGAAAAAGAA
	CGGACTTTTCGGCAACTTGATCGCTCTCTCACTGGGACTCACTC
	CCAATTTCAAGTCCAATTTTGACCTGGCCGAGGACGCGAAGCT
	GCAACTCTCAAAGGACACCTACGACGACGACTTGGACAATTTG
	CTGGCACAAATTGGCGATCAGTACGCGGATCTGTTCCTTGCCG
	CTAAGAACCTTTCGGACGCAATCTTGCTGTCCGATATCCTGCG
	CGTGAACACCGAAATAACCAAAGCGCCGCTTAGCGCCTCGAT
	GATTAAGCGGTACGACGAGCATCACCAGGATCTCACGCTGCTC
	AAAGCGCTCGTGAGACAGCAACTGCCTGAAAAGTACAAGGAG
	ATCTTCTTCGACCAGTCCAAGAATGGGTACGCAGGGTACATCG
	ATGGAGGCGCTAGCCAGGAAGAGTTCTATAAGTTCATCAAGC
	CAATCCTGGAAAAGATGGACGGAACCGAAGAACTGCTGGTCA
	AGCTGAACAGGGAGGATCTGCTCCGGAAACAGAGAACCTTTG
	ACAACGGATCCATTCCCCACCAGATCCATCTGGGTGAGCTGCA
	CGCCATCTTGCGGCGCCAGGAGGACTTTTACCCATTCCTCAAG
	GACAACCGGGAAAAGATCGAGAAAATTCTGACGTTCCGCATC
	CCGTATrACGTGGGCCCACTGGCGCGCGGCAATTCGCGCTTCG
	CGTGGATGACTAGAAAATCAGAGGAAACCATCACTCCTTGGA
	ATTTCGAGGAAGTTGTGGATAAGGGAGCTTCGGCACAAAGCTT
	CATCGAACGAATGACCAACTTCGACAAGAATCTCCCAAACGA
	GAAGGTGCTTCCTAAGCACAGCCTCCTTTACGAATACTTCACT
	GTCTACAACGAACTGACTAAAGTGAAATACGTTACTGAAGGA
	ATGAGGAAGCCGGCCTTTCTGTCCGGAGAACAGAAGAAAGCA
	ATTGTCGATCTGCTGTTCAAGACCAACCGCAAGGTGACCGTCA
	AGCAGCTTAAAGAGGACTACTTCAAGAAGATCGAGTGTTTCG
	ACTCAGTGGAAATCAGCGGGGTGGAGGACAGATTCAACGCTT
	CGCTGGGAACCTATCATGATCTCCTGAAGATCATCAAGGACAA
	GGACTTCCTTGACAACGAGGAGAACGAGGACATCCTGGAAGA
	TATCGTCCTGACCTTGACCCTTTTCGAGGATCGCGAGATGATC
	GAGGAGAGGCTTAAGACCTACGCTCATCTCTTCGACGATAAGG
	TCATGAAACAACTCAAGCGCCGCCGGTACACTGGTTGGGGCC
	GCCTCTCCCGCAAGCTGATCAACGGTATTCGCGATAAACAGAG
	CGGTAAAACTATCCTGGATTTCCTCAAATCGGATGGCTTCGCT
	AATCGTAACTTCATGCAATTGATCCACGACGACAGCCTGACCT
	TTAAGGAGGACATCCAAAAAGCACAAGTGTCCGGACAGGGAG
	ACTCACTCCATGAACACATCGCGAATCTGGCCGGTTCGCCGGC
	GATTAAGAAGGGAATTCTGCAAACTGTGAAGGTGGTCGACGA
	GCTGGTGAAGGTCATGGGACGGCACAAACCGGAGAATATCGT
	GATTGAAATGGCCCGAGAAAACCAGACTACCCAGAAGGGCCA
	GAAAAACTCCCGCGAAAGGATGAAGCGGATCGAAGAAGGAAT
	CAAGGAGCTGGGCAGCCAGATCCTGAAAGAGCACCCGGTGGA
	AAACACGCAGCTGCAGAACGAGAAGCTCTACCTGTACTATTTG
	CAAAATGGACGGGACATGTACGTGGACCAAGAGCTGGACATC
	AATCGGTTGTCTGATTACGACGTGGACCACATCGTTCCACAGT
	CCTTTCTGAAGGATGACTCGATCGATAACAAGGTGTTGACTCG
	CAGCGACAAGAACAGAGGGAAGTCAGATAATGTGCCATCGGA
	GGAGGTCGTGAAGAAGATGAAGAATTACTGGCGGCAGCTCCT
	GAATGCGAAGCTGATTACCCAGAGAAAGTTTGACAATCTCACT
	AAAGCCGAGCGCGGCGGACTCTCAGAGCTGGATAAGGCTGGA
	TTCATCAAACGGCAGCTGGTCGAGACTCGGCAGATTACCAAGC
	ACGTGGCGCAGATCTTGGACTCCCGCATGAACACTAAATACGA
	CGAGAACGATAAGCTCATCCGGGAAGTGAAGGTGATTACCCT
	GAAAAGCAAACTTGTGTCGGACTTTCGGAAGGACTTTCAGTTT
	TACAAAGTGAGAGAAATCAACAACTACCATCACGCGCATGAC
	GCATACCTCAACGCTGTGGTCGGTACCGCCCTGATCAAAAAGT
	ACCCTAAACTTGAATCGGAGTTTGTGTACGGAGACTACAAGGT
	CTACGACGTGAGGAAGATGATAGCCAAGTCCGAACAGGAAAT
	CGGGAAAGCAACTGCGAAATACTTCTTTTACTCAAACATCATG
	AACTTTTTCAAGACTGAAATTACGCTGGCCAATGGAGAAATCA
	GGAAGAGGCCACTGATCGAAACTAACGGAGAAACGGGCGAA
	ATCGTGTGGGACAAGGGCAGGGACTTCGCAACTGTTCGCAAA
	GTGCTCTCTATGCCGCAAGTCAATATTGTGAAGAAAACCGAAG
	TGCAAACCGGCGGATTTTCAAAGGAATCGATCCTCCCAAAGA
	GAAATAGCGACAAGCTCATTGCACGCAAGAAAGACTGGGACC
	CGAAGAAGTACGGAGGATTCGATTCGCCGACTGTCGCATACTC
	CGTCCTCGTGGTGOCCAAGGTGGAGAAGGGAAAGAGCAAAAA
	GCTCAAATCCGTCAAAGAGCTGCTGGGGATTACCATCATGGAA
	CGATCCTCGTTCGAGAAGAACCCGATTGATTTCCTCGAGGCGA
	AGGGTTACAAGGAGGTGAAGAAGGATCTGATCATCAAACTCC
	CCAAGTACTCACTGTTCGAACTGGAAAATGGTCGGAAGCGCAT
	GCTGGCTTCGGCCGGAGAACTCCAAAAAGGAAATGAGCTGGC
	CTTGCCTAGCAAGTACGTCAACTTCCTCTATCTTGCTTCGCACT
	ACGAAAAACTCAAAGGGTCACCGGAAGATAACGAACAGAAGC
	AGCTTTTCGTGGAGCAGCACAAGCATTATCTGGATGAAATCAT
	CGAACAAATCTCCGAGTTTTCAAAGCGCGTGATCCTCGCCGAC
	GCCAACCTCGACAAAGTCCTGTCGGCCTACAATAAGCATAGA
	GATAAGCCGATCAGAGAACAGGCCGAGAACATTATCCACTTG
	TTCACCCTGACTAACCTGGGAGCCCCAGCCGCCTTCAAGTACT
	TCGATACTACTATCGATCGCAAAAGATACACGTCCACCAAGGA
	AGTTCTGGACGCGACCCTGATCCACCAAAGCATCACTGGACTC
	TACGAAACTAGGATCGATCTGTCGCAGCTGGGTGGCGATTGAT
	AGTCTAGCCATCACATTTAAAAGCATCTCAGCCTACCATGAGA
	ATAAGAGAAAGAAAATGAAGATCAATAGCTTATTCATCTCTTT
	TTCTTTTTCGTTGGTGTAAAGCCAACACCCTGTCTAAAAAACA
	TAAATTTCTTTAATCATTTTGCCTCTTTTCTCTGTGCTTCAATTA
	ATAAAAAATGGAAAGAACCTCGAG
Cas9 ORF	ATGGACAAGAAGTACAGCATCGGACTGGACATCGGAACAAAC	50
with splice	AGCGTCGGATGGGCAGTCATCACAGACGAATACAAGGTCCCG
junctions	AGCAAGAAGTTCAAGGTCCTGGGAAACACAGACAGACACAGC
removed;	ATCAAGAAGAACCTGATCGGAGCACTGCTGTTCGACAGCGGA
12.75% U	GAAACAGCAGAAGCAACAAGACTGAAGAGAACAGCAAGAAG
content	AAGATACACAAGAAGAAAGAACAGAATCTGCTACCTGCAGGA
	AATCTTCAGCAACGAAATGGCAAAGGTCGACGACAGCTTCTTC
	CACcggCTGGAAGAAAGCTTCCTGGTCGAAGAAGACAAGAAGC
	ACGAAAGACACCCGATCTTCGGAAACATCGTCGACGAAGTCG
	CATACCACGAAAAGTACCCGACAATCTACCACCTGAGAAAGA
	AGCTGGTCGACAGCACAGACAAGGCAGACCTGAGACTGATCT
	ACCTGGCACTGGCACACATGATCAAGTTCAGAGGACACTTCCT
	GATCGAAGGAGACCTGAACCCGGACAACAGCGACGTCGACAA
	GCTGTTCATCCAGCTGGTCCAGACATACAACCAGCTGTTCGAA
	GAAAACCCGATCAACGCAAGCGGAGTCGACGCAAAGGCAATC
	CTGAGCGCAAGACTGAGCAAGAGCAGAAGACTGGAAAACCTG
	ATCGCACAGCTGCCGGGAGAAAAGAAGAACGGACTGTTCGGA
	AACCTGATCGCACTGAGCCTGGGACTGACACCGAACTTCAAG
	AGCAACTTCGACCTGGCAGAAGACGCAAAGCTGCAGCTGAGC
	AAGGACACATACGACGACGACCTGGACAACCTGCTGGCACAG
	ATCGGAGACCAGTACGCAGACCTGTTCCTGGCAGCAAAGAAC
	CTGAGCGACGCAATCCTGCTGAGCGACATCCTGAGAGTCAAC
	ACAGAAATCACAAAGGCACCGCTGAGCGCAAGCATGATCAAG
	AGATACGACGAACACCACCAGGACCTGACACTGCTGAAGGCA
	CTGGTCAGACAGCAGCTGCCGGAAAAGTACAAGGAAATCTTC
	TTCGACCAGAGCAAGAACGGATACGCAGGATACATCGACGGA
	GGAGCAAGCCAGGAAGAATTCTACAAGTTCATCAAGCCGATC
	CTGGAAAAGATGGACGGAACAGAAGAACTGCTGGTCAAGCTG
	AACAGAGAAGACCTGCTGAGAAAGCAGAGAACATTCGACAAC
	GGAAGCATCCCGCACCAGATCCACCTGGGAGAACTGCACGCA
	ATCCTGAGAAGACAGGAAGACTTCTACCCGTTCCTGAAGGAC
	AACAGAGAAAAGATCGAAAAGATCCTGACATTCAGAATCCCG
	TACTACGTCGGACCGCTGGCAAGAGGAAACAGCAGATTCGCA
	TGGATGACAAGAAAGAGCGAAGAAACAATCACACCGTGGAAC
	TTCGAAGAAGTCGTCGACAAGGGAGCAAGCGCACAGAGCTTC
	ATCGAAAGAATGACAAACTTCGACAAGAACCTGCCGAACGAA
	AAGGTCCTGCCGAAGCACAGCCTGCTGTACGAATACTTCACAG
	TCTACAACGAACTGACAAAGGTCAAGTACGTCACAGAAGGAA
	TGAGAAAGCCGGCATTCCTGAGCGGAGAACAGAAGAAGGCAA
	TCGTCGACCTGCTGTTCAAGACAAACAGAAAGGTCACAGTCA
	AGCAGCTGAAGGAAGACTACTTCAAGAAGATCGAATGCTTCG
	ACAGCGTCGAAATCAGCGGAGTCGAAGACAGATTCAACGCAA
	GCCTGGGAACATACCACGACCTGCTGAAGATCATCAAGGACA
	AGGACITCCTGGACAACGAAGAAAACGAAGACATCCTGGAAG
	ACATCGTCCTGACACTGACACTGTTCGAAGACAGAGAAATGAT
	CGAAGAAAGACTGAAGACATACGCACACCTGTTCGACGACAA
	GGTCATGAAGCAGCTGAAGAGAAGAAGATACACAGGATGGGG
	AAGACTGAGCAGAAAGCTGATCAACGGAATCAGAGACAAGCA
	GAGCGGAAAGACAATCCTGGACTTCCTGAAGAGCGACGGATT
	CGCAAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCT
	GACATTCAAGGAAGACATCCAGAAGGCACAGGTCAGCGGACA
	GGGAGACAGCCTGCACGAACACATCGCAAACCTGGCAGGAAG
	CCCGGCAATCAAGAAGGGAATCCTGCAGACAGTCAAGGTCGT
	CGACGAACTGGTCAAGGTCATGGGAAGACACAAGCCGGAAAA
	CATCGTCATCGAAATGGCAAGAGAAAACCAGACAACACAGAA
	GGGACAGAAGAACAGCAGAGAAAGAATGAAGAGAATCGAAG
	AAGGAATCAAGGAACTGGGAAGCCAGATCCTGAAGGAACACC
	CGGTCGAAAACACACAGCTGCAGAACGAAAAGCTGTACCTGT
	ACTACCTGCAaAACGGAAGAGACATGTACGTCGACCAGGAACT
	GGACATCAACAGACTGAGCGACTACGACGTCGACCACATCGT
	CCCGCAGAGCTTCCTGAAGGACGACAGCATCGACAACAAGGT
	CCTGACAAGAAGCGACAAGAACAGAGGAAAGAGCGACAACG
	TCCCGAGCGAAGAAGTCGTCAAGAAGATGAAGAACTACTGGA
	GACAGCTGCTGAACGCAAAGCTGATCACACAGAGAAAGTTCG
	ACAACCTGACAAAGGCAGAGAGAGGAGGACTGAGCGAACTG
	GACAAGGCAGGATTCATCAAGAGACAGCTGGTCGAAACAAGA
	CAGATCACAAAGCACGTCGCACAGATCCTGGACAGCAGAATG
	AACACAAAGTACGACGAAAACGACAAGCTGATCAGAGAAGTC
	AAGGTCATCACACTGAAGAGCAAGCTGGTCAGCGACTTCAGA
	AAGGACTTCCAGTTCTACAAGGTCAGAGAAATCAACAACTAC
	CACCACGCACACGACGCATACCTGAACGCAGTCGTCGGAACA
	GCACTGATCAAGAAGTACCCGAAGCTGGAAAGCGAATTCGTC
	TACGGAGACTACAAGGTCTACGACGTCAGAAAGATGATCGCA
	AAGAGCGAACAGGAAATCGGAAAGGCAACAGCAAAGTACTTC
	TTCTACAGCAACATCATGAACTTCTTCAAGACAGAAATCACAC
	TGGCAAACGGAGAAATCAGAAAGAGACCGCTGATCGAAACAA
	ACGGAGAAACAGGAGAAATCGTCTGGGACAAGGGAAGAGAC
	TTCGCAACAGTCAGAAAGGTCCTGAGCATGCCGCAGGTCAAC
	ATCGTCAAGAAGACAGAAGTCCAGACAGGAGGATTCAGCAAG
	GAAAGCATCCTGCCGAAGAGAAACAGCGACAAGCTGATCGCA
	AGAAAGAAGGACTGGGACCCGAAGAAGTACGGAGGATTCGAC
	AGCCCGACAGTCGCATACAGCGTCCTGGTCGTCGCAAAGGTCG
	AAAAGGGAAAGAGCAAGAAGCTGAAGAGCGTCAAGGAACTG
	CTGGGAATCACAATCATGGAAAGAAGCAGCTTCGAAAAGAAC
	CCGATCGACTTCCTGGAAGCAAAGGGATACAAGGAAGTCAAG
	AAGGACCTGATCATCAAGCTGCCGAAGTACAGCCTGTTCGAAC
	TGGAAAACGGAAGAAAGAGAATGCTGGCAAGCGCAGGAGAA
	CTGCAGAAGGGAAACGAACTGGCACTGCCGAGCAAGTACGTC
	AACTTCCTGTACCTGGCAAGCCACTACGAAAAGCTGAAGGGA
	AGCCCGGAAGACAACGAACAGAAGCAGCTGTTCGTCGAACAG
	CACAAGCACTACCTGGACGAAATCATCGAACAGATCAGCGAA
	TTCAGCAAGAGAGTCATCCTGGCAGACGCAAACCTGGACAAG
	GTCCTGAGCGCATACAACAAGCACAGAGACAAGCCGATCAGA
	GAACAGGCAGAAAACATCATCCACCTGTTCACACTGACAAAC
	CTGGGAGCACCGGCAGCATTCAAGTACTTCGACACAACAATC
	GACAGAAAGAGATACACAAGCACAAAGGAAGTCCTGGACGCA
	ACACTGATCCACCAGAGCATCACAGGACTGTACGAAACAAGA
	ATCGACCTGAGCCAGCTGGGAGGAGACGGAGGAGGAAGCCCG
	AAGAAGAAGAGAAAGGTCTAG
Cas9	GGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT	51
transcript	GTGTCGTTGCAGGCCTTATTCGGATCCGCCACCATGGACAAGA
with 5′ UTR	AGTACAGCATCGGACTGGACATCGGAACAAACAGCGTCGGAT
ofHSD.	GGGCAGTCATCACAGACGAATACAAGGTCCCGAGCAAGAAGT
ORF	TCAAGGTCCTGGGAAACACAGACAGACACAGCATCAAGAAGA
corresponding	ACCTGATCGGAGCACTGCTGTTCGACAGCGGAGAAACAGCAG
to SEQ	AAGCAACAAGACTGAAGAGAACAGCAAGAAGAAGATACACA
ID NO: 50,	AGAAGAAAGAACAGAATCTGCTACCTGCAGGAAATCTTCAGC
Kozak	AACGAAATGGCAAAGGTCGACGACAGCTTCTTCCACcggCTGG
sequence,	AAGAAAGCTTCCTGGTCGAAGAAGACAAGAAGCACGAAAGAC
and 3′ UTR	ACCCGATCTTCGGAAACATCGTCGACGAAGTCGCATACCACGA
of ALB	AAAGTACCCGACAATCTACCACCTGAGAAAGAAGCTGGTCGA
	CAGCACAGACAAGGCAGACCTGAGACTGATCTACCTGGCACT
	GGCACACATGATCAAGTTCAGAGGACACTTCCTGATCGAAGG
	AGACCTGAACCCGGACAACAGCGACGTCGACAAGCTGTTCAT
	CCAGCTGGTCCAGACATACAACCAGCTGTTCGAAGAAAACCC
	GATCAACGCAAGCGGAGTCGACGCAAAGGCAATCCTGAGCGC
	AAGACTGAGCAAGAGCAGAAGACTGGAAAACCTGATCGCACA
	GCTGCCGGGAGAAAAGAAGAACGGACTGTTCGGAAACCTGAT
	CGCACTGAGCCTGGGACTGACACCGAACTTCAAGAGCAACTTC
	GACCTGGCAGAAGACGCAAAGCTGCAGCTGAGCAAGGACACA
	TACGACGACGACCTGGACAACCTGCTGGCACAGATCGGAGAC
	CAGTACGCAGACCTGTTCCTGGCAGCAAAGAACCTGAGCGAC
	GCAATCCTGCTGAGCGACATCCTGAGAGTCAACACAGAAATC
	ACAAAGGCACCGCTGAGCGCAAGCATGATCAAGAGATACGAC
	GAACACCACCAGGACCTGACACTGCTGAAGGCACTGGTCAGA
	CAGCAGCTGCCGGAAAAGTACAAGGAAATCTTCTTCGACCAG
	AGCAAGAACGGATACGCAGGATACATCGACGGAGOAGCAAGC
	CAGGAAGAATTCTACAAGTTCATCAAGCCGATCCTGGAAAAG
	ATGGACGGAACAGAAGAACTGCTGGTCAAGCTGAACAGAGAA
	GACCTGCTGAGAAAGCAGAGAACATTCGACAACGGAAGCATC
	CCGCACCAGATCCACCTGGGAGAACTGCACGCAATCCTGAGA
	AGACAGGAAGACTTCTACCCGTTCCTGAAGGACAACAGAGAA
	AAGATCGAAAAGATCCTGACATTCAGAATCCCGTACTACGTCG
	GACCGCTGGCAAGAGGAAACAGCAGATTCGCATGGATGACAA
	GAAAGAGCGAAGAAACAATCACACCGTGGAACTTCGAAGAAG
	TCGTCGACAAGGGAGCAAGCGCACAGAGCTTCATCGAAAGAA
	TGACAAACTTCGACAAGAACCTGCCGAACGAAAAGGTCCTGC
	CGAAGCACAGCCTGCTGTACGAATACTTCACAGTCTACAACGA
	ACTGACAAAGGTCAAGTACGTCACAGAAGGAATGAGAAAGCC
	GGCATTCCTGAGCGGAGAACAGAAGAAGGCAATCGTCGACCT
	GCTGTTCAAGACAAACAGAAAGGTCACAGTCAAGCAGCTGAA
	GGAAGACTACTTCAAGAAGATCGAATGCTTCGACAGCGTCGA
	AATCAGCGGAGTCGAAGACAGATTCAACGCAAGCCTGGGAAC
	ATACCACGACCTGCTGAAGATCATCAAGGACAAGGACTTCCTG
	GACAACGAAGAAAACGAAGACATCCTGGAAGACATCGTCCTG
	ACACTGACACTGTTCGAAGACAGAGAAATGATCGAAGAAAGA
	CTGAAGACATACGCACACCTGTTCGACGACAAGGTCATGAAG
	CAGCTGAAGAGAAGAAGATACACAGGATGGGGAAGACTGAG
	CAGAAAGCTGATCAACGGAATCAGAGACAAGCAGAGCGGAA
	AGACAATCCTGGACTTCCTGAAGAGCGACGGATTCGCAAACA
	GAAACTTCATGCAGCTGATCCACGACGACAGCCTGACATTCAA
	GGAAGACATCCAGAAGGCACAGGTCAGCGGACAGGGAGACA
	GCCTGCACGAACACATCGCAAACCTGGCAGGAAGCCCGGCAA
	TCAAGAAGGGAATCCTGCAGACAGTCAAGGTCGTCGACGAAC
	TGGTCAAGGTCATGGGAAGACACAAGCCGGAAAACATCGTCA
	TCGAAATGGCAAGAGAAAACCAGACAACACAGAAGGGACAG
	AAGAACAGCAGAGAAAGAATGAAGAGAATCGAAGAAGGAAT
	CAAGGAACTGGGAAGCCAGATCCTGAAGGAACACCCGGTCGA
	AAACACACAGCTGCAGAACGAAAAGCTGTACCTGTACTACCT
	GCAaAACGGAAGAGACATGTACGTCGACCAGGAACTGGACAT
	CAACAGACTGAGCGACTACGACGTCGACCACATCGTCCCGCA
	GAGCTTCCTGAAGGACGACAGCATCGACAACAAGGTCCTGAC
	AAGAAGCGACAAGAACAGAGGAAAGAGCGACAACGTCCCGA
	GCGAAGAAGTCGTCAAGAAGATGAAGAACTACTGGAGACAGC
	TGCTGAACGCAAAGCTGATCACACAGAGAAAGTTCGACAACC
	TGACAAAGGCAGAGAGAGGAGGACTGAGCGAACTGGACAAG
	GCAGGATTCATCAAGAGACAGCTGGTCGAAACAAGACAGATC
	ACAAAGCACGTCGCACAGATCCTGGACAGCAGAATGAACACA
	AAGTACGACGAAAACGACAAGCTGATCAGAGAAGTCAAGGTC
	ATCACACTGAAGAGCAAGCTGGTCAGCGACTTCAGAAAGGAC
	TTCCAGTTCTACAAGGTCAGAGAAATCAACAACTACCACCACG
	CACACGACGCATACCTGAACGCAGTCGTCGGAACAGCACTGA
	TCAAGAAGTACCCGAAGCTGGAAAGCGAATTCGTCTACGGAG
	ACTACAAGGTCTACGACGTCAGAAAGATGATCGCAAAGAGCG
	AACAGGAAATCGGAAAGGCAACAGCAAAGTACTTCTTCTACA
	GCAACATCATGAACTTCTTCAAGACAGAAATCACACTGGCAA
	ACGGAGAAATCAGAAAGAGACCGCTGATCGAAACAAACGGA
	GAAACAGGAGAAATCGTCTGGGACAAGGGAAGAGACTTCGCA
	ACAGTCAGAAAGGTCCTGAGCATGCCGCAGGTCAACATCGTC
	AAGAAGACAGAAGTCCAGACAGGAGGATTCAGCAAGGAAAG
	CATCCTGCCGAAGAGAAACAGCGACAAGCTGATCGCAAGAAA
	GAAGGACTGGGACCCGAAGAAGTACGGAGGATTCGACAGCCC
	GACAGTCGCATACAGCGTCCTGGTCGTCGCAAAGGTCGAAAA
	GGGAAAGAGCAAGAAGCTGAAGAGCGTCAAGGAACTGCTGG
	GAATCACAATCATGGAAAGAAGCAGCTTCGAAAAGAACCCGA
	TCGACTTCCTGGAAGCAAAGGGATACAAGGAAGTCAAGAAGG
	ACCTGATCATCAAGCTGCCGAAGTACAGCCTGTTCGAACTGGA
	AAACGGAAGAAAGAGAATGCTGGCAAGCGCAGGAGAACTGC
	AGAAGGGAAACGAACTGGCACTGCCGAGCAAGTACGTCAACT
	TCCTGTACCTGGCAAGCCACTACGAAAAGCTGAAGGGAAGCC
	CGGAAGACAACGAACAGAAGCAGCTGTTCGTCGAACAGCACA
	AGCACTACCTGGACGAAATCATCGAACAGATCAGCGAATTCA
	GCAAGAGAGTCATCCTGGCAGACGCAAACCTGGACAAGGTCC
	TGAGCGCATACAACAAGCACAGAGACAAGCCGATCAGAGAAC
	AGGCAGAAAACATCATCCACCTGTTCACACTGACAAACCTGG
	GAGCACCGGCAGCATTCAAGTACTTCGACACAACAATCGACA
	GAAAGAGATACACAAGCACAAAGGAAGTCCTGGACGCAACAC
	TGATCCACCAGAGCATCACAGGACTGTACGAAACAAGAATCG
	ACCTGAGCCAGCTGGGAGGAGACGGAGGAGGAAGCCCGAAG
	AAGAAGAGAAAGGTCTAGCTAGCCATCACATTTAAAAGCATC
	TCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAT
	AGCTTATTCATCTCTTTTTCTTTTTCGTTGGTGTAAAGCCAACA
	CCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCTCTTT
	TCTCTGTGCTTCAATTAATAAAAAATGGAAAGAACCTCGAG
Cas9 ORF	ATGGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAAC	52
with	AGCGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCC
minimal	AGCAAGAAGTTCAAGGTGCTGGGCAACACCGACAGACACAGC
uridine	ATCAAGAAGAACCTGATCGGCGCCCTGCTGTTCGACAGCGGC
codons	GAGACCGCCGAGGCCACCAGACTGAAGAGAACCGCCAGAAGA
frequently	AGATACACCAGAAGAAAGAACAGAATCTGCTACCTGCAGGAG
used in	ATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCC
humans in	ACAGACTGGAGGAGAGCTTCCTGGTGGAGGAGGACAAGAAGC
general;	ACGAGAGACACCCCATCTTCGGCAACATCGTGGACGAGGTGG
12.75% U	CCTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGA
content	AGCTGGTGGACAGCACCGACAAGGCCGACCTGAGACTGATCT
	ACCTGGCCCTGGCCCACATGATCAAGTTCAGAGGCCACTTCCT
	GATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAA
	GCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAG
	GAGAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATC
	CTGAGCGCCAGACTGAGCAAGAGCAGAAGACTGGAGAACCTG
	ATCGCCCAGCTGCCCGGCGAGAAGAAGAACGGCCTGTTCGGC
	AACCTGATCGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGA
	GCAACTTCGACCTGGCCGAGGACGCCAAGCTGCAGCTGAGCA
	AGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGA
	TCGGCGACCAGTACGCCGACCTGTTCCTGGCCGCCAAGAACCT
	GAGCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACAC
	CGAGATCACCAAGGCCCCCCTGAGCGCCAGCATGATCAAGAG
	ATACGACGAGCACCACCAGGACCTGACCCTGCTGAAGGCCCT
	GGTGAGACAGCAGCTGCCCGAGAAGTACAAGGAGATCTTCTT
	CGACCAGAGCAAGAACGGCTACGCCGGCTACATCGACGGCGG
	CGCCAGCCAGGAGGAGTTCTACAAGTTCATCAAGCCCATCCTG
	GAGAAGATGGACGGCACCGAGGAGCTGCTGGTGAAGCTGAAC
	AGAGAGGACCTGCTGAGAAAGCAGAGAACCTTCGACAACGGC
	AGCATCCCCCACCAGATCCACCTGGGCGAGCTGCACGCCATCC
	TGAGAAGACAGGAGGACTTCTACCCCTTCCTGAAGGACAACA
	GAGAGAAGATCGAGAAGATCCTGACCTTCAGAATCCCCTACT
	ACGTGGGCCCCCTGGCCAGAGGCAACAGCAGATTCGCCTGGA
	TGACCAGAAAGAGCGAGGAGACCATCACCCCCTGGAACTTCG
	AGGAGGTGGTGGACAAGGGCGCCAGCGCCCAGAGCTTCATCG
	AGAGAATGACCAACTTCGACAAGAACCTGCCCAACGAGAAGG
	TGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTA
	CAACGAGCTGACCAAGGTGAAGTACGTGACCGAGGGCATGAG
	AAAGCCCGCCTTCCTGAGCGGCGAGCAGAAGAAGGCCATCGT
	GGACCTGCTGTTCAAGACCAACAGAAAGGTGACCGTGAAGCA
	GCTGAAGGAGGACTACTTCAAGAAGATCGAGTGCTTCGACAG
	CGTGGAGATCAGCGGCGTGGAGGACAGATTCAACGCCAGCCT
	GGGCACCTACCACGACCTGCTGAAGATCATCAAGGACAAGGA
	CTTCCTGGACAACGAGGAGAACGAGGACATCCTGGAGGACAT
	CGTGCTGACCCTGACCCTGTTCGAGGACAGAGAGATGATCGA
	GGAGAGACTGAAGACCTACGCCCACCTGTTCGACGACAAGGT
	GATGAAGCAGCTGAAGAGAAGAAGATACACCGGCTGGGGCAG
	ACTGAGCAGAAAGCTGATCAACGGCATCAGAGACAAGCAGAG
	CGGCAAGACCATCCTGGACTTCCTGAAGAGCGACGGCTTCGCC
	AACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCT
	TCAAGGAGGACATCCAGAAGGCCCAGGTGAGCGGCCAGGGCG
	ACAGCCTGCACGAGCACATCGCCAACCTGGCCGGCAGCCCCG
	CCATCAAGAAGGGCATCCTGCAGACCGTGAAGGTGGTGGACG
	AGCTGGTGAAGGTGATGGGCAGACACAAGCCCGAGAACATCG
	TGATCGAGATGGCCAGAGAGAACCAGACCACCCAGAAGGGCC
	AGAAGAACAGCAGAGAGAGAATGAAGAGAATCGAGGAGGGC
	ATCAAGGAGCTGGGCAGCCAGATCCTGAAGGAGCACCCCGTG
	GAGAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTAC
	CTGCAGAACGGCAGAGACATGTACGTGGACCAGGAGCTGGAC
	ATCAACAGACTGAGCGACTACGACGTGGACCACATCGTGCCC
	CAGAGCTTCCTGAAGGACGACAGCATCGACAACAAGGTGCTG
	ACCAGAAGCGACAAGAACAGAGGCAAGAGCGACAACGTGCC
	CAGCGAGGAGGTGGTGAAGAAGATGAAGAACTACTGGAGACA
	GCTGCTGAACGCCAAGCTGATCACCCAGAGAAAGTTCGACAA
	CCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAGCTGGACAA
	GGCCGGCTTCATCAAGAGACAGCTGGTGGAGACCAGACAGAT
	CACCAAGCACGTGGCCCAGATCCTGGACAGCAGAATGAACAC
	CAAGTACGACGAGAACGACAAGCTGATCAGAGAGGTGAAGGT
	GATCACCCTGAAGAGCAAGCTGGTGAGCGACTTCAGAAAGGA
	CTTCCAGTTCTACAAGGTGAGAGAGATCAACAACTACCACCAC
	GCCCACGACGCCTACCTGAACGCCGTGGTGGGCACCGCCCTGA
	TCAAGAAGTACCCCAAGCTGGAGAGCGAGTTCGTGTACGGCG
	ACTACAAGGTGTACGACGTGAGAAAGATGATCGCCAAGAGCG
	AGCAGGAGATCGGCAAGGCCACCGCCAAGTACTTCTTCTACA
	GCAACATCATGAACTTCTTCAAGACCGAGATCACCCTGGCCAA
	CGGCGAGATCAGAAAGAGACCCCTGATCGAGACCAACGGCGA
	GACCGGCGAGATCGTGTGGGACAAGGGCAGAGACTTCGCCAC
	CGTGAGAAAGGTGCTGAGCATGCCCCAGGTGAACATCGTGAA
	GAAGACCGAGGTGCAGACCGGCGGCTTCAGCAAGGAGAGCAT
	CCTGCCCAAGAGAAACAGCGACAAGCTGATCGCCAGAAAGAA
	GGACTGGGACCCCAAGAAGTACGGCGGCTTCGACAGCCCCAC
	CGTGGCCTACAGCGTGCTGGTGGTGGCCAAGGTGGAGAAGGG
	CAAGAGCAAGAAGCTGAAGAGCGTGAAGGAGCTGCTGGGCAT
	CACCATCATGGAGAGAAGCAGCTTCGAGAAGAACCCCATCGA
	CTTCCTGGAGGCCAAGGGCTACAAGGAGGTGAAGAAGGACCT
	GATCATCAAGCTGCCCAAGTACAGCCTGTTCGAGCTGGAGAAC
	GGCAGAAAGAGAATGCTGGCCAGCGCCGGCGAGCTGCAGAAG
	GGCAACGAGCTGGCCCTGCCCAGCAAGTACGTGAACTTCCTGT
	ACCTGGCCAGCCACTACGAGAAGCTGAAGGGCAGCCCCGAGG
	ACAACGAGCAGAAGCAGCTGTTCGTGGAGCAGCACAAGCACT
	ACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCAGCAAGA
	GAGTGATCCTGGCCGACGCCAACCTGGACAAGGTGCTGAGCG
	CCTACAACAAGCACAGAGACAAGCCCATCAGAGAGCAGGCCG
	AGAACATCATCCACCTGTTCACCCTGACCAACCTGGGCGCCCC
	CGCCGCCTTCAAGTACTTCGACACCACCATCGACAGAAAGAG
	ATACACCAGCACCAAGGAGGTGCTGGACGCCACCCTGATCCA
	CCAGAGCATCACCGGCCTGTACGAGACCAGAATCGACCTGAG
	CCAGCTGGGCGGCGACGGCGGCGGCAGCCCCAAGAAGAAGAG
	AAAGGTGTGA
Cas9	GGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT	53
transcript	GTGTCGTTGCAGGCCTTATTCGGATCCGCCACCATGGACAAGA
with 5′ UTR	AGTACAGCATCGGCCTGGACATCGGCACCAACAGCGTGGGCT
of HSD,	GGGCCGTGATCACCGACGAGTACAAGGTGCCCAGCAAGAAGT
ORF	TCAAGGTGCTGGGCAACACCGACAGACACAGCATCAAGAAGA
corresponding	ACCTGATCGGCGCCCTGCTGTTCGACAGCGGCGAGACCGCCGA
to SEQ	GGCCACCAGACTGAAGAGAACCGCCAGAAGAAGATACACCAG
ID NO: 52,	AAGAAAGAACAGAATCTGCTACCTGCAGGAGATCTTCAGCAA
Kozak	CGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGA
sequence,	GGAGAGCTTCCTGGTGGAGGAGGACAAGAAGCACGAGAGACA
and 3′ UTR	CCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAG
of ALB	AAGTACCCCACCATCTACCACCTGAGAAAGAAGCTGGTGGAC
	AGCACCGACAAGGCCGACCTGAGACTGATCTACCTGGCCCTG
	GCCCACATGATCAAGTTCAGAGGCCACTTCCTGATCGAGGGCG
	ACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCC
	AGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAGAACCCCA
	TCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGAGCGCCA
	GACTGAGCAAGAGCAGAAGACTGGAGAACCTGATCGCCCAGC
	TGCCCGGCGAGAAGAAGAACGGCCTGTTCGGCAACCTGATCG
	CCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGA
	CCTGGCCGAGGACGCCAAGCTGCAGCTGAGCAAGGACACCTA
	CGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCA
	GTACGCCGACCTGTTCCTGGCCGCCAAGAACCTGAGCGACGCC
	ATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACC
	AAGGCCCCCCTGAGCGCCAGCATGATCAAGAGATACGACGAG
	CACCACCAGGACCTGACCCTGCTGAAGGCCCTGGTGAGACAG
	CAGCTGCCCGAGAAGTACAAGGAGATCTTCTTCGACCAGAGC
	AAGAACGGCTACGCCGGCTACATCGACGGCGGCGCCAGCCAG
	GAGGAGTTCTACAAGTTCATCAAGCCCATCCTGGAGAAGATG
	GACGGCACCGAGGAGCTGCTGGTGAAGCTGAACAGAGAGGAC
	CTGCTGAGAAAGCAGAGAACCTTCGACAACGGCAGCATCCCC
	CACCAGATCCACCTGGGCGAGCTGCACGCCATCCTGAGAAGA
	CAGGAGGACTTCTACCCCTTCCTGAAGGACAACAGAGAGAAG
	ATCGAGAAGATCCTGACCTTCAGAATCCCCTACTACGTGGGCC
	CCCTGGCCAGAGGCAACAGCAGATTCGCCTGGATGACCAGAA
	AGAGCGAGGAGACCATCACCCCCTGGAACTTCGAGGAGGTGG
	TGGACAAGGGCGCCAGCGCCCAGAGCTTCATCGAGAGAATGA
	CCAACTTCGACAAGAACCTGCCCAACGAGAAGGTGCTGCCCA
	AGCACAGCCTGCTGTACGAGTACTTCACCGTGTACAACGAGCT
	GACCAAGGTGAAGTACGTGACCGAGGGCATGAGAAAGCCCGC
	CTTCCTGAGCGGCGAGCAGAAGAAGGCCATCGTGGACCTGCT
	GTTCAAGACCAACAGAAAGGTGACCGTGAAGCAGCTGAAGGA
	GGACTACTTCAAGAAGATCGAGTGCTTCGACAGCGTGGAGAT
	CAGCGGCGTGGAGGACAGATTCAACGCCAGCCTGGGCACCTA
	CCACGACCTGCTGAAGATCATCAAGGACAAGGACTTCCTGGA
	CAACGAGGAGAACGAGGACATCCTGGAGGACATCGTGCTGAC
	CCTGACCCTGTTCGAGGACAGAGAGATGATCGAGGAGAGACT
	GAAGACCTACGCCCACCTGTTCGACGACAAGGTGATGAAGCA
	GCTGAAGAGAAGAAGATACACCGGCTGGGGCAGACTGAGCAG
	AAAGCTGATCAACGGCATCAGAGACAAGCAGAGCGGCAAGAC
	CATCCTGGACTTCCTGAAGAGCGACGGCTTCGCCAACAGAAAC
	TTCATGCAGCTGATCCACGACGACAGCCTGACCTTCAAGGAGG
	ACATCCAGAAGGCCCAGGTGAGCGGCCAGGGCGACAGCCTGC
	ACGAGCACATCGCCAACCTGGCCGGCAGCCCCGCCATCAAGA
	AGGGCATCCTGCAGACCGTGAAGGTGGTGGACGAGCTGGTGA
	AGGTGATGGGCAGACACAAGCCCGAGAACATCGTGATCGAGA
	TGGCCAGAGAGAACCAGACCACCCAGAAGGGCCAGAAGAAC
	AGCAGAGAGAGAATGAAGAGAATCGAGGAGGGCATCAAGGA
	GCTGGGCAGCCAGATCCTGAAGGAGCACCCCGTGGAGAACAC
	CCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAA
	CGGCAGAGACATGTACGTGGACCAGGAGCTGGACATCAACAG
	ACTGAGCGACTACGACGTGGACCACATCGTGCCCCAGAGCTTC
	CTGAAGGACGACAGCATCGACAACAAGGTGCTGACCAGAAGC
	GACAAGAACAGAGGCAAGAGCGACAACGTGCCCAGCGAGGA
	GGTGGTGAAGAAGATGAAGAACTACTGGAGACAGCTGCTGAA
	CGCCAAGCTGATCACCCAGAGAAAGTTCGACAACCTGACCAA
	GGCCGAGAGAGGCGGCCTGAGCGAGCTGGACAAGGCCGGCTT
	CATCAAGAGACAGCTGGTGGAGACCAGACAGATCACCAAGCA
	CGTGGCCCAGATCCTGGACAGCAGAATGAACACCAAGTACGA
	CGAGAACGACAAGCTGATCAGAGAGGTGAAGGTGATCACCCT
	GAAGAGCAAGCTGGTGAGCGACTTCAGAAAGGACTTCCAGTT
	CTACAAGGTGAGAGAGATCAACAACTACCACCACGCCCACGA
	CGCCTACCTGAACGCCGTGGTGGGCACCGCCCTGATCAAGAA
	GTACCCCAAGCTGGAGAGCGAGTTCGTGTACGGCGACTACAA
	GGTGTACGACGTGAGAAAGATGATCGCCAAGAGCGAGCAGGA
	GATCGGCAAGGCCACCGCCAAGTACTTCTTCTACAGCAACATC
	ATGAACTTCTTCAAGACCGAGATCACCCTGGCCAACGGCGAG
	ATCAGAAAGAGACCCCTGATCGAGACCAACGGCGAGACCGGC
	GAGATCGTGTGGGACAAGGGCAGAGACTTCGCCACCGTGAGA
	AAGGTGCTGAGCATGCCCCAGGTGAACATCGTGAAGAAGACC
	GAGGTGCAGACCGGCGGCTTCAGCAAGGAGAGCATCCTGCCC
	AAGAGAAACAGCGACAAGCTGATCGCCAGAAAGAAGGACTG
	GGACCCCAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGC
	CTACAGCGTGCTGGTGGTGGCCAAGGTGGAGAAGGGCAAGAG
	CAAGAAGCTGAAGAGCGTGAAGGAGCTGCTGGGCATCACCAT
	CATGGAGAGAAGCAGCTTCGAGAAGAACCCCATCGACTTCCT
	GGAGGCCAAGGGCTACAAGGAGGTGAAGAAGGACCTGATCAT
	CAAGCTGCCCAAGTACAGCCTGTTCGAGCTGGAGAACGGCAG
	AAAGAGAATGCTGGCCAGCGCCGGCGAGCTGCAGAAGGGCAA
	CGAGCTGGCCCTGCCCAGCAAGTACGTGAACTTCCTGTACCTG
	GCCAGCCACTACGAGAAGCTGAAGGGCAGCCCCGAGGACAAC
	GAGCAGAAGCAGCTGTTCGTGGAGCAGCACAAGCACTACCTG
	GACGAGATCATCGAGCAGATCAGCGAGTTCAGCAAGAGAGTG
	ATCCTGGCCGACGCCAACCTGGACAAGGTGCTGAGCGCCTAC
	AACAAGCACAGAGACAAGCCCATCAGAGAGCAGGCCGAGAA
	CATCATCCACCTGTTCACCCTGACCAACCTGGGCGCCCCCGCC
	GCCTTCAAGTACTTCGACACCACCATCGACAGAAAGAGATAC
	ACCAGCACCAAGGAGGTGCTGGACGCCACCCTGATCCACCAG
	AGCATCACCGGCCTGTACGAGACCAGAATCGACCTGAGCCAG
	CTGGGCGGCGACGGCGGCGGCAGCCCCAAGAAGAAGAGAAA
	GGTGTGACTAGCCATCACATTTAAAAGCATCTCAGCCTACCAT
	GAGAATAAGAGAAAGAAAATGAAGATCAATAGCTTATTCATC
	TCTTTTTCTTTTTCGTTGGTGTAAAGCCAACACCCTGTCTAAAA
	AACATAAATTTCTTTAATCATTTTGCCTCTTTTCTCTGTGCTTCA
	ATTAATAAAAAATGGAAAGAACCTCGAG
Cas9 ORF	ATGGACAAAAAATACAGCATAGGGCTAGACATAGGGACGAAC	54
with	AGCGTAGGGTGGGCGGTAATAACGGACGAATACAAAGTACCG
minimal	AGCAAAAAATTCAAAGTACTAGGGAACACGGACCGACACAGC
uridine	ATAAAAAAAAACCTAATAGGGGCGCTACTATTCGACAGCGGG
codons	GAAACGGCGGAAGCGACGCGACTAAAACGAACGGCGCGACG
infrequently	ACGATACACGCGACGAAAAAACCGAATATGCTACCTACAAGA
used in	AATATTCAGCAACGAAATGGCGAAAGTAGACGACAGCTTCTT
humans in	CCACCGACTAGAAGAAAGCTTCCTAGTAGAAGAAGACAAAAA
general;	ACACGAACGACACCCGATATTCGGGAACATAGTAGACGAAGT
12.75% U	AGCGTACCACGAAAAATACCCGACGATATACCACCTACGAAA
content	AAAACTAGTAGACAGCACGGACAAAGCGGACCTACGACTAAT
	ATACCTAGCGCTAGCGCACATGATAAAATTCCGAGGGCACTTC
	CTAATAGAAGGGGACCTAAACCCGGACAACAGCGACGTAGAC
	AAACTATTCATACAACTAGTACAAACGTACAACCAACTATTCG
	AAGAAAACCCGATAAACGCGAGCGGGGTAGACGCGAAAGCG
	ATACTAAGCGCGCGACTAAGCAAAAGCCGACGACTAGAAAAC
	CTAATAGCGCAACTACCGGGGGAAAAAAAAAACGGGCTATTC
	GGGAACCTAATAGCGCTAAGCCTAGGGCTAACGCCGAACTTC
	AAAAGCAACTTCGACCTAGCGGAAGACGCGAAACTACAACTA
	AGCAAAGACACGTACGACGACGACCTAGACAACCTACTAGCG
	CAAATAGGGGACCAATACGCGGACCTATTCCTAGCGGCGAAA
	AACCTAAGCGACGCGATACTACTAAGCGACATACTACGAGTA
	AACACGGAAATAACGAAAGCGCCGCTAAGCGCGAGCATGATA
	AAACGATACGACGAACACCACCAAGACCTAACGCTACTAAAA
	GCGCTAGTACGACAACAACTACCGGAAAAATACAAAGAAATA
	TTCTTCGACCAAAGCAAAAACGGGTACGCGGGGTACATAGAC
	GGGGGGGCGAGCCAAGAAGAATTCTACAAATTCATAAAACCG
	ATACTAGAAAAAATGGACGGGACGGAAGAACTACTAGTAAAA
	CTAAACCGAGAAGACCTACTACGAAAACAACGAACGTTCGAC
	AACGGGAGCATACCGCACCAAATACACCTAGGGGAACTACAC
	GCGATACTACGACGACAAGAAGACTTCTACCCGTTCCTAAAAG
	ACAACCGAGAAAAAATAGAAAAAATACTAACGTTCCGAATAC
	CGTACTACGTAGGGCCGCTAGCGCGAGGGAACAGCCGATTCG
	CGTGGATGACGCGAAAAAGCGAAGAAACGATAACGCCGTGGA
	ACTTCGAAGAAGTAGTAGACAAAGGGGCGAGCGCGCAAAGCT
	TCATAGAACGAATGACGAACTTCGACAAAAACCTACCGAACG
	AAAAAGTACTACCGAAACACAGCCTACTATACGAATACTTCAC
	GGTATACAACGAACTAACGAAAGTAAAATACGTAACGGAAGG
	GATGCGAAAACCGGCGTTCCTAAGCGGGGAACAAAAAAAAGC
	GATAGTAGACCTACTATTCAAAACGAACCGAAAAGTAACGGT
	AAAACAACTAAAAGAAGACTACTTCAAAAAAATAGAATGCTT
	CGACAGCGTAGAAATAAGCGGGGTAGAAGACCGATTCAACGC
	GAGCCTAGGGACGTACCACGACCTACTAAAAATAATAAAAGA
	CAAAGACTTCCTAGACAACGAAGAAAACGAAGACATACTAGA
	AGACATAGTACTAACGCTAACGCTATTCGAAGACCGAGAAAT
	GATAGAAGAACGACTAAAAACGTACGCGCACCTATTCGACGA
	CAAAGTAATGAAACAACTAAAACGACGACGATACACGGGGTG
	GGGGCGACTAAGCCGAAAACTAATAAACGGGATACGAGACAA
	ACAAAGCGGGAAAACGATACTAGACTTCCTAAAAAGCGACGG
	GTTCGCGAACCGAAACTTCATGCAACTAATACACGACGACAG
	CCTAACGTTCAAAGAAGACATACAAAAAGCGCAAGTAAGCGG
	GCAAGGGGACAGCCTACACGAACACATAGCGAACCTAGCGGG
	GAGCCCGGCGATAAAAAAAGGGATACTACAAACGGTAAAAGT
	AGTAGACGAACTAGTAAAAGTAATGGGGCGACACAAACCGGA
	AAACATAGTAATAGAAATGGCGCGAGAAAACCAAACGACGCA
	AAAAGGGCAAAAAAACAGCCGAGAACGAATGAAACGAATAG
	AAGAAGGGATAAAAGAACTAGGGAGCCAAATACTAAAAGAA
	CACCCGGTAGAAAACACGCAACTACAAAACGAAAAACTATAC
	CTATACTACCTACAAAACGGGCGAGACATGTACGTAGACCAA
	GAACTAGACATAAACCGACTAAGCGACTACGACGTAGACCAC
	ATAGTACCGCAAAGCTTCCTAAAAGACGACAGCATAGACAAC
	AAAGTACTAACGCGAAGCGACAAAAACCGAGGGAAAAGCGA
	CAACGTACCGAGCGAAGAAGTAGTAAAAAAAATGAAAAACTA
	CTGGCGACAACTACTAAACGCGAAACTAATAACGCAACGAAA
	ATTCGACAACCTAACGAAAGCGGAACGAGGGGGGCTAAGCGA
	ACTAGACAAAGCGGGGTTCATAAAACGACAACTAGTAGAAAC
	GCGACAAATAACGAAACACGTAGCGCAAATACTAGACAGCCG
	AATGAACACGAAATACGACGAAAACGACAAACTAATACGAGA
	AGTAAAAGTAATAACGCTAAAAAGCAAACTAGTAAGCGACTT
	CCGAAAAGACTTCCAATTCTACAAAGTACGAGAAATAAACAA
	CTACCACCACGCGCACGACGCGTACCTAAACGCGGTAGTAGG
	GACGGCGCTAATAAAAAAATACCCGAAACTAGAAAGCGAATT
	CGTATACGGGGACTACAAAGTATACGACGTACGAAAAATGAT
	AGCGAAAAGCGAACAAGAAATAGGGAAAGCGACGGCGAAAT
	ACTTCTTCTACAGCAACATAATGAACTTCTTCAAAACGGAAAT
	AACGCTAGCGAACGGGGAAATACGAAAACGACCGCTAATAGA
	AACGAACGGGGAAACGGGGGAAATAGTATGGGACAAAGGGC
	GAGACTTCGCGACGGTACGAAAAGTACTAAGCATGCCGCAAG
	TAAACATAGTAAAAAAAACGGAAGTACAAACGGGGGGGTTCA
	GCAAAGAAAGCATACTACCGAAACGAAACAGCGACAAACTAA
	TAGCGCGAAAAAAAGACTGGGACCCGAAAAAATACGGGGGGT
	TCGACAGCCCGACGGTAGCGTACAGCGTACTAGTAGTAGCGA
	AAGTAGAAAAAGGGAAAAGCAAAAAACTAAAAAGCGTAAAA
	GAACTACTAGGGATAACGATAATGGAACGAAGCAGCTTCGAA
	AAAAACCCGATAGACTTCCTAGAAGCGAAAGGGTACAAAGAA
	GTAAAAAAAGACCTAATAATAAAACTACCGAAATACAGCCTA
	TTCGAACTAGAAAACGGGCGAAAACGAATGCTAGCGAGCGCG
	GGGGAACTACAAAAAGGGAACGAACTAGCGCTACCGAGCAAA
	TACGTAAACTTCCTATACCTAGCGAGCCACTACGAAAAACTAA
	AAGGGAGCCCGGAAGACAACGAACAAAAACAACTATTCGTAG
	AACAACACAAACACTACCTAGACGAAATAATAGAACAAATAA
	GCGAATTCAGCAAACGAGTAATACTAGCGGACGCGAACCTAG
	ACAAAGTACTAAGCGCGTACAACAAACACCGAGACAAACCGA
	TACGAGAACAAGCGGAAAACATAATACACCTATTCACGCTAA
	CGAACCTAGGGGCGCCGGCGGCGTTCAAATACTTCGACACGA
	CGATAGACCGAAAACGATACACGAGCACGAAAGAAGTACTAG
	ACGCGACGCTAATACACCAAAGCATAACGGGGCTATACGAAA
	CGCGAATAGACCTAAGCCAACTAGGGGGGGACGGGGGGGGG
	AGCCCGAAAAAAAAACGAAAAGTATGA
Cas9	GGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT	55
transcript	GTGTCGTTGCAGGCCTTATTCGGATCCGCCACCATGGACAAAA
with 5′ UTR	AATACAGCATAGGGCTAGACATAGGGACGAACAGCGTAGGGT
ofHSD.	GGGCGGTAATAACGGACGAATACAAAGTACCGAGCAAAAAAT
ORF	TCAAAGTACTAGGGAACACGGACCGACACAGCATAAAAAAAA
corresponding	ACCTAATAGGGGCGCTACTATTCGACAGCGGGGAAACGGCGG
to SEQ	AAGCGACGCGACTAAAACGAACGGCGCGACGACGATACACGC
ID NO: 54,	GACGAAAAAACCGAATATGCTACCTACAAGAAATATTCAGCA
Kozak	ACGAAATGGCGAAAGTAGACGACAGCTTCTTCCACCGACTAG
sequence,	AAGAAAGCTTCCTAGTAGAAGAAGACAAAAAACACGAACGAC
and 3′ UTR	ACCCGATATTCGGGAACATAGTAGACGAAGTAGCGTACCACG
of ALB	AAAAATACCCGACGATATACCACCTACGAAAAAAACTAGTAG
	ACAGCACGGACAAAGCGGACCTACGACTAATATACCTAGCGC
	TAGCGCACATGATAAAATTCCGAGGGCACTTCCTAATAGAAG
	GGGACCTAAACCCGGACAACAGCGACGTAGACAAACTATTCA
	TACAACTAGTACAAACGTACAACCAACTATTCGAAGAAAACC
	CGATAAACGCGAGCGGGGTAGACGCGAAAGCGATACTAAGCG
	CGCGACTAAGCAAAAGCCGACGACTAGAAAACCTAATAGCGC
	AACTACCGGGGGAAAAAAAAAACGGGCTATTCGGGAACCTAA
	TAGCGCTAAGCCTAGGGCTAACGCCGAACTTCAAAAGCAACTT
	CGACCTAGCGGAAGACGCGAAACTACAACTAAGCAAAGACAC
	GTACGACGACGACCTAGACAACCTACTAGCGCAAATAGGGGA
	CCAATACGCGGACCTATTCCTAGCGGCGAAAAACCTAAGCGA
	CGCGATACTACTAAGCGACATACTACGAGTAAACACGGAAAT
	AACGAAAGCGCCGCTAAGCGCGAGCATGATAAAACGATACGA
	CGAACACCACCAAGACCTAACGCTACTAAAAGCGCTAGTACG
	ACAACAACTACCGGAAAAATACAAAGAAATATTCTTCGACCA
	AAGCAAAAACGGGTACGCGGGGTACATAGACGGGGGGGCGA
	GCCAAGAAGAATTCTACAAATTCATAAAACCGATACTAGAAA
	AAATGGACGGGACGGAAGAACTACTAGTAAAACTAAACCGAG
	AAGACCTACTACGAAAACAACGAACGTTCGACAACGGGAGCA
	TACCGCACCAAATACACCTAGGGGAACTACACGCGATACTAC
	GACGACAAGAAGACTTCTACCCGTTCCTAAAAGACAACCGAG
	AAAAAATAGAAAAAATACTAACGTTCCGAATACCGTACTACG
	TAGGGCCGCTAGCGCGAGGGAACAGCCGATTCGCGTGGATGA
	CGCGAAAAAGCGAAGAAACGATAACGCCGTGGAACTTCGAAG
	AAGTAGTAGACAAAGGGGCGAGCGCGCAAAGCTTCATAGAAC
	GAATGACGAACTTCGACAAAAACCTACCGAACGAAAAAGTAC
	TACCGAAACACAGCCTACTATACGAATACTTCACGGTATACAA
	CGAACTAACGAAAGTAAAATACGTAACGGAAGGGATGCGAAA
	ACCGGCGTTCCTAAGCGGGGAACAAAAAAAAGCGATAGTAGA
	CCTACTATTCAAAACGAACCGAAAAGTAACGGTAAAACAACT
	AAAAGAAGACTACTTCAAAAAAATAGAATGCTTCGACAGCGT
	AGAAATAAGCGGGGTAGAAGACCGATTCAACGCGAGCCTAGG
	GACGTACCACGACCTACTAAAAATAATAAAAGACAAAGACTT
	CCTAGACAACGAAGAAAACGAAGACATACTAGAAGACATAGT
	ACTAACGCTAACGCTATTCGAAGACCGAGAAATGATAGAAGA
	ACGACTAAAAACGTACGCGCACCTATTCGACGACAAAGTAAT
	GAAACAACTAAAACGACGACGATACACGGGGTGGGGGCGACT
	AAGCCGAAAACTAATAAACGGGATACGAGACAAACAAAGCG
	GGAAAACGATACTAGACTTCCTAAAAAGCGACGGGTTCGCGA
	ACCGAAACTTCATGCAACTAATACACGACGACAGCCTAACGTT
	CAAAGAAGACATACAAAAAGCGCAAGTAAGCGGGCAAGGGG
	ACAGCCTACACGAACACATAGCGAACCTAGCGGGGAGCCCGG
	CGATAAAAAAAGGGATACTACAAACGGTAAAAGTAGTAGACG
	AACTAGTAAAAGTAATGGGGCGACACAAACCGGAAAACATAG
	TAATAGAAATGGCGCGAGAAAACCAAACGACGCAAAAAGGG
	CAAAAAAACAGCCGAGAACGAATGAAACGAATAGAAGAAGG
	GATAAAAGAACTAGGGAGCCAAATACTAAAAGAACACCCGGT
	AGAAAACACGCAACTACAAAACGAAAAACTATACCTATACTA
	CCTACAAAACGGGCGAGACATGTACGTAGACCAAGAACTAGA
	CATAAACCGACTAAGCGACTACGACGTAGACCACATAGTACC
	GCAAAGCTTCCTAAAAGACGACAGCATAGACAACAAAGTACT
	AACGCGAAGCGACAAAAACCGAGGGAAAAGCGACAACGTAC
	CGAGCGAAGAAGTAGTAAAAAAAATGAAAAACTACTGGCGAC
	AACTACTAAACGCGAAACTAATAACGCAACGAAAATTCGACA
	ACCTAACGAAAGCGGAACGAGGGGGGCTAAGCGAACTAGACA
	AAGCGGGGTTCATAAAACGACAACTAGTAGAAACGCGACAAA
	TAACGAAACACGTAGCGCAAATACTAGACAGCCGAATGAACA
	CGAAATACGACGAAAACGACAAACTAATACGAGAAGTAAAAG
	TAATAACGCTAAAAAGCAAACTAGTAAGCGACTTCCGAAAAG
	ACTTCCAATTCTACAAAGTACGAGAAATAAACAACTACCACCA
	CGCGCACGACGCGTACCTAAACGCGGTAGTAGGGACGGCGCT
	AATAAAAAAATACCCGAAACTAGAAAGCGAATTCGTATACGG
	GGACTACAAAGTATACGACGTACGAAAAATGATAGCGAAAAG
	CGAACAAGAAATAGGGAAAGCGACGGCGAAATACTTCTTCTA
	CAGCAACATAATGAACTTCTTCAAAACGGAAATAACGCTAGC
	GAACGGGGAAATACGAAAACGACCGCTAATAGAAACGAACG
	GGGAAACGGGGGAAATAGTATGGGACAAAGGGCGAGACTTCG
	CGACGGTACGAAAAGTACTAAGCATGCCGCAAGTAAACATAG
	TAAAAAAAACGGAAGTACAAACGGGGGGGTTCAGCAAAGAA
	AGCATACTACCGAAACGAAACAGCGACAAACTAATAGCGCGA
	AAAAAAGACTGGGACCCGAAAAAATACGGGGGGTTCGACAGC
	CCGACGGTAGCGTACAGCGTACTAGTAGTAGCGAAAGTAGAA
	AAAGGGAAAAGCAAAAAACTAAAAAGCGTAAAAGAACTACT
	AGGGATAACGATAATGGAACGAAGCAGCTTCGAAAAAAACCC
	GATAGACTTCCTAGAAGCGAAAGGGTACAAAGAAGTAAAAAA
	AGACCTAATAATAAAACTACCGAAATACAGCCTATTCGAACTA
	GAAAACGGGCGAAAACGAATGCTAGCGAGCGCGGGGGAACT
	ACAAAAAGGGAACGAACTAGCGCTACCGAGCAAATACGTAAA
	CTTCCTATACCTAGCGAGCCACTACGAAAAACTAAAAGGGAG
	CCCGGAAGACAACGAACAAAAACAACTATTCGTAGAACAACA
	CAAACACTACCTAGACGAAATAATAGAACAAATAAGCGAATT
	CAGCAAACGAGTAATACTAGCGGACGCGAACCTAGACAAAGT
	ACTAAGCGCGTACAACAAACACCGAGACAAACCGATACGAGA
	ACAAGCGGAAAACATAATACACCTATTCACGCTAACGAACCT
	AGGGGCGCCGGCGGCGTTCAAATACTTCGACACGACGATAGA
	CCGAAAACGATACACGAGCACGAAAGAAGTACTAGACGCGAC
	GCTAATACACCAAAGCATAACGGGGCTATACGAAACGCGAAT
	AGACCTAAGCCAACTAGGGGGGGACGGGGGGGGGAGCCCGA
	AAAAAAAACGAAAAGTATGACTAGCCATCACATTTAAAAGCA
	TCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCA
	ATAGCTTATTCATCTCTTTTTCTTTTTCGTTGGTGTAAAGCCAA
	CACCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCTCT
	TTTCTCTGTGCTTCAATTAATAAAAAATGGAAAGAACCTCGAG
Cas9	AGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT	56
transcript	GTGTCGTTGCAGGCCTTATTCGGATCCGCCACCATGGACAAGA
with AGGas	AGTACAGCATCGGACTGGACATCGGAACAAACAGCGTCGGAT
first three	GGGCAGTCATCACAGACGAATACAAGGTCCCGAGCAAGAAGT
nucleotides	TCAAGGTCCTGGGAAACACAGACAGACACAGCATCAAGAAGA
for use with	ACCTGATCGGAGCACTGCTGTTCGACAGCGGAGAAACAGCAG
CleanCap™,	AAGCAACAAGACTGAAGAGAACAGCAAGAAGAAGATACACA
5′ UTR of	AGAAGAAAGAACAGAATCTGCTACCTGCAGGAAATCTTCAGC
HSD, ORF	AACGAAATGGCAAAGGTCGACGACAGCTTCTTCCACAGACTG
corresponding	GAAGAAAGCTTCCTGGTCGAAGAAGACAAGAAGCACGAAAGA
to SEQ	CACCCGATCTTCGGAAACATCGTCGACGAAGTCGCATACCACG
ID NO: 4,	AAAAGTACCCGACAATCTACCACCTGAGAAAGAAGCTGGTCG
Kozak	ACAGCACAGACAAGGCAGACCTGAGACTGATCTACCTGGCAC
sequence,	TGGCACACATGATCAAGTTCAGAGGACACTTCCTGATCGAAGG
and 3′ UTR	AGACCTGAACCCGGACAACAGCGACGTCGACAAGCTGTTCAT
of ALB	CCAGCTGGTCCAGACATACAACCAGCTGTTCGAAGAAAACCC
	GATCAACGCAAGCGGAGTCGACGCAAAGGCAATCCTGAGCGC
	AAGACTGAGCAAGAGCAGAAGACTGGAAAACCTGATCGCACA
	GCTGCCGGGAGAAAAGAAGAACGGACTGTTCGGAAACCTGAT
	CGCACTGAGCCTGGGACTGACACCGAACTTCAAGAGCAACTTC
	GACCTGGCAGAAGACGCAAAGCTGCAGCTGAGCAAGGACACA
	TACGACGACGACCTGGACAACCTGCTGGCACAGATCGGAGAC
	CAGTACGCAGACCTGTTCCTGGCAGCAAAGAACCTGAGCGAC
	GCAATCCTGCTGAGCGACATCCTGAGAGTCAACACAGAAATC
	ACAAAGGCACCGCTGAGCGCAAGCATGATCAAGAGATACGAC
	GAACACCACCAGGACCTGACACTGCTGAAGGCACTGGTCAGA
	CAGCAGCTGCCGGAAAAGTACAAGGAAATCTTCTTCGACCAG
	AGCAAGAACGGATACGCAGGATACATCGACGGAGGAGCAAGC
	CAGGAAGAATTCTACAAGTTCATCAAGCCGATCCTGGAAAAG
	ATGGACGGAACAGAAGAACTGCTGGTCAAGCTGAACAGAGAA
	GACCTGCTGAGAAAGCAGAGAACATTCGACAACGGAAGCATC
	CCGCACCAGATCCACCTGGGAGAACTGCACGCAATCCTGAGA
	AGACAGGAAGACTTCTACCCGTTCCTGAAGGACAACAGAGAA
	AAGATCGAAAAGATCCTGACATTCAGAATCCCGTACTACGTCG
	GACCGCTGGCAAGAGGAAACAGCAGATTCGCATGGATGACAA
	GAAAGAGCGAAGAAACAATCACACCGTGGAACTTCGAAGAAG
	TCGTCGACAAGGGAGCAAGCGCACAGAGCTTCATCGAAAGAA
	TGACAAACTTCGACAAGAACCTGCCGAACGAAAAGGTCCTGC
	CGAAGCACAGCCTGCTGTACGAATACTTCACAGTCTACAACGA
	ACTGACAAAGGTCAAGTACGTCACAGAAGGAATGAGAAAGCC
	GGCATTCCTGAGCGGAGAACAGAAGAAGGCAATCGTCGACCT
	GCTGTTCAAGACAAACAGAAAGGTCACAGTCAAGCAGCTGAA
	GGAAGACTACTTCAAGAAGATCGAATGCTTCGACAGCGTCGA
	AATCAGCGGAGTCGAAGACAGATTCAACGCAAGCCTGGGAAC
	ATACCACGACCTGCTGAAGATCATCAAGGACAAGGACTTCCTG
	GACAACGAAGAAAACGAAGACATCCTGGAAGACATCGTCCTG
	ACACTGACACTGTTCGAAGACAGAGAAATGATCGAAGAAAGA
	CTGAAGACATACGCACACCTGTTCGACGACAAGGTCATGAAG
	CAGCTGAAGAGAAGAAGATACACAGGATGGGGAAGACTGAG
	CAGAAAGCTGATCAACGGAATCAGAGACAAGCAGAGCGGAA
	AGACAATCCTGGACTTCCTGAAGAGCGACGGATTCGCAAACA
	GAAACTTCATGCAGCTGATCCACGACGACAGCCTGACATTCAA
	GGAAGACATCCAGAAGGCACAGGTCAGCGGACAGGGAGACA
	GCCTGCACGAACACATCGCAAACCTGGCAGGAAGCCCGGCAA
	TCAAGAAGGGAATCCTGCAGACAGTCAAGGTCGTCGACGAAC
	TGGTCAAGGTCATGGGAAGACACAAGCCGGAAAACATCGTCA
	TCGAAATGGCAAGAGAAAACCAGACAACACAGAAGGGACAG
	AAGAACAGCAGAGAAAGAATGAAGAGAATCGAAGAAGGAAT
	CAAGGAACTGGGAAGCCAGATCCTGAAGGAACACCCGGTCGA
	AAACACACAGCTGCAGAACGAAAAGCTGTACCTGTACTACCT
	GCAGAACGGAAGAGACATGTACGTCGACCAGGAACTGGACAT
	CAACAGACTGAGCGACTACGACGTCGACCACATCGTCCCGCA
	GAGCTTCCTGAAGGACGACAGCATCGACAACAAGGTCCTGAC
	AAGAAGCGACAAGAACAGAGGAAAGAGCGACAACGTCCCGA
	GCGAAGAAGTCGTCAAGAAGATGAAGAACTACTGGAGACAGC
	TGCTGAACGCAAAGCTGATCACACAGAGAAAGTTCGACAACC
	TGACAAAGGCAGAGAGAGGAGGACTGAGCGAACTGGACAAG
	GCAGGATTCATCAAGAGACAGCTGGTCGAAACAAGACAGATC
	ACAAAGCACGTCGCACAGATCCTGGACAGCAGAATGAACACA
	AAGTACGACGAAAACGACAAGCTGATCAGAGAAGTCAAGGTC
	ATCACACTGAAGAGCAAGCTGGTCAGCGACTTCAGAAAGGAC
	TICCAGTTCTACAAGGTCAGAGAAATCAACAACTACCACCACG
	CACACGACGCATACCTGAACGCAGTCGTCGGAACAGCACTGA
	TCAAGAAGTACCCGAAGCTGGAAAGCGAATTCGTCTACGGAG
	ACTACAAGGTCTACGACGTCAGAAAGATGATCGCAAAGAGCG
	AACAGGAAATCGGAAAGGCAACAGCAAAGTACTTCTTCTACA
	GCAACATCATGAACTTCTTCAAGACAGAAATCACACTGGCAA
	ACGGAGAAATCAGAAAGAGACCGCTGATCGAAACAAACGGA
	GAAACAGGAGAAATCGTCTGGGACAAGGGAAGAGACTTCGCA
	ACAGTCAGAAAGGTCCTGAGCATGCCGCAGGTCAACATCGTC
	AAGAAGACAGAAGTCCAGACAGGAGGATTCAGCAAGGAAAG
	CATCCTGCCGAAGAGAAACAGCGACAAGCTGATCGCAAGAAA
	GAAGGACTGGGACCCGAAGAAGTACGGAGGATTCGACAGCCC
	GACAGTCGCATACAGCGTCCTGGTCGTCGCAAAGGTCGAAAA
	GGGAAAGAGCAAGAAGCTGAAGAGCGTCAAGGAACTGCTGG
	GAATCACAATCATGGAAAGAAGCAGCTTCGAAAAGAACCCGA
	TCGACTTCCTGGAAGCAAAGGGATACAAGGAAGTCAAGAAGG
	ACCTGATCATCAAGCTGCCGAAGTACAGCCTGTTCGAACTGGA
	AAACGGAAGAAAGAGAATGCTGGCAAGCGCAGGAGAACTGC
	AGAAGGGAAACGAACTGGCACTGCCGAGCAAGTACGTCAACT
	TCCTGTACCTGGCAAGCCACTACGAAAAGCTGAAGGGAAGCC
	CGGAAGACAACGAACAGAAGCAGCTGTTCGTCGAACAGCACA
	AGCACTACCTGGACGAAATCATCGAACAGATCAGCGAATTCA
	GCAAGAGAGTCATCCTGGCAGACGCAAACCTGGACAAGGTCC
	TGAGCGCATACAACAAGCACAGAGACAAGCCGATCAGAGAAC
	AGGCAGAAAACATCATCCACCTGTTCACACTGACAAACCTGG
	GAGCACCGGCAGCATTCAAGTACTTCGACACAACAATCGACA
	GAAAGAGATACACAAGCACAAAGGAAGTCCTGGACGCAACAC
	TGATCCACCAGAGCATCACAGGACTGTACGAAACAAGAATCG
	ACCTGAGCCAGCTGGGAGGAGACGGAGGAGGAAGCCCGAAG
	AAGAAGAGAAAGGTCTAGCTAGCCATCACATTTAAAAGCATC
	TCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAT
	AGCTTATTCATCTCTTTTTCTTTTTCGTTGGTGTAAAGCCAACA
	CCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCTCTTT
	TCTCTGTGCTTCAATTAATAAAAAATGGAAAGAACCTCGAG
Cas9	GGGCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCC	57
transcript	ATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCGGGAAC
with 5′ UTR	GGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACTCACC
from CMV,	GTCCTTGACACGGCCACCATGGACAAGAAGTACAGCATCGGA
ORF	CTGGACATCGGAACAAACAGCGTCGGATGGGCAGTCATCACA
corresponding	GACGAATACAAGGTCCCGAGCAAGAAGTTCAAGGTCCTGGGA
to SEQ	AACACAGACAGACACAGCATCAAGAAGAACCTGATCGGAGCA
ID NO: 4,	CTGCTGTTCGACAGCGGAGAAACAGCAGAAGCAACAAGACTG
Kozak	AAGAGAACAGCAAGAAGAAGATACACAAGAAGAAAGAACAG
sequence,	AATCTGCTACCTGCAGGAAATCTTCAGCAACGAAATGGCAAA
and 3′ UTR	GGTCGACGACAGCTTCTTCCACAGACTGGAAGAAAGCTTCCTG
of ALB	GTCGAAGAAGACAAGAAGCACGAAAGACACCCGATCTTCGGA
	AACATCGTCGACGAAGTCGCATACCACGAAAAGTACCCGACA
	ATCTACCACCTGAGAAAGAAGCTGGTCGACAGCACAGACAAG
	GCAGACCTGAGACTGATCTACCTGGCACTGGCACACATGATCA
	AGTTCAGAGGACACTTCCTGATCGAAGGAGACCTGAACCCGG
	ACAACAGCGACGTCGACAAGCTGTTCATCCAGCTGGTCCAGAC
	ATACAACCAGCTGTTCGAAGAAAACCCGATCAACGCAAGCGG
	AGTCGACGCAAAGGCAATCCTGAGCGCAAGACTGAGCAAGAG
	CAGAAGACTGGAAAACCTGATCGCACAGCTGCCGGGAGAAAA
	GAAGAACGGACTGTTCGGAAACCTGATCGCACTGAGCCTGGG
	ACTGACACCGAACTTCAAGAGCAACTTCGACCTGGCAGAAGA
	CGCAAAGCTGCAGCTGAGCAAGGACACATACGACGACGACCT
	GGACAACCTGCTGGCACAGATCGGAGACCAGTACGCAGACCT
	GTTCCTGGCAGCAAAGAACCTGAGCGACGCAATCCTGCTGAG
	CGACATCCTGAGAGTCAACACAGAAATCACAAAGGCACCGCT
	GAGCGCAAGCATGATCAAGAGATACGACGAACACCACCAGGA
	CCTGACACTGCTGAAGGCACTGGTCAGACAGCAGCTGCCGGA
	AAAGTACAAGGAAATCTTCTTCGACCAGAGCAAGAACGGATA
	CGCAGGATACATCGACGGAGGAGCAAGCCAGGAAGAATTCTA
	CAAGTTCATCAAGCCGATCCTGGAAAAGATGGACGGAACAGA
	AGAACTGCTGGTCAAGCTGAACAGAGAAGACCTGCTGAGAAA
	GCAGAGAACATTCGACAACGGAAGCATCCCGCACCAGATCCA
	CCTGGGAGAACTGCACGCAATCCTGAGAAGACAGGAAGACTT
	CTACCCGTTCCTGAAGGACAACAGAGAAAAGATCGAAAAGAT
	CCTGACATTCAGAATCCCGTACTACGTCGGACCGCTGGCAAGA
	GGAAACAGCAGATTCGCATGGATGACAAGAAAGAGCGAAGA
	AACAATCACACCGTGGAACTTCGAAGAAGTCGTCGACAAGGG
	AGCAAGCGCACAGAGCTTCATCGAAAGAATGACAAACTTCGA
	CAAGAACCTGCCGAACGAAAAGGTCCTGCCGAAGCACAGCCT
	GCTGTACGAATACTTCACAGTCTACAACGAACTGACAAAGGTC
	AAGTACGTCACAGAAGGAATGAGAAAGCCGGCATTCCTGAGC
	GGAGAACAGAAGAAGGCAATCGTCGACCTGCTGTTCAAGACA
	AACAGAAAGGTCACAGTCAAGCAGCTGAAGGAAGACTACTTC
	AAGAAGATCGAATGCTTCGACAGCGTCGAAATCAGCGGAGTC
	GAAGACAGATTCAACGCAAGCCTGGGAACATACCACGACCTG
	CTGAAGATCATCAAGGACAAGGACTTCCTGGACAACGAAGAA
	AACGAAGACATCCTGGAAGACATCGTCCTGACACTGACACTGT
	TCGAAGACAGAGAAATGATCGAAGAAAGACTGAAGACATACG
	CACACCTGTTCGACGACAAGGTCATGAAGCAGCTGAAGAGAA
	GAAGATACACAGGATGGGGAAGACTGAGCAGAAAGCTGATCA
	ACGGAATCAGAGACAAGCAGAGCGGAAAGACAATCCTGGACT
	TCCTGAAGAGCGACGGATTCGCAAACAGAAACTTCATGCAGC
	TGATCCACGACGACAGCCTGACATTCAAGGAAGACATCCAGA
	AGGCACAGGTCAGCGGACAGGGAGACAGCCTGCACGAACACA
	TCGCAAACCTGGCAGGAAGCCCGGCAATCAAGAAGGGAATCC
	TGCAGACAGTCAAGGTCGTCGACGAACTGGTCAAGGTCATGG
	GAAGACACAAGCCGGAAAACATCGTCATCGAAATGGCAAGAG
	AAAACCAGACAACACAGAAGGGACAGAAGAACAGCAGAGAA
	AGAATGAAGAGAATCGAAGAAGGAATCAAGGAACTGGGAAG
	CCAGATCCTGAAGGAACACCCGGTCGAAAACACACAGCTGCA
	GAACGAAAAGCTGTACCTGTACTACCTGCAGAACGGAAGAGA
	CATGTACGTCGACCAGGAACTGGACATCAACAGACTGAGCGA
	CTACGACGTCGACCACATCGTCCCGCAGAGCTTCCTGAAGGAC
	GACAGCATCGACAACAAGGTCCTGACAAGAAGCGACAAGAAC
	AGAGGAAAGAGCGACAACGTCCCGAGCGAAGAAGTCGTCAAG
	AAGATGAAGAACTACTGGAGACAGCTGCTGAACGCAAAGCTG
	ATCACACAGAGAAAGTTCGACAACCTGACAAAGGCAGAGAGA
	GGAGGACTGAGCGAACTGGACAAGGCAGGATTCATCAAGAGA
	CAGCTGGTCGAAACAAGACAGATCACAAAGCACGTCGCACAG
	ATCCTGGACAGCAGAATGAACACAAAGTACGACGAAAACGAC
	AAGCTGATCAGAGAAGTCAAGGTCATCACACTGAAGAGCAAG
	CTGGTCAGCGACTTCAGAAAGGACTTCCAGTTCTACAAGGTCA
	GAGAAATCAACAACTACCACCACGCACACGACGCATACCTGA
	ACGCAGTCGTCGGAACAGCACTGATCAAGAAGTACCCGAAGC
	TGGAAAGCGAATTCGTCTACGGAGACTACAAGGTCTACGACG
	TCAGAAAGATGATCGCAAAGAGCGAACAGGAAATCGGAAAG
	GCAACAGCAAAGTACTTCTTCTACAGCAACATCATGAACTTCT
	TCAAGACAGAAATCACACTGGCAAACGGAGAAATCAGAAAGA
	GACCGCTGATCGAAACAAACGGAGAAACAGGAGAAATCGTCT
	GGGACAAGGGAAGAGACTTCGCAACAGTCAGAAAGGTCCTGA
	GCATGCCGCAGGTCAACATCGTCAAGAAGACAGAAGTCCAGA
	CAGGAGGATTCAGCAAGGAAAGCATCCTGCCGAAGAGAAACA
	GCGACAAGCTGATCGCAAGAAAGAAGGACTGGGACCCGAAGA
	AGTACGGAGGATTCGACAGCCCGACAGTCGCATACAGCGTCC
	TGGTCGTCGCAAAGGTCGAAAAGGGAAAGAGCAAGAAGCTGA
	AGAGCGTCAAGGAACTGCTGGGAATCACAATCATGGAAAGAA
	GCAGCTTCGAAAAGAACCCGATCGACTTCCTGGAAGCAAAGG
	GATACAAGGAAGTCAAGAAGGACCTGATCATCAAGCTGCCGA
	AGTACAGCCTGTTCGAACTGGAAAACGGAAGAAAGAGAATGC
	TGGCAAGCGCAGGAGAACTGCAGAAGGGAAACGAACTGGCAC
	TGCCGAGCAAGTACGTCAACTTCCTGTACCTGGCAAGCCACTA
	CGAAAAGCTGAAGGGAAGCCCGGAAGACAACGAACAGAAGC
	AGCTGTTCGTCGAACAGCACAAGCACTACCTGGACGAAATCAT
	CGAACAGATCAGCGAATTCAGCAAGAGAGTCATCCTGGCAGA
	CGCAAACCTGGACAAGGTCCTGAGCGCATACAACAAGCACAG
	AGACAAGCCGATCAGAGAACAGGCAGAAAACATCATCCACCT
	GTTCACACTGACAAACCTGGGAGCACCGGCAGCATTCAAGTA
	CTTCGACACAACAATCGACAGAAAGAGATACACAAGCACAAA
	GGAAGTCCTGGACGCAACACTGATCCACCAGAGCATCACAGG
	ACTGTACGAAACAAGAATCGACCTGAGCCAGCTGGGAGGAGA
	CGGAGGAGGAAGCCCGAAGAAGAAGAGAAAGGTCTAGCTAG
	CCATCACATTFAAAAGCATCTCAGCCTACCATGAGAATAAGAG
	AAAGAAAATGAAGATCAATAGCTTATTCATCTCTTTTTCTTTTT
	CGTTGGTGTAAAGCCAACACCCTGTCTAAAAAACATAAATTTC
	TTTAATCATTTTGCCTCTTTTCTCTGTGCTTCAATTAATAAAAA
	ATGGAAAGAACCTCGAG
Cas9	GGGacatttgcttctgacacaactgtgttcactagcaacctcaaacagacaccggatctgccaccAT	58
transcript	GGACAAGAAGTACAGCATCGGACTGGACATCGGAACAAACAG
with 5′ UTR	CGTCGGATGGGCAGTCATCACAGACGAATACAAGGTCCCGAG
from HBB,	CAAGAAGTTCAAGGTCCTGGGAAACACAGACAGACACAGCAT
ORF	CAAGAAGAACCTGATCGGAGCACTGCTGTTCGACAGCGGAGA
corresponding	AACAGCAGAAGCAACAAGACTGAAGAGAACAGCAAGAAGAA
to SEQ	GATACACAAGAAGAAAGAACAGAATCTGCTACCTGCAGGAAA
ID NO: 4,	TCTTCAGCAACGAAATGGCAAAGGTCGACGACAGCTTCTTCCA
Kozak	CAGACTGGAAGAAAGCTTCCTGGTCGAAGAAGACAAGAAGCA
sequence,	CGAAAGACACCCGATCTTCGGAAACATCGTCGACGAAGTCGC
and 3′ UTR	ATACCACGAAAAGTACCCGACAATCTACCACCTGAGAAAGAA
of HBB	GCTGGTCGACAGCACAGACAAGGCAGACCTGAGACTGATCTA
	CCTGGCACTGGCACACATGATCAAGTTCAGAGGACACTTCCTG
	ATCGAAGGAGACCTGAACCCGGACAACAGCGACGTCGACAAG
	CTGTTCATCCAGCTGGTCCAGACATACAACCAGCTGTTCGAAG
	AAAACCCGATCAACGCAAGCGGAGTCGACGCAAAGGCAATCC
	TGAGCGCAAGACTGAGCAAGAGCAGAAGACTGGAAAACCTGA
	TCGCACAGCTGCCGGGAGAAAAGAAGAACGGACTGTTCGGAA
	ACCTGATCGCACTGAGCCTGGGACTGACACCGAACTTCAAGA
	GCAACTTCGACCTGGCAGAAGACGCAAAGCTGCAGCTGAGCA
	AGGACACATACGACGACGACCTGGACAACCTGCTGGCACAGA
	TCGGAGACCAGTACGCAGACCTGTTCCTGGCAGCAAAGAACC
	TGAGCGACGCAATCCTGCTGAGCGACATCCTGAGAGTCAACA
	CAGAAATCACAAAGGCACCGCTGAGCGCAAGCATGATCAAGA
	GATACGACGAACACCACCAGGACCTGACACTGCTGAAGGCAC
	TGGTCAGACAGCAGCTGCCGGAAAAGTACAAGGAAATCTTCT
	TCGACCAGAGCAAGAACGGATACGCAGGATACATCGACGGAG
	GAGCAAGCCAGGAAGAATTCTACAAGTTCATCAAGCCGATCC
	TGGAAAAGATGGACGGAACAGAAGAACTGCTGGTCAAGCTGA
	ACAGAGAAGACCTGCTGAGAAAGCAGAGAACATTCGACAACG
	GAAGCATCCCGCACCAGATCCACCTGGGAGAACTGCACGCAA
	TCCTGAGAAGACAGGAAGACTTCTACCCGTTCCTGAAGGACA
	ACAGAGAAAAGATCGAAAAGATCCTGACATTCAGAATCCCGT
	ACTACGTCGGACCGCTGGCAAGAGGAAACAGCAGATTCGCAT
	GGATGACAAGAAAGAGCGAAGAAACAATCACACCGTGGAACT
	TCGAAGAAGTCGTCGACAAGGGAGCAAGCGCACAGAGCTTCA
	TCGAAAGAATGACAAACTTCGACAAGAACCTGCCGAACGAAA
	AGGTCCTGCCGAAGCACAGCCTGCTGTACGAATACTTCACAGT
	CTACAACGAACTGACAAAGGTCAAGTACGTCACAGAAGGAAT
	GAGAAAGCCGGCATTCCTGAGCGGAGAACAGAAGAAGGCAAT
	CGTCGACCTGCTGTTCAAGACAAACAGAAAGGTCACAGTCAA
	GCAGCTGAAGGAAGACTACTTCAAGAAGATCGAATGCTTCGA
	CAGCGTCGAAATCAGCGGAGTCGAAGACAGATTCAACGCAAG
	CCTGGGAACATACCACGACCTGCTGAAGATCATCAAGGACAA
	GGACTTCCTGGACAACGAAGAAAACGAAGACATCCTGGAAGA
	CATCGTCCTGACACTGACACTGTTCGAAGACAGAGAAATGATC
	GAAGAAAGACTGAAGACATACGCACACCTGTTCGACGACAAG
	GTCATGAAGCAGCTGAAGAGAAGAAGATACACAGGATGGGGA
	AGACTGAGCAGAAAGCTGATCAACGGAATCAGAGACAAGCAG
	AGCGGAAAGACAATCCTGGACTTCCTGAAGAGCGACGGATTC
	GCAAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTG
	ACATTCAAGGAAGACATCCAGAAGGCACAGGTCAGCGGACAG
	GGAGACAGCCTGCACGAACACATCGCAAACCTGGCAGGAAGC
	CCGGCAATCAAGAAGGGAATCCTGCAGACAGTCAAGGTCGTC
	GACGAACTGGTCAAGGTCATGGGAAGACACAAGCCGGAAAAC
	ATCGTCATCGAAATGGCAAGAGAAAACCAGACAACACAGAAG
	GGACAGAAGAACAGCAGAGAAAGAATGAAGAGAATCGAAGA
	AGGAATCAAGGAACTGGGAAGCCAGATCCTGAAGGAACACCC
	GGTCGAAAACACACAGCTGCAGAACGAAAAGCTGTACCTGTA
	CTACCTGCAGAACGGAAGAGACATGTACGTCGACCAGGAACT
	GGACATCAACAGACTGAGCGACTACGACGTCGACCACATCGT
	CCCGCAGAGCTTCCTGAAGGACGACAGCATCGACAACAAGGT
	CCTGACAAGAAGCGACAAGAACAGAGGAAAGAGCGACAACG
	TCCCGAGCGAAGAAGTCGTCAAGAAGATGAAGAACTACTGGA
	GACAGCTGCTGAACGCAAAGCTGATCACACAGAGAAAGTTCG
	ACAACCTGACAAAGGCAGAGAGAGGAGGACTGAGCGAACTG
	GACAAGGCAGGATTCATCAAGAGACAGCTGGTCGAAACAAGA
	CAGATCACAAAGCACGTCGCACAGATCCTGGACAGCAGAATG
	AACACAAAGTACGACGAAAACGACAAGCTGATCAGAGAAGTC
	AAGGTCATCACACTGAAGAGCAAGCTGGTCAGCGACTTCAGA
	AAGGACTTCCAGTTCTACAAGGTCAGAGAAATCAACAACTAC
	CACCACGCACACGACGCATACCTGAACGCAGTCGTCGGAACA
	GCACTGATCAAGAAGTACCCGAAGCTGGAAAGCGAATTCGTC
	TACGGAGACTACAAGGTCTACGACGTCAGAAAGATGATCGCA
	AAGAGCGAACAGGAAATCGGAAAGGCAACAGCAAAGTACTTC
	TTCTACAGCAACATCATGAACTTCTTCAAGACAGAAATCACAC
	TGGCAAACGGAGAAATCAGAAAGAGACCGCTGATCGAAACAA
	ACGGAGAAACAGGAGAAATCGTCTGGGACAAGGGAAGAGAC
	TTCGCAACAGTCAGAAAGGTCCTGAGCATGCCGCAGGTCAAC
	ATCGTCAAGAAGACAGAAGTCCAGACAGGAGGATTCAGCAAG
	GAAAGCATCCTGCCGAAGAGAAACAGCGACAAGCTGATCGCA
	AGAAAGAAGGACTGGGACCCGAAGAAGTACGGAGGATTCGAC
	AGCCCGACAGTCGCATACAGCGTCCTGGTCGTCGCAAAGGTCG
	AAAAGGGAAAGAGCAAGAAGCTGAAGAGCGTCAAGGAACTG
	CTGGGAATCACAATCATGGAAAGAAGCAGCTTCGAAAAGAAC
	CCGATCGACTTCCTGGAAGCAAAGGGATACAAGGAAGTCAAG
	AAGGACCTGATCATCAAGCTGCCGAAGTACAGCCTGTTCGAAC
	TGGAAAACGGAAGAAAGAGAATGCTGGCAAGCGCAGGAGAA
	CTGCAGAAGGGAAACGAACTGGCACTGCCGAGCAAGTACGTC
	AACTTCCTGTACCTGGCAAGCCACTACGAAAAGCTGAAGGGA
	AGCCCGGAAGACAACGAACAGAAGCAGCTGTTCGTCGAACAG
	CACAAGCACTACCTGGACGAAATCATCGAACAGATCAGCGAA
	TTCAGCAAGAGAGTCATCCTGGCAGACGCAAACCTGGACAAG
	GTCCTGAGCGCATACAACAAGCACAGAGACAAGCCGATCAGA
	GAACAGGCAGAAAACATCATCCACCTGTTCACACTGACAAAC
	CTGGGAGCACCGGCAGCATTCAAGTACTTCGACACAACAATC
	GACAGAAAGAGATACACAAGCACAAAGGAAGTCCTGGACGCA
	ACACTGATCCACCAGAGCATCACAGGACTGTACGAAACAAGA
	ATCGACCTGAGCCAGCTGGGAGGAGACGGAGGAGGAAGCCCG
	AAGAAGAAGAGAAAGGTCTAGctagcgctcgctttcttgctgtccaatttctattaaa
	ggttcctttgttccctaagtccaactactaaactgggggatattatgaagggccttgagcatctggattctg
	cctaataaaaaacatttattttcattgcctcgag
Cas9	GGGaagctcagaataaacgctcaactttggccggatctgccacCATGGACAAGAAGT	59
transcript	ACAGCATCGGACTGGACATCGGAACAAACAGCGTCGGATGGG
with 5′ UTR	CAGTCATCACAGACGAATACAAGGTCCCGAGCAAGAAGTTCA
from XBG,	AGGTCCTGGGAAACACAGACAGACACAGCATCAAGAAGAACC
ORF	TGATCGGAGCACTGCTGTTCGACAGCGGAGAAACAGCAGAAG
corresponding	CAACAAGACTGAAGAGAACAGCAAGAAGAAGATACACAAGA
to SEQ	AGAAAGAACAGAATCTGCTACCTGCAGGAAATCTTCAGCAAC
ID NO: 4,	GAAATGGCAAAGGTCGACGACAGCTTCTTCCACAGACTGGAA
Kozak	GAAAGCTTCCTGGTCGAAGAAGACAAGAAGCACGAAAGACAC
sequence,	CCGATCTTCGGAAACATCGTCGACGAAGTCGCATACCACGAA
and 3′ UTR	AAGTACCCGACAATCTACCACCTGAGAAAGAAGCTGGTCGAC
of XBG	AGCACAGACAAGGCAGACCTGAGACTGATCTACCTGGCACTG
	GCACACATGATCAAGTTCAGAGGACACTTCCTGATCGAAGGA
	GACCTGAACCCGGACAACAGCGACGTCGACAAGCTGTTCATC
	CAGCTGGTCCAGACATACAACCAGCTGTTCGAAGAAAACCCG
	ATCAACGCAAGCGGAGTCGACGCAAAGGCAATCCTGAGCGCA
	AGACTGAGCAAGAGCAGAAGACTGGAAAACCTGATCGCACAG
	CTGCCGGGAGAAAAGAAGAACGGACTGTTCGGAAACCTGATC
	GCACTGAGCCTGGGACTGACACCGAACTTCAAGAGCAACTTC
	GACCTGGCAGAAGACGCAAAGCTGCAGCTGAGCAAGGACACA
	TACGACGACGACCTGGACAACCTGCTGGCACAGATCGGAGAC
	CAGTACGCAGACCTGTTCCTGGCAGCAAAGAACCTGAGCGAC
	GCAATCCTGCTGAGCGACATCCTGAGAGTCAACACAGAAATC
	ACAAAGGCACCGCTGAGCGCAAGCATGATCAAGAGATACGAC
	GAACACCACCAGGACCTGACACTGCTGAAGGCACTGGTCAGA
	CAGCAGCTGCCGGAAAAGTACAAGGAAATCTTCTTCGACCAG
	AGCAAGAACGGATACGCAGGATACATCGACGGAGGAGCAAGC
	CAGGAAGAATTCTACAAGTTCATCAAGCCGATCCTGGAAAAG
	ATGGACGGAACAGAAGAACTGCTGGTCAAGCTGAACAGAGAA
	GACCTGCTGAGAAAGCAGAGAACATTCGACAACGGAAGCATC
	CCGCACCAGATCCACCTGGGAGAACTGCACGCAATCCTGAGA
	AGACAGGAAGACTTCTACCCGTTCCTGAAGGACAACAGAGAA
	AAGATCGAAAAGATCCTGACATTCAGAATCCCGTACTACGTCG
	GACCGCTGGCAAGAGGAAACAGCAGATTCGCATGGATGACAA
	GAAAGAGCGAAGAAACAATCACACCGTGGAACTTCGAAGAAG
	TCGTCGACAAGGGAGCAAGCGCACAGAGCTTCATCGAAAGAA
	TGACAAACTTCGACAAGAACCTGCCGAACGAAAAGGTCCTGC
	CGAAGCACAGCCTGCTGTACGAATACTTCACAGTCTACAACGA
	ACTGACAAAGGTCAAGTACGTCACAGAAGGAATGAGAAAGCC
	GGCATTCCTGAGCGGAGAACAGAAGAAGGCAATCGTCGACCT
	GCTGTTCAAGACAAACAGAAAGGTCACAGTCAAGCAGCTGAA
	GGAAGACTACTTCAAGAAGATCGAATGCTTCGACAGCGTCGA
	AATCAGCGGAGTCGAAGACAGATTCAACGCAAGCCTGGGAAC
	ATACCACGACCTGCTGAAGATCATCAAGGACAAGGACTTCCTG
	GACAACGAAGAAAACGAAGACATCCTGGAAGACATCGTCCTG
	ACACTGACACTGTTCGAAGACAGAGAAATGATCGAAGAAAGA
	CTGAAGACATACGCACACCTGTTCGACGACAAGGTCATGAAG
	CAGCTGAAGAGAAGAAGATACACAGGATGGGGAAGACTGAG
	CAGAAAGCTGATCAACGGAATCAGAGACAAGCAGAGCGGAA
	AGACAATCCTGGACTTCCTGAAGAGCGACGGATTCGCAAACA
	GAAACTTCATGCAGCTGATCCACGACGACAGCCTGACATTCAA
	GGAAGACATCCAGAAGGCACAGGTCAGCGGACAGGGAGACA
	GCCTGCACGAACACATCGCAAACCTGGCAGGAAGCCCGGCAA
	TCAAGAAGGGAATCCTGCAGACAGTCAAGGTCGTCGACGAAC
	TGGTCAAGGTCATOGGAAGACACAAGCCGGAAAACATCGTCA
	TCGAAATGGCAAGAGAAAACCAGACAACACAGAAGGGACAG
	AAGAACAGCAGAGAAAGAATGAAGAGAATCGAAGAAGGAAT
	CAAGGAACTGGGAAGCCAGATCCTGAAGGAACACCCGGTCGA
	AAACACACAGCTGCAGAACGAAAAGCTGTACCIGTACTACCT
	GCAGAACGGAAGAGACATGTACGTCGACCAGGAACTGGACAT
	CAACAGACTGAGCGACTACGACGTCGACCACATCGTCCCGCA
	GAGCTTCCTGAAGGACGACAGCATCGACAACAAGGTCCTGAC
	AAGAAGCGACAAGAACAGAGGAAAGAGCGACAACGTCCCGA
	GCGAAGAAGTCGTCAAGAAGATGAAGAACTACTGGAGACAGC
	TGCTGAACGCAAAGCTGATCACACAGAGAAAGTTCGACAACC
	TGACAAAGGCAGAGAGAGGAGGACTGAGCGAACTGGACAAG
	GCAGGATTCATCAAGAGACAGCTGGTCGAAACAAGACAGATC
	ACAAAGCACGTCGCACAGATCCTGGACAGCAGAATGAACACA
	AAGTACGACGAAAACGACAAGCTGATCAGAGAAGTCAAGGTC
	ATCACACTGAAGAGCAAGCTGGTCAGCGACTTCAGAAAGGAC
	TTCCAGTTCTACAAGGTCAGAGAAATCAACAACTACCACCACG
	CACACGACGCATACCTGAACGCAGTCGTCGGAACAGCACTGA
	TCAAGAAGTACCCGAAGCTGGAAAGCGAATTCGTCTACGGAG
	ACTACAAGGTCTACGACGTCAGAAAGATGATCGCAAAGAGCG
	AACAGGAAATCGGAAAGGCAACAGCAAAGTACTTCTTCTACA
	GCAACATCATGAACTTCTTCAAGACAGAAATCACACTGGCAA
	ACGGAGAAATCAGAAAGAGACCGCTGATCGAAACAAACGGA
	GAAACAGGAGAAATCGTCTGGGACAAGGGAAGAGACTTCGCA
	ACAGTCAGAAAGGTCCTGAGCATGCCGCAGGTCAACATCGTC
	AAGAAGACAGAAGTCCAGACAGGAGGATTCAGCAAGGAAAG
	CATCCTGCCGAAGAGAAACAGCGACAAGCTGATCGCAAGAAA
	GAAGGACTGGGACCCGAAGAAGTACGGAGGATTCGACAGCCC
	GACAGTCGCATACAGCGTCCTGGTCGTCGCAAAGGTCGAAAA
	GGGAAAGAGCAAGAAGCTGAAGAGCGTCAAGGAACTGCTGG
	GAATCACAATCATGGAAAGAAGCAGCTTCGAAAAGAACCCGA
	TCGACTTCCTGGAAGCAAAGGGATACAAGGAAGTCAAGAAGG
	ACCTGATCATCAAGCTGCCGAAGTACAGCCTGTTCGAACTGGA
	AAACGGAAGAAAGAGAATGCTGGCAAGCGCAGGAGAACTGC
	AGAAGGGAAACGAACTGGCACTGCCGAGCAAGTACGTCAACT
	TCCTGTACCTGGCAAGCCACTACGAAAAGCTGAAGGGAACCC
	CGGAAGACAACGAACAGAAGCAGCTGTTCGTCGAACAGCACA
	AGCACTACCTGGACGAAATCATCGAACAGATCAGCGAATTCA
	GCAAGAGAGTCATCCTGGCAGACGCAAACCTGGACAAGGTCC
	TGAGCGCATACAACAAGCACAGAGACAAGCCGATCAGAGAAC
	AGGCAGAAAACATCATCCACCTGTTCACACTGACAAACCTGG
	GAGCACCGGCAGCATTCAAGTACTTCGACACAACAATCGACA
	GAAAGAGATACACAAGCACAAAGGAAGTCCTGGACGCAACAC
	TGATCCACCAGAGCATCACAGGACTGTACGAAACAAGAATCG
	ACCTGAGCCAGCTGGGAGGAGACGGAGGAGGAAGCCCGAAG
	AAGAAGAGAAAGGTCTAGctagcaccagcctcaagaacacccgaatggagtctctaa
	gctacataataccaacttacactttacaaaatgttgtcccccaaaatgtagccattcgtatctgctcctaata
	aaaagaaagtttcttcacattctctcgag
Cas9	AGGaagctcagaataaacgctcaactttggccggatctgccacCATGGACAAGAAGT	60
transcript	ACAGCATCGGACTGGACATCGGAACAAACAGCGTCGGATGGG
with AGG as	CAGTCATCACAGACGAATACAAGGTCCCGAGCAAGAAGTTCA
first three	AGGTCCTGGGAAACACAGACAGACACAGCATCAAGAAGAACC
nucleotides	TGATCGGAGCACTGCTGTTCGACAGCGGAGAAACAGCAGAAG
for use with	CAACAAGACTGAAGAGAACAGCAAGAAGAAGATACACAAGA
CleanCap™,	AGAAAGAACAGAATCTGCTACCTGCAGGAAATCTTCAGCAAC
5′ UTR from	GAAATGGCAAAGGTCGACGACAGCTTCTTCCACAGACTGGAA
XBG, ORF	GAAAGCTTCCTGGTCGAAGAAGACAAGAAGCACGAAAGACAC
corresponding	CCGATCTTCGGAAACATCGTCGACGAAGTCGCATACCACGAA
to SEQ	AAGTACCCGACAATCTACCACCTGAGAAAGAAGCTGGTCGAC
ID NO: 4,	AGCACAGACAAGGCAGACCTGAGACTGATCTACCTGGCACTG
Kozak	GCACACATGATCAAGTTCAGAGGACACTTCCTGATCGAAGGA
sequence,	GACCTGAACCCGGACAACAGCGACGTCGACAAGCTGTTCATC
and 3′ UTR	CAGCTGGTCCAGACATACAACCAGCTGTTCGAAGAAAACCCG
of XBG	ATCAACGCAAGCGGAGTCGACGCAAAGGCAATCCTGAGCGCA
	AGACTGAGCAAGAGCAGAAGACTGGAAAACCTGATCGCACAG
	CTGCCGGGAGAAAAGAAGAACGGACTGTTCGGAAACCTGATC
	GCACTGAGCCTGGGACTGACACCGAACTTCAAGAGCAACTTC
	GACCTGGCAGAAGACGCAAAGCTGCAGCTGAGCAAGGACACA
	TACGACGACGACCTGGACAACCTGCTGGCACAGATCGGAGAC
	CAGTACGCAGACCTGTTCCTGGCAGCAAAGAACCTGAGCGAC
	GCAATCCTGCTGAGCGACATCCTGAGAGTCAACACAGAAATC
	ACAAAGGCACCGCTGAGCGCAAGCATGATCAAGAGATACGAC
	GAACACCACCAGGACCTGACACTGCTGAAGGCACTGGTCAGA
	CAGCAGCTGCCGGAAAAGTACAAGGAAATCTTCTTCGACCAG
	AGCAAGAACGGATACGCAGGATACATCGACGGAGGAGCAAGC
	CAGGAAGAATTCTACAAGTTCATCAAGCCGATCCTGGAAAAG
	ATGGACGGAACAGAAGAACTGCTGGTCAAGCTGAACAGAGAA
	GACCTGCTGAGAAAGCAGAGAACATTCGACAACGGAAGCATC
	CCGCACCAGATCCACCTGGGAGAACTGCACGCAATCCTGAGA
	AGACAGGAAGACTTCTACCCGTTCCTGAAGGACAACAGAGAA
	AAGATCGAAAAGATCCTGACATTCAGAATCCCGTACTACGTCG
	GACCGCTGGCAAGAGGAAACAGCAGATTCGCATGGATGACAA
	GAAAGAGCGAAGAAACAATCACACCGTGGAACTTCGAAGAAG
	TCGTCGACAAGGGAGCAAGCGCACAGAGCTTCATCGAAAGAA
	TGACAAACITCGACAAGAACCTGCCGAACGAAAAGGTCCTGC
	CGAAGCACAGCCTGCTGTACGAATACTTCACAGTCTACAACGA
	ACTGACAAAGGTCAAGTACGTCACAGAAGGAATGAGAAAGCC
	GGCATTCCTGAGCGGAGAACAGAAGAAGGCAATCGTCGACCT
	GCTGTTCAAGACAAACAGAAAGGTCACAGTCAAGCAGCTGAA
	GGAAGACTACTTCAAGAAGATCGAATGCTTCGACAGCGTCGA
	AATCAGCGGAGTCGAAGACAGATTCAACGCAAGCCTGGGAAC
	ATACCACGACCTGCTGAAGATCATCAAGGACAAGGACTTCCTG
	GACAACGAAGAAAACGAAGACATCCTGGAAGACATCGTCCTG
	ACACTGACACTGTTCGAAGACAGAGAAATGATCGAAGAAAGA
	CTGAAGACATACGCACACCTGTTCGACGACAAGGTCATGAAG
	CAGCTGAAGAGAAGAAGATACACAGGATGGGGAAGACTGAG
	CAGAAAGCTGATCAACGGAATCAGAGACAAGCAGAGCGGAA
	AGACAATCCTGGACTTCCTGAAGAGCGACGGATTCGCAAACA
	GAAACTTCATGCAGCTGATCCACGACGACAGCCTGACATTCAA
	GGAAGACATCCAGAAGGCACAGGTCAGCGGACAGGGAGACA
	GCCTGCACGAACACATCGCAAACCTGGCAGGAAGCCCGGCAA
	TCAAGAAGGGAATCCTGCAGACAGTCAAGGTCGTCGACGAAC
	TGGTCAAGGTCATGGGAAGACACAAGCCGGAAAACATCGTCA
	TCGAAATGGCAAGAGAAAACCAGACAACACAGAAGGGACAG
	AAGAACAGCAGAGAAAGAATGAAGAGAATCGAAGAAGGAAT
	CAAGGAACTGGGAAGCCAGATCCTGAAGGAACACCCGGTCGA
	AAACACACAGCTGCAGAACGAAAAGCTGTACCTGTACTACCT
	GCAGAACGGAAGAGACATGTACGTCGACCAGGAACTGGACAT
	CAACAGACTGAGCGACTACGACGTCGACCACATCGTCCCGCA
	GAGCTTCCTGAAGGACGACAGCATCGACAACAAGGTCCTGAC
	AAGAAGCGACAAGAACAGAGGAAAGAGCGACAACGTCCCGA
	GCGAAGAAGTCGTCAAGAAGATGAAGAACTACTGGAGACAGC
	TGCTGAACGCAAAGCTGATCACACAGAGAAAGTTCGACAACC
	TGACAAAGGCAGAGAGAGGAGGACTGAGCGAACTGGACAAG
	GCAGGATTCATCAAGAGACAGCTGGTCGAAACAAGACAGATC
	ACAAAGCACGTCGCACAGATCCTGGACAGCAGAATGAACACA
	AAGTACGACGAAAACGACAAGCTGATCAGAGAAGTCAAGGTC
	ATCACACTGAAGAGCAAGCTGGTCAGCGACTTCAGAAAGGAC
	TTCCAGTTCTACAAGGTCAGAGAAATCAACAACTACCACCACG
	CACACGACGCATACCTGAACGCAGTCGTCGGAACAGGACTGA
	TCAAGAAGTACCCGAAGCTGGAAAGCGAATTCGTCTACGGAG
	ACTACAAGGTCTACGACGTCAGAAAGATGATCGCAAAGAGCG
	AACAGGAAATCGGAAAGGCAACAGCAAAGTACTTCTTCTACA
	GCAACATCATGAACTTCTTCAAGACAGAAATCACACTGGCAA
	ACGGAGAAATCAGAAAGAGACCGCTGATCGAAACAAACGGA
	GAAACAGGAGAAATCGTCTGGGACAAGGGAAGAGACTTCGCA
	ACAGTCAGAAAGGTCCTGAGCATGCCGCAGGTCAACATCGTC
	AAGAAGACAGAAGTCCAGACAGGAGGATTCAGCAAGGAAAG
	CATCCTGCCGAAGAGAAACAGCGACAAGCTGATCGCAAGAAA
	GAAGGACTGGGACCCGAAGAAGTACGGAGGATTCGACAGCCC
	GACAGTCGCATACAGCGTCCTGGTCGTCGCAAAGGTCGAAAA
	GGGAAAGAGCAAGAAGCTGAAGAGCGTCAAGGAACTGCTGG
	GAATCACAATCATGGAAAGAAGCAGCTTCGAAAAGAACCCGA
	TCGACTTCCTGGAAGCAAAGGGATACAAGGAAGTCAAGAAGG
	ACCTGATCATCAAGCTGCCGAAGTACAGCCTGTTCGAACTGGA
	AAACGGAAGAAAGAGAATGCTGGCAAGCGCAGGAGAACTGC
	AGAAGGGAAACGAACTGGCACTGCCGAGCAAGTACGTCAACT
	TCCTGTACCTGGCAAGCCACTACGAAAAGCTGAAGGGAAGCC
	CGGAAGACAACGAACAGAAGCAGCTGTTCGTCGAACAGCACA
	AGCACTACCTGGACGAAATCATCGAACAGATCAGCGAATTCA
	GCAAGAGAGTCATCCTGGCAGACGCAAACCTGGACAAGGTCC
	TGAGCGCATACAACAAGCACAGAGACAAGCCGATCAGAGAAC
	AGGCAGAAAACATCATCCACCTGTTCACACTGACAAACCTGG
	GAGCACCGGCAGCATTCAAGTACTTCGACACAACAATCGACA
	GAAAGAGATACACAAGCACAAAGGAAGTCCTGGACGCAACAC
	TGATCCACCAGAGCATCACAGGACTGTACGAAACAAGAATCG
	ACCTGAGCCAGCTGGGAGGAGACGGAGGAGGAAGCCCGAAG
	AAGAAGAGAAAGGTCTAGctagcaccagcctcaagaacacccgaatggagtctctaa
	gctacataataccaacttacactttacaaaatgttgtcccccaaaatgtagccattcgtatctgctcctaata
	aaaagaaagtttcttcacattctctcgag
Cas9	AGGTCCCGCAGTCGGCGTCCAGCGGCTCTGCTTGTTCGTGTGT	61
transcript	GTGTCGTTGCAGGCCTTATTCGGATCCGCCACCATGGACAAGA
with AGGas	AGTACAGCATCGGACTGGACATCGGAACAAACAGCGTCGGAT
first three	GGGCAGTCATCACAGACGAATACAAGGTCCCGAGCAAGAAGT
nucleotides	TCAAGGTCCTGGGAAACACAGACAGACACAGCATCAAGAAGA
for use with	ACCTGATCGGAGCACTGCTGTTCGACAGCGGAGAAACAGCAG
CleanCap™,	AAGCAACAAGACTGAAGAGAACAGCAAGAAGAAGATACACA
5′ UTR from	AGAAGAAAGAACAGAATCTGCTACCTGCAGGAAATCTTCAGC
HSD, ORF	AACGAAATGGCAAAGGTCGACGACAGCTTCTTCCACAGACTG
corresponding	GAAGAAAGCTTCCTGGTCGAAGAAGACAAGAAGCACGAAAGA
to SEQ	CACCCGATCTTCGGAAACATCGTCGACGAAGTCGCATACCACG
ID NO: 4,	AAAAGTACCCGACAATCTACCACCTGAGAAAGAAGCTGGTCG
Kozak	ACAGCACAGACAAGGCAGACCTGAGACTGATCTACCTGGCAC
sequence,	TGGCACACATGATCAAGTTCAGAGGACACTTCCTGATCGAAGG
and 3′ UTR	AGACCTGAACCCGGACAACAGCGACGTCGACAAGCTGTTCAT
of ALB	CCAGCTGGTCCAGACATACAACCAGCTGTTCGAAGAAAACCC
	GATCAACGCAAGCGGAGTCGACGCAAAGGCAATCCTGAGCGC
	AAGACTGAGCAAGAGCAGAAGACTGGAAAACCTGATCGCACA
	GCTGCCGGGAGAAAAGAAGAACGGACTGTTCGGAAACCTGAT
	CGCACTGAGCCTGGGACTGACACCGAACTTCAAGAGCAACTTC
	GACCTGGCAGAAGACGCAAAGCTGCAGCTGAGCAAGGACACA
	TACGACGACGACCTGGACAACCTGCTGGCACAGATCGGAGAC
	CAGTACGCAGACCTGTTCCTGGCAGCAAAGAACCTGAGCGAC
	GCAATCCTGCTGAGCGACATCCTGAGAGTCAACACAGAAATC
	ACAAAGGCACCGCTGAGCGCAAGCATGATCAAGAGATACGAC
	GAACACCACCAGGACCTGACACTGCTGAAGGCACTGGTCAGA
	CAGCAGCTGCCGGAAAAGTACAAGGAAATCTTCTTCGACCAG
	AGCAAGAACGGATACGCAGGATACATCGACGGAGGAGCAAGC
	CAGGAAGAATTCTACAAGTTCATCAAGCCGATCCTGGAAAAG
	ATGGACGGAACAGAAGAACTGCTGGTCAAGCTGAACAGAGAA
	GACCTGCTGAGAAAGCAGAGAACATTCGACAACGGAAGCATC
	CCGCACCAGATCCACCTGGGAGAACTGCACGCAATCCTGAGA
	AGACAGGAAGACTTCTACCCGTTCCTGAAGGACAACAGAGAA
	AAGATCGAAAAGATCCTGACATTCAGAATCCCGTACTACGTCG
	GACCGCTGGCAAGAGGAAACAGCAGATTCGCATGGATGACAA
	GAAAGAGCGAAGAAACAATCACACCGTGGAACTTCGAAGAAG
	TCGTCGACAAGGGAGCAAGCGCACAGAGCTTCATCGAAAGAA
	TGACAAACTTCGACAAGAACCTGCCGAACGAAAAGGTCCTGC
	CGAAGCACAGCCTGCTGTACGAATACTTCACAGTCTACAACGA
	ACTGACAAAGGTCAAGTACGTCACAGAAGGAATGAGAAAGCC
	GGCATTCCTGAGCGGAGAACAGAAGAAGGCAATCGTCGACCT
	GCTGTTCAAGACAAACAGAAAGGTCACAGTCAAGCAGCTGAA
	GGAAGACTACTTCAAGAAGATCGAATGCTTCGACAGCGTCGA
	AATCAGCGGAGTCGAAGACAGATTCAACGCAAGCCTGGGAAC
	ATACCACGACCTGCTGAAGATCATCAAGGACAAGGACTTCCTG
	GACAACGAAGAAAACGAAGACATCCTGGAAGACATCGTCCTG
	ACACTGACACTGTTCGAAGACAGAGAAATGATCGAAGAAAGA
	CTGAAGACATACGCACACCTGTTCGACGACAAGGTCATGAAG
	CAGCTGAAGAGAAGAAGATACACAGGATGGGGAAGACTGAG
	CAGAAAGCTGATCAACGGAATCAGAGACAAGCAGAGCGGAA
	AGACAATCCTGGACTTCCTGAAGAGCGACGGATTCGCAAACA
	GAAACTTCATGCAGCTGATCCACGACGACAGCCTGACATTCAA
	GGAAGACATCCAGAAGGCACAGGTCAGCGGACAGGGAGACA
	GCCTGCACGAACACATCGCAAACCTGGCAGGAAGCCCGGCAA
	TCAAGAAGGGAATCCTGCAGACAGTCAAGGTCGTCGACGAAC
	TGGTCAAGGTCATGGGAAGACACAAGCCGGAAAACATCGTCA
	TCGAAATGGCAAGAGAAAACCAGACAACACAGAAGGGACAG
	AAGAACAGCAGAGAAAGAATGAAGAGAATCGAAGAAGGAAT
	CAAGGAACTGGGAAGCCAGATCCTGAAGGAACACCCGGTCGA
	AAACACACAGCTGCAGAACGAAAAGCTGTACCTGTACTACCT
	GCAGAACGGAAGAGACATGTACGTCGACCAGGAACTGGACAT
	CAACAGACTGAGCGACTACGACGTCGACCACATCGTCCCGCA
	GAGCTTCCTGAAGGACGACAGCATCGACAACAAGGTCCTGAC
	AAGAAGCGACAAGAACAGAGGAAAGAGCGACAACGTCCCGA
	GCGAAGAAGTCGTCAAGAAGATGAAGAACTACTGGAGACAGC
	TGCTGAACGCAAAGCTGATCACACAGAGAAAGTTCGACAACC
	TGACAAAGGCAGAGAGAGGAGGACTGAGCGAACTGGACAAG
	GCAGGATTCATCAAGAGACAGCTGGTCGAAACAAGACAGATC
	ACAAAGCACGTCGCACAGATCCTGGACAGCAGAATGAACACA
	AAGTACGACGAAAACGACAAGCTGATCAGAGAAGTCAAGGTC
	ATCACACTGAAGAGCAAGCTGGTCAGCGACTTCAGAAAGGAC
	TTCCAGTTCTACAAGGTCAGAGAAATCAACAACTACCACCACG
	CACACGACGCATACCTGAACGCAGTCGTCGGAACAGCACTGA
	TCAAGAAGTACCCGAAGCTGGAAAGCGAATTCGTCTACGGAG
	ACTACAAGGTCTACGACGTCAGAAAGATGATCGCAAAGAGCG
	AACAGGAAATCGGAAAGGCAACAGCAAAGTACTTCTTCTACA
	GCAACATCATGAACTTCTTCAAGACAGAAATCACACTGGCAA
	ACGGAGAAATCAGAAAGAGACCGCTGATCGAAACAAACGGA
	GAAACAGGAGAAATCGTCTGGGACAAGGGAAGAGACTTCGCA
	ACAGTCAGAAAGGTCCTGAGCATGCCGCAGGTCAACATCGTC
	AAGAAGACAGAAGTCCAGACAGGAGGATTCAGCAAGGAAAG
	CATCCTGCCGAAGAGAAACAGCGACAAGCTGATCGCAAGAAA
	GAAGGACTGGGACCCGAAGAAGTACGGAGGATTCGACAGCCC
	GACAGTCGCATACAGCGTCCTGGTCGTCGCAAAGGTCGAAAA
	GGGAAAGAGCAAGAAGCTGAAGAGCGTCAAGGAACTGCTGG
	GAATCACAATCATGGAAAGAAGCAGCTTCGAAAAGAACCCGA
	TCGACTTCCTGGAAGCAAAGGGATACAAGGAAGTCAAGAAGG
	ACCTGATCATCAAGCTGCCGAAGTACAGCCTGTTCGAACTGGA
	AAACGGAAGAAAGAGAATGCTGGCAAGCGCAGGAGAACTGC
	AGAAGGGAAACGAACTGGCACTGCCGAGCAAGTACGTCAACT
	TCCTGTACCTGGCAAGCCACTACGAAAAGCTGAAGGGAAGCC
	CGGAAGACAACGAACAGAAGCAGCTGTTCGTCGAACAGCACA
	AGCACTACCTGGACGAAATCATCGAACAGATCAGCGAATTCA
	GCAAGAGAGTCATCCTGGCAGACGCAAACCTGGACAAGGTCC
	TGAGCGCATACAACAAGCACAGAGACAAGCCGATCAGAGAAC
	AGGCAGAAAACATCATCCACCTGTTCACACTGACAAACCTGG
	GAGCACCGGCAGCATTCAAGTACTTCGACACAACAATCGACA
	GAAAGAGATACACAAGCACAAAGGAAGTCCTGGACGCAACAC
	TGATCCACCAGAGCATCACAGGACTGTACGAAACAAGAATCG
	ACCTGAGCCAGCTGGGAGGAGACGGAGGAGGAAGCCCGAAG
	AAGAAGAGAAAGGTCTAGCTAGCCATCACATTTAAAAGCATC
	TCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAT
	AGCTTATTCATCTCTTTTTCTTTTTCGTTGGTGTAAAGCCAACA
	CCCTGTCTAAAAAACATAAATTTCTTTAATCATTTTGCCTCTTT
	TCTCTGTGCTTCAATTAATAAAAAATGGAAAGAACCTCGAG
30/30/39	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGCGAAAAAAA	62
poly-A	AAAAAAAAAAAAAAAAAAAAAAACCGAAAAAAAAAAAAAAA
sequence	AAAAAAAAAAAAAAAAAAAAAAAA
poly-A100	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	63
sequence	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
	AAAAAAAAAAAAA
G209 guide	mC*mC*mA*GUCCAGCGAGGCAAAGGGUUUUAGAGCUAGAAA	64
RNA	UAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAA
	AGUGGCACCGAGUCGGUGCmU*mU*mU*U
ORF	ATGGCAGCATTCAAGCCGAACTCGATCAACTACATCCTGGGAC	65
encoding	TGGACATCGGAATCGCATCGGTCGGATGGGCAATGGTCGAAA
Neisseria	TCGACGAAGAAGAAAACCCGATCAGACTGATCGACCTGGGAG
meningitidis	TCAGAGTCTTCGAAAGAGCAGAAGTCCCGAAGACAGGAGACT
Cas9	CGCTGGCAATGGCAAGAAGACTGGCAAGATCGGTCAGAAGAC
	TGACAAGAAGAAGAGCACACAGACTGCTGAGAACAAGAAGA
	CTGCTGAAGAGAGAAGGAGTCCTGCAGGCAGCAAACTTCGAC
	GAAAACGGACTGATCAAGTCGCTGCCGAACACACCGTGGCAG
	CTGAGAGCAGCAGCACTGGACAGAAAGCTGACACCGCTGGAA
	TGGTCGGCAGTCCTGCTGCACCTGATCAAGCACAGAGGATACC
	TGTCGCAGAGAAAGAACGAAGGAGAAACAGCAGACAAGGAA
	CTGGGAGCACTGCTGAAGGGAGTCGCAGGAAACGCACACGCA
	CTGCAGACAGGAGACTTCAGAACACCGGCAGAACTGGCACTG
	AACAAGTTCGAAAAGGAATCGGGACACATCAGAAACCAGAGA
	TCGGACTACTCGCACACATTCTCGAGAAAGGACCTGCAGGCA
	GAACTGATCCTGCTGTTCGAAAAGCAGAAGGAATTCGGAAAC
	CCGCACGTCTCGGGAGGACTGAAGGAAGGAATCGAAACACTG
	CTGATGACACAGAGACCGGCACTGTCGGGAGACGCAGTCCAG
	AAGATGCTGGGACACTGCACATTCGAACCGGCAGAACCGAAG
	GCAGCAAAGAACACATACACAGCAGAAAGATTCATCTGGCTG
	ACAAAGCTGAACAACCTGAGAATCCTGGAACAGGGATCGGAA
	AGACCGCTGACAGACACAGAAAGAGCAACACTGATGGACGAA
	CCGTACAGAAAGTCGAAGCTGACATACGCACAGGCAAGAAAG
	CTGCTGGGACTGGAAGACACAGCATTCTTCAAGGGACTGAGA
	TACGGAAAGGACAACGCAGAAGCATCGACACTGATGGAAATG
	AAGGCATACCACGCAATCTCGAGAGCACTGGAAAAGGAAGGA
	CTGAAGGACAAGAAGTCGCCGCTGAACCTGTCGCCGGAACTG
	CAGGACGAAATCGGAACAGCATTCTCGCTGTTCAAGACAGAC
	GAAGACATCACAGGAAGACTGAAGGACAGAATCCAGCCGGAA
	ATCCTGGAAGCACTGCTGAAGCACATCTCGTTCGACAAGTTCG
	TCCAGATCTCGCTGAAGGCACTGAGAAGAATCGTCCCGCTGAT
	GGAACAGGGAAAGAGATACGACGAAGCATGCGCAGAAATCTA
	CGGAGACCACTACGGAAAGAAGAACACAGAAGAAAAGATCT
	ACCTGCCGCCGATCCCGGCAGACGAAATCAGAAACCCGGTCG
	TCCTGAGAGCACTGTCGCAGGCAAGAAAGGTCATCAACGCAG
	TCGTCAGAAGATACGGATCGCCGGCAAGAATCCACATCGAAA
	CAGCAAGAGAAGTCGGAAAGTCGTTCAAGGACAGAAAGGAA
	ATCGAAAAGAGACAGGAAGAAAACAGAAAGGACAGAGAAAA
	GGCAGCAGCAAAGTTCAGAGAATACTTCCCGAACTTCGTCGG
	AGAACCGAAGTCGAAGGACATCCTGAAGCTGAGACTGTACGA
	ACAGCAGCACGGAAAGTGCCTGTACTCGGGAAAGGAAATCAA
	CCTGGGAAGACTGAACGAAAAGGGATACGTCGAAATCGACCA
	CGCACTGCCGTTCTCGAGAACATGGGACGACTCGTTCAACAAC
	AAGGTCCTGGTCCTGGGATCGGAAAACCAGAACAAGGGAAAC
	CAGACACCGTACGAATACTTCAACGGAAAGGACAACTCGAGA
	GAATGGCAGGAATTCAAGGCAAGAGTCGAAACATCGAGATTC
	CCGAGATCGAAGAAGCAGAGAATCCTGCTGCAGAAGTTCGAC
	GAAGACGGATTCAAGGAAAGAAACCTGAACGACACAAGATAC
	GTCAACAGATTCCTGTGCCAGTTCGTCGCAGACAGAATGAGAC
	TGACAGGAAAGGGAAAGAAGAGAGTCTTCGCATCGAACGGAC
	AGATCACAAACCTGCTGAGAGGATTCTGGGGACTGAGAAAGG
	TCAGAGCAGAAAACGACAGACACCACGCACTGGACGCAGTCG
	TCGTCGCATGCTCGACAGTCGCAATGCAGCAGAAGATCACAA
	GATTCGTCAGATACAAGGAAATGAACGCATTCGACGGAAAGA
	CAATCGACAAGGAAACAGGAGAAGTCCTGCACCAGAAGACAC
	ACTTCCCGCAGCCGTGGGAATTCTTCGCACAGGAAGTCATGAT
	CAGAGTCTTCGGAAAGCCGGACGGAAAGCCGGAATTCGAAGA
	AGCAGACACACTGGAAAAGCTGAGAACACTGCTGGCAGAAAA
	GCTGTCGTCGAGACCGGAAGCAGTCCACGAATACGTCACACC
	GCTGTTCGTCTCGAGAGCACCGAACAGAAAGATGTCGGGACA
	GGGACACATGGAAACAGTCAAGTCGGCAAAGAGACTGGACGA
	AGGAGTCTCGGTCCTGAGAGTCCCGCTGACACAGCTGAAGCTG
	AAGGACCTGGAAAAGATGGTCAACAGAGAAAGAGAACCGAA
	GCTGTACGAAGCACTGAAGGCAAGACTGGAAGCACACAAGGA
	CGACCCGGCAAAGGCATTCGCAGAACCGTTCTACAAGTACGA
	CAAGGCAGGAAACAGAACACAGCAGGTCAAGGCAGTCAGAGT
	CGAACAGGTCCAGAAGACAGGAGTCTGGGTCAGAAACCACAA
	CGGAATCGCAGACAACGCAACAATGGTCAGAGTAGACGTCTT
	CGAAAAGGGAGACAAGTACTACCTGGTCCCGATCTACTCGTG
	GCAGGTCGCAAAGGGAATCCTGCCGGACAGAGCAGTCGTCCA
	GGGAAAGGACGAAGAAGACTGGCAGCTGATCGACGACTCGTT
	CAACTTCAAGTTCTCGCTGCACCCGAACGACCTGGTCGAAGTC
	ATCACAAAGAAGGCAAGAATGTTCGGATACTTCGCATCGTGCC
	ACAGAGGAACAGGAAACATCAACATCAGAATCCACGACCTGG
	ACCACAAGATCGGAAAGAACGGAATCCTGGAAGGAATCGGAG
	TCAAGACAGCACTGTCGTTCCAGAAGTACCAGATCGACGAACT
	GGGAAAGGAAATCAGACCGTGCAGACTGAAGAAGAGACCGCC
	GGTCAGATCCGGAAAGAGAACAGCAGACGGATCGGAATTCGA
	ATCGCCGAAGAAGAAGAGAAAGGTCGAATGA
ORF	GCAGCATTCAAGCCGAACTCGATCAACTACATCCTGGGACTGG	66
encoding	ACATCGGAATCGCATCGGTCGGATGGGCAATGGTCGAAATCG
Neisseria	ACGAAGAAGAAAACCCGATCAGACTGATCGACCTGGGAGTCA
meningitidis	GAGTCTTCGAAAGAGCAGAAGTCCCGAAGACAGGAGACTCGC
Cas9 (no	TGGCAATGGCAAGAAGACTGGCAAGATCGGTCAGAAGACTGA
start or stop	CAAGAAGAAGAGCACACAGACTGCTGAGAACAAGAAGACTGC
codons;	TGAAGAGAGAAGGAGTCCTGCAGGCAGCAAACTTCGACGAAA
suitable for	ACGGACTGATCAAGTCGCTGCCGAACACACCGTGGCAGCTGA
inclusion in	GAGCAGCAGCACTGGACAGAAAGCTGACACCGCTGGAATGGT
fusion	CGGCAGTCCTGCTGCACCTGATCAAGCACAGAGGATACCTGTC
protein	GCAGAGAAAGAACGAAGGAGAAACAGCAGACAAGGAACTGG
coding	GAGCACTGCTGAAGGGAGTCGCAGGAAACGCACACGCACTGC
sequence)	AGACAGGAGACTTCAGAACACCGGCAGAACTGGCACTGAACA
	AGTTCGAAAAGGAATCGGGACACATCAGAAACCAGAGATCGG
	ACTACTCGCACACATTCTCGAGAAAGGACCTGCAGGCAGAAC
	TGATCCTGCTGTTCGAAAAGCAGAAGGAATTCGGAAACCCGC
	ACGTCTCGGGAGGACTGAAGGAAGGAATCGAAACACTGCTGA
	TGACACAGAGACCGGCACTGTCGGGAGACGCAGTCCAGAAGA
	TGCTGGGACACTGCACATTCGAACCGGCAGAACCGAAGGCAG
	CAAAGAACACATACACAGCAGAAAGATTCATCTGGCTGACAA
	AGCTGAACAACCTGAGAATCCTGGAACAGGGATCGGAAAGAC
	CGCTGACAGACACAGAAAGAGCAACACTGATGGACGAACCGT
	ACAGAAAGTCGAAGCTGACATACGCACAGGCAAGAAAGCTGC
	TGGGACTGGAAGACACAGCATTCTTCAAGGGACTGAGATACG
	GAAAGGACAACGCAGAAGCATCGACACTGATGGAAATGAAGG
	CATACCACGCAATCTCGAGAGCACTGGAAAAGGAAGGACTGA
	AGGACAAGAAGTCGCCGCTGAACCTGTCGCCGGAACTGCAGG
	ACGAAATCGGAACAGCATTCTCGCTGTTCAAGACAGACGAAG
	ACATCACAGGAAGACTGAAGGACAGAATCCAGCCGGAAATCC
	TGGAAGCACTGCTGAAGCACATCTCGTTCGACAAGTTCGTCCA
	GATCTCGCTGAAGGCACTGAGAAGAATCGTCCCGCTGATGGA
	ACAGGGAAAGAGATACGACGAAGCATGCGCAGAAATCTACGG
	AGACCACTACGGAAAGAAGAACACAGAAGAAAAGATCTACCT
	GCCGCCGATCCCGGCAGACGAAATCAGAAACCCGGTCGTCCT
	GAGAGCACTGTCGCAGGCAAGAAAGGTCATCAACGGAGTCGT
	CAGAAGATACGGATCGCCGGCAAGAATCCACATCGAAACAGC
	AAGAGAAGTCGGAAAGTCGTTCAAGGACAGAAAGGAAATCGA
	AAAGAGACAGGAAGAAAACAGAAAGGACAGAGAAAAGGCAG
	CAGCAAAGTTCAGAGAATACTTCCCGAACTTCGTCGGAGAACC
	GAAGTCGAAGGACATCCTGAAGCTGAGACTGTACGAACAGCA
	GCACGGAAAGTGCCTGTACTCGGGAAAGGAAATCAACCTGGG
	AAGACTGAACGAAAAGGGATACGTCGAAATCGACCACGCACT
	GCCGTTCTCGAGAACATGGGACGACTCGTTCAACAACAAGGTC
	CTGGTCCTGGGATCGGAAAACCAGAACAAGGGAAACCAGACA
	CCGTACGAATACTTCAACGGAAAGGACAACTCGAGAGAATGG
	CAGGAATTCAAGGCAAGAGTCGAAACATCGAGATTCCCGAGA
	TCGAAGAAGCAGAGAATCCTGCTGCAGAAGTTCGACGAAGAC
	GGATTCAAGGAAAGAAACCTGAACGACACAAGATACGTCAAC
	AGATTCCTGTGCCAGTTCGTCGCAGACAGAATGAGACTGACAG
	GAAAGGGAAAGAAGAGAGTCTTCGCATCGAACGGACAGATCA
	CAAACCTGCTGAGAGGATTCTGGGGACTGAGAAAGGTCAGAG
	CAGAAAACGACAGACACCACGCACTGGACGCAGTCGTCGTCG
	CATGCTCGACAGTCGCAATGCAGCAGAAGATCACAAGATTCG
	TCAGATACAAGGAAATGAACGCATTCGACGGAAAGACAATCG
	ACAAGGAAACAGGAGAAGTCCTGCACCAGAAGACACACTTCC
	CGCAGCCGTGGGAATTCTTCGCACAGGAAGTCATGATCAGAGT
	CTTCGGAAAGCCGGACGGAAAGCCGGAATTCGAAGAAGCAGA
	CACACTGGAAAAGCTGAGAACACTGCTGGCAGAAAAGCTGTC
	GTCGAGACCGGAAGCAGTCCACGAATACGTCACACCGCTGTTC
	GTCTCGAGAGCACCGAACAGAAAGATGTCGGGACAGGGACAC
	ATGGAAACAGTCAAGTCGGCAAAGAGACTGGACGAAGGAGTC
	TCGGTCCTGAGAGTCCCGCTGACACAGCTGAAGCTGAAGGAC
	CTGGAAAAGATGGTCAACAGAGAAAGAGAACCGAAGCTGTAC
	GAAGCACTGAAGGCAAGACTGGAAGCACACAAGGACGACCCG
	GCAAAGGCATTCGCAGAACCGTTCTACAAGTACGACAAGGCA
	GGAAACAGAACACAGCAGGTCAAGGCAGTCAGAGTCGAACAG
	GTCCAGAAGACAGGAGTCTGGGTCAGAAACCACAACGGAATC
	GCAGACAACGCAACAATGGTCAGAGTAGACGTCTTCGAAAAG
	GGAGACAAGTACTACCTGGTCCCGATCTACTCGTGGCAGGTCG
	CAAAGGGAATCCTGCCGGACAGAGCAGTCGTCCAGGGAAAGG
	ACGAAGAAGACTGGCAGCTGATCGACGACTCGTTCAACTTCA
	AGTTCTCGCTGCACCCGAACGACCTGGTCGAAGTCATCACAAA
	GAAGGCAAGAATGTTCGGATACTTCGCATCGTGCCACAGAGG
	AACAGGAAACATCAACATCAGAATCCACGACCTGGACCACAA
	GATCGGAAAGAACGGAATCCTGGAAGGAATCGGAGTCAAGAC
	AGCACTGTCGTTCCAGAAGTACCAGATCGACGAACTGGGAAA
	GGAAATCAGACCGTGCAGACTGAAGAAGAGACCGCCGGTCAG
	ATCCGGAAAGAGAACAGCAGACGGATCGGAATTCGAATCGCC
	GAAGAAGAAGAGAAAGGTCGAA
Transcript	GGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGGATCC	67
comprising	GCCACCATGGCAGCATTCAAGCCGAACTCGATCAACTACATCC
SEQ ID NO:	TGGGACTGGACATCGGAATCGCATCGGTCGGATGGGCAATGG
65 (encoding	TCGAAATCGACGAAGAAGAAAACCCGATCAGACTGATCGACC
Neisseria	TGGGAGTCAGAGTCTTCGAAAGAGCAGAAGTCCCGAAGACAG
meningitidis	GAGACTCGCTGGCAATGGCAAGAAGACTGGCAAGATCGGTCA
Cas9)	GAAGACTGACAAGAAGAAGAGCACACAGACTGCTGAGAACA
	AGAAGACTGCTGAAGAGAGAAGGAGTCCTGCAGGCAGCAAAC
	TTCGACGAAAACGGACTGATCAAGTCGCTGCCGAACACACCG
	TGGCAGCTGAGAGCAGCAGCACTGGACAGAAAGCTGACACCG
	CTGGAATGGTCGGCAGTCCTGCTGCACCTGATCAAGCACAGAG
	GATACCTGTCGCAGAGAAAGAACGAAGGAGAAACAGCAGAC
	AAGGAACTGGGAGCACTGCTGAAGGGAGTCGCAGGAAACGCA
	CACGCACTGCAGACAGGAGACTTCAGAACACCGGCAGAACTG
	GCACTGAACAAGTTCGAAAAGGAATCGGGACACATCAGAAAC
	CAGAGATCGGACTACTCGCACACATTCTCGAGAAAGGACCTG
	CAGGCAGAACTGATCCTGCTGTTCGAAAAGCAGAAGGAATTC
	GGAAACCCGCACGTCTCGGGAGGACTGAAGGAAGGAATCGAA
	ACACTGCTGATGACACAGAGACCGGCACTGTCGGGAGACGCA
	GTCCAGAAGATGCTGGGACACTGCACATTCGAACCGGCAGAA
	CCGAAGGCAGCAAAGAACACATACACAGCAGAAAGATTCATC
	TGGCTGACAAAGCTGAACAACCTGAGAATCCTGGAACAGGGA
	TCGGAAAGACCGCTGACAGACACAGAAAGAGCAACACTGATG
	GACGAACCGTACAGAAAGTCGAAGCTGACATACGCACAGGCA
	AGAAAGCTGCTGGGACTGGAAGACACAGCATTCTTCAAGGGA
	CTGAGATACGGAAAGGACAACGCAGAAGCATCGACACTGATG
	GAAATGAAGGCATACCACGCAATCTCGAGAGCACTGGAAAAG
	GAAGGACTGAAGGACAAGAAGTCGCCGCTGAACCTGTCGCCG
	GAACTGCAGGACGAAATCGGAACAGCATTCTCGCTGTTCAAG
	ACAGACGAAGACATCACAGGAAGACTGAAGGACAGAATCCAG
	CCGGAAATCCTGGAAGCACTGCTGAAGCACATCTCGTTCGACA
	AGTTCGTCCAGATCTCGCTGAAGGCACTGAGAAGAATCGTCCC
	GCTGATGGAACAGGGAAAGAGATACGACGAAGCATGCGCAGA
	AATCTACGGAGACCACTACGGAAAGAAGAACACAGAAGAAA
	AGATCTACCTGCCGCCGATCCCGGCAGACGAAATCAGAAACC
	CGGTCGTCCTGAGAGCACTGTCGCAGGCAAGAAAGGTCATCA
	ACGGAGTCGTCAGAAGATACGGATCGCCGGCAAGAATCCACA
	TCGAAACAGCAAGAGAAGTCGGAAAGTCGTTCAAGGACAGAA
	AGGAAATCGAAAAGAGACAGGAAGAAAACAGAAAGGACAGA
	GAAAAGGCAGCAGCAAAGTTCAGAGAATACTTCCCGAACTTC
	GTCGGAGAACCGAAGTCGAAGGACATCCTGAAGCTGAGACTG
	TACGAACAGCAGCACGGAAAGTGCCTGTACTCGGGAAAGGAA
	ATCAACCTGGGAAGACTGAACGAAAAGGGATACGTCGAAATC
	GACCACGCACTGCCGTTCTCGAGAACATGGGACGACTCGTTCA
	ACAACAAGGTCCTGGTCCTGGGATCGGAAAACCAGAACAAGG
	GAAACCAGACACCGTACGAATACTTCAACGGAAAGGACAACT
	CGAGAGAATGGCAGGAATTCAAGGCAAGAGTCGAAACATCGA
	GATTCCCGAGATCGAAGAAGCAGAGAATCCTGCTGCAGAAGT
	TCGACGAAGACGGATTCAAGGAAAGAAACCTGAACGACACAA
	GATACGTCAACAGATTCCTGTGCCAGTTCGTCGCAGACAGAAT
	GAGACTGACAGGAAAGGGAAAGAAGAGAGTCTTCGCATCGAA
	CGGACAGATCACAAACCTGCTGAGAGGATTCTGGGGACTGAG
	AAAGGTCAGAGCAGAAAACGACAGACACCACGCACTGGACGC
	AGTCGTCGTCGCATGCTCGACAGTCGCAATGCAGCAGAAGATC
	ACAAGATTCGTCAGATACAAGGAAATGAACGCATTCGACGGA
	AAGACAATCGACAAGGAAACAGGAGAAGTCCTGCACCAGAAG
	ACACACTTCCCGCAGCCGTGGGAATTCTTCGCACAGGAAGTCA
	TGATCAGAGTCTTCGGAAAGCCGGACGGAAAGCCGGAATTCG
	AAGAAGCAGACACACTGGAAAAGCTGAGAACACTGCTGGCAG
	AAAAGCTGTCGTCGAGACCGGAAGCAGTCCACGAATACGTCA
	CACCGCTGTTCGTCTCGAGAGCACCGAACAGAAAGATGTCGG
	GACAGGGACACATGGAAACAGTCAAGTCGGCAAAGAGACTGG
	ACGAAGGAGTCTCGGTCCTGAGAGTCCCGCTGACACAGCTGA
	AGCTGAAGGACCTGGAAAAGATGGTCAACAGAGAAAGAGAA
	CCGAAGCTGTACGAAGCACTGAAGGCAAGACTGGAAGCACAC
	AAGGACGACCCGGCAAAGGCATTCGCAGAACCGTTCTACAAG
	TACGACAAGGCAGGAAACAGAACACAGCAGGTCAAGGCAGTC
	AGAGTCGAACAGGTCCAGAAGACAGGAGTCTGGGTCAGAAAC
	CACAACGGAATCGCAGACAACGCAACAATGGTCAGAGTAGAC
	GTCTTCGAAAAGGGAGACAAGTACTACCTGGTCCCGATCTACT
	CGTGGCAGGTCGCAAAGGGAATCCTGCCGGACAGAGCAGTCG
	TCCAGGGAAAGGACGAAGAAGACTGGCAGCTGATCGACGACT
	CGTTCAACTTCAAGTTCTCGCTGCACCCGAACGACCTGGTCGA
	AGTCATCACAAAGAAGGCAAGAATGTTCGGATACTTCGCATC
	GTGCCACAGAGGAACAGGAAACATCAACATCAGAATCCACGA
	CCTGGACCACAAGATCGGAAAGAACGGAATCCTGGAAGGAAT
	CGGAGTCAAGACAGCACTGTCGTTCCAGAAGTACCAGATCGA
	CGAACTGGGAAAGGAAATCAGACCGTGCAGACTGAAGAAGAG
	ACCGCCGGTCAGATCCGGAAAGAGAACAGCAGACGGATCGGA
	ATTCGAATCGCCGAAGAAGAAGAGAAAGGTCGAATGATAGCT
	AGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCTC
	GACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCC
	CCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTT
	TCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGT
	GTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGG
	GGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGG
	TGGGCTCTATGG
Amino acid	MAAFKPNSINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVF	68
secpence of	ERAEVPKTGDSLAMARRLARSVRRLTRRRAHRLLRTRRLLKREG
Neisseria	VLQAANFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLI
meningitidis	KHRGYLSQRKNEGETADKELGALLKGVAGNAHALQTGDFRTPA
Cas9	ELALNKFEKESGHIRNQRSDYSHTFSRKDLQAELILLFEKQKEFGN
	PHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAA
	KNTYTAERFIWLTKLNNLRILEQGSERPLTDTERATLMDEPYRKS
	KLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKAYHAI
	SRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDR
	IQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIY
	GDHYGKKNTEEKIYLPPIPADEIRNPVVLRALSQARKVINGVVRR
	YGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFRE
	YFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYV
	EIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDN
	SREWQEFKARVETSRFPRSKKQRILLQKFDEDGFKERNLNDTRYV
	NRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVR
	AENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTID
	KETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLE
	KLRTLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVK
	SAKRLDEGVSVLRVPLTQLKLKDLEKMVNREREPKLYEALKARL
	EAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKTGVW
	VRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDR
	AVVQGKDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFGYFA
	SCHRGTGNGNIRIHDLDHKIGKNGILEGIGVKTALSFQKYQIDELG
	KEIRPCRLKKRPPVRSGKRTADGSEPESPKKKRKVE
G390 guide	mG*mC*mC*GAGUCUGGAGAGCUGCAGUUUUAGAmGmCmUm	69
RNA	AmGmAmAmAmUmAmGmCAAGUUAAAAUAAGGCUAGUCCGU
	UAUCAmAmCmUmUmGmAmAmAmAmAmGmUmGmGmCmAmC
	mCmGmAmGmUmCmGmGmUmGmCmU*mU*mU*mU
G502 guide	mA*mC*mA*CAAAUACCAGUCCAGCGGUUUUAGAmGmCmUm	70
RNA	AmGmAmAmAmUmAmGmCAAGUUAAAAUAAGGCUAGUCCGU
	UAUCAmAmCmUmUmGmAmAmAmAmAmGmUmGmGmCmAmC
	mCmGmAmGmUmCmGmGmUmGmCmU*mU*mU*mU
G509 guide	mA*mA*mA*GUUCUAGAUGCCGUCCGGUUUUAGAmGmCmUm	71
RNA	AmGmAmAmAmUmAmGmCAAGUUAAAAUAAGGCUAGUCCGU
	UAUCAmAmCmUmUmGmAmAmAmAmAmGmUmGmGmCmAmC
	mCmGmAmGmUmCmGmGmUmGmCmU*mU*mU*mU
G534 guide	mA*mC*mG*CAAAUAUCAGUCCAGCGGUUUUAGAmGmCmUm	72
RNA	AmGmAmAmAmUmAmGmCAAGUUAAAAUAAGGCUAGUCCGU
	UAUCAmAmCmUmUmGmAmAmAmAmAmGmUmGmGmCmAmC
	mCmGmAmGmUmCmGmGmUmCmCmU*mU*mU*mU
* = PS linkage; ‘m’ = 2′-O-Me nucleotide
Mouse G000282 NGS primer sequences
Forward primer:
CACTCTTTCCCTACACGACGCTCTTCCGATCTGTTTTGTTCCAGAGTCTATCACCG
Reverse primer:
GGAGTTCAGACGTGTGCTCTTCCGATCTACACGAATAAGAGCAAATGGGAAC
Rat G000390 NGS primer sequences
Forward Primer:
CACTCTTTCCCTACACGACGCTCTTCCGATCTTGCATTTCATGAGACCGAAAACA
Reverse Primer:
GGAGTTCAGACGTGTGCTCTTCCGATCTGCTACAGTAGAGCTGTACATAAAACTT
GFP sequence:
TCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGAC
GGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGC
GTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCA
GATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAG
GAGAAAATACCGCATCAGGCGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGA
AGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATG
TGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGT
AAAACGACGGCCAGTGAATTCTAATACGACTCACTATAGGGTCCCGCAGTCGGC
GTCCAGCGGCTCTGCTTGTTCGTGTGTGTGTCGTTGCAGGCCTTATTCGGATCCAT
GGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCT
GGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCG
ATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCC
CGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGC
CGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAA
GGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACC
CGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAG
GGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAAC
TACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAG
GTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGAC
CACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAAC
CACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGAT
CACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACG
AGCTGTACAAGTAATAGGAATTATGCAGTCTAGCCATCACATTTAAAAGCATCTC
AGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAATAGCTTATTCATCTC
TTTTTCTTTTTCGTTGGTGTAAAGCCAACACCCTGTCTAAAAAACATAAATTTCTT
TAATCATTTTGCCTCTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAAGAACCTC
GAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAT
CTAGACTTAAGCTTGATGAGCTCTAGCTTGGCGTAATCATGGTCATAGCTGTTTC
CTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCAT
AAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTG
CGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAA
TCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTC
GCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCAC
TCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAAC
ATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCT
GGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCA
AGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCT
GGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGT
CCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTAT
CTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCG
TTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGT
AAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGC
GAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTAC
ACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAA
AAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTT
TTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCC
TTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGG
ATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAA
AATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTA
CCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCA
TAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATC
TGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTA
TCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACT
TTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTT
CGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTC
ACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGA
GTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGA
TCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACT
GCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGT
ACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCC
GGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCAT
CATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGA
TCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTT
CACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGG
GAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTA
TTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTT
AGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTG
ACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCAC
GAGGCCCTTTCGTCG

Claims

1. A lipid nanoparticle (“LNP”) composition comprising: an RNA component; anda lipid component, wherein the lipid component comprises: about 50-60 mol-% amine lipid;about 8-10 mol-% neutral lipid; andabout 2.5-4 mol-% PEG lipid,wherein the remainder of the lipid component is helper lipid,the amine lipid is represented by the following structural formula

2. An LNP composition comprising: an RNA component; about 50-60 mol-% amine lipid;about 27-39.5 mol-% helper lipid;about 8-10 mol-% neutral lipid; andabout 2.5-4 mol-% PEG lipid,wherein the amine lipid is represented by the following structural formula

3. The LNP composition of claim 2, wherein the N/P ratio is about 6.

4. An LNP composition comprising: an RNA component; anda lipid component, wherein the lipid component comprises about 50-60 mol-% amine lipid;about 5-15 mol-% neutral lipid; andabout 2.5-4 mol-% PEG lipid,wherein the remainder of the lipid component is helper lipid,the amine lipid is represented by the following structural formula

5. An LNP composition comprising: an RNA component; anda lipid component, wherein the lipid component comprises about 40-60 mol-% amine lipid;about 5-15 mol-% neutral lipid; andabout 2.5-4 mol-% PEG lipid,wherein the remainder of the lipid component is helper lipid,the amine lipid is represented by the following structural formula

6. An LNP composition comprising: an RNA component; anda lipid component, wherein the lipid component comprises about 50-60 mol-% amine lipid;about 5-15 mol-% neutral lipid; andabout 1.5-10 mol-% PEG lipid,wherein the remainder of the lipid component is helper lipid,the amine lipid is represented by the following structural formula

8. An LNP composition comprising: an RNA component; anda lipid component, wherein the lipid component comprises: about 40-60 mol-% amine lipid;less than about 1 mol-% neutral lipid; andabout 1.5-10 mol-% PEG lipid, whereinthe remainder of the lipid component is helper lipid,the amine lipid is represented by the following structural formula

9. An LNP composition comprising: an RNA component; anda lipid component, wherein the lipid component comprises: about 40-60 mol-% amine lipid; andabout 1.5-10 mol-% PEG lipid, whereinthe remainder of the lipid component is helper lipid,the amine lipid is represented by the following structural formula

10. An LNP composition comprising: an RNA component; anda lipid component, wherein the lipid component comprises: about 50-60 mol-% amine lipid;about 8-10 mol-% neutral lipid; andabout 2.5-4 mol-% PEG lipid, whereinthe remainder of the lipid component is helper lipid,the amine lipid is represented by the following structural formula

11. The composition of claim 1, wherein the RNA component comprises an mRNA.

12. The composition of claim 1, wherein the RNA component encodes an RNA guided DNA-binding agent.

13. The composition of claim 1, wherein the RNA component comprises a Class 2 Cas nuclease mRNA.

14. The composition of claim 1, wherein the RNA component comprises a Cas9 nuclease mRNA.

15. The composition of claim 7, wherein the mRNA is a modified mRNA.

16. The composition of claim 1, wherein the RNA component comprises an RNA comprising an open reading frame encoding an RNA-guided DNA-binding agent, wherein the open reading frame has a uridine content ranging from its minimum uridine content to 150% of the minimum uridine content.

17. The composition of claim 1, wherein the RNA component comprises an mRNA comprising an open reading frame encoding an RNA-guided DNA-binding agent, wherein the open reading frame has a uridine dinucleotide content ranging from its minimum uridine dinucleotide content to 150% of the minimum uridine dinucleotide content.

18. The composition of claim 1, wherein the RNA component comprises an mRNA comprising a sequence with at least 90% identity to any one of SEQ ID NO: 1, 4, 7, 9, 10, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 50, 52, 54, 65, or 66, wherein the mRNA comprises an open reading frame encoding an RNA-guided DNA-binding agent.

19. The composition of claim 1, wherein the RNA component comprises a gRNA nucleic acid.

20. The composition of claim 19, wherein the gRNA nucleic acid is a gRNA.

21. The composition of claim 1, wherein the RNA component comprises a Class 2 Cas nuclease mRNA and a gRNA.

22. The composition of claim 19, wherein the gRNA nucleic acid is or encodes a dual-guide RNA (dgRNA).

23. The composition of claim 19, wherein the gRNA nucleic acid is or encodes a single guide RNA (sgRNA).

24. The composition of claim 19, wherein the gRNA is modified.

25. The composition of claim 24, wherein the gRNA comprises a modification chosen from 2′-O-methyl (2′-O-Me) modified nucleotide, a phosphorothioate (PS) bond between nucleotides; and a 2′-fluoro (2′-F) modified nucleotide.

26. The composition of claim 24, wherein the gRNA comprises a modification at one or more of the first five nucleotides at the 5′ end.

27. The composition of claim 24, wherein the gRNA comprises a modification at one or more of the last five nucleotides at the 3′ end.

28. The composition of claim 24, wherein the gRNA comprises PS bonds between the first four nucleotides.

29. The composition of claim 24, wherein the gRNA comprises PS bonds between the last four nucleotides.

30. The composition of claim 24, further comprising 2′-O-Me modified nucleotides at the first three nucleotides at the 5′ end.

31. The composition of claim 24, further comprising 2′-O-Me modified nucleotides at the last three nucleotides at the 3′ end.

32. The composition of claim 19, wherein the gRNA and Class 2 Cas nuclease mRNA are present in a ratio ranging from about 10:1 to about 1:10 by weight.

33. The composition of claim 19, wherein the gRNA and Class 2 Cas nuclease mRNA are present in a ratio ranging from about 5:1 to about 1:5 by weight.

34. The composition of claim 19, wherein the gRNA and Class 2 Cas nuclease mRNA are present in a ratio ranging from about 3:1 to about 1:1 by weight.

35. The composition of claim 19, wherein the gRNA and Class 2 Cas nuclease mRNA are present in a ratio ranging from about 2:1 to about 1:1 by weight.

36. The composition of claim 19, wherein the gRNA and Class 2 Cas nuclease mRNA are present in a ratio of about 2:1 by weight

37. The composition of claim 19, wherein the gRNA and Class 2 Cas nuclease mRNA are present in a ratio of about 1:1 by weight.

38. The composition of claim 1, further comprising at least one template.

39. The composition of claim 1, wherein the mol-% PEG lipid is about 3.

40. The composition of claim 1, wherein the mol-% amine lipid is about 50.

41. The composition of claim 1, wherein the mol-% amine lipid is about 55.

42. The composition of claim 1, wherein the mol-% amine lipid is ±3 mol-% of a target mol-% of amine lipid.

43. The composition of claim 1, wherein the mol-% amine lipid is ±2 mol-% of a target mol-% of amine lipid.

44. The composition of claim 1, wherein the mol-% amine lipid is 47-53 mol-%.

45. The composition of claim 1, wherein the mol-% amine lipid is 48-53 mol-%.

46. The composition of claim 1, wherein the mol-% amine lipid is 53-57 mol-%.

47. The composition of claim 1, wherein the N/P ratio is 6±1.

48. The composition of claim 1, wherein the N/P ratio is 6±0.5.

49. The composition of claim 1, wherein the amine lipid is Lipid A, wherein Lipid A is represented by the following structural formula:

50-52. (canceled)

53. The composition of claim 1, wherein R1 and R2 is each independently a C5-C12 alkyl.

54. The composition of claim 1, wherein R1 and R2 is each independently a C5-C10 alkyl.

55. The composition of claim 1, wherein R1 and R2 are each independently chosen from a C4, C5, C6, C7, C8, C9, C10, C11, and C12 alkyl.

56. The composition of claim 1, wherein the helper lipid is cholesterol.

57. The composition of claim 1, wherein the neutral lipid is DSPC.

58. The composition of claim 1, wherein the neutral lipid is DPPC.

59. The composition of claim 1, wherein the PEG lipid comprises dimyristoylglycerol (DMG).

60. The composition of claim 1, wherein the PEG lipid comprises a PEG-2k.

61. The composition of claim 1, wherein the PEG lipid is a PEG-DMG.

62. The composition of claim 61, wherein the PEG-DMG is a PEG2k-DMG.

63. The composition of claim 9, wherein the LNP composition is essentially free of neutral lipid.

64. The composition of claim 63, wherein the neutral lipid is a phospholipid.

65. A method of gene editing, comprising contacting a cell with an LNP composition of claim 21.

66. A method of gene editing, comprising delivering a Class 2 Cas nuclease mRNA and a guide RNA nucleic acid to a cell, wherein the Class 2 Cas nuclease mRNA and the guide RNA nucleic acid are formulated as at least one LNP composition of claim 21.

67. A method of producing a genetically engineered cell, comprising contacting a cell with at least one LNP composition of claim 21.

68. The method of claim 65, wherein the LNP composition is administered at least two times.

69. The method of claim 68, wherein the LNP composition is administered 2-5 times.

70. The method of claim 68, wherein editing improves upon readministration.

71. The method of claim 65, further comprising introducing at least one template nucleic acid to the cell.

72. The method of claim 65, wherein the mRNA is formulated in a first LNP composition and the guide RNA nucleic acid is formulated in a second LNP composition.

73. The method of claim 72, wherein the first and second LNP compositions are administered simultaneously.

74. The method of claim 72, wherein the first and second LNP compositions are administered sequentially.

75. The method of claim 65, wherein the mRNA and the guide RNA nucleic acid are formulated in a single LNP composition.

76. The composition of claim 12, wherein the RNA component comprises a Cas nuclease mRNA.